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1. Thesis Abstract 
Chromosome copy number errors (or aneuploidy) of gametes and embryos occurs in humans 
more frequently than in any other studied species, with a spectrum of manifestations from 
implantation failure to affected live births. It is predominantly problem arising in maternal meiosis 
with at least 20% of oocytes being aneuploid, a proportion that increases dramatically with 
advancing maternal age. Currently the only intervention to reduce the chances of transmitting 
aneuploidy is by invasive embryo biopsy procedures in high-risk groups (mainly patients with 
advanced maternal age) undergoing in-vitro fertilisation. Despite the severity of this problem, 
aneuploidy of the human preimplantation embryo is relatively poorly understood. With this in mind 
the purpose of this thesis is to explore the premise underpinning the use of preimplantation 
genetic screening (PGS) in human embryos and investigate its clinical applications and current 
methodologies. A series of published works demonstrate what I believe to be a significant 
contribution to the development of applications for studying human preimplantation aneuploidy, 
also providing insight into its origins and mechanisms at the earliest stages of human 
development. 
Specifically, I present a novel standard set of protocols as a general reference work from 
practitioners in the fields of embryo biopsy and array comparative genomic hybridisation (CGH - 
the current ‘gold standard’ for preimplantation aneuploidy screening). I present a summary of 
work encapsulated in three published clinical papers using a linkage based analysis of Single 
Nucleotide Polymorphism (SNP) karyotypes (Karyomapping). Karyomapping was designed as a 
near-universal approach for the simultaneous detection of chromosomal and monogenic 
disorders in a PGS setting and these results demonstrate the utility of the technique in three 
separate scenarios. 
In order to study the underlying mechanisms of female meiosis I present my findings on the use 
of a calcium ionophore to activate human oocytes artificially. An algorithm based on 
Karyomapping (termed MeioMapping) is demonstrated for the first time specifically to investigate 
human female meiosis. By recovering all three products of human female meiosis (oocyte, and 
14 
 
both polar biopsies – herein termed “Trios”) using calcium ionophore, I present a novel protocol 
(commissioned by Nature Protocols) to allow exploration of the full extent of meiotic chromosome 
recombination and segregation that occurs in the female germline. Finally I present a published 
set of experiments using this protocol to provide new insight into meiotic segregation patterns and 
recombination in human oocytes. This work uncovers a previously undescribed pattern of meiotic 
segregation (termed Reverse Segregation), providing an association between recombination 
rates and chromosome mis-segregation (aneuploidy). This work demonstrates that there is 
selection for higher recombination rates in the female germline and that there is a role for meiotic 
drive for recombinant chromatids at meiosis II in human female meiosis. 
The work presented in this thesis provides deeper understanding of meiotically derived maternal 
aneuploidy and recombination. More importantly it provides a vehicle within an ethical framework 
to continue to expand our knowledge and uncover new insights into the basis of meiotic errors 






2. General Introduction 
2.1. Context of this Thesis 
Aneuploidy is defined as extra or missing chromosomes in the nucleus of a cell. It occurs during 
cell division when chromosomes do not disjoin (separate equally) between the two new daughter 
cells (Hassold & Hunt 2001). Chromosome imbalance typically results in non-viability, manifesting 
as developmental arrest prior to implantation, miscarriage or stillbirth. Depending on the 
chromosomes involved, aneuploidy can also result in viable, but developmentally abnormal 
pregnancies, e.g. Down or Klinefelter Syndrome. Other clinical manifestations can include 
intrauterine growth retardation, infertility or imprinting (e.g. Prader Willi) syndromes, particularly if 
the original conceptus was mosaic (i.e. contained normal and aneuploid cells). As such, 
aneuploidy is arguably the most significant genetic hazard facing mankind. 
Aneuploidy is also predominantly a human-specific problem, occurring more frequently than any 
other animal studies during both human gametogenesis and early embryogenesis. The most 
cited mechanism by which it arises is classical ‘nondisjunction’, however this textbook definition 
has been challenged repeatedly and alternative mechanisms have been proposed. It is estimated 
that at least 20% of human oocytes are aneuploid; a number that increases dramatically with 
advancing maternal age (over the age of 35 years) (Dailey et al. 1996b; Hassold & Hunt 2001). 
Conversely, the incidence of aneuploidy in sperm cells from a normal fertile male is estimated to 
be as low as 4-7% (Martin et al. 1991; Shi & Martin 2000). This can however significantly increase 
in some cases of severe male factor infertility (Tempest et al. 2004; Tempest & Griffin 2004). 
Given that, once aneuploidy arises in an individual, treatment is limited to mitigation of its worse 
effects (e.g. Down syndrome); clinical intervention mostly concentrates on reducing the chances 
of transmitting aneuploidy for high-risk groups, i.e. through preimplantation genetic diagnosis 
(PGD). 
The idea of screening preimplantation embryos to eliminate the aneuploid ones is not new. A 
derivative of this was first achieved by Gardner and Edwards (in rabbits) in the 1960s (Gardner & 
Edwards 1968) but the ability to do it effectively has required rapid evolution of diagnostic 
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technologies to combine speed, accuracy and reliability. To date, only direct analysis of 
chromosomes from cells in gametes and preimplantation embryos (rather than indirect methods 
such as metabolic analysis) has proved successful in accurately detecting aneuploidy. Performing 
PGD in this way (sometimes referred to as PGS – preimplantation genetic screening – or PGD-A 
– PGD for aneuploidy) involves the biopsy of cellular material from the embryo or oocyte at 
different stages of development. Since embryo biopsy is an invasive procedure (and thus not 
currently considered appropriate for routine embryo selection), PGS remains a test for high-risk 
patient groups only, rather than for routine universal application, and is thus only offered to 
patients presenting with advanced maternal age, recurrent miscarriage, recurrent implantation 
failure and in some cases severe male factor infertility (Fritz 2008). Due to the invasive nature of 
embryo biopsy and the complexity of human aneuploidy in the human in vitro fertilisation (IVF) 
embryo, cost benefit analysis is crucial to achieve positive outcomes. It could be argued that, in 
the past, the practice of PGS has not given proper concern to these issues and thus, going 
forward, patient selection and understanding the mechanisms of aneuploidy should be central to 
an effective PGS strategy. The purpose of this thesis is to explore the premise underpinning the 
use of PGS in human embryos, its clinical applications and current methodologies, then make a 
significant contribution to the development of applications while, at the same time, providing 
insight into the origin of aneuploidy at the earliest stages of human development.  
 
2.2. Origin of Aneuploidy in Humans: Current Thinking 
Aneuploidy in human IVF embryos (and presumably those naturally conceived also) can primarily 
arise during three developmental stages: (i) pre-meiotic divisions during gametogenesis (gonadal 
mosaicism); (ii) meiotic divisions during gametogenesis; and (iii) early mitotic divisions of 
embryogenesis. Understanding the mechanism behind the mal-segregation of chromosomes at 





2.2.1. Gonadal Mosaicism 
Errors in germ cell proliferation, or errors inherited in an otherwise somatically normal individual 
resulting in germ cell aneuploidy (gonadal mosaicism), can also contribute to aneuploidy of the 
gametes. This is perhaps the least studied of the three stages but has been proposed to account 
for a small yet significant proportion of aneuploid conceptions, particularly in younger women 
(Delhanty 2011). Generally mosaic individuals (for example mosaic Turner or Klinefelter 
syndrome) may be at increased risk of producing aneuploid gametes and PGD should be 
considered in these cases. In any event, the outcome is a hyper- or hypo-gamete and thus can 
be considered in a similar way to a meiotic error in the PGS context. 
 
2.2.2. Meiosis and Chromosomal Segregation Errors 
Meiosis is the production of a haploid gamete by two specialised cell divisions in which the diploid 
chromosome complement of normal somatic cells is reduced (a requisite for sexual reproduction). 
Errors in chromosome segregation during these divisions typically result in gamete aneuploidy 
and, it is believed, subsequent ‘uniform’ aneuploidy in any resulting embryo (Hassold & Hunt 
2001). Although the basic principle of chromosome mal-segregation holds for both male and 
female meiosis in humans, the processes and resulting gametes are vastly different. Female 
meiosis – the process by which a single diploid germ cell develops into a single haploid ovum – 
involves two unequal meiotic divisions producing a mature ovum and two non-functional products 
containing mirror images of the chromosomes present in the ovum. These are known as polar 
bodies and, once extruded, apparently take no further part in development, thus making them a 
useful sample for inferring chromosome constitution of the oocyte itself. Failures in female 
meiosis make, by far, the biggest contribution to aneuploidy in human preimplantation embryos. 
Cytogenetic studies on oocytes and first polar bodies from assisted conception cycles have 
shown more than 20% of oocytes from patients with an average age under 35 to be aneuploid 
(Selva et al. 1991; Fragouli et al. 2006). The percentage of aneuploid oocytes increases 
significantly with age and has been shown to affect an average of around 70% of oocytes for 
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patients of advanced maternal age (Van Blerkom 1989; Angell et al. 1993; Kuliev et al. 2003; 
Gutierrez-Mateo et al. 2004; Kuliev et al. 2005). 
There is conflicting evidence on the frequency of errors in both the first and second meiotic 
division with groups showing errors in both the first meiotic division (MI) (Kuliev et al. 2003) and 
more recently in the second meiotic division (MII) (Fragouli et al. 2011; Handyside et al. 2011) 
occurring more frequently. This discrepancy may be due in part to differences in patient maternal 
age of the study groups and the difference in resolution of the cytogenetic techniques used. Either 
way, it is clear that chromosome segregation errors occur at significant rates during both the first 
and second meiotic divisions of oogenesis. 
Based on studies of yeast, Drosophila and mouse models it is generally believed that aneuploidy 
arises as a result of classic nondisjunction and involves the segregation of a whole chromosome 
to the same pole as its homologue during meiosis. Studies of human oocytes have led to an 
alternative model for the origin of aneuploidy (Angell 1991) suggesting that errors in meiosis can 
result in extra or missing chromatids (known as premature or precocious separation of sister 
chromatids – PSSC), as well as whole chromosomes in the daughter cells (see Figure 2.1). Early 
studies of human oocytes supporting the hypothesis that PSSC was the predominant mechanism 
leading to human aneuploidy (Angell 1991; 1993; 1994; Pellestor et al. 2002; Kuliev et al. 2003) 
were, however, subject to recurring criticism. It was argued that use of ‘failed IVF’ oocytes 
prolonged time in culture, sub-optimal metaphase preparation technique, and lack of rigour in the 
analysis may have led to interpretation errors (Dailey et al. 1996a; Lamb et al. 1996; Lamb et al. 
1997; Mahmood et al. 2000). Recently, several groups performed analyses using methodology 
less prone to these confounding criticisms – the results of which support the hypothesis. 
Quantitative analysis of loss or gain of all 24 chromosomes on PB1 (Gabriel et al. 2011b) and 
sequential 24 chromosome analysis of the first (PB1) and second (PB2) polar bodies (and 
zygote) performed on freshly harvested oocytes used in IVF treatments have shown PSSC to be 
the predominant mechanism of chromosome mal-segregation in assisted reproduction derived 
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oocytes. One of the purposes of this thesis is to study the role of PSSC further using tools 
developed, in part, as a result of this thesis.  
 
 
Figure 2.1. Diagrammatic representation of classic non disjunction (A) and premature 
separation of the sister chromatids (PSSC) (B) - the two ways aneuploidy can arise in the 
first meiotic division in humans (Ottolini et al. 2012). 
In contrast to oogenesis, male meiosis results in four equivalent, functional spermatozoa from a 
single progenitor germ cell. The presence of typically millions of sperm per ejaculate make them 
easy to study en masse, however it is impossible, with current technology, to screen a sperm 
head for aneuploidy them subsequently use it for IVF/PGS. This is because aneuploidy 
assessment of a sperm cell inevitably results in its destruction, and unlike in the ovum, there are 
no by-products available from which a determination of chromosome complement can be 
inferred. 
The overall incidence of aneuploidy in human sperm is estimated to be around 4-7% (Martin et al. 
1991; Shi & Martin 2000) although some studies suggest it is as high as 14% in some infertile 
men (Johnson 1998; Shi & Martin 2001; Tempest & Griffin 2004). Spermatogenesis can 
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theoretically continue unchanged throughout the life of a man, however several studies have 
shown there to be a correlation between increased sperm aneuploidy and advanced paternal age 
(Griffin et al. 1995; Robbins et al. 1995; Fonseka & Griffin 2011), albeit not as dramatic as in the 
female. Other factors such as male factor infertility, smoking and chemotherapy can however 
increase sperm aneuploidy levels (Templado et al. 2005), making individual couples in which 
these risk factors are present possible candidates for PGS. 
 
2.2.3. Mitosis and Chromosome Segregation in Early Human Development 
Mitosis is the process by which a diploid cell usually divides into two chromosomally identical 
daughter cells. It is the primary mechanism by which a multicellular individual develops from a 
single fertilised oocyte (zygote). Human mitotic divisions are generally not prone to chromosome 
segregation errors to any great extent, except in the case of early embryo cleavage stages where 
cells are thought to be exquisitely prone to segregation errors (Bean et al. 2001). Indeed, recent 
studies using a variety of cytogenetic techniques on early IVF human embryos have 
demonstrated that more than 50% are subject to some form of mitotic error (Bielanska et al. 
2002; Munné et al. 2004; Delhanty 2005; Munné 2006). 
Most mitotic errors in early embryo development will lead to chromosomal mosaicism, which is 
defined as the presence of two or more chromosome complements within an embryo developed 
from a single zygote. There are three mechanisms by which mitotic aneuploidy can arise: (i) 
mitotic nondisjunction (resulting in one cell line with chromosome loss and one with gain); (ii) 
anaphase lag (resulting in chromosome loss in one cell line); or (iii) chromosome duplication 
(resulting in chromosome gain in one cell line) (Taylor et al. 2014) (see Figure 2.2). Following 
observations of increased incidence of chromosome loss in preimplantation embryos compared 
to gains and the relative paucity of reciprocal events (which would indicate nondisjunction) 
(Daphnis et al. 2005; Delhanty 2005), the predominant mechanism leading to post-zygotic errors 
in human embryos is likely to be anaphase lag (Coonen et al. 2004). Anaphase lag is described 
as the delayed movement during mitotic anaphase of a homologous chromosome resulting in it 
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not being incorporated into the nucleus of the daughter cell. The result of this is one euploid 
daughter cell and a daughter cell with a monosomy for the lagging chromosome (Coonen et al. 
2004). 
 
Figure 2.2. Diagrammatic representation of mitotic nondisjunction (A), anaphase lag (B) 
and chromosome duplication (C) - the three types of mitotic errors in humans resulting in 
embryo mosaicism (Ottolini et al. 2012). 
Mosaicism is usually considered to occur largely independent of age (Delhanty 2005). However, it 
has been shown that mosaicism originating by the mechanism of mitotic nondisjunction could 
perhaps be related to advanced maternal age (Munné et al. 2002). Results also suggest that 
mosaicism involving multiple chromosomes in a high proportion of cells (chaotic embryos) appear 
to impair early embryo development considerably (Delhanty 2005)..  
The general consensus for the viability of mosaic embryos is that, if more than half of the cells at 
Day 3 post fertilisation are aneuploid, the embryo is unlikely to be viable. Conversely, if a small 
proportion of cells are aneuploid in an otherwise healthy and euploid background, it is likely to be 
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viable (Delhanty 2005). Moreover, in a conceptus that is predominantly aneuploid, the primary 
error is usually considered to have arisen meiotically (with a second, post-zygotic event creating 
the euploid lineage) whereas a predominantly euploid mosaic embryo is considered to have 
arisen purely through a post zygotic error or errors. The occurrence of mosaicism is clearly a 
primary consideration for a clinical intervention that involves removal (biopsy) of cells to perform a 
diagnosis, based on the assumption that the diagnosis from the biopsied cells is representative of 
the embryo as a whole (Bielanska et al. 2002; Delhanty 2005). 
 
2.2.4. Abnormal Fertilisation and its Role in Chromosome Abnormality 
Abnormal fertilisation can also contribute to chromosome errors in preimplantation embryos. 
Approximately 1% of conceptions contain more than two paired homologous sets of 
chromosomes (referred to as polyploidy rather than aneuploidy) (Hassold 1986). There are two 
ways in which a polyploid embryo can arise: Firstly, if a diploid (2n) sperm or oocyte is involved in 
the fertilisation event; and secondly, if two or more haploid sperm are involved in the fertilisation of 
a haploid oocyte (polyspermy). The majority of all polyploid embryos are the result of polyspermy 
and account for around 60% of polyploid conceptions (Egozcue et al. 2002). Following IVF with 
intra-cytoplasmic sperm injection (ICSI) in which only a single sperm is inserted into each oocyte, 
the main mechanism leading to polyploidy in the embryo is the failure of the oocyte to extrude the 
second polar body (Grossmann et al. 1997). This results in a triploid embryo when fertilisation is 
achieved with a haploid sperm. Non-reduced or diploid sperm have also been shown to be 
involved in as many as 8.3% of polyploid conceptions (Egozcue et al. 2002). 
 
2.3. Aneuploidy and the IVF Embryo 
Since the first human IVF success in 1978 (Steptoe & Edwards 1978), advances in morphologic 
embryo grading and technologies aiding morphologic embryo selection have contributed to vastly 
improved IVF outcomes (Figure 2.3). Unfortunately, the morphological selection criteria for 
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human gametes and embryos across all developmental stages have shown only weak 
correlations with aneuploidy levels (Munné 2006; Gianaroli et al. 2007; Alfarawati et al. 2011a). 
Karyotypic analysis indicates that there is a higher rate of chromosome abnormalities in 
morphologically abnormal monospermic embryos than morphologically normal embryos 
(Pellestor 1995; Almeida & Bolton 1996). However, clear distinctions cannot be made between 
chromosomally normal and abnormal human embryos by morphological assessment alone 
(Zenzes & Casper 1992). This may be because chromosome abnormalities detected at the early 
stages of embryogenesis cannot induce dysmorphism, since embryonic gene expression has not 
yet commenced (Braude et al. 1988; Tesarik et al. 1988). There is evidence from 24 chromosome 
copy number analysis that morphology and aneuploidy are linked at the later stages of 
preimplantation embryo development (blastocyst stage). However, again the association is weak, 
and consequently morphologic analysis still cannot be relied upon to ensure transfer of 
chromosomally normal embryos. A significant proportion of aneuploid embryos are capable of 
achieving the highest morphologic scores even at the later stages of preimplantation 
development and, conversely, some euploid embryos achieve only poor morphological scores or 
even fail to develop (Alfarawati et al. 2011a).  
 
Figure 2.3. Overall IVF and IVF/ICSI success rates by maternal age in the UK from 
1992-2005. 





Other indirect aneuploidy screening methods have been trialled in the past with limited success. 
More recently, proteomic studies have shown to be a potentially useful tool in prenatal aneuploidy 
screening (Cho & Diamandis 2011; Kolialexi et al. 2011). By applying the same principle to 
preimplantation embryos, one study has identified the first protein secreted by human blastocysts 
that is associated with generic chromosome aneuploidy (McReynolds et al. 2011). Although 
promising, this technology is still some way from becoming a routine aneuploidy screening test, 
and oocyte or embryo biopsy with molecular cytogenetic analysis is still the preferred technique 
for PGS (Ottolini et al. 2014). 
All molecular cytogenetic techniques involving gametes and embryos require direct access to the 
nuclear material of the gametes or blastomeres themselves. This process is achieved for 
embryos and polar bodies by cell biopsy and inevitably results in the destruction of the cells 
involved. With this in mind, it is important that fertilisation or embryogenesis is not compromised 
and the biopsy procedure impacts minimally on developmental potential. 
Recent clinical trials and meta-analyses of cases have suggested no benefit, and in some cases 
worse IVF pregnancy outcomes following PGS; presumably the result of discard of normal 
embryos (diagnosed as abnormal – false positives), detrimental effects of the biopsy including 
reduction of cellular mass and excessive micromanipulation outside of the incubator 
(Mastenbroek et al. 2007; Twisk et al. 2008). These results have, however, been dismissed by 
many PGS practitioners due to questionable experimental design (Handyside & Thornhill 2007; 
Munné et al. 2007). Nevertheless, at the very least, these trials have reinforced the idea that 
embryo biopsy can only be justifiable when the benefit of the testing outweighs the cost to the 
embryo, since the ultimate aim of PGS is to identify chromosomally competent embryos without 





2.4. The Biopsy of Oocytes and Embryos for PGS 
Biopsy for PGS is currently a two-step micromanipulation process involving the penetration of the 
zona pellucida followed by the removal of one or more cells for chromosome analysis. Breaching 
the zona is now generally performed by laser ablation (as opposed to the original techniques 
involving acid Tyrode’s solution) as it has been shown, when used appropriately, to have no 
detrimental effects on embryo development in both animal and human studies (Montag et al. 
1998; Park et al. 1999; Han et al. 2003). Specialised micromanipulation pipettes are then used to 
separate the required cells from the oocyte or embryo. Theoretically, PGS can be accomplished 
at any developmental stage from the mature (MII) oocyte to the blastocyst stage. To date, 
however, only three discrete stages have been proposed for clinical use: (i) polar body (oocyte 
and/or zygote); (ii) cleavage stage (day 3 embryo); and (iii) blastocyst (day 5, 6 or 7 embryo). 
Each of these stages is biologically distinct, thus having different diagnostic limitations in terms of 
information to be gained and impact on embryo viability. A more complete technical overview and 
set of guidelines for the practice of embryo biopsy was a specific aim of this thesis and is given in 
the subsequent chapter. For context, however, the basic principles of the approach are given 
below. 
 
2.4.1. Polar Body Biopsy 
The removal of the first and/or second polar body (PB1/PB2) from a human oocyte should, 
theoretically, have no deleterious effect on subsequent embryo, foetal and infant development as 
neither is required for successful fertilisation or embryogenesis (Gianaroli 2000; Strom et al. 
2000). Biopsy and subsequent analysis of the first and second polar bodies allows the indirect 
interpretation of the chromosome complement of the corresponding oocyte, thereby allowing the 
detection of maternally derived aneuploidy in resulting embryos (Verlinsky et al. 1996). While 
biopsy of PB1 alone and a combined PB1 and PB2 strategy have been used clinically for PGS, it 
is becoming increasingly evident that PB1 alone has limited applicability to PGS, as only errors in 
MI can be detected and even MI chromatid segregation errors may not all be detected without 
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analysis of both polar bodies. Indeed, as much as 30% of aneuploidy of maternal origin will not be 
diagnosed if only PB1 is sampled (Handyside et al. 2011). It is therefore now becoming 
increasingly apparent that biopsy of both first and second polar body is essential for optimal 
detection of oocyte aneuploidy if used as an embryo selection tool. A further limitation is that 
cytogenetic analysis of either polar body does not allow the detection of aneuploidies of paternal 
origin nor aneuploidies arising after fertilisation in the embryo. 
The process of polar body biopsy is relatively labour intensive and may involve the 
micromanipulation of oocytes that ultimately do not develop into therapeutic quality embryos. 
Sometimes up to four manipulations – ICSI, PB1, PB2 and blastomere biopsy (as a reflexive test 
following test failure or an ambiguous PB result) – may be required. However, in experienced 
hands, even 3 independent biopsy manipulations appear to have no deleterious effect on 
development (Magli et al. 2004; Cieslak-Janzen et al. 2006). Although simultaneous removal of 
PB1 and PB2 is possible on day 1 of embryo development (Magli et al. 2011) there may be 
advantages to sequential biopsy where PB1 is removed on day 0 (day of insemination) followed 
by the removal of PB2 on day 1. This is to avoid any degeneration of PB1 leading to possible 
diagnostic failure, and also to allow for the distinction between polar bodies, thereby allowing 
accurate identification of errors in the first and second meiotic divisions. 
 
2.4.2. Cleavage Stage Embryo Biopsy 
Historically cleavage stage biopsy was the most widely practised form of embryo biopsy for PGS 
worldwide. This biopsy strategy is now becoming less popular however, due to its potential 
detrimental effect on embryo viability and the problem of mosaicism in human cleavage stage 
embryos (Scott et al. 2013; Taylor et al. 2014). A typical procedure for cleavage stage biopsy 
involves the removal of one or two blastomeres from an embryo on day 3 post-fertilisation – 
usually those of suitable quality with at least five cells having entered the third cleavage division. 
Although cleavage stage biopsy allows the detection of maternally and paternally derived 
aneuploidy as well as meiosis I, II and post-zygotic errors, they are considered as a uniform group 
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and not distinguishable from one another. One purpose of this thesis is to make a significant step 
towards rectifying this issue. Indeed, the main problem of PGS associated with cleavage stage 
biopsy is chromosomal mosaicism, that can result in an increased rate of false positive and 
negative results from single cell (or two cell) analysis (Figure 2.4). As mentioned above, however, 




Figure 2.4. Schematic representation of possible misdiagnosis following cleavage stage 
biopsy of a single cell (Ottolini et al. 2012). 
Some studies comparing undiagnosed cleavage-stage biopsied embryos and non-biopsied 
control embryos have shown a detrimental effect of biopsy on implantation (Cohen & Grifo 2007; 
Mastenbroek et al. 2007), most evident in embryos of suboptimal quality. Studies of animal 
models have also shown that the potential for the embryo to continue to develop and implant is 
progressively compromised the greater the proportion of the embryo is removed (Liu et al. 1993). 
While such evidence provides fuel for the argument against performing biopsy at early cleavage 
stages at all, evidence from frozen-thawed embryo transfers (as a proxy for biopsied embryos) in 
which successful implantations and live births can be achieved even following embryonic cell 
death demonstrates that a certain degree of cell loss is tolerated (Cohen et al. 2007). However, 
just as in the animal models, success is inversely correlated with the amount of cellular mass lost. 
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The successful application of cleavage stage biopsy minimising cell removal from good quality 
embryos shows it is compatible with normal embryo metabolism, blastocyst development and 
foetal growth (Hardy et al. 1990). Moreover, studies of pregnancies and children born after 
cleavage stage biopsy have identified no significant increase in abnormalities above the rate seen 
in routine IVF (Harper et al. 2006; Banerjee et al. 2008; Nekkebroeck et al. 2008). 
A general consensus therefore is that cleavage stage biopsy of one cell may reduce the 
implantation potential of an IVF embryo of around 10%, although this figure would inevitably 
increase in less experienced hands (Cohen & Grifo 2007). The challenge for any future 
application of cleavage stage biopsy PGS, therefore, is to ensure that any benefits outweigh 
these costs; and it remains a question whether this will be possible even with more accurate and 
reliable tests, given the high levels of mosaicism. 
 
2.4.3. Blastocyst Stage Biopsy 
Blastocyst biopsy involves the sampling of trophectoderm (TE) cells, the spherical outer epithelial 
monolayer of the blastocyst stage embryo. Just as at cleavage stage, TE biopsy is able to detect 
aneuploidy arising in either gamete or post-fertilisation. It is more akin to early prenatal diagnosis 
when compared to the other biopsy stages as it involves the removal of around 10 cells without 
depleting the inner cell mass from which the foetus is derived (discussed in more detail in Aim 1a 
of this thesis). TE biopsy is most commonly achieved by partial zona dissection followed by a 
period of culture, in which time the expansion of the blastocyst will cause herniation of several 
cells through the artificial breach. The herniating cells (~4-10 cells) are then easily removed by 
excision or aspiration using micromanipulation tools with or without the aid of a laser. Sampling of 
several cells at this stage lessens the effect of mosaicism on producing false positive results, also 
overcoming the limitations of extreme sensitivity apparent with conventional single cell diagnosis 
(discussed in more detail in Aim 1a of this thesis). 
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As with cleavage stage biopsy, it has been suggested that the removal of cells may negatively 
impact on the embryo’s developmental potential. However, skilled biopsy practitioners are able to 
remove trophectoderm cells and achieve comparable implantation rates to non-biopsied 
blastocyst stage embryos (Kokkali et al. 2007). It has also been proposed that sampling of the TE 
may not reflect the genetic composition of the inner cell mass (ICM) (Kalousek & Vekemans 
1996). However, recent data comparing TE to ICM suggests 100% concordance with the 
exception of structural abnormalities (Johnson et al. 2010a). 
Currently the main limitation of blastocyst biopsy is the low number of embryos that reach the 
blastocyst stage; a number that significantly decreases with advanced maternal age (Pantos et al. 
1999). If very few blastocysts are available, particularly in older patients, biopsy for selection 
purposes may be of no benefit. Also, time constraints at the blastocyst stage dictate, in many 
cases, the need to cryopreserve biopsied blastocysts awaiting diagnosis. Thus, the effect of 
cryopreservation and subsequent thawing on embryo viability must be taken into account. 
Nonetheless, improved culture techniques, possible vitrification and rapid molecular analysis 
regimes are making blastocyst biopsy an increasingly attractive option (Schoolcraft et al. 2010). 
 
2.5. Techniques Involved in PGS for Aneuploidy Screening 
2.5.1. The Rise and Fall of Fluorescence In-Situ Hybridisation (FISH) as a Diagnostic 
Tool for PGS 
Following embryo or oocyte biopsy, PGS requires cytogenetic techniques with high sensitivity and 
specificity to establish the chromosome composition of the embryo via the analysis of one or very 
few cells. Classic karyotyping techniques have proved unsuitable for preimplantation testing due 
to the difficulty of achieving good metaphase spreads with the limited cells available for testing 
(Angell et al. 1986; Papadopoulos et al. 1989). In 1993 the application of Fluorescent In-situ 
Hybridisation (FISH) for the single cell detection of the sex chromosomes in preimplantation 
embryos provided a springboard for aneuploidy detection, and clinical application of PGS soon 
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followed (Griffin et al. 1992; 1993; 1994). FISH is a highly sensitive, relatively inexpensive 
molecular cytogenetic tool enabling the determination of chromosome copy number at the single 
cell level. Its successful application rapidly led to the implementation of PGS as a clinical adjunct 
to IVF globally (Wilton 2002). To date, tens of thousands of PGS cases have been performed 
globally, attesting to its popularity (Verlinsky et al. 2004; De Rycke et al. 2015). Nonetheless, 
advances in technology are making FISH for PGS in oocytes and embryos a less attractive option 
due to a range of technical and biological considerations that are becoming increasingly apparent. 
These are summarised in Table 2.1. 
 
Table 2.1: Scope and Limitations of the Three Molecular Cytogenetic Techniques on 
Embryo Biopsy (Ottolini et al. 2012). 
 
 
2.5.2. The FISH Technique 
FISH requires the fixation of biopsied cells to a glass slide before visual analysis of hybridised 
fluorescent chromosome-specific DNA probes. That advantage to the observer of being able to 
view the presence of chromosome copy number directly is considerable. Technical problems, 
however, include the fact that FISH signals can overlap (making two signals appear as one, or 
three as two) or ‘split’ according to the stage of the cell cycle, making a single signal appear as 
two (Cohen et al. 2009). In the early days of clinical PGS up to five different fluorescent probes, 
attached to different chromosomes (typically 13, 16, 18, 21, 22 or 13, 18, 21 X and Y), were used. 
However, more recent studies analysing up to 12 chromosomes (X, Y, 2, 4, 13, 15, 16, 18, 19, 
parent of origin MI or MII
Fluorescence in situ 
hybridization (FISH)
5 to 12 low no yes no no no
Array comparative genomic 
hybridisation (aCGH)
24 high no no no no no
Single nucleotide 
polymorphism (SNP) array














20, 21 and 22) at the cleavage stage described detection of 91% of chromosomally abnormal 
embryos reaching the blastocyst stage (Munné et al. 2010). In this case, if the misdiagnosis rate 
of each probe averaged 1%, over the two rounds of hybridisation required, an accuracy of only 
88% per embryo could be achieved. The test’s ability to diagnose only 91% of aneuploid embryos 
compounded by the 12% misdiagnosis rate per embryo would result in only 80% efficiency of the 
test in its ability to diagnose aneuploidy per embryo. This would inevitably result in the transfer of 
aneuploid embryos (false negative) or the discarding of euploid embryos (false positive). It has 
been widely accepted that the efficiency of each probe is reduced in subsequent hybridisation 
rounds (Harrison et al. 2000); however, a 24 chromosome FISH assay has recently been applied 
to preimplantation human embryos with no apparent loss of signal, even after four rounds of 
hybridisation (Ioannou et al. 2011; 2012). This technique, albeit more comprehensive, is still 
prone to the other issues as described above and has not been validated clinically. 
The importance of low error rates on the diagnostic efficiency of PGS is strongly argued 
(Summers & Foland 2009; Munné et al. 2010), as is the need to detect all chromosomes 
simultaneously for aneuploidy. Notwithstanding the ability now to detect all 24 chromosomes by 
FISH, the issues of mosaicism, signal interpretation, clinical trial data and the development of 
microarray-based methods for detecting 24 chromosome copy number are now signalling the 
demise of FISH-based PGS approaches. Microarray-based tests are now becoming the standard 
and these have been made possible through the advancement of whole genome amplification 
(WGA) technology. 
 
2.5.3. Whole Genome Amplification (WGA) as a Prerequisite for Chromosome 
Analysis for PGS 
The introduction of WGA techniques has led to new, more efficient 24 chromosome molecular 
karyotyping tests. WGA brought with it the potential to increase the amount of cytogenetic 
information that can be obtained from a single nuclear genome contained in one cell. A single cell 
contains 6pg of DNA – far less than the 0.2-1.0µg usually required for microarray analysis – and 
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thus the need for amplification is paramount (Wells & Delhanty 2000). The process simply 
involves the transfer of the cell(s) to a microfuge tube followed by cell lysis prior to genome 
amplification, either by polymerase chain reaction-based methods or, more recently, multiple 
displacement amplification (MDA) to yield quantities of DNA in excess of 20µg from a single cell. 
These products can in turn be used for genome-wide analysis studies to establish chromosome 
copy number with impressive accuracy. One of the biggest drawbacks of single cell DNA 
amplification is a phenomenon known as allele dropout (ADO), where only one of the two alleles 
at a locus successfully amplify (Walsh et al. 1992; Findlay et al. 1995; Piyamongkol et al. 2003). 
This proved a limiting factor on the resolution and reliability of PGD for single gene disorders 
where individual gene sequences are analysed, but is less of an issue for array-based PGS 
where many probes along each chromosome are used (Ling et al. 2009). Further problems 
involving the extreme sensitivity of single cell analysis still exist in the form of failed or poor 
amplification. However, these failure rates can be maintained at less than 3% in experienced 
laboratories (Gutierrez-Mateo et al. 2011).  
 
2.5.4. Comparative Genomic Hybridisation (CGH) 
A detailed overview of array CGH including technical guidelines is a specific aim of this thesis and 
is thus given in a subsequent chapter. A general overview is given here, however, for contextual 
purposes.  
Originally designed for molecular karyotyping of tumour cells (Kallioniemi et al. 1992; Kallioniemi 
et al. 1993), comparative genomic hybridisation (CGH) has been successfully adapted for the 
analysis of human polar bodies and preimplantation embryonic cells (Voullaire et al. 2000; Wells 
et al. 2002). Originally a labour-intensive and time-consuming procedure involving hybridisation to 
and analysis of standard cytogenetic metaphase chromosome preparations, CGH was adapted 
for use in microarray technology, which allowed streamlining of the process. Recent successful 
applications of the technology have enabled array CGH (aCGH) to become the gold standard for 
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PGS and is the current platform of choice for all biopsy stages in the majority of laboratories 
around the world (Hellani et al. 2008; Alfarawati et al. 2011b; Harton et al. 2013). 
The process involves the separate labelling of the amplified DNA and normal reference sample 
using different fluorescent dyes followed by co-hybridisation to several thousand probes derived 
from known regions of the genome printed on a glass slide. Using quantitative image analysis, 
differences in the fluorescence ratio are interpreted to identify gained or lost regions along all 
chromosomes simultaneously, with an error rate of less than 2% (Gutierrez-Mateo et al. 2011). 
The main technical limitations of this process are: (i) that it does not supply information about 
chromosomal ploidy per se, only deviations from the most frequent level of the combined 
fluorescence signal; and (ii) the origin of the error is not determined. Thus haploid and polyploid 
embryos will appear diploid or ‘normal’ and meiotic errors are not distinguished from post-zygotic 
ones. Despite these limitations, aCGH is rapidly establishing itself as the ‘gold standard’ for PGS, 
replacing FISH-based approaches in most laboratories.  
 
2.5.5. Single Nucleotide Polymorphism (SNP) Arrays 
Single Nucleotide Polymorphisms (SNPs) are the most frequent form of DNA variation in the 
genome. To date over six million SNPs have been identified in the human genome (Javed & 
Mukesh 2010). SNPs are bi-allelic genetic markers that can be used in a variety of ways to detect 
chromosome copy number. SNP micro-arrays are used to detect the specific alleles present in 
polar bodies or embryos at up to 500,000 SNP loci. This information can, in turn, be interpreted in 
several ways to obtain massive amounts of genetic information. Simple quantification of the SNP 
alleles and analysis of heterozygosity enables diagnosis of aneuploidy including uniparental 
isodisomy (Northrop et al. 2010; Brezina et al. 2011; Treff et al. 2011). Using this method, results 
can be difficult to interpret above the level of background ‘noise’ due to the problem of 
amplification from a single or few cells. For this reason, methods involving comparison with 
parental DNA have been developed (Handyside et al. 2010; Johnson et al. 2010b; Gabriel et al. 
2011b). Since all embryonic chromosomes are derived from parental chromosomes, predicted 
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genotypes based on known parental data can be used to ‘clean’ noisy single cell data resulting in 
a comprehensive and highly reliable molecular cytogenetic test for chromosome copy number 
(Johnson et al. 2010b). In addition to this, again with the aid of the known parental genotypes, a 
test involving Mendelian inheritance analysis of SNPs known as ‘Karyomapping’ has been 
developed. By establishing the four parental haplotypes, only informative ‘key’ SNPs are 
analysed to establish chromosome copy number, parental origin and points of meiotic 
recombination of the tested cells can be ‘Karyomapped’ (Handyside et al. 2010). Karyomapping 
has the added advantage of being able to detect not only meiotic aneuploidy, but the presence of 
the chromosomes carrying the mutant allele for cases involving the risk of transmission of specific 
known inherited disorders. Karyomapping is a technique that is central to this thesis, and part of 
its development as both a clinical tool and a means of understanding chromosome segregation in 
humans is a core element.  
SNP genotyping has the potential to be the most comprehensive means for PGS. The 
interpretation of a SNP genotype allows diagnosis of all possible chromosome copy number 
aberrations. It has the capacity to perform as a high-resolution molecular cytogenetic test at 
higher resolution than aCGH for all types of chromosomal gains and losses, with the added ability 
of linkage-based analysis allowing diagnosis of inherited genetic disease (Handyside et al. 2010). 
Although largely clinically un-validated, comparative data with other platforms suggest better 
efficiency than both FISH and aCGH for aneuploidy screening (Johnson et al. 2010b; Treff et al. 
2010a; Treff et al. 2010b). Recently presented clinical data of SNP array-based PGS on cleavage 
stage embryos suggests significant improvement of pregnancy rates following embryo transfer 
(Rabinowitz et al. 2010). One purpose of this thesis is to establish that, with further clinical 
validation, SNP genotyping will become part of the gold standard for PGS in the near future. 
 
2.5.6. The Principles of Karyomapping: a technique for the simultaneous detection of 
single gene disorders and (the phase and parent of origin of) chromosome copy 
number abnormality  
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As mentioned previously, Karyomapping is a technique by which Mendelian principles are applied 
to SNP genotypes (genome-wide) to establish inheritance of chromosomes or parts of 
chromosomes through generations in the same family (Handyside et al. 2010). When applied to 
biopsied cells from preimplantation embryos this allows for: 1) detection of inherited diseases 
without patient specific test development; 2) detection of chromosomal aneuploidy or imbalance; 
3) determining the parental origin of aneuploidies; 4) determining the meiotic origin of any 
detected trisomic chromosomes; and 5) pinpointing of meiotic genetic recombination sites. 
The basic principles of Karyomapping are as follows: 
1. Identifying informative SNP loci for parental haplotypes. Informative SNPs are defined as 
any SNP locus at which one parent is homozygous and the other parent is heterozygous. 
The heterozygous SNPs are informative. The minor allele (the allele that is only present in 
the heterozygous parent) is considered the Key SNP allele. 
2. Identifying the genotype of an embryo at the predefined informative loci for both maternal 
and paternal SNPs. This is performed on WGA products of biopsied cells from the 
embryo. The embryo’s genotype will identify which parental haplotype (SNP) was 
inherited from the heterozygous parent. 
3. Using a reference genotype to establish phase. By comparing the embryo’s genotype to 
that of a close relative (usually either genomic DNA from a sibling or grandparent for 
highest resolution), phase can be established. Comparing the embryo’s genotype to a 
reference reveals which grandparental SNP (grandparental chromosome) was inherited 
in relation to the reference, unscrambling the haplotypes. By following the Key SNP allele, 
the SNP will either be the same or different to the reference and when successive loci are 
mapped it produces the Karyomap (Figure 2.5).  
4. Identifying points of meiotic recombination (or crossover) as a shift from one 
grandparental haplotype to another within a chromosome. Crossovers in the reference 
will appear in an embryo’s Karyomap as an inherent part of the process. If necessary, 
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these can be identified and removed; a technique that was developed as part of this 
thesis. This is discussed in detail in chapters 4 and 5. 
Currently Karyomapping has been optimised using MDA for WGA and the Illumina platform for 
SNP genotyping. However, these principles can be theoretically adapted to any platform that 




Figure 2.5. Schematic representation of the rules for Karyomapping. 
Paternal, maternal, reference and a single embryo’s SNP genotypes are displayed in sequence. 
Highlighted in pink are the heterozygous loci which enable the identification of the Key SNPs 
(where one parent is heterozygous) and the Key SNP allele (the allele that is present in only one 
of the four paternal haplotypes). By comparing the genotype of the embryo to the genotype of the 
reference at all informative loci the pattern of inheritance is established. The following rules apply: 
i) If the key SNP allele is present in both embryo and reference the parental haplotype (1) is 
allocated for the Karyomap (solid colour same as reference); ii) If the Key SNP allele is present in 
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the embryo but not the reference the parental haplotype (2) is allocated for the Karyomap (solid 
colour different to reference); iii) If the Key SNP allele is not present in the embryo but is present 
in the reference no parental haplotype is allocated for the Karyomap (grey). These loci are only 
considered semi-informative due to the relatively high potential of ADO of the Key SNP following 
WGA of single cells. 
 
2.6. What we Have Learnt from PGS Thus Far? 
It is estimated that 30% or more of even naturally conceived embryos contain the incorrect 
number of chromosomes (Hassold & Hunt 2001). PGS results indicate that this value may be 
significantly higher following assisted reproduction technology (ART) even in younger patients 
(Baart et al. 2006). Increased aneuploidy is especially evident in poor prognosis patients such as 
those with recurrent implantation failure (RIF) and recurrent miscarriage (RM) (Magli et al. 1998; 
Baart et al. 2006). Furthermore, early cytogenetic analysis also revealed evidence that reduced 
fecundity with advancing maternal age is, in part, due to increasing rates of aneuploidy (Munné et 
al. 1995). In these groups of patients the success rates of ART remains low despite significant 
advances in other patient groups (Figure 2.6). It was therefore hypothesised that if embryo ploidy 
could be determined and euploid embryos selected for embryo transfer, IVF pregnancy rates 
would increase and poor outcomes such as implantation failure and miscarriage would decrease. 
Few disagree with this premise, underpinning PGS as scientifically and clinically sound. 
Since its inception in the mid-1990s, PGS has primarily involved the biopsy of one or two cells on 
the third day of embryo development followed by targeted chromosome analysis using FISH. 
Subsequently, diagnosed euploid embryos (for the limited number of chromosomes analysed) 
were transferred or cryopreserved, with the remaining embryos diagnosed as aneuploid being 
discarded (with or without follow-up confirmation analysis). This work was based on the 
theoretical premise of PGS without the support of randomised controlled trials (RCTs). All recent 
RCTs using cleavage stage biopsy followed by FISH analysis showed no improvement in delivery 
rates after PGS, with some even suggesting adverse outcomes (Staessen et al. 2004; 
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Mastenbroek et al. 2007; Blockeel et al. 2008; Hardarson et al. 2008; Mersereau et al. 2008; 
Debrock et al. 2010). The largest of these trials included over 200 patients in each of the 
experimental arms (control and treatment groups) and concluded that PGS resulted in a reduced 
delivery rate following IVF (Mastenbroek et al. 2007). These results, contrary to the original 
premise of PGS, sparked much debate with several institutions, including the practice committees 
of the Society of Assisted Reproductive Technology and the American Society of Reproductive 
Medicine (SART & ASRM) (2008b) and the British Fertility Society (Anderson & Pickering 2008), 
issuing statements that PGS should no longer be performed. Meanwhile, several groups criticised 
the trials for their poor diagnostic efficiency, practical skill levels, inappropriate patient selection 
and generally low pregnancy rates. They claimed that the trials were performed by inexperienced 
practitioners, thereby generating invalid or questionable results (Cohen & Grifo 2007; Simpson 
2008). 
What is not in question is that these trials have ultimately highlighted the complexity of 
considerations PGS requires when applied clinically. FISH of cleavage stage biopsies has clearly 
outlined that both technical and practical limitations exist when performing PGS to improve 
pregnancy outcomes. Furthermore, there is great importance and careful consideration needed in 
patient selection as well as an effective test selection and implementation on a case-by-case 
basis (Handyside & Thornhill 2007). 
The success of aneuploidy screening as a selection tool for IVF to improve pregnancy rates is 
dependent on the efficacy of the entire testing process. It is now clear that FISH, especially for 
cleavage stage biopsy, is not the optimal tool for PGS. The process is subject to the following 
technical limitations: (i) the efficacy of the cell preparation technique; and (ii) the accuracy of the 
FISH test itself and its reliable interpretation. Biologically, we are constrained by the products we 
have to work with (embryo quality, mosaicism and nucleation) and the time in which to work with 
them. I believe that there is scope for PGS to improve pregnancy rates in ART, but the test used 
must be optimised and tailored to suit the biological and technical limitations that exist to 





2.7. Clinical Applications and Decision-Making 
Aneuploidy screening by PGS using 24 chromosome micro-array analyses should improve IVF 
outcomes with the implementation of case-by-case cost-benefit analysis. For best results, PGS 
should be performed with the most comprehensive cytogenetic platform available. Currently, PGS 
is still considered too invasive to be employed as a routine embryo selection tool for IVF; thus, at 
present, it should be offered only to patients at high risk of aneuploidy. The cost of the biopsy on 
embryo development is only justifiable if the information gained will outweigh the cost to the 
cohort of embryos as a whole. For this reason, false positive results due to mosaicism and the 
number of testable embryos in a cohort are important in the decision-making process. Advanced 
maternal age (AMA) is the single largest indication for PGS as an adjunct to embryo selection to 
improve IVF success. Careful patient selection is still required within this group of patients to 
achieve the best results (see Figure 2.6). There are a number of other indications for which PGS 
is likely to be of most benefit, all of which are associated with a potential increased risk of 
aneuploidy including patients with RIF and RM. Patients with diagnosed high levels of sperm 
aneuploidy or severe male factor infertility may also benefit.  
 
Figure 2.6. Three distinct patient groups in relation to age and IVF success rates 
(Ottolini et al. 2012). 
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Note the drop in success rates beyond maternal age 35 across all years (consistent with 
increasing rates of aneuploidy). High number of embryos and low rate of aneuploidy are 
expected in patient group under 35 years of age (1), thus PGS is not recommended as cost 
outweighs benefit of PGD. Moderate embryo numbers and increased rate of aneuploidy 
consistent with reduced IVF success rates of patients above 35 years (2) indicate a target 
group for PGS, so benefit of PGS outweighs its cost. PGS is suggested to be of no benefit 
for embryo selection in patients of severe AMA due to low number of embryos and high rate 
of aneuploidy (3), so cost outweighs benefit of PGD. Figure adapted from Human 
Fertilisation and Embryology Authority website (HFEA) (2008a) http://www.hfea.gov.uk  
Biopsy is generally performed at three discrete developmental stages (PB, cleavage and 
blastocyst stage), each of which has distinct diagnostic advantages and limitations. 
Information gained at each developmental stage of the biopsy is critical, and specific 
strategies for PGS should be employed for different combinations of indication factors rather 
than a one-size-fits-all approach (Table 2.2). 
PB biopsy theoretically has the lowest cost to embryo development but only gives information 
about maternally derived aneuploidy. PB biopsy is therefore of most benefit to patients of AMA 
with no other suspected aneuploidy input. Both PB1 and PB2 should be sampled to ensure that 
the majority of maternally aneuploidy is detected (Geraedts et al. 2011). 
Theoretically, blastocyst stage biopsy is the optimal stage as it partially negates the problem of 
mosaicism and gives maximum aneuploidy information from maternal, paternal and post-zygotic 
events. In addition, the biopsy of 5-10 cells virtually eliminates the problem of ADO following 
WGA (Ling et al. 2009). However, the logistical downside is that embryos may need 
cryopreservation whist awaiting genetics results, a potential additional ‘cost’ to embryos. 
Furthermore, blastocyst development may be limited in some patients, leading to a limited cohort 
of blastocysts that can be biopsied simultaneously, reducing the chance of a live birth and genetic 
information from the cohort (Janny & Menezo 1996). Thus it should only be considered for 
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patients with RIF and RM, including male factor, with evidence of good blastocyst formation or 
proven fertility. 
The inherent problem of mosaicism and false positive results is a major problem for biopsy at the 
cleavage stage. This, paired with the cost of removing a significant amount of the cell mass (up to 
25%), suggests that use of cleavage stage biopsy should be limited to cases of male factor 
aneuploidy with known poor ability for blastocyst development. Removal of only a single cell is 
recommended to minimise cost to the embryo and prevent the dilemma of discordant results due 
to mosaicism (Cohen et al. 2007). Cleavage stage biopsy may also be considered as follow-up 




Table 2.2: Technical Limitations, Costs and Benefits of the Established Biopsy Stages for 
PGD-AS (Ottolini et al. 2012) 
 
Biopsy, irrespective of stage, should only be performed if there are a sufficient number of oocytes 
or embryos to be tested. If there is limited or no embryo selection to be achieved by PGS then it 
(PGS) should be avoided, as there will be no benefit to IVF success rates and may even be a 
detrimental effect (Summers & Foland 2009). An exception to this is when PGS is used not as an 
embryo selection tool but as a diagnostic tool to avoid or diagnose aneuploidy. Some patients 
may require elimination of the possibility of aneuploidy resulting in poor outcomes such as 
miscarriage or birth of a child with a genetic defect. These ‘must screen’ patients for PGS should 
be considered a more likely diagnosis of inherited genetic disease and all embryos, irrespective of 
the number and quality, should be tested. 
 
2.8. Specific Aims of the Thesis 
Since the introduction of molecular cytogenetics into the field of human preimplantation embryos 
a wealth of information has been gathered on the incidence, origin and aetiology of aneuploidy. It 
is now well documented when and how extra or missing chromosomes arise but the big question 
remains ‘why’. Research into the origin of human aneuploidy is clearly much needed and will 
MI MII MI MII
PB1 yes no no no no no
Day 0                
(day of fertilisation)
Minimal manpulations.                              
No removal of viable cells.                           
Maximum time for analysis prior to 
embryo transfer.
Only information from maternal MI.
PB1 & PB2 yes yes no no no no Day 0 and 1
No removal of viable cells.                       
Maximum time for analysis prior to 
embryo transfer.




yes yes yes yes yes
no                       
(Yes with limited 
sensitivity if >1 cell 
analysed)
Day 3
Information for all origin of 
aneuploidy.                                        
Maximise number of embryos tested.       
Paternal aneuploidy detected.                   
Mosaicism resulting in false positive 
and negative results.                                        




yes yes yes yes yes
yes                    
(only with limitation 
on sensitivity)
Days 5 and 6
Information for all origin of 
aneuploidy.                                                                              
Biopsy of several cells (~10 cells).              
No harm to ICM.                                                
Paternal aneuploidy detected.
Reduced number of embryos for 
testing (requires good blastocyst 
formation).                                                         
Reduced time for diagnosis (embryo 
cryopreservation potentially nececary).                  
Maternal Paternal









continue to provide new and exciting insights in the field. The primary purpose of this thesis is to 
help provide such insight. The introduction of new array technology, including SNP genotyping 
Karyomapping, will further improve PGS strategies and a further aim of this thesis is to bring 
these techniques to full clinical application. 
Along with advanced maternal age, altered recombination in meiosis is the most important known 
aetiology related to aneuploidy and gives clues to the overall mechanism (Hassold et al. 2007). 
Algorithms applied to SNP genotyping data, including Karyomapping, can be applied for high 
resolution pinpointing of recombination points (Handyside et al. 2010; Gabriel et al. 2011a) and in 
this thesis I will explore this role further. Patterns of recombination across the genome can be 
correlated with chromosome mal-segregation in meiosis in an attempt to find aberrant patterns 
that predispose to aneuploidy. Similar strategies can be employed to different patient profiles to 
ascertain further aetiologies associated with aneuploidies of different origin. Further 
understanding of the predisposition to human aneuploidy may ultimately therefore lead to specific 
patient treatment, and more importantly guide the direction of studies on the molecular basis of 
aneuploidy. Once the mechanisms leading to aneuploidy are understood and there is an 
understanding of why it occurs, interventions to prevent aneuploidy could be usefully investigated. 
Both scientific and clinical advance, however, require novel and robust tools and with this in mind, 
the specific aims of this thesis were as follows: 
1. To review the literature, produce and publish a state of the art standard set of 
protocols as a general reference work from practitioners in the fields of: 
a. Embryo Biopsy; 
b. Array CGH. 
2. To produce the first clinical cases to bring Karyomapping to full medical application, 
comparing it to ‘gold standard’ approaches and demonstrating how a linkage-based 
analysis of SNP karyotypes can be used simultaneously to detect monogenic 
disorders and (phase and parent of origin of) chromosome copy number: 
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a. For a couple at risk of transmitting Marfan syndrome; 
b. For a couple at risk of transmitting Smith Lemli Opitz syndrome (in this case 
comparing array CGH (polar body) and Karyomapping (embryo) data. 
3. To apply Karyomapping to demonstrate its clinical utility as a genome-wide ‘chromosome 
fingerprint’ in a clinical setting. 
4. To investigate the use of a calcium ionophore protocol to activate human oocytes, 
ultimately to investigate the incidence of chromosomal aneuploidy in the activated 
oocytes using array CGH and Karyomapping: 
a. To induce the resumption of the second meiotic division of mature (MII 
arrested) human oocytes; 
b. To demonstrate patterns of pronuclear formation and polar body extrusion;  
c. To discuss the clinical implications of the observed activation patterns. 
5. To develop an algorithm based on Karyomapping (termed MeioMapping) to 
investigate the mechanisms of human female meiosis (using the calcium ionophore 
protocol above) by recovering of all three products of human female meiosis from 
individual oocytes (termed Trios) to allow exploration of the full extent of meiotic 
chromosome recombination and segregation that occurs in the female germline.  
6. To combine the techniques developed above and use both Karyomapping and 
MeioMapping to explore the full extent of meiotic chromosome recombination and 
segregation that occurs in the human oocyte: 
a. To provide new insight into meiotic segregation patterns in humans; 
b. To confirm the existence of a previously undescribed pattern of meiotic 
segregation (herein termed Reverse Segregation), a phenomenon that was 
observed in the pilot data and work performed in specific aim 5; 
c. To test the hypothesis that there is selection for higher recombination rates in 
the female germline; 
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d. To test the hypothesis that there is an association between recombination 
rates and chromosome mis-segregation (aneuploidy); 
e. To test the hypothesis that there is a role for meiotic drive for recombinant 
chromatids at meiosis II in human female meiosis. 
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3. Specific Aim 1a. To review the literature, produce and publish a state of the 
art standard set of protocols as a general reference work from practitioners in 
the fields of Embryo Biopsy  
This is an adaptation of the book chapter entitled ‘Human Embryo Biopsy Procedures’ by Alan R 
Thornhill, Christian Ottolini and Alan H Handyside, published in The Textbook of Assisted 
Reproductive Techniques, Volume 1: Laboratory perspectives Fourth Edition (2012). 
 
3.1. My Personal Contribution to the Work 
I was involved in the research, writing and editing of the published review chapter above. What 
follows is an adaptation of the published manuscript. 
  
3.2. Introduction 
In the mid-1980s, the development of polymerase chain reaction (PCR) strategies for 
amplification of specific fragments of DNA from single cells (Li et al. 1988; Coutelle et al. 1989; 
Holding & Monk 1989) facilitated preimplantation genetic diagnosis (PGD) of inherited disease 
using one or more cells biopsied from embryos at preimplantation stages after in vitro fertilisation 
(IVF) (Handyside & Delhanty 1997). As discussed in the General Introduction of this thesis, 
currently genetic analysis of embryos (or PGD) requires the removal of one or more cells from 
each embryo, making embryo biopsy comparable to amniocentesis or chorionic villus sample 
(CVS) at foetal stages, since the primary aim is the removal of sufficient embryonic tissue to allow 
diagnosis. Embryo biopsy is a two-step micromanipulation process involving the penetration or 
removal of part of the zona pellucida surrounding the oocyte or embryo, followed by removal of 
one or more cells. Theoretically, this can be accomplished at any developmental stage between 
the mature oocyte and blastocyst, but to date only three discrete stages have been proposed: 
polar body; cleavage stage; and blastocyst. Clearly, each of these stages is biologically different 
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and thus the strategic considerations have both advantages and disadvantages (Table 3.1). 
Furthermore, the different biopsy strategies both between and within developmental stages 
require different technical approaches (Table 3.2) each providing varying prospects of success. 
Many of the biopsy techniques currently in use for human embryos (Tarin & Handyside 1993) 
were pioneered in animal models, notably the mouse (Monk et al. 1988; Wilton et al. 1989), rabbit 
(Yand & Foot 1987), cow (Ozil 1983) and marmoset (Summers et al. 1988). While the total 
number of human embryos biopsied in clinical cases is vast, relatively little work has been 
published to define the relative merits of different biopsy methods and their safety and efficacy in 
clinical application. This chapter will describe the three stages of biopsy (polar body, cleavage 
stage [blastomere] and blastocyst [trophectoderm]) which have been used in routine clinical 
practice (Harper et al. 2012). 
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Table 3.2: Embryo Biopsy Methods – Benefits, Limitations and Factors Critical to Success (Thornhill, Ottolini & Handyside 2012) 
Zona penetration method Benefits Limitations Factors critical to success
Mechanical Least invasive to embryo (safer) Steep learning curve Operator skill and speed
Inexpensive, portable technique Operator dependent Appropriate microtools needed
Improved survival after freeze-thaw? Time consuming Double tool holder optimal
Chemical (acidified tyrodes) Relatively inexpensive Operator dependent Acidified tyrodes pH 2.2-2.4
Widespread clinical use Effect on cryopreservation Sensitive control of acid flow
Portable technique Difficult to limit aperture size Rinsing acid from embryos
Double tool holder optimal
Laser (1.48 µm non-contact) Rapid and Reproducible Cost (30-60,000 US dollars) Laser alignment and calibration
Simple to use Not all systems portable Pulse number, location & duration 
Integrated archiving/analysis software Invisible thermal damage/stress Distance between laser and zona
Appropriate training and validation
Cell removal method
Cleavage stage blastomere biopsy
Aspiration Ability to select a specific cell for analysis Cell lysis during aspiration Appropriate microtools needed
Sensitive suction device needed
Fluid displacement No contact between pipette and cells Limited ability to select cell Operator skill essential
Rapid
Mechanical displacement No contact between pipette and cells Limited ability to select cell Operator skill essential
Rapid Damage to non-biopsied cells
Trophectoderm sampling
Spontaneous hatching/herniation Non-invasive (cells undisturbed within zona) No control over timing/cell numbers High blastocyst development rate
Time for analysis very limited Hatching blastocyst in vitro
Asynchronous development/hatching
Zona penetration + herniation or Pre-empts spontaneous hatching As above
Stitch and pull or Rapid/some control over cells sampled  Biopsied/non-biopsied cell damage Operator skill essential
aspiration/laser ablation Rapid/some control over cells sampled  Biopsied/non-biopsied cell damage Operator skill essential
Zona ablation and immediate aspiration Blastocysts biopsied at optimal stages Laser damage may reduce diagnostic reliability of sampled cellsOperator skill es ential
with laser dissocaition of sampled cells Control over hatching site (away from ICM)
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3.3. Penetration of the Zona Pellucida 
Until the advent of noncontact lasers for use in micromanipulation (see below), two basic 
methods were employed for penetrating the zona. Both of these were pursued initially as a 
means to enhance fertilisation rates with oligozoospermic men, and have now been overtaken for 
this purpose by the use of intracytoplasmic sperm injection (ICSI). 
The first approach, partial zona dissection (PZD), involves using a fine needle to penetrate 
through the zona and, avoiding damage to the oocyte or embryo, penetrating out through the 
zona again at a distance around the circumference (Cohen et al. 1989). The embryo can then be 
detached from the holding pipette as it is effectively held on the needle, and a gentle rubbing 
action against the side of the holding pipette used to make a slit between the two apertures 
generated by the needle. Although a narrow-diameter micro-pipette can be pushed through such 
a slit, it is difficult to use one large enough to aspirate cleavage-stage blastomeres and, with the 
human embryo pressure on the zona, can lead to lysis of blastomeres and/or, where a slit has 
been made, force blastomeres out through the slit. The latter approach is used for embryo biopsy 
in some centres, but requires highly skilled micromanipulation, can be difficult to control, does not 
allow precise selection of blastomeres, and the risk of lysis can be high. A modification is to make 
two slits to create a ‘flap’ or ‘cross’ in the zona that can be flipped open, allowing more flexibility in 
the size of the opening created. This method is effective for both polar body and blastomere 
biopsy (Cieslak et al. 1999). 
In general, mechanical methods for zona penetration are time-consuming and require skilful 
micromanipulation, possibly making them inaccessible to some IVF laboratories. As an 
alternative, zona drilling using acidified Tyrode’s solution (pH 2.2-2.4) to dissolve the zona 
glycoproteins has been extensively used and is commercially available from most culture medium 
manufacturers. Again, this method was developed in the mouse embryo model, as a possible 
means to improve fertilisation rates with low sperm densities (Gordon & Talansky 1986). 
However, its use with human oocytes, while increasing the incidence of fertilisation, arrested the 
further development of the zygote, presumably consequent to changes in intracellular pH (Malter 
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& Cohen 1989). With zona drilling, the effect of the acid Tyrode’s is localised to a small area of 
the zona using a fine micro-pipette, with an inner diameter of 5-10μm. The micro-pipette filled with 
acid Tyrode’s is brought into direct contact with the zona at the appropriate position, and a 
combination of slight pulling away and ‘stroking’ movements, used to control the flow of acid and 
the area to be drilled respectively. Medium pH was originally maintained by employing phosphate 
buffered saline, but is now routinely maintained using modified culture medium buffered with 
either 4-Morpholinopropanesulphonic acid (MOPS) or 4-(2-hydroxyethyl)-1-piperazine-
ethanesulfonic acid (HEPES). When the drilling is complete the micro-pipette is immediately 
withdrawn.  
The shift across centres worldwide from zona drilling using acid Tyrode’s (Geraedts et al. 1999) to 
laser ablation of the zona pellucida has been dramatic. Indeed, according to a survey of PGD 
centres, the laser has overtaken acidified Tyrode’s solution as the most popular form of zona 
ablation accounting for more than 70% cleavage stage embryo biopsies (Harper et al. 2012). This 
shift may be more to do with ease of use and the elimination of the need for a double tool holder, 
rather than any measurable improvement in safety or efficacy. 
The preferred model of laser is the near infrared (NIR) solid state compact diode 1.48m laser. 
The advantage of using light as a cutting tool is that it obviates the need for disposable or 
reusable cutting tools, it is extremely precise and, if used appropriately, provides consistent, 
repeatable and rapid results. Moreover, since neither microtools nor reagents are required to 
dissect the zona, the opportunity for introducing contamination or pH changes in the medium 
surrounding the embryo is greatly reduced. The 1.48m diode laser is small but at the appropriate 
pulse duration can emit light at power levels sufficient to cause selective thermal disruption of the 
zona pellucida glycoproteins and is not absorbed by water. This non-contact laser can be inserted 
into the body of the microscope on which the manipulations take place or be integrated in a 
special objective and the beam delivered to the target through the dish. Since the laser beam 
travels up through an objective that lies below the sample, localised heating causes denaturation 
of the zona proteins in a cylindrical spot where the laser beam is focused; the size of the aperture 
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created is controlled by adjusting the duration of the laser pulse. The thermal energy created 
produces a groove in the zona perpendicular to the microscope stage, rather than a circular 
aperture. However, an ‘aperture’ is produced in the zona at the point at which the zona is 
perpendicular to the microscope stage. The size of the aperture (or more accurately the width of 
the groove at its widest point) created in the zona ranges from 5 to 20m and is governed by the 
pulse irradiation time (ranging from 3 to 100 milliseconds) or the accumulation of pulses along the 
length of the zona margin. The precision of the laser is illustrated by the fact that drilled mouse 
and human embryos show no sign of extraneous thermal damage under light or scanning 
microscopy (Germond et al. 1995).  
Most clinics use this equipment for assisted hatching as well as PGD (Boada et al. 1998) and 
there appears to be no detrimental effect of the laser itself on development to the blastocyst stage 
or pregnancy rates in animal and human studies (Montag & Van der Ven 1999; Montag et al. 
1998; Park et al. 1999; Han et al. 2003; Joris et al. 2003). However, studies of the immediate 
effects at the blastomere level in a mouse model have shown that the laser can cause damage if 
used inappropriately (Chatzimeletiou et al. 2001). Certainly, if the laser beam is fired in an area in 
direct contact with a blastomere, its viability is always compromised. However, as the pulse length 
and therefore localised heating is increased, the distance between the laser beam and 
blastomere required to avoid damage increases. Hence, care is required to drill the zona away 
from underlying blastomeres and from as far away as possible, and also to use minimum pulse 
lengths to restrict any damaging effects. Several practical guidelines have emerged to ensure 
safe and effective use of the laser for human embryo biopsy as follows. Wherever possible, a 
single aperture for cellular aspiration – double or multiple apertures may cause problems during 
embryo hatching as the embryo will attempt to hatch out of multiple openings which could 
compromise further inner cell mass development or lead to increased monozygotic twinning rate. 
To generate the desired aperture it is preferable to use several pulses of short duration rather 
than a single pulse of long duration and higher energy that could cause thermal damage. During 
laser use, it is imperative to maintain the oocyte or embryo as close to the bottom of the biopsy 
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dish as possible to allow a focussed beam to ablate the zona pellucida. As the embryo is raised 
above the dish surface the beam energy is diffused and can create localised heating or simply 
prevent effective ablation of the zona.  
 
3.4. Polar Body Biopsy 
Neither the first nor second polar body is required for successful fertilisation or normal embryonic 
development. Thus removal of either the first or second polar body or both for the purposes of 
genetic diagnosis should have no deleterious effect per se on the developing embryo. Originally, 
it was suggested that biopsy and genetic analysis of the first polar body would allow PGD of 
maternal defects prior to conception (Verlinsky et al. 1990). Apart from some arguable practical 
advantages (see below), this concept was also attractive as it involves manipulation of only the 
human egg and not the fertilised embryo, and would therefore be more acceptable to those with 
moral or ethical objections to screening embryos; as is the legal situation in some European 
countries including Switzerland (Corveleyn et al. 2008). For preconception diagnosis, either the 
first polar body alone or both the first and second polar bodies may be biopsied to provide genetic 
information relating to a particular embryo. Initially preconception diagnosis focussed on the 
former approach. However, biopsy of the first polar body has limited applicability for PGD for a 
number of reasons. The process of polar body biopsy is relatively labour-intensive and may 
involve the micromanipulation of oocytes that ultimately do not develop into therapeutic quality 
embryos. The procedure only allows the detection of maternal genetic defects and crossing over 
of homologous chromosomes during meiosis I can prevent identification of the maternal allele 
remaining in the oocyte, leading to a reduction in the number of embryos available for transfer 
(Dreesen et al. 1995). Also there is only the possibility of a single cell for analysis leading to a 
lower overall reliability (in contrast to cleavage stage biopsy in which two cells may be taken for 
independent analysis). As a consequence, it was suggested that more misdiagnoses would result 
from polar body analyses when compared with blastomere analysis (Navidi & Amheim 1991) and, 
to overcome these disadvantages, both the first and second polar bodies were removed for 
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analysis (Verlinsky et al. 1997) after first assessing the safety of removing the second polar body 
in a mouse model (Kaplan et al. 1995). This approach has been successfully applied to PGD for 
the detection of a large number and variety of different single gene disorders, chromosomal 
aneuploidies and maternal chromosome translocations (Verlinsky et al. 2004).  
The first polar body can be removed from the oocyte on the day of the oocyte collection between 
36 and 42 hours post-human Chorionic Gonadotrophin (hCG) injection as long as the oocyte has 
entered metaphase II and fully extruded the first polar body (Verlinsky et al. 1990). To perform 
polar body biopsy by mechanical means, a holding pipette and a bevelled micro-pipette (12-15m 
in diameter) are needed. The oocyte is held in place with the polar body at the 12 o’clock position. 
The bevelled micro-pipette is passed through the zona and into the perivitelline space tangentially 
towards the polar body. The polar body may then be aspirated into the pipette. Alternatively, after 
mechanical zona dissection to form a flap or cross or laser ablation, an aspiration micro-pipette is 
introduced into the perivitelline space, and the polar body removed. If the polar body is still 
attached to the ooplasm, further incubation may be required to permit complete extrusion 
(Verlinsky et al. 1990). Most approaches to polar body biopsy have adopted mechanical or laser 
techniques rather than chemical methods. While live offspring resulted after treating the zona 
pellucida of mouse oocytes with acidified Tyrode’s solution, studies using human oocytes showed 
that, despite fertilisation, there was an inhibitory effect on embryonic development (Malter & 
Cohen 1989) due to a direct effect of acid on the oocyte spindle; possibly as a result of the 
difference in thickness of the human and mouse zona pellucida. 
The first and second polar body can be removed simultaneously (Verlinsky et al. 1997) from the 
zygote between 18 and 22hrs post-insemination but the first polar body may have degenerated 
by this time, leading to possible diagnostic failure and in turn leading practitioners to aim for much 
earlier simultaneous biopsy at eight to nine hours post-ICSI (Magli et al. 2011). Simultaneous 
biopsy of the two polar bodies is acceptable for Fluorescent In-situ Hybridisation (FISH) analysis 
since they can provide distinguishable results (Verlinsky et al. 1998). Moreover, the polar bodies 
are morphologically distinguishable: the first polar body tends to have a crinkled surface and may 
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fragment; the second polar body is generally smooth and may have a visible interphase nucleus 
under interference contrast. However, sequential biopsy of polar bodies, where the first polar 
body is removed on day zero and the second polar body on day one, is recommended for PCR 
analysis to determine recombination events between the first and second polar body. In addition 
to the obvious advantages of not damaging the embryo and allowing a maximum time for genetic 
analysis, at a technical level, analysis of both polar bodies allows detection of allele drop-out 
(ADO). ADO is the random amplification failure of one parental allele after PCR from single cells 
(Ray et al. 1996), and is therefore a significant source of potential error in PGD. Despite the 
removal of both polar bodies, in many cases, cleavage stage biopsy may also be required to 
confirm the polar body diagnosis. 
Despite the large number of cycles reported using polar body biopsy and analysis, relatively few 
centres have used the approach. This may be due to a number of factors. First, the approach can 
only be applied to maternally inherited diseases. Second, diseases that are detected by 
assessing changes in gene product (Eldadah et al. 1995) would not be candidates for this 
approach. Third, polar body biopsy cannot be used for gender determination. Finally, biopsy of 
both the first and second polar bodies is required for optimal diagnostic efficiency and although 
this can be achieved by either sequential or simultaneous biopsy with successful results, it is 
labour intensive and may involve oocytes and zygotes that, ultimately, do not develop into 
therapeutic quality embryos. If polar bodies are sampled sequentially and cleavage stage 
blastomere confirmation is required, three independent manipulations are required with the 
possibility of ICSI in between (for PCR-based cases), making a total of four manipulations on the 
same oocyte and embryo. However, in experienced hands, the three independent biopsy 
manipulations appear to have no deleterious effect on development (Magli et al. 2004; Cieslak-






3.5. Cleavage-Stage Embryo Biopsy 
The first PGD cycles were carried out in late 1989 in a series of couples at risk of X-linked 
disease and involved cleavage stage embryo biopsy (Handyside et al. 1990). Cleavage-stage 
biopsy has remained the most widely practised form of embryo biopsy worldwide (according to 
ESHRE PGD Consortium accounting for around 90% of all reported PGD cycles) (Harper et al. 
2012). However, there have been a number of modifications and improvements since 1989. In 
the first cases, a tapered micro-pipette with a narrow lumen (internal diameter 5-7m) containing 
acidified Tyrode’s solution (pH2.2-2.4) was used to drill relatively large apertures (20-30m) in the 
zona. The pipette is placed close to the zona pellucida and the acidified solution gently expelled 
from the pipette until the zona thins and an aperture is drilled (in some cases, the zona can be 
seen to ‘pop’ as an aperture is made). The flow can be controlled via an oil-filled syringe 
(hydraulic), air-filled syringe (pneumatic) or by using a mouth pipette. The human zona is 
bilayered and the zona drilling process must be carefully monitored as the outer layer dissolves 
more rapidly than the inner layer. Moreover, there is great variation in zonae pellucidae both 
between and within cohorts of human oocytes and embryos. The final diameter of the aperture 
made will be determined by a combination of the above factors. An excessively large aperture 
may result in the unwanted loss of blastomeres but, more significantly, may indicate that the 
blastomeres were exposed to potentially damaging quantities of acid that could compromise 
further development. A second micro-pipette, filled with biopsy medium and held in a double 
holder alongside the acid Tyrode’s pipette, can be used to aspirate single cells (Hardy et al. 1990; 
Ao & Handyside 1995; Handyside & Thornhill 1998). It is possible to use a single micro-pipette for 
both drilling and aspiration, but care is needed to prevent over-exposure to acid (Inzunza et al. 
1998; Levinson et al. 1992). Any advantage accrued in terms of speed of the procedure may be 
offset by potential damage as a result of over-exposure to acid.  
Cleavage stage biopsy using laser and blastomere aspiration is typically performed as follows: 
briefly, following laser ablation of the zona pellucida adjacent to the blastomere selected for 
analysis, the blastomere is aspirated by gentle suction using a polished pipette. The aperture may 
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be sited adjacent to either a selected blastomere or a sub-zonal space between blastomeres. A 
finely polished ‘sampling’ pipette (internal diameter of 30-40m depending on the cell size) is 
used to aspirate the blastomere. The pipette is placed through the aperture, close to the 
blastomere to be aspirated. By gentle suction, the blastomere is drawn into the pipette whilst the 
pipette is withdrawn from the aperture. The aperture of the sampling pipette is critical for 
successful biopsy. If the internal diameter is too large for the cell being removed, the pipette will 
have little purchase on that cell and may result in unwanted suction on non-biopsied cells. 
Conversely, an undersized pipette will cause the biopsied cell to be squeezed unnecessarily, 
resulting in blebbing on the cell membrane and ultimately lysis, which will likely reduce the 
chances of a successful diagnosis in that embryo. Similarly, use of a holding pipette with an 
internal diameter of 30μm (i.e. larger than a regular ICSI holding pipette) ensures safe and 
reliable suction on the zona, particularly during difficult biopsies. 
Once the blastomere is free of the embryo, it is gently expelled from the sampling pipette. 
Following biopsy the embryo should be rinsed in culture medium at least twice to remove residual 
embryo biopsy medium and acid Tyrode’s (if applicable) before returning to culture. The 
blastomere should be washed extensively in handling medium before proceeding to the analysis. 
The most frequently used method of blastomere removal is aspiration, but other methods have 
been described and used clinically; although no studies have been conducted to compare their 
relative safety and efficacy. 
In the extrusion method, after zona pellucida drilling the blastomere is extruded through the 
aperture by pushing against the zona at another site (usually at 90 degrees to the aperture) using 
a blunt pipette (Levinson et al. 1992). The slit in the zona pellucida can be introduced using 
mechanical means, chemical (acid Tyrode’s) exposure or laser ablation.  
Another variation in the method of cell removal involves fluid displacement whereby culture 
medium surrounding the embryo is used to displace individual cells following a zona breach. This 
method was pioneered in mouse embryos by introducing a slit in the zona with a sharpened 
needle and, through a second puncture site, injecting medium to dislodge the blastomere through 
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the first puncture site (Roudebush et al. 1990). This method requires the production of two 
separate apertures and considerable skill to displace the blastomere of choice, but has since 
been modified for clinical application (Pierce et al. 1997). Challenges common to both of these 
methods arise when ensuring the selected cell is removed and the difficulties encountered when 
two different cells are required for analysis.  
 
3.5.1. Practical Considerations for Embryo Biopsy 
3.5.1.1. Preparation Before Biopsy 
ICSI is recommended for all PCR cases to reduce the chance of paternal contamination from 
extraneous sperm attached to the zona pellucida or non-decondensed sperm within blastomeres. 
Similarly, all cumulus cells should be removed before biopsy as these cells can contaminate both 
FISH and PCR diagnosis. Embryo and blastomere identity (individual drops or dishes) should be 
checked throughout the procedure so that diagnostic results can be reliably linked to specific 
embryos (Thornhill et al. 2005; Preimplantation Genetic Diagnosis International Society 2008). 
The use of standard IVF culture medium during biopsy is acceptable but its effectiveness may be 
highly dependent upon the developmental stage of the embryo biopsied. Commercially produced 
calcium- and magnesium-free (Ca2+/Mg2+-free) medium is widely available and is used by many 
centres for routine clinical cleavage-stage biopsy, with the benefit of reducing the frequency of cell 
lysis (Thornhill et al. 2005) combined with a shorter time needed to perform the biopsy procedure. 
 
3.5.1.2. Timing of Biopsy 
Since the first clinical application of PGD, culture media have been improved and optimised and 
the new generation of media are designed, tested and manufactured to high-quality control 
standards specifically for clinical use. Although embryos developed to the blastocyst stage, 
pregnancy rates after transfer were very low and, importantly for embryo biopsy, most embryos 
did not appear to compact. With the newer media, compaction on day three is much more 
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pronounced, which has necessitated the use of Ca2+/Mg2+-free medium to reverse the initial 
calcium-dependent adhesion (Dumoulin et al. 1998). The use of Ca2+/Mg2+-free medium also 
facilitates later biopsy (i.e. beyond 8-cell stage), making the timings more flexible. 
Most cleavage stage biopsy takes place on the third morning following insemination, although the 
exact timing varies according to timings of procedures in different laboratories.  One 
variation is to alter the timing of ICSI to allow cleavage stage biopsy at the same embryonic stage, 
but late on day two (biopsy at earlier cleavage stages on day two may adversely affect embryo 
development) (Tarin et al. 1992) allowing more time for genetic analysis. In cases where retarded 
development is observed, the possibility of delaying the biopsy procedure to allow diagnosis of a 
larger proportion of the embryo cohort should be considered. Furthermore, as a result of 
increased use of sequential media and experience with blastocyst culture and transfer, most 
groups routinely delay transfer until day four or five, allowing more time for analysis and with the 
additional aim of improving pregnancy and implantation rates, because developing embryos that 
have undergone further cleavage divisions following biopsy can be preferentially selected for 
transfer. 
Most laboratories exclude very poor quality embryos or those not reaching a predefined cell stage 
from the embryo biopsy procedure. Of centres surveyed, most will consider only embryos at the 
five-cell stage and beyond only for biopsy (Geraedts et al. 1999). Biopsy at the four-cell stage in 
mouse results in a distorted allocation of cells to inner cell mass and trophectoderm and abnormal 
post-implantation development (Tsunoda & McLaren 1983), whereas human embryos biopsied 
on day two show cleavage rate retardation and smaller blastocysts (Tarin et al. 1992). 
Conversely, four-cell stage human embryos surviving freeze-thaw procedures with the loss of one 
or more blastomeres can develop, implant and result in live birth, albeit at a reduced rate 
compared with non-frozen embryos. Stringent biopsy policies have the benefits that fewer 
embryos need to be biopsied, fewer cells prepared and tested with only developmentally 
competent embryos considered. On the down side, an opportunity to identify genotypes on a full 




3.5.1.3. Number of Cells to Remove During Cleavage Stage Biopsy 
In deciding how many cells to biopsy from cleavage stage embryos, it is necessary to balance 
diagnostic accuracy with potential to implant and develop, which is progressively compromised as 
a greater proportion of the embryo is removed (Liu et al. 1993). There is no consensus on the 
number of blastomeres that can be safely removed during cleavage stage embryo biopsy. In 
many centres, a second blastomere is removed from embryos having seven or more cells 
regardless of the type of analysis involved, but this approach has been criticised as compromising 
the implantation potential of the biopsied embryo based on extrapolation from frozen-thaw 
embryo implantation rates (Cohen et al. 2007). The decision to remove one or two cells is based 
on many factors, including the embryo cell number and the accuracy and reliability of the 
diagnostic test used. If removal of two cells is considered, it is recommended to be undertaken 
only on embryos with six or more cells (Van de Velde et al. 2000). While removal of two 
blastomeres decreases the likelihood of blastocyst formation, compared with removal of one 
blastomere, day three in-vitro developmental stage is a stronger predictor for day five 
developmental potential than the removal of one or two cells. The biopsy of only one cell 
significantly lowers the efficiency of a PCR-based diagnosis, whereas the efficiency of the FISH 
PGD procedure remains similar whether one or two cells are removed. However, a randomised 
trial demonstrated that live birth rate was compromised at a level of one birth for every 33 cycles 
of two-cell embryo biopsy suggesting that, ideally, one cell biopsy should always be performed 
unless the diagnostic test is sub-optimal (Goossens et al. 2008). 
In the case of lost or anucleate blastomeres and failed diagnosis, rebiopsy of embryos is possible 
but embryo cell number and timing of rebiopsy should be considered to avoid excessive harm to 
the embryo. Although technically challenging, the original zona breach site should be accessed to 
prevent later problems with embryos hatching via multiple hatching sites. No specific 
recommendations for time limits for embryos out of the incubator are available but, ideally, biopsy 
should be performed as quickly as possible to ensure pH, temperature and osmolality are 
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maintained. A documented record for biopsy timings is recommended for quality control/quality 
assurance purposes (Thornhill et al. 2005; Thornhill & Repping 2008). 
 
3.5.1.4. Safety and Success Rates After Biopsy 
The reliability of cleavage-stage biopsy has been established in many centres, and in the latest 
European Society for Human Reproduction and Embryology (ESHRE) PGD Consortium report 
the efficiency of successful embryo biopsy is reported as 98% in over 70,000 cleavage-stage 
embryos in clinical PGD cycles (Harper et al. 2012). Pregnancy rates after PGD are notoriously 
difficult to assess between different indications and centres. Nevertheless, in the largest series 
analysed in detail to date, mostly following cleavage-stage biopsy, pregnancy rates are only 17-
22% per oocyte retrieval and 26-29% per embryo transfer depending on the indication (Harper et 
al. 2012). The reasons for the apparently low success rates are many-fold but unsurprising, 
considering that a proportion of embryos cannot be transferred because they are diagnosed as 
affected, and in many countries the number of embryos transferred is limited to a maximum of 
two. It is anticipated that pregnancy rates per embryo transfer will be significantly higher 
regardless of indication following blastocyst biopsy, primarily because of the higher implantation 
potential per biopsied embryo, but a rigorous assessment of pregnancies per started cycle will 
provide a true assessment of the value of blastocyst biopsy. The potentially detrimental effects of 
embryo biopsy, particularly if performed poorly, also contribute to reduced success rates. Data 
from a randomised trial provides some insight into the possible detrimental effects of biopsy with a 
reduction in implantation potential evident in undiagnosed biopsied embryos compared with non-
biopsied control embryos (Mastenbroek et al. 2007; Cohen & Grifo 2007). A separate trial 
dramatically reduced implantation rates from biopsied versus non-biopsied cleavage-stage 
embryos (without any genetic selection), which further supports the notion that cleavage-stage 
embryo biopsy is costly to the embryo particularly if poorly performed (Scott et al. 2013). It is well 
established in mammalian embryos that as an increasing proportion of the embryo is removed or 
destroyed before transfer, implantation and foetal development rates decline suggesting a lower 
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limit of embryo mass compatible with implantation and development (Rossant 1976). Reduction 
of 50% or more of the cell mass frequently results in cell proliferation in the absence of normal 
differentiation, thus it is important to minimise the cellular mass removed at biopsy. However, cell 
reduction within this limit is compatible with normal embryo metabolism, blastocyst development, 
and foetal growth, while cell numbers in the trophectoderm (TE) and inner cell mass (ICM) of 
blastocysts were in proportion to the cellular mass removed at biopsy, making cleavage stage 
biopsy for PGD a viable option (Hardy et al. 1990). Hence, human cleavage-stage biopsy is 
delayed until just before the beginning of compaction, the process of intercellular adhesion and 
junction formation, which progressively makes removal of blastomeres more difficult and 
eventually impossible without causing damage to the embryo. Generally, cells identified as having 
completed the third cleavage division (on the basis of their size) are selected for biopsy. 
Theoretically, therefore, each blastomere removes only one-eighth of the cellular mass of the 
embryo. As zona drilling for assisted hatching may be beneficial, it is also possible that this offsets 
to some extent the adverse effects of reducing the cell mass of the embryo. 
In frozen embryo transfer (FET) cases, viable pregnancies can be achieved and no increase in 
foetal abnormalities has been reported following transfer of cryopreserved embryos in which 
some cells have been destroyed by freezing and subsequent thawing (Sutcliffe et al. 1995). 
Indeed, estimates of the loss of implantation potential have been made based on outcomes 
following FET involving embryos with one or more non-viable cells after thawing (Cohen et al. 
2007). It is now apparent that cleavage-stage biopsy should be considered a ‘cost’ to the embryo 




3.5.1.5. Selection of Cells in the Cleavage-Stage Embryo 
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Biopsy at cleavage stages is based on the principle that at these stages the blastomeres remain 
totipotent and equivalent such that the removal of a single blastomere will: (a) provide a 
representative sample of the entire embryo; and (b) compromise the embryo only to the extent of 
one-eighth of the embryo mass rather than removal of a developmentally important blastomere. 
The importance of selecting a blastomere with a single visible interphase nucleus cannot be 
stressed enough. It is probably the most challenging aspect of cleavage-stage biopsy, and time 
spent in careful examination of the embryo and orienting it to selectively remove specific 
blastomeres is essential to attain the high diagnostic efficiencies required for clinical 
effectiveness. The reasons for this are that, first, an interphase nucleus is essential for FISH 
analysis, since the nucleus is prepared on a slide by a process of cell lysis in which individual 
chromosomes will not be visible and are likely to be lost (Harper et al. 1994). Second, post-
zygotic chromosomal mosaicism arising during cleavage is known to be associated with nuclear 
abnormalities (Munné & Cohen 1993). The exception is binucleate blastomeres, in which there 
are two normal-sized nuclei. In most cases, these are generated through failure of cytokinesis, 
and both nuclei contain the normal diploid chromosomal complement for that embryo (Kuo et al. 
1998). In general, multinucleate cells should not be selected at biopsy if FISH analysis 
for aneuploidy detection follows and the removal of mononucleate cells only is 
recommended (Strom et al. 2000). For accuracy during FISH-based diagnosis, it is 
advisable to only use bi- or multinucleated cells as a backup to biopsied mononucleated 
cells. This may be less critical for PCR based testing in which presence or absence of a 
specific parental chromosome is important, rather than copy number per se. However, 
even with careful blastomere selection, diagnostic efficiency is not 100%, and aneuploid results 
are common even in mononucleate blastomeres primarily as a result of chromosomal mosaicism 
(Kuo et al. 1998). Biopsy of two nucleated blastomeres is only possible in good-quality embryos 
at a sufficiently advanced stage, such that even with a two-cell biopsy policy, a mixture of 
embryos with one or two blastomeres for analysis is common (Van de Velde et al. 2000). Where 
possible, one of the smaller blastomeres should be selected to minimise the reduction in 
mass and the relative sizes of cells may provide an indication of recent mitosis. This 
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may also reduce the risk that a cell in metaphase will be taken, the chromosomes of 
which could be lost during the fixation process. 
 
3.5.2. Concerns Surrounding Cleavage-Stage Embryo Biopsy 
As with any micromanipulation procedure involving human gametes or embryos, every 
reasonable precaution should be taken to minimise damage and stress during the procedure. 
General precautions include the correct installation, calibration and maintenance of all 
micromanipulation equipment (particularly the laser). In advance of all clinical procedures, one 
should ensure that all appropriate reagents and micromanipulation tools are available, sterile and 
within their expiration date. Biopsy should be performed by a suitably qualified and trained 
person. Regular reviews of biopsy efficiency, post-biopsy morphology and cell numbers of 
embryos not transferred provide an indication of the possible harm as a result of biopsy as do 
pregnancy rates after biopsy; particularly those not developing beyond the biochemical stage 
(Thornhill & Repping 2008). Clearly, effects on post implantation development should also be 
closely monitored, as any increase in foetal malformations or congenital abnormalities would be 
unacceptable. To date, studies of pregnancies and children born after PGD have identified no 
significant increase in abnormalities above the rate seen in routine IVF (Harper et al. 2012; Strom 
et al. 2000; Banerjee et al. 2008; Nekkebroeck et al. 2008). The main problem in terms of 
diagnostic efficiency with cleavage-stage biopsy is the presence of chromosomal mosaicism that 
is reported to occur in up to 80% embryos (Harper et al. 1995; Magli et al. 2000; Bielanska et al. 
2002). A full discussion of the impact of chromosomal mosaicism on the accuracy of PGD is 
beyond the scope of this thesis, but its impact is likely to be significant. Mosaicism is thought to be 
the primary reason for the high rate of false positives depleting the pool of chromosomally 
‘normal’ embryos for transfer, and hence significantly lowering the chance of live birth following 
preimplantation genetic screening for chromosomal aneuploidy (PGS) compared with controls in 
a randomised controlled trial (Mastenbroek et al. 2007). Preliminary work using array comparative 
genomic hybridisation techniques to compare individual blastomere chromosomal constitutions 
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from ‘normal’ cleavage stage embryos suggests that the false positive rate in diploid/aneuploid 
mosaic embryos may be as low as 7%, but this requires larger scale corroboration (Wilton 2012).  
 
3.6. Blastocyst Stage Biopsy (Trophectoderm Biopsy) 
The number of cells present at the blastocyst stage make blastocyst biopsy more akin to early 
prenatal diagnosis and therefore, to some, more ethically acceptable (Figure 3.1). In theory, TE 
cells, which form the spherical outer epithelial monolayer of the blastocyst, can be removed 
without harming or depleting the ICM from which the foetus is derived. For blastocyst biopsy, it is 
therefore possible to remove up to 10 TE cells, which would overcome many of the problems 
encountered in single cell DNA amplification and FISH. In the case of PCR, the problems of 
amplification failure and allele dropout or preferential amplification would be much reduced. FISH 
analysis would be more successful with a virtual guarantee of a result for each sample and the 
problems of split signal, signal overlap or probe failure would be significantly less misleading. 
Indeed, when more than two cells are present in the same sample tube these problems have 
been shown to virtually disappear (Holding et al. 1993), particularly if using whole genome 
amplification (WGA) techniques (Nijs & Van Steirteghem 1990). With or without WGA, the 
availability of more cells automatically increases the diagnostic possibilities (more chromosomes 





Figure 3.1. Blastocyst biopsy following laser ablation of the zona pellucida on a day five 
human embryo (Thornhill, Ottolini & Handyside 2012).  
Aspiration of trophectodermal cells follows immediately after ablation without additional embryo 
culture prior to biopsy. For a more detailed account, following the steps a-f, see clinical protocol in 
Section 3.8. 
 In the mouse, TE biopsy is easily achieved by partial zona dissection using mechanical means, 
followed by a period in culture during which the expansion of the blastocoel cavity forces the TE 
to herniate out of the slit (Dokras et al. 1991). The herniating TE vesicle can then be excised on a 
bed of agarose by using a needle (which can be hand-held or attached to a micromanipulator) 
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and a cutting action close to the zona, which causes the embryo to roll. Both the biopsied embryo 
and TE vesicles often remain expanded, since they appear to be resealed possibly as a 
consequence of twisting at the constriction. Furthermore, to some extent, the size of the TE 
biopsy can be controlled by the size of the slit and the length of incubation. A similar approach 
was used to biopsy human blastocysts on day five or six post-insemination (Dokras et al. 1991) 
and was later used to examine effects on viability post-biopsy, with the finding that hCG 
production was equivalent for biopsied and non-biopsied controls (Muggleton-Harris et al. 1993). 
Another more aggressive technique to remove trophectoderm cells during blastocyst biopsy is the 
mechanical stitch and pull method (Veiga et al. 1997). The best technique seems to be to 
stabilise the blastocyst by gentle suction and make an incision at the pole opposite to the inner 
cell mass using a 2m bevelled pipette. The pipette is pushed in and out through the zona and 
pulled upwards to make the incision. The blastocysts are then left for six to 24 hours until some 
trophectoderm herniates though the slit. When herniation involves about 10-25% of the blastocyst 
(10-30 cells), the trophectoderm is excised using a glass needle. As with the other stages of 
embryo biopsy, noncontact infrared lasers are now routinely used to not only create an opening in 
the zona pellucida but also to excise the herniating trophectoderm (Papanikolaou et al. 2008) 
(See Section 3.8. for a clinical protocol describing this method in more detail).  
Originally, blastocyst development rates were not consistently high in laboratories and pregnancy 
rates following blastocyst-stage transfers were too low to consider biopsy at this stage. With 
improvements in culture systems, the proportion of embryos developing to the blastocyst stage 
has increased, and implantation rates per blastocyst transferred are significantly better than at 
cleavage stages (Kokkali et al. 2007). Another concern was the effect that removal of a proportion 
of the TE cells and damage of additional cells in the process would have on implantation. 
However, skilled practitioners are able to reliably biopsy up to 10 TE cells from blastocysts on day 
five using a noncontact infrared laser for zona drilling and excision of herniating TE cells, and 
pregnancy and implantation rates are comparable to those for non-biopsied controls (Khalaf et al. 
1996). The high incidence of multiple pregnancies in PGD demands efforts to reduce the number 
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of unaffected embryos transferred, and transfer of blastocysts with high implantation potential is 
an effective strategy (Kalousek & Vekemans 1996). 
 
3.6.1. Challenges Associated with Blastocyst Biopsy  
The main limitation of blastocyst biopsy is the low or unpredictable number of embryos that reach 
the blastocyst stage in vitro for unselected patients, even with improved culture conditions. Since 
a high number of embryos are needed for successful PGD to allow for sufficient embryo selection 
from the desired genotype, blastocyst culture may not produce enough embryos for diagnosis 
and transfer to make PGD at this stage effective for all patients and may be more appropriate for 
younger, good-prognosis patients.  
An additional problem is that TE cells may have diverged genetically from the ICM as, in 
approximately 2% of human conceptions, confined placental mosaicism (CPM) is observed 
(James & West 1994) in which the chromosome status of the embryo is different from the 
placenta. In a mouse model, abnormal cells were preferentially allocated to the trophectoderm 
(Ruangvutilert et al. 2000) but the situation is less clear in the human. 
The level of mosaicism in the human blastocyst is lower than that in cleavage stage embryos 
(Evsikov & Verlinsky 1998) and, where present, often takes the form of polyploidy in the 
trophectodermal lineage (Derhaag et al. 2003) with no obvious preferential allocation of aneuploid 
cells to the TE lineage (Baart et al. 2006). Considering polyploidy cells, for PGD analyses using 
FISH, if enough chromosomes are analysed then any underlying abnormality (such as trisomy 
21) may be recognised within the polyploidy (Kuo & Handyside, unpublished observation). 
Similarly, for PCR based diagnoses the presence of multiple copies of each chromosome in 
polyploid cells should pose few problems, so long as both parental copies of the chromosome are 
represented. Clearly, chromosomal differences between the ICM and TE as a consequence of 
high levels of mosaicism at the cleavage stage even in younger women (Geber et al. 1995) will 
reduce the accuracy of diagnosis even when multiple biopsied TE cells are available. However, 
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comparisons between biopsied trophectoderm and inner cell mass demonstrated high 
concordance in chromosomal status (Johnson 2010; Capalbo et al. 2011). 
In summary, blastocyst biopsy is rapidly becoming a popular choice for embryo biopsy (Kokkali et 
al. 2005; de Boer et al. 2004) and, in contrast to previous practice focusing on poor prognosis 
patients, is particularly promising for younger patients aiming for single embryo transfer, with a 
randomised controlled trial demonstrating a 66% relative increase in ongoing pregnancy rate 
following 24 chromosome aneuploidy screening (Yang et al. 2012). Its widespread adoption in 
laboratories previously performing biopsy at other developmental stages is predicted allowing 
large-scale clinical assessment. At present, the logistics of blastocyst biopsy dictate a limited 
time-frame in which to perform diagnosis that might necessitate cryopreservation of biopsied 
blastocysts for transfer in a later unstimulated thaw cycle which, despite growing evidence of 
safety and efficacy, will require a cultural shift for both patients and providers.  
 
3.7. Future Developments 
A major challenge in PGD, where high value test normal embryos are available and single 
embryo transfer is becoming common, has been to develop an effective standardised method for 
cryopreservation of biopsied embryos. Attempts to use conventional slow-freezing protocols, 
either in the mouse model or in humans, have shown extensive damage after thawing, 
presumably because of the loss of protection from ice crystals in the medium provided by an 
intact zona pellucida (Joris et al. 1999; Magli et al. 1999; Magli et al. 2006). However, improved 
slow freezing protocols have been reported in which damage is reduced (Jericho et al. 2003; 
Stachecki et al. 2005; Parriago et al. 2007). Nevertheless, following successful application in 
animal models, vitrification looks set to replace slow freezing for both cleavage and blastocyst 
stage embryos after polar body or embryo biopsy (Agca et al. 1998; Baranyai et al. 2005; 
Isachenko et al. 2005). With the high rate of multiple pregnancies reported after PGD, it is 
imperative to develop effective methods of cryopreservation that will: (i) allow storage of 
unaffected embryos for later transfer so that the numbers transferred can be limited to two or 
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even single embryo transfers; and (ii) provide additional time to perform more extensive 
diagnostic tests. Indeed, the growing body of evidence suggesting comparable success rates 
(Schoolcraft et al. 2011) and normalised birthweights (Henningsen et al. 2011) from frozen-thaw 
transfer cycles (compared with fresh stimulated transfer cycles) may lead to a new era in which 
PGD cycles separate the stimulation and embryo production phase of treatment from diagnostic 
testing and embryo transfer phase. As a consequence, outcomes may improve overall with the 
added benefit to patients of having sufficient time for informed decision 
With the introduction of quality management systems and accreditation in IVF laboratories 
(Thornhill et al. 2005; Preimplantation Genetic Diagnosis International Society 2008; Thornhill & 
Repping 2008), safer biopsy can be anticipated through agreed definitions of successful and safe 
biopsy, standardised training and procedures, validation of new techniques as well as calibration 
of new and existing instruments such as the laser. It has become clear that embryo biopsy, as 
with any form of invasive testing or manipulation, exacts a cost to the embryo in the form of either 
cellular depletion, metabolic stress or both. Thus, it is imperative to assess the potential benefit to 
the embryo itself in terms of improved selection or disease-free status before performing embryo 
biopsy. However, in the future it may be possible to diagnose inherited diseases or chromosomal 
imbalance in early human embryos by non-invasive analysis. The new development of time-lapse 
imaging in human embryology allows changes in developmental growth rates to be measured by 
morphokinetic analysis (Wong et al. 2010; Meseguer et al. 2011). If this approach can be 
developed to detect aneuploid embryos, it would shift the cost-benefit ratio away from the cost of 
invasive biopsy heavily towards potential benefit. 
 
3.8. Clinical Protocol for Blastocyst Stage Embryo Biopsy  
This clinical protocol describes the biopsy of human blastocysts on day five or day six of 
development to obtain multicellular samples for DNA amplification and genetic testing. The 
protocol is suitable for both hatching and non-hatching blastocysts and requires no zona breach 
during cleavage stages or period of culture prior to biopsy. For brevity all culture media reagents 
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described below are from the Quinn’s Advantage Culture Media Suite (Sage, Cooper Surgical, 
Inc. Trumbull, CT, USA). 
 
3.8.1. Preparation Prior to Biopsy 
1. Prepare sufficient Embryo GPS culture dishes (EGPS-100, LifeGlobal) with Blastocyst 
medium for all embryos eligible for biopsy on the day prior to biopsy to allow for 
equilibration in the patient-allocated incubator section. Dish(es) should have sufficient 
30µL outer wells to allow individual culture of every embryo that has undergone biopsy. 
Spare medium in the 60µL inner wells should also be available for washing embryos after 
biopsy to remove buffered medium. 
2. Turn on workstation, micromanipulators and heated stage (perform routine QC checks for 
temperature, etc.) 
3. Ensure anti-vibration table is inflated and functioning. 
4.  Set up one biopsy dish per embryo with QA HEPES buffered medium +10% Synthetic 
Serum Replacement (buffered biopsy medium – BBM) and oil for tissue culture. In Falcon 
50 × 9mm Petri dish (code 351006), 3 × 10µL drops of BBM are aliquoted and covered 
with 4ml oil. These should be kept on a heated stage to equilibrate to 37°C for at least 15 
minutes prior to use and used within 120 minutes. 
5. Turn on ‘SATURN’ laser (Research Instruments Ltd, Falmouth, UK) and workstation 
computer. Open ‘CRONUS’ software and follow instruction booklet for alignment of laser 
using ‘pilot’ to check target is correct (refer to SATURN laser manual for additional 
guidance). 
6. Pipette set-up is essentially the same as that done for ICSI, however in the place of the 
injection pipette a blastomere aspiration pipette (code K-EBPH-3035, Cook Medical 
Europe Ltd, Limerick Ireland) is inserted into the holder. Biopsy pipettes are available in a 
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range of diameters and can be bevelled if required. Current diameters used are between 
25µm and 35µm and are available commercially from a number of different providers. 
7.  If required the angle of the biopsy pipette can be adjusted between 30° to 40° to allow 
optimal movement during biopsy. 
 
3.8.2. Biopsy 
1. Label the biopsy dish with the patient details, embryo number and attach a Radio 
Frequency Identification (RFID) tag for use with the RI WitnessTM system (Research 
Instruments, UK). 
2. Allocate the biopsy dish appropriately on the witness system and transfer one embryo to 
the central drop in the dish. The embryos should be ‘rinsed’ in the extra ‘wash’ drops so 
that excess culture media does not dilute the BBM. This also reduces the chance of 
debris carry over and allows removal of loose cumulus cells that may otherwise present a 
risk of false diagnosis. 
3. Place the dish on the heated stage of the micromanipulator workstation. 
4. Carefully lower the holding and aspiration pipettes into the central drop (with the embryo) 
taking care to avoid damaging the embryo using a low powered objective (Figure 3.1a). 
5. Ensure both pipettes have equilibrated and are offering sensitive control then, with gentle 
aspiration, secure the embryo to the holding pipette avoiding any herniating cells. 
For hatching blastocysts go directly to step 9. 
For non-hatching blastocysts continue with step 6. 
6. Position the embryo on the holding pipette to give a clear view of the inner cell mass at 9 
o’clock (i.e. away from the biopsy pipette) under high power magnification (Figure 3.1b). 
7. Select appropriate laser pulse duration for the desired aperture size (Figure 3.1c) and, 
after selecting the laser objective, begin to make an opening in the embryo zona with a 
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series of laser pulses working inwards from the outer surface of the zona taking care to 
avoid damaging the embryo. Zona thickness variation between embryos will mean that 
pulse time are number of pulses will vary. Pulse duration can be altered manually if 
required. The exact duration and number of pulses varies with different commercially 
available lasers and should be validated within each centre. 
8. As soon as the aperture is wide enough to accommodate the passage of several 
trophectoderm cells (~ 10μm), carefully press the biopsy pipette against the zona, gently 
expelling medium through the breach to release the cells from the internal surface of the 
zona (Figure 3.1d).  
9. Once the trophectoderm is free from the zona, aspirate three to 10 cells into the biopsy 
pipette with gentle suction (Figure 3.1e). In the case of hatching blastocysts, aspirate 
herniating cells into the biopsy pipette. 
10. Direct the laser to the thinnest part of the aspirated cells and use several laser pulses at 
the junctions between cells to disconnect the aspirated cells from the body of the embryo. 
It may be necessary to apply more suction with the biopsy pipette, taking care not to 
inadvertently aspirate additional cells into the biopsy pipette. 
11. When the biopsied cells are free from the embryo (i.e. within the biopsy pipette), move the 
biopsy pipette away from the embryo and gently release the aspirated cells (Figure 3.1f). 
Record the approximate number of cells, their appearance and location in the drop to aid 
relocation at time of cell preparation. 
12. Label a pre-equilibrated post-biopsy (GPS) culture dish clearly with the patient’s details 
and attach an RFID tag. Mark the embryo number adjacent to each culture well, on the 
dish base with indelible marker. 
13. Allocate the culture dish appropriately on the witness system and return the biopsied 
embryo to this culture dish – each numbered embryo in the biopsy dish should be moved 
to the culture well with the corresponding number. Ensure that wash drops are used to 
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minimise any carry-over of HEPES medium into the culture drop. Use a 275μm pipette tip 
to minimise any additional stress to the embryo during this movement. Manual human 
double witnessing must be performed and recorded for every embryo that is moved 
following biopsy to ensure appropriate identification. 
14. Return the dish to the patient incubator section and culture until embryo transfer, 
vitrification or disposal. 
15. The dish containing the aspirated cells for analysis should be given to the scientist 
performing the cell preparation (tubing or cell fixation) immediately or can be placed in the 
workstation for later preparation (if validated) once the biopsy is completed.  
16.  Perform biopsy procedure on the next eligible embryo. 
17. Biopsy all embryos that are of suitable quality and have reached the appropriate stage of 
development. This is normally a full blastocyst of average quality or above (grade 3BB or 
better using Gardner’s blastocyst scoring system). 
 
3.8.3. Special Considerations 
1. In many cases results of the genetic analysis can be ready within 24 hours. Embryos 
biopsied early on day five may be transferred fresh on day six. Any embryos biopsied 
later on day five or day six should be vitrified and transferred in a frozen embryo transfer 
cycle pending genetics results. 
2. If no embryos in a cohort reach the full blastocyst stage by day six or no embryos are 
suitable for biopsy, the case should be reviewed by the appropriate team members. 
Considerations can be made to perform embryo transfer without biopsy and subsequent 
genetic testing subject to the patients being counselled on the risks and the chance of 
pregnancy. For example, patients for aneuploidy screening may elect to proceed with 




4. Specific Aim 1b. To review the literature, produce and publish a state of the 
art standard set of protocols as a general reference work from practitioners in 
the fields of Array CGH  
This is an adaptation of the book chapter entitled ‘Aneuploidy testing by array-CGH: Applications 
in Preimplantation Testing’ by Alan R Thornhill, Christian Ottolini, Gary Harton and Darren Griffin 
published in A Practical Guide to Selecting Gametes and Embryos (2014). 
 
4.1. My Personal Contribution to the Work 
I was involved in the research and writing and editing of the published review chapter above. 
What follows is an adaptation of the published manuscript.  
 
4.2. Introduction 
As described in sections 2.1 to 2.3 of the General Introduction, aneuploidy is the term used to 
describe gross chromosomal imbalance in an organism or embryo, presenting as either additional 
(e.g. trisomy) or missing (e.g. monosomy) chromosomes. Aneuploidy arises during cell division 
when chromosomes fail to separate equally between the two new daughter cells (Hassold & Hunt 
2001). Aneuploidy may be present in all the cells of the body and extra embryonic membranes or 
be represented in a conceptus having both normal and aneuploid cells (so-called mosaicism). 
The consequences of aneuploidy constitute a wide phenotypic spectrum from early embryonic 
arrest to mild infertility, with the best-known being Down syndrome (trisomy 21) and first trimester 
spontaneous abortion (mostly trisomies and monosomy X). The origins of aneuploidy lie in the 
meiotic divisions (principally in the ovary) and the early cleavage divisions of the preimplantation 
embryo. Arising by either nondisjunction, precocious separation of sister chromatids or anaphase 
lag (Hassold & Hunt 2001), the impact of aneuploidy on families can be devastating; e.g. when 
faced with pregnancy loss, stillbirth or a severely affected child. In all cases, aneuploidy results in 
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an unfavourable outcome for the family in question and is undoubtedly a major contributing factor 
to the relatively low fecundity of humans when compared with other species. 
The concept of preimplantation genetic screening (PGS) for aneuploidy in oocytes or 
preimplantation embryos to both lower the risk of the above phenotypic consequences and to 
improve in vitro fertilisation (IVF) success rates is not new. Indeed it was proposed alongside the 
earliest developments of preimplantation genetic diagnosis (Penketh & McLaren 1987). The 
ability to do this effectively has required rapid evolution of diagnostic technologies to combine 
speed, accuracy and reliability. To date, only direct analysis of chromosome copy number has 
been applied clinically as indirect approaches (e.g. metabolomic analysis of embryonic products 
or detailed morphokinetic analysis using time-lapse imaging technology) have yet to be 
convincingly associated with aneuploidy incidence.  
Explanations for the failure of a Fluorescence In-Situ Hybridisation (FISH) approach on 
blastomeres from cleavage stage embryos to demonstrate a clinical benefit in a large randomised 
controlled trial (Mastenbroek et al. 2007) and in subsequent trials (see meta-analysis) 
(Mastenbroek et al. 2011) are well documented (Cohen & Grifo 2007), focusing primarily on the 
safety of biopsy, the importance of low error rates on the diagnostic efficiency of PGS (Summers 
& Foland 2009), as is the need to detect all chromosomes simultaneously for aneuploidy. 
Notwithstanding the ability now to detect all 24 chromosomes by FISH using successive rounds 
of hybridisation, the issues of mosaicism, signal interpretation, clinical trial data and the 
development of microarray based methods for detecting 24 chromosome copy number are now 
signalling the demise of FISH-based cleavage stage embryo biopsy approaches to PGS. 
Microarray-based tests are now the standard and these have been made possible through the 
advancement of whole genome amplification (WGA) technology. Despite the undoubtedly 
superior technical capabilities of array comparative genomic hybridisation (CGH) compared with 
FISH, several prospective clinical trials showing benefit and widespread clinical use of array 
CGH, the policy position regarding PGS among both professional and regulatory bodies is 
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regrettably out of date and refers only to the historic and flawed FISH approach (Anderson & 
Pickering 2008; American Society of Reproductive Medicine Society Practice Committee 2008). 
The classical approaches to embryo biopsy for preimplantation genetic diagnosis – polar body, 
cleavage stage, trophectoderm (Magli et al. 2004; Cieslak-Janzen et al. 2006; Kokkali et al. 2007 
and reviewed in Thornhill et al. 2012) – are all in current clinical application for PGS, with first 
polar body (Wells et al. 2002) and combined first and second polar body (Geraedts et al. 2011) as 
well as trophectoderm biopsy (Schoolcraft et al. 2010), increasingly finding favour. The more well 
established cleavage-stage approach, while once thought to be harmless (Hardy et al. 1990), is 
now considered to reduce implantation potential especially when two cells are biopsied 
(Mastenbroek et al. 2007; Cohen et al. 2007), and should ideally only be used after conducting a 
cost-benefit analysis. The invasive nature of embryo or oocyte biopsy means that PGS has 
historically been targeted to specific high-risk patient groups (advanced maternal age; repeated 
implantation failure; recurrent pregnancy loss; and elevated sperm aneuploidy levels common in 
patients presenting with severe male factor infertility). More recently, PGS has been used to 
improve the effectiveness of elective single embryo transfer in good prognosis patients to reduce 
multiple birth rates while maintaining high success rates (Yang et al. 2012). The complex 
spectrum of chromosome abnormalities in the human preimplantation embryo has yet to be fully 
described and diagnostic procedures can be expensive to implement. Moreover, embryo biopsy 
is invasive, as already discussed in Specific Aim 1, and thus a robust cost-benefit analysis is 
essential to achieve widespread patient benefit through the use of PGS. This part of the thesis 
explores the current methodologies used to perform PGS using array CGH and a description of 
alternative and future approaches. 
 
4.3. Biopsy Strategies 
A number of different strategies have been proposed and utilised to detect aneuploidy using array 
CGH in oocytes and embryos. The relative merits of each have been dealt with in earlier chapters 
of this thesis. Briefly, first polar body (PB1) biopsy alone and combined PB1 and second polar 
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body (PB2) strategies have both been used clinically for PGS. However, it is increasingly evident 
that PB1 alone has limited applicability for PGS as up to 30% of aneuploidy of maternal origin will 
not be diagnosed if only PB1 is analysed (Handyside et al. 2012). As precocious separation of 
sister chromatids appears to be the predominant cause of maternal meiotic aneuploidies 
(Handyside et al. 2012; Gabriel et al. 2011a), PB2 must be biopsied to accurately identify all 
maternal aneuploidies and ensure even abnormal segregations in PB1 are not corrected in the 
second meiotic division. The timings of both PB1 and PB2 biopsy are critical to the efficiency of 
diagnosis. This was relevant when aneuploidy screening using the FISH approach was used 
(Verlinsky et al. 1996) and is equally critical when using array CGH (Magli et al. 2011).  
Theoretically, blastocyst stage biopsy is the optimal stage for aneuploidy screening (see previous 
chapter) as it partially negates the problem of mosaicism and gives maximum aneuploidy 
information from maternal, paternal and post-zygotic events at the latest possible stage of embryo 
development possible in current in-vitro culture systems. In addition, the biopsy of three or more 
cells virtually eliminates the problem of allelic dropout (ADO) following WGA (Ling et al. 2009). 
Historically it has been viewed as a downside that embryos may need cryopreservation following 
trophectoderm (TE) biopsy whist awaiting genetics results. However it is becoming increasingly 
apparent that vitrification is a viable strategy to maintain or even potentially increase live birth 
rates following biopsy (Schoolcraft & Katz-Jaffe 2013). Furthermore, embryo vitrification may be 
considered for all PGS cases to overcome logistic issues with sample transportation and 
diagnostic timings. It should be noted that TE biopsy does not entirely eliminate the problem of 
mosaicism. Furthermore, it is possible that some embryos failing to reach blastocyst stage in vitro 
may be viable in vivo (Glujovsky et al. 2012). 
 
4.4. Principles of Array Comparative Genomic Hybridisation (aCGH) 
Originally designed for molecular karyotyping of tumour cells (Kallioniemi et al. 1992), CGH is a 
method whereby the chromosomal genotype of an unknown DNA sample can be inferred 
according to its relative ability to competitively hybridise with reference DNA of known genotype to 
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either: (i) metaphase chromosomes from a karyotypically normal reference male (metaphase 
CGH); or (ii) a series of specified DNA sequences at specified spots or positions on a glass slide 
(aCGH). A schematic representation of the principles of CGH is shown in Figure 1b.1. Like its 
more time-consuming predecessor, metaphase CGH, which has been used for clinical PGS 
(Voullaire et al. 2000; Wells & Delhanty 2000), array CGH is a relatively DNA hungry technique 
and commonly requires nanogram to microgram amounts of DNA for optimal performance. Since 
there is typically only approximately six picograms of DNA in a single blastomere, it is essential to 
perform WGA prior to the aCGH procedure itself. While array CGH can be performed using either 
bacterial artificial chromosome (BAC) DNA clones or specific oligonucleotides across the 
genome, this chapter will focus on the BAC clone approach as this has been validated and used 
for well over 250,000 clinical preimplantation genetic samples to date. The current 24SureTM 
microarray contains 2,900 unique BAC clones spaced approximately 1Mb apart, which have 
been extensively validated in over 2,000 post-natal clinical array experiments to exclude copy 
number polymorphisms and their genomic locations confirmed by reverse painting of labelled 
single chromosome preparations onto arrays, FISH mapping and sequencing verification. Array 
CGH for preimplantation testing has been pioneered by BlueGnome (Fulbourn, Cambridge, UK) 
and all reagents for WGA, labelling, hybridisation, washing, reference DNA, microarray slides and 




Figure 4.1. Schematic of comparative genomic hybridisation (Thornhill et al. 2014a). 
 
4.4.1. Array CGH for Chromosome Enumeration 
Following egg (polar body 1 and/or 2), embryo (cleavage stage) or blastocyst biopsy, the biopsied 
material is washed in a buffer, typically phosphate buffered saline (PBS) with an additive such as 
polyvinyl alcohol (PVA) to reduce cell stickiness (Harton et al. 2011). Following washing, the 
biopsy material is picked up in a very small volume (<2µl) and placed into a sterile, 0.2ml 
Eppendorf tube for transport to the testing laboratory. A more detailed description of this process 
(specifically for trophectoderm biopsy of the blastocyst) is given in section 3.8. Most laboratories 
perform a quick centrifugation step to ensure that the cellular material and all of the fluid are 
collected at the bottom of the tube. Most labs then freeze each sample prior to transport to the 
testing lab; however, this is not essential depending on the length of time the sample will be in 
transit prior to further processing. It is very important to note that mineral oil, which is typically 
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used as an overlay on top of biopsy material destined for polymerase chain reaction (PCR) 
testing, should never be used prior to WGA and aCGH as it inhibits the amplification process. 
 
4.4.2. Whole Genome Amplification (WGA) and Labelling 
A number of different WGA methods have been used historically for array CGH with the current, 
most often utilised method being SureplexTM (Rubicon Genomics Inc., Ann Arbor, MI, USA and 
BlueGnome) that is fragment amplification-based. Self-inert degenerative primers are annealed at 
multiple sites along the genome. Extension then displaces downstream strands to generate 
multiple fragments spanning each region. The reaction produces large fragment sizes, which are 
reproducible between samples and are optimised for array CGH. Many of the other WGA 
techniques have been adapted for use in array CGH but were originally used for other purposes 
(for example single locus PCR and mutation detection). SurePlexTM is suitable because of its 
simple, short protocol, highly representative amplification and low allele dropout rates.  Briefly, 
following sample receipt in the lab, each tube is opened in a dedicated DNA amplification clean-
room, under laminar flow conditions, and the WGA reagents added (SurePlexTM kit). Amplification 
is performed according to the manufacturer’s instructions as these kits have been validated using 
single cells. For SurePlexTM, there is a 15 minute cell lysis (DNA extraction) step, followed by the 
pre-amplification steps (90 minutes) and finally amplification (30 minutes). All of these steps are 
performed in a single tube which reduces the likelihood of sample switches and contamination. In 
addition, all of these steps require the use of a PCR thermal cycler machine as they are time and 
temperature dependent. As the arrays are the most expensive consumable in the process, it is 
best to ensure amplification prior to taking the sample further through the process. Following 
amplification, most laboratories run an agarose gel electrophoresis step to confirm amplification. 
A smear of high molecular weight DNA, observed on the gel following electrophoresis, is 
indicative of positive amplification and all such samples may be taken forward to the fluorescent 
labelling steps. Low molecular weight DNA or the absence of any smear indicates poor or failed 
amplification. In such cases, it may be prudent to avoid running such samples on the microarrays. 
82 
 
Successfully amplified WGA product is labelled through nick translation with either Cy3 (green) or 
Cy5 (red) fluorescence and purified.  
 
4.4.3. Hybridisation 
Samples with unknown genotype (i.e. embryo biopsy) labelled in one fluorescent colour and 
control reference DNA (typically a karyotypically normal male) labelled in the opposite colour are 
separately denatured (to render them single-stranded) at 74oC, prior to being mixed together in 
equal proportions in hybridisation buffer containing formamide and cot-1 human DNA before 
adding to each 24SureTM microarray. Microarrays are hybridised at 47oC for at least four hours or 
overnight in a humidified chamber. The length of hybridisation time varies depending on the 
number of samples in the lab on any given day, the time samples are received during the day and 
the local staffing levels and shift patterns. During validation of the array in the lab, hybridisation 
times as short as three hours and as long as 16 hours (overnight) were tested with no differences 
noted (BlueGnome (now Illumina), unpublished data). On the basis of these results, hybridisation 
for at least four hours and no longer than 16 hours is deemed to be interchangeable 
(Reprogenetics Ltd, unpublished data).  
 
4.4.4. Post-Hybridisation Washing 
Following hybridisation, each microarray is washed as follows: 10 minutes in 2xSSC/0.05% 
Tween 20 at room temperature, 10 minutes in 1xSSC at room temperature, 5 minutes in 








Each microarray slide is scanned using a dual channel fluorescent laser scanner is used to create 
TIFF images (e.g. ClearScanTM, BlueGnome) for green fluorescence at 632nm and for red 
fluorescence at 587nm. Raw images are loaded automatically into BlueFuseTM software allowing 
for automated evaluation of fluorescent signals (ratio analysis).  
 
4.4.6. Scoring 
Each sample is scored by a trained technologist who assesses traces for all 24 chromosomes, 
noting all gains and losses, as well as determining the gender of each sample. A second 
technologist then scores the sample blindly, with no knowledge of the initial score by the first 
technologist. A final score for each sample is assigned by comparing the two scores. Any 
discrepancies are noted and are adjudicated by a third technologist and/or the laboratory 
supervisor or director. Single chromatid errors can be distinguished from whole chromosome 
errors through examination of the mean per-chromosome hybridisation ratios (see Figure 4.2 and 





Figure 4.2. Determining chromatid versus chromosome loss in first polar body samples 
by array CGH (Thornhill et al. 2014a). 
For most chromosomes (i.e. not the sex chromosomes or the aneuploid chromosomes) a clear 
and consistent 1:1 ratio is observed along the chromosome length. As the polar body sample was 
co-hybridised with male genomic DNA, a hybridisation pattern representing a 2:1 ratio for the X 
chromosome and a ‘0:2’ ratio for the Y chromosome is observed. This polar body clearly shows 
multiple aneuploidies with chromatid gains on chromosomes 1 and 10 (single chromatid gains are 
consistent with a 3:2 [or 1.5:1] ratio, i.e. approximately half that of the X chromosome shift) and a 
loss of whole chromosome 15 (similar to the shift seen for the absent Y chromosome). 
  
4.4.7. Reporting 
Once results for all samples from each patient are finalised, a diagnostic report is prepared, 
signed off by an appropriately qualified person (on site or remotely) and shared with the referring 








In extensive validation using single cells from known cell lines against the gold standard of 
karyotyping, 24SureTM demonstrated 98% accuracy. In contrast to the use of cell lines, validation 
for embryo aneuploidy is difficult as ideally to obtain reliable and robust results one needs truth 
data (i.e. samples of known genotype). While the same is true of human oocytes, in that they are 
of unknown genotype, the ability to biopsy both the first and second polar bodies from the oocyte 
provides the opportunity to obtain relatively robust validation data comparing results from so-
called ‘trios’ of both polar bodies and their corresponding oocyte, zygotes or embryos. The 
expectation is to see reciprocal results (i.e. chromosomal gains and losses) from aneuploid polar 
body and oocytes (see Figure 4.3). The presence of chromosomal mosaicism in human embryos 
makes it difficult to categorically identify embryos as having a single specific genotype. Thus from 
a mosaic embryo, individual single cell results may appear to be unrepresentative and 
multicellular results (e.g. from trophectoderm biopsy) potentially difficult to interpret (see Figure 
4.4) and therefore help to make decisions regarding embryo selection. 
To date, 24sureTM and 24Sure-plusTM arrays have been validated using a number of different cell 
types to evaluate both technical and biological performance, some examples of which are listed in 
Table 1b.1. Following clinical implementation it is essential to maintain accuracy and overall 
quality assurance of the test offered by means of test quality control measures and external 
quality assessment (EQA). The sex chromosomes provide a good internal control by observing 
the X and Y chromosome deviation from the autosomes within a euploid DNA complement. This 
level of deviation can be used as a guide to assess aneuploid and euploid positions on the array 
CGH plot. For EQA, a scheme for single cell array CGH is currently in development based on 
earlier single cell PGD schemes (Deans et al. 2013) and in many countries such schemes are 
required for laboratory accreditation and to meet regulatory requirements. 
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(a) Second polar body 
 
(b) Corresponding zygote 
 
Figure 4.3. Array CGH trace from second polar body and corresponding oocyte sample 
(Thornhill et al. 2014a). 
Multiple aneuploidies (gains or losses) detected in (a) the second polar body (-2, -5, -9, -15, -21) 
are seen in the reciprocal form in (b) the corresponding zygote (+2, +5, +9, +15, +21 and 
additionally -19). Note the increased amplitude of the signal:noise ratio for the polar body sample 






Figure 4.4. Detection of mosaicism in trophectoderm samples using array CGH (Thornhill 
et al. 2014a). 
A sample of the trophectoderm from a human blastocyst show likely chromosomal mosaicism. 
This male embryo is euploid for all autosomes except for a mosaic trisomy of chromosome 7. 
Mosaicism is suspected because the signals for the chromosomes are relatively uniform and the 
log2 ratio shift for chromosome 7 is uniform along the length of the chromosome but does not 
exceed the threshold (bottom red and top green line respectively) required to call it uniformly 
aneuploid. It is unclear whether the presence of mosacism identifies this embryo as 
chromosomally abnormal and potentially nonviable. Note the generally high signal-to-noise ratio 
for this multicellular sample compared with that seen for polar body samples in Figure 1b.3 
(aCGH traces courtesy of Dr. Francesco Fiorentino, Genoma Laboratories, Rome, Italy.) 
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Table 4.1: Formal Pre-Clinical Validation of 24SureTM BAC Microarray (Thornhill et al. 
2014a) 
Cell/sample type Known genotype Accuracy of aCGH 
diagnosis (%) 
Blinded euploid/aneuploid ovarian 
carcinoma cell lines 
(single cells) (Dr Joyce Harper, UCL 
Centre for PGD, 
Personal Communication) 
Yes 51/51 (100%) 
Blinded aneuploidic cell lines (single cells) 
( BlueGnome, 
unpublished data) 
45, X; 47, XY +13; 47, XY +21; 
47, XYY; 47, XXY 
118/121 (98%) 
Human embryonic blastomeres 
(reanalyzed embryos) (Gutierrez-Mateo et 
al. 2011) 
Various genotypes established 
by 12 colour FISH  
53/54 (98%) 
Human oocytes and polar bodies 
(Geraedts et al. 2011) 
Various genotypes deduced by 
reciprocity between PB1/2 and 
corresponding oocyte 
90% concordance in 226 
trios (PB1/2 and oocyte) 
 
4.5. High Resolution Array CGH for Detection of Chromosome Imbalance 
Where array CGH is used to detect chromosomal imbalance in embryos derived from couples in 
whom at least one partner carries a balanced translocation, an assessment of: (i) the likely 
outcomes should be made by a qualified genetics professional; and (ii) the likely size of 
unbalanced products using a prediction tool (available from BlueGnome) to ensure the microarray 
has sufficient resolution to detect smaller products. For example, the current version of 24Sure-
plusTM contains 4,800 BAC clones and claims to be able to accurately detect products as small as 
10Mb (with possible detection to the 2.5Mb resolution level in regions with good clone coverage). 
The protocol for use of 24Sure-plusTM is essentially the same as for 24SureTM, the primary 
difference being the higher resolution microarray slide using in the 24Sure-plusTM test. Aside from 
improved accuracy and effectively eliminating the need to provide couple specific test 
development, an additional benefit of using array CGH for translocation carriers is the 
simultaneous detection of aneuploidy for all the other chromosomes not involved in the 
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translocation (Alfarawati et al. 2011a). An example of the array trace showing reciprocal gains 
and losses in the predicted chromosomes (involved in the translocation) is shown in Figure 4.5. 
 
(a) Chromosome 2     (b) Chromosome 5 
 
Figure 4.5. Detection of partial aneuploidies in embryonic samples from a reciprocal 
translocation carrier – t(2;5)(q21;q31) – using array CGH (Thornhill et al. 2014a). 
 
Embryos from reciprocal translocation carriers can be used to validate 24SureTM detection of 
segmental aneuploidies since each affected embryo will have segmental aneuploidies based at 
two specific breakpoints. Detecting gains and losses at these two specific breakpoints internally 
validates the accuracy of the test. In this case, one parent carried the translocation 
t(2;5)(q21;q31) resulting in gains and losses of chromosomal material in the single blastomeres of 
affected embryos. Even though the deletion/duplications can be relatively small, the combination 
of a higher resolution microarray, known breakpoints and their predicted meiotic products and a 




4.6. Limitations of Array CGH 
Array CGH is highly accurate (98%) and in competent hands delivers a 98% result rate. Despite 
its proven accuracy, array CGH has clinically relevant limitations in the field of preimplantation 
genetics. For example, it cannot discriminate between maternal and paternal errors. Nor can it 
distinguish between meiotic and mitotic errors of chromosome segregation. For the purposes of 
the cycle in which the testing is being done, this is not so relevant. However such additional 
information may provide clues as to how to treat the patient in the future. Finally, as array CGH is 
a method predicated on high quality DNA and successful hybridisation the possibility exists that 
borderline results could be mis-called (as with FISH). 
 
4.7. Future Opportunities 
While array CGH has become the gold standard for direct chromosome enumeration in embryos 
and oocytes, there are a number of alternatives available which could, in time, challenge its 
dominance. As with all competing technologies there are advantages and disadvantages 
(Bisignano et al. 2011; Handyside 2013). Comprehensive chromosomal screening using 
multiplex quantitative fluorescent PCR (Treff et al. 2012) may provide a cheaper alternative but it 
is not currently commercially available, thereby restricting its use. Aneuploidy can also be 
detected using single nucleotide polymorphism arrays using a combination of loss of 
heterozygosity (monosomy), quantitation of specific SNP loci and incongruous SNP calls 
compared with predicted Mendelian results using parental information that are incompatible with 
normal disomy (Handyside et al. 2010; Johnson et al. 2010; Treff et al. 2010; Gabriel et al. 2011b; 
Brezina et al. 2011). Next Generation sequencing promises to supersede all other methodologies 
(Handyside 2013) but currently is only cheaper than array based methods if large numbers of 





4.7.1. Non-Invasive Indirect Methods of Determining Aneuploidy  
Weak correlations exist between the presence of embryonic aneuploidy and morphological 
aspects of embryo development following retrospective analysis (Munné 2006; Alfarawati et al. 
2011b). Such findings have stimulated the field of non-invasive analysis of embryos in an attempt 
to identify aneuploidy in a real-time clinical setting. Time-lapse imaging and analysis appears to 
demonstrate that morphologic features and developmental timings of the embryo have some 
relationship to aneuploidy with an algorithm based on the onset and duration of blastulation 
correlating well with implantation rates (Campbell et al. 2013a; Campbell et al. 2013b). However 
this finding is only on a small sample size and is likely to be confounded by a maternal age effect 
(Ottolini et al. 2014). If the finding is confirmed in larger data sets and with appropriate sub-group 
analysis stratified by maternal age it may provide some useful prioritisation criteria but cannot, at 
present, replace the specificity and accuracy of aneuploidy testing using array CGH on biopsy 
samples. 
Another promising morphokinetic approach is to assess dynamic fragmentation patterns within 
early embryos but again, it currently does not identify specific aneuploidies and cannot be 
regarded as a challenge to direct genetic analysis (Chavez et al. 2012). Indeed, it is important to 
note that, no morphokinetic parameter has yet been observed to discriminate between euploid 
and simple aneuploid (e.g. trisomy 21) embryos. Moreover, while there have been some useful 
predictors of viability related to specific metabolites, none so far has been linked specifically to 
aneuploidy rather than viability, or been able to differentiate between general chromosomal 
aneuploidy and specific aneuploidy (Picton et al. 2010; McReynolds et al. 2011). 
 
4.8. Summary and Essentials 
At present, array CGH may be considered the gold standard for detecting aneuploidy in single 
cells or multicellular samples from oocytes and embryos as a result of its reliability, reproducibility, 
accuracy and the large worldwide experience with it. It is possible to obtain results within 12 hours 
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following biopsy making it accessible to most laboratories regardless of the biopsy stage selected. 
While there remains some controversy over the benefit of PGS for specific patient indications, 
there appears to be a recent shift towards trophectoderm (multicellular) biopsy of the highest 
quality embryos from good prognosis patients in contrast to the historic focus on cleavage-stage 
biopsy of few, poor quality embryos in poor prognosis patients. Irrespective of the approach 
taken, the following tips below should be considered critical for effective use of this technology.  
 
4.8.1. Quality of the IVF Laboratory 
Overall quality of the in vitro fertilisation (IVF) programme is critical. Whenever an oocyte or 
embryo is subjected to a procedure outside of the incubator there is a risk involved. Thus a 
fundamental principle underpinning the use of aneuploidy screening is that the benefit gained 
should outweigh the harm, if any, caused. Thus if the success rates of the programme are 
already sub-optimal it is difficult to see any procedure providing sufficient benefit to rescue the 
cycle.  
 
4.8.2. Embryo Biopsy 
Embryo biopsy has become simpler with the availability of the non-contact infra-red laser which is 
common in many IVF laboratories (see section 3.3). With this laser, it is relatively simple to 
perform oocyte or embryo biopsy, in many cases without apparent damage to the subject. 
However, following indiscriminate use, invisible thermal damage might be caused which, while 
not immediately lethal, could have later consequences compromising development and 
subsequent implantation. For this reason, it is vital to perform the embryo biopsy as quickly as 
possible with minimal exposures to laser energy to complete the task safely and effectively. The 
issue of embryo selection for biopsy is not straightforward as there is inevitably a balance 
between the cost and efficacy of performing a biopsy on all embryos in the cohort against the 
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need for all information and the small chance that apparently delayed embryos (either at cleavage 
or blastocyst stages) still may have some implantation potential.  
 
4.8.3. Sample Preparation and Transportation 
Proper preparation of the biopsied sample, while mundane, is of critical importance. A focus on 
the sterility of the working area and solutions, precise volume of buffer in the microcentrifuge tube 
with minimal carryover of embryo culture medium (which can reduce amplification efficiency) and 
subsequent storage of the sample pre-analysis is paramount to ensure high diagnostic success 
rates. Particular care must be taken not to contaminate the sample with foreign DNA by means of 
good laboratory practice, appropriate apparel and dedicated cleanroom, equipment and 
consumables for amplification steps. A negative control of the embryo media and collection buffer 
should always be taken at this point to check for the absence of contamination as array CGH is 
not able to identify the origin of any contamination. While published protocols exist and diagnostic 
service laboratories generally provide their own standard operating procedures, a series of 
laboratory-specific validation experiments is extremely useful prior to offering the service clinically. 
 
4.8.4. Whole Genome Amplification 
A number of different methods are available and have been reported for use in preimplantation 
genetic testing. However, the specifications of the amplified DNA optimal for array CGH are DNA 
fragments of a specific size corresponding to the specific array type. For 24SureTM BAC arrays, 







4.8.5. Array CGH Procedure 
Hybridisation is fairly robust but care should be taken to ensure microarray slides do not dry out 
prior to washing. The high temperature high stringency wash post-hybridisation must be 
temperature controlled. Lower temperatures prevent the removal of non-specific labelled DNA 
from the array potentially resulting in ratio data compression and generally generating noisy or 
ambiguous results. If the temperature is too high too much of the labelled DNA will be stripped 
from the array and could result in too few probes per chromosome to accurately call the result 
particularly for smaller chromosomes. Drying of the microarray slides is also critical; the most 
effective way is to mechanically remove wash buffer by centrifugation. If wash buffer is left to dry 
on the slides this fluoresces and will reduce data quality. After drying, slides should be scanned 
immediately as in some circumstances the fluorescent dyes can be degraded by atmospheric 
ozone. While the software is highly accurate, a combination of both automated and manual 
calling of results is recommended.  
 
4.8.6. Target Population for Testing 
Regardless of the testing method used, it is important to properly identify the appropriate patients 
who would benefit from the test. Indications for testing vary widely and it is crucial for both 
providers and patients to understand the difference between using the test to provide diagnostic 
information (for example in the case where there are very few embryos present but they are 
highly likely to be grossly aneuploidy) or information to enable selection of euploid embryos (to 
improve the likelihood of success in that embryo transfer cycle). Essentially, in the absence of 
comprehensive prospective randomised controlled clinical trials for each putative indication for 
PGS, clinics must conduct a cost-benefit exercise weighing up the potential prognostic (selection) 
and diagnostic (closure or alternative therapy) benefits against the financial cost to the patient and 
biological cost to the biopsied embryo (see General Introduction section 2.3.) 
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5. Specific Aim 2: To produce the first clinical cases to bring Karyomapping to 
full medical application, comparing it to ‘gold standard’ approaches and 
demonstrating how a linkage-based analysis of SNP karyotypes can be used 
simultaneously to detect monogenic disorders and (phase and parent of origin 
of) chromosome copy number. 
The principles of Karyomapping are outlined in section 2.5.6 of the general introduction and thus 
the next logical step was to apply the work in a clinical setting. What follows is an account of the 
first two clinical cases of Karyomapping, the first for a family at risk of transmitting Marfan 
Syndrome, the second at risk of transmitting Smith Lemli Opitz Syndrome with a history of 
aneuploid embryos from previous PGD cycles. This work has been recently published as follows: 
 
Case 1 
Thornhill AR, Handyside AH, Ottolini CS, Taylor J, Sage K, Harton GL, Cliffe K, Affara N, 
Konstantinidis M, Wells D, Griffin DK. Karyomapping – a comprehensive means of simultaneous 
monogenic and cytogenetic PGD: Comparison with standard approaches in real time for Marfan 
syndrome. J Assist Reprod Genet. 2015 Mar;32(3):347-56 
Case 2 
Natesan S, Handyside AH, Thornhill AR, Ottolini CS, Sage K, Summers MC, Gordon A, 
Michaelis Konstantidis M, Wells D, Griffin DK. Live birth by PGD following confirmation by a 
comprehensive approach (Karyomapping) for simultaneous detection of monogenic and 







5.1. My Personal Contribution to the Work 
Case 1: 
I was involved in the clinical decision-making process of how the case was run. I performed the 
majority of the embryology, blastomere biopsy and tubing work of both clinical and follow-up 
samples. I performed the Karyomapping analysis using the Karyomapping Microsoft Excel macro 
developed by Professor Alan H. Handyside (Handyside et al. 2010) to compare with the standard 
short tandem repeat (STR) analysis. I also analysed all samples for chromosome copy number 
using the same Macro. 
Case 2: 
I recruited these patients into the Bridge Centre’s Karyomapping program during a prospective 
patient seminar after the couple discussed their clinical history with me. I was involved in the 
clinical decision-making process of how the case was run. I performed all of the embryology work 
including sequential polar body biopsy of the first and second polar bodies, blastomere biopsy 
and tubing work of both clinical and follow-up samples. I performed the Karyomapping analysis 
using the Karyomapping Microsoft Excel macro developed by Professor Alan H. Handyside 
(Handyside et al. 2010) to compare with the standard STR analysis. I also analysed all samples 
for chromosome copy number using the same Excel macro for comparison to the array 
comparative genomic hybridisation (CGH) results of the corresponding polar bodies. 
The following text is adapted from that in the original manuscripts: 
 
5.2. Introduction 
As outlined in Specific Aim 2 of this thesis, preimplantation genetic diagnosis (PGD) of single 
gene defects by genetic analysis of biopsied material from oocytes and embryos is clinically well 
established. However, there are significant drawbacks associated with current technologies in 
that there is an inherent need to tailor the diagnostic approach to the disorder and individual 
family under investigation. Diagnostic strategies also need to be optimised for single or small 
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numbers of cells. In practice, this can take days or weeks, with the corresponding delay, stress 
and reduction in fertility potential to couples as they wait for test validation. An approach that does 
not require individual-specific validation therefore is a priority for all families seeking PGD. 
Moreover, the ability to combine monogenic disorder detection with high-resolution chromosome 
analysis in a single test would potentially find widespread clinical application (Handyside & Xu 
2012).  
Targeted haplotyping by multiplex fluorescent polymerase chain reaction (PCR) of closely linked 
or intragenic STR markers combined with direct mutation detection improves the accuracy of 
embryo biopsy analysis significantly and minimises potential errors caused by undetected allele 
dropout (ADO) or contamination (Harton et al. 2011). ADO refers to the failure of one of the two 
alleles of a heterozygous locus to amplify. This makes a heterozygous cell appear homozygous 
at the affected locus, potentially leading to misdiagnosis. Furthermore, using high order multiplex 
protocols, this approach has been extended to multiple loci, including analysis of the human 
leukocyte antigen (HLA) region for selection of embryos tissue matched to existing sick children 
and diagnosis of translocation chromosome imbalance. However, the development of patient, 
disease or locus-specific protocols, and testing with single cells, is time-consuming and labour 
intensive. Also, this targeted approach only provides limited information on chromosome 
aneuploidy, which is recognised to be a major cause of in vitro fertilisation (IVF) failure and 
pregnancy loss. 
As outlined in section 2.5.6, Karyomapping (Handyside et al. 2010) uses the principles of linkage 
analysis to detect monogenic disorder plus the spectrum of molecular cytogenetic abnormalities 
in a single assay. Thus, meiotic trisomies, including their parental origin, can be identified by the 
presence of both haplotypes from one parent in segments of the chromosome, resulting from the 
inheritance of two chromosomes with different patterns of recombination. Moreover, monosomies 
or deletions can be identified by the absence of either chromosome haplotype from the parent of 
origin. Mitotic chromosome duplication, which can arise through malsegregation of chromosomes 
in the cleavage divisions following fertilisation, cannot be detected by Karyomapping per se, since 
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the sequence of both chromosomes is identical. However, chromosome duplications may be 
clinically less significant, since they are often associated with poor morphology and 
developmental arrest. Karyomapping can also diagnose triploidy, parthenogenetic activation and 
uniparental disomy (both hetero- and iso-disomy in the presence of meiotic recombination only) 
(Handyside et al. 2010). 
The purpose of this chapter was to extend Karyomapping into a clinical setting by reporting its 
successful use for PGD in confirming (in real time) current standards of mini-sequencing, linked 
markers and array CGH (aCGH). The main challenge of this work was to apply Karyomapping, 
firstly by adapting the protocol for clinical use in a regular PGD timeframe (24 hours), and 
secondly by detection of the autosomal dominant condition Marfan syndrome (Case 1) and the 
autosomal recessive disorder Smith-Lemli-Opitz (SLO) syndrome (Case 2). The aim was that 
both would ultimately lead to unaffected live births. 
 
5.3. Materials and Methods 
5.3.1. Case 1 
5.3.1.1. Patient History 
Marfan syndrome is an autosomal dominant disorder of the connective tissue predisposing to 
aortic aneurism and caused by mutations in the fibrillin-1 (FBN1) gene on ch romosome 15q21.1. 
A couple, in which the father is affected by Marfan syndrome and has had an aorta replacement 
and treatment for a detached retina, requested PGD. The father was previously referred to the 
Bridge Centre genetics department by an accredited National Health Service (NHS) laboratory as 
heterozygous for two mutations in FBN1, c.235C>T and c.3089A>G. The first, c.235C>T 
(p.Gln79X) is a nonsense change that has been reported in the FBN1 online mutation database 
http://www.umd.be/FBN1/4DACTION/WV/2699. The second variant is a missense change 
c.3089A>G (p.Asn1030Ser), this was not reported in the database at the time of writing. While the 
database does not assign specific pathologies to each mutation, the reasonable assumption was 
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made that one or both of these mutations in FBN1 were the cause of Marfan syndrome in this 
patient. While there was no molecular work up of older family members there was also no prior 
family history of the syndrome. Both were found to be present in his affected daughter (5 years 
old at the time of treatment) establishing that they are present in cis on the same paternal 
chromosome. The mother (36 years old at the time of treatment) had only one other natural 
pregnancy that resulted in a hydatidiform mole. 
The patients gave informed consent for treatment by PGD/Karyomapping. Ethical approval was 
granted by the treatment licences awarded to the Bridge Centre, London, the Clinical Pathology 
Accreditation, Certificate of Accreditation awarded to the Institute of Reproductive Sciences, 
Oxford and the University of Kent Local Research and Ethics Committee. The patients received 
counselling for intra-cytoplasmic sperm injection (ICSI)/PGD at the Bridge Centre prior to 
treatment. 
 
5.3.1.2. IVF Cycle 
An antagonist protocol was used for ovarian stimulation. When the average follicular diameter 
was >16mm, 5000IU β-human Chorionic Gonadotrophin (β-hCG) was administered and the 
oocytes retrieved 36 hours later by ultrasound-guided transvaginal aspiration under local 
anaesthesia. ICSI was used for insemination of mature oocytes, six to eight hours after the oocyte 
retrieval, to avoid contamination by extraneous sperm. The following morning (Day 1), each 
injected oocyte was checked for pronuclei to confirm fertilisation. 
 
5.3.1.3. Embryo Biopsy 
Normally fertilised embryos (with two pronuclei on Day 1), which developed to the 6- to 10-cell 
stages on Day 3 following ICSI were transferred to calcium- and magnesium-free medium 
(Quinn’s Advantage, Cooper Surgical, CT, USA) and one or two single blastomeres were 
biopsied for genetic analysis by micromanipulation after making an opening in the zona pellucida 
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using a non-contact infrared laser (Saturn 3, Research Instruments Ltd, Penryn, UK). The 
embryos were then returned to culture while the biopsied cells were thoroughly washed in non-
stick wash buffer (phosphate buffered saline [PBS] with 0.1% polyvinyl pyrrolidone). The washed 
cells were transferred to 0.2ml PCR tubes in approximately 1-2μl of the wash buffer and frozen 
before transportation to Reprogenetics UK (Oxford, UK) for further processing. 
 
5.3.1.4. Whole Genome Amplification 
The whole genome of the single blastomeres was amplified by multiple displacement 
amplification (MDA) according to the manufacturer’s instructions with modifications (Repli-g Midi 
kit, Qiagen, Germany). In brief, 1.5μL of PCR-grade water was added to each sample and 
alkaline lysis carried out by adding 2.5µl of lysis buffer (0.75μL of PCR-grade water, 1.25μL of 
0.1M DTT and 0.5μL of 1M NaOH) and incubation at 60°C for 10 min. Neutralisation buffer (2.5µl 
0.4M Tricine), 12.5µl PCR grade water, 29µl reaction buffer and, finally, 1µl of DNA polymerase 
(Repli-g Midi kit, Qiagen, Germany) was added to each sample individually for a final reaction 
volume of 50µl. The samples were then incubated in a thermocycler at 30C for two hours, 
followed by enzyme inactivation at 65C for 5 min. 
 
5.3.1.5. Short Tandem Repeat and Mutation Analysis 
For dominant conditions, PGD protocols that focus on the analysis of the mutation site alone are 
associated with an unacceptably high risk of misdiagnosis caused by ADO. Allele dropout is 
common at the single cell level and, as explained in section 2.5.3., results in a heterozygous cell 
appearing to be homozygous. In the case of PGD for Marfan syndrome, ADO affecting the 
mutation site on the copy of chromosome 15 carrying the mutation, could cause an affected 
embryo to appear normal (as only the normal allele is successfully amplified). To reduce the risk 
of misdiagnosis, a strategy employing a combination of mutation detection and analysis of closely 
linked STRs was used, revealing the paternal 15q21.1 haplotype associated with the mutation. 
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Only one STR marker (D15S659) was found that had different repeat alleles on each of the four 
parental chromosomes and was fully informative (Table 5.1; Figure 5.1). To increase accuracy, a 
further two STRs, one intragenic (D15S196) and a second proximal STR (D15S143), were 
selected which had two paternal alleles, one of which was shared with the single maternal allele. 
 
Table 5.1: STR Sizes for Family Members (see also Figure 2.1) (Thornhill et al. 2014) 







Father (affected carrier) 185 / 193 271 / 275 176 / 180  
Mother (unaffected) 193 275 192 / 200 
Daughter (affected carrier) 185 / 193 271 / 275 176 / 200 
 




Figure 5.1. Analysis of three short tandem repeat (STR) markers and the c.235C>T mutation in FBN1 by capillary electrophoresis (Thornhill 
et al. 2014). 
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Following isothermal MDA, the products were amplified in a series of singleplex PCR reactions. 
Reaction mixtures contained PCR grade water (Roche, Germany), 1x HotMaster Taq Buffer (with 25 
mM Mg2+) (5 Prime, Germany), dNTPs (200µM each) (Thermo Scientific, USA), 0.8µM each primer, 
0.6 units HotMaster Taq DNA polymerase and 1µl MDA WGA DNA for a final volume of 15µl. 
Thermal cycling consisted of an initial denaturation step of 96ºC for 1 min, followed by 50 cycles of 
94ºC for 15s, 60ºC for 15s, and 65ºC for 45s, then a final extension step of 65ºC for 2 min. Primer 
sequences for the linked STRs were obtained from the NCBI ‘UniSTS’ 
database(http://www.ncbi.nlm.nih.gov/unists):  
D15S1435’-CCTAAGGAGGCAACAGCAAAG-3’ and 5’-GTAAAGACTGGTATCTGTAGCAC-3’); 
D15S196 (5’-GACCTGTAGCTGAAGGGAAG-3’ and 5’- ATAAAAGTGGTGGGGAAGGATG-
3’);D15S659(5’- GTGGATAGACACATGACAGATAGG-3’ and 5’- 
TATTTGGCAAGGATAGATACAGG-3’).  
The primers utilised for amplification of the mutation site were:  
5’- TGGATGGAAAACCTTACCTG-3’ and 5’- CAGTTACAAAAGGCCACATTC-3’. Only the 
c.235C>T mutation was targeted since the two mutations identified in father and daughter were 
determined to be in cis (i.e. located within the same gene on the same chromosome and therefore 
inherited together).  
 
5.3.1.6. Mutation Detection 
The procedure for carrying out minisequencing involved two separate reactions. Initially, products 
derived from PCR amplification of the mutation site were treated with ExoSAP-IT (USB, Affymetrix, 
USA) according to manufacturer’s instructions. Treated products were then subjected to 
minisequencing through the usage of the SNaPshot Multiplex Kit (Applied Biosystems, USA). 
Specifically, the reaction mixture contained 2.5µl of SNaPshot Multiplex Ready Reaction Mix, 0.5µl of 
2µM minisequencing primer (F–5’-AAACCTTACCTGGCGGAAAT-3’), 0.5µl PCR grade water and 
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1.5µl of treated amplified product for a final volume of 5µl. Thermal cycling consisted of 25 cycles of 
96C for 10s, 50C for 5s, 60C for 30s.  
Confirmation of the above was performed by Karyomapping on the same whole genome amplified 
material. Single Nucleotide Polymorphism (SNP) genotyping proceeded using the Illumina Bead chip 
system (Illumina inc, Cambridge UK). Genomic DNA from father, mother, affected daughter and 
MDA product from the embryo samples were used to interrogate the arrays. Following scanning, 
image data were transferred to the GenomeStudio Software framework V2010.1 (Illumina inc, 
Cambridge UK) and converted from fluorescence data to genotypic data based on design algorithms 
consistent with bead chip content (BeadStudio Software Suite, v3.1, Illumina, Inc). The genotype 
data was exported as an Excel compatible file for Karyomapping analysis. 
A Visual Basic for Applications (VBA) macro has been described previously (Handyside et al. 2010) 
to process and analyse the SNP genotype data and construct Karyomaps in Microsoft Excel. 
Karyomapping was performed for diagnostic and confirmatory purposes and results were compared 
with the original diagnosis of PCR analysis of markers linked to the DHCR7 gene and mini-
sequencing of the mutation directly. Cytogenetic data was compared with the array CGH data 
derived from polar bodies. 
 
5.3.2. Case 2 
5.3.2.1. Patient History 
This couple was at risk of transmitting SLO syndrome; an autosomal recessive condition leading to 
multiple congenital abnormalities and mental retardation. Both parents are unaffected carriers with 
mutations in the 7-dehydrocholesterol reductase gene (DHCR7) on chromosome 11q12-q13. The 
female patient is of advanced maternal age with evidence of decreased ovarian reserve. The couple 
noted six natural pregnancies: a full term healthy daughter; two terminations for foetal SLO 
syndrome; two first trimester spontaneous abortions of unknown aetiology and one second trimester 
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pregnancy loss diagnosed with SLO syndrome. They previously completed, without success, two 
treatment cycles of IVF/ICSI/PGD using standard approaches. 
The patients gave informed consent for treatment by PGD/Karyomapping. Ethical approval was 
granted by the treatment licences awarded to the Bridge Centre, London, the Clinical Pathology 
Accreditation, Certificate of Accreditation awarded to the Institute of Reproductive Sciences, Oxford 
and the University of Kent Local Research and Ethics Committee. The patients received counselling 
for ICSI/PGD at the Bridge Centre prior to treatment. 
 
5.3.2.2. IVF Cycle 
A short cycle flare protocol was used for ovarian stimulation. An hCG trigger (Ovitrelle) was 
administered after 11 days of stimulation and transvaginal ultrasound-guided oocyte retrieval 
performed 35 hours later.  
For PGD, the primary diagnosis of chromosome constitution was performed on first and second 
polar bodies using array CGH. The diagnosis of SLO status was performed on cleavage stage 
biopsied single cells (as is common practice in the Oxford laboratory) using mini-sequencing and 
linked markers on whole genome amplified material from the cleavage-stage biopsied blastomeres. 
Karyomapping was performed to confirm the above on the same whole genome amplified material 
and at exactly the same time. From the outset, the decision was made to disclose all results with the 
exception of the Karyomapping results on the transferred embryos. 
 
5.3.2.3. Biopsy and WGA 
Biopsy of the first polar body in each oocyte was performed on the day of egg collection followed by 
ICSI. Biopsy of the second polar body was performed post-fertilisation. Polar bodies were subjected 
to whole genome amplification (WGA) using SureplexTM then aCGH using a commercial service 
(BlueGnome, now Illumina, Cambridge, UK) to determine aneuploidy status. Cleavage stage biopsy 
106 
 
proceeded at Day 3 post-fertilisation and, to perform WGA, cells were amplified using multiple 
displacement amplification (Repli-g Midi kit, Qiagen, Germany, with modifications). All blastomeres 
were tested directly for mutations in the DHCR7 gene. STR primers for three loci-linked to the 
DHCR7 gene (D11S4139, D11S4143. D11S4207 – Molecular Genetics Laboratory, Rome, Italy) 
were amplified in separate singleplex PCR reactions using Hot Master Taq DNA polymerase 
(5PRIME, Hilden, Germany), which were detected by capillary electrophoresis (3130 Genetic 
Analyzer [Applied Biosystems, USA]) and analysed using GeneMapper software v4.0 (Applied 
Biosystems, USA). Minisequencing involved the SNaPshot Multiplex Kit (Applied Biosystems, USA).  
 
5.3.2.4. PGS and PGD 
For PGD, the primary diagnosis of chromosome constitution was performed on first and second 
polar bodies using array CGH. The diagnosis of SLO status was performed on cleavage stage 
biopsied single cells (as is common practice in the Oxford laboratory) using mini-sequencing and 
linked markers on whole genome amplified material from the cleavage stage biopsied blastomeres. 
Karyomapping was performed to confirm the above on the same whole genome amplified material 
and at exactly the same time. From the outset, the decision was made to disclose all results with the 
exception of the Karyomapping results on the transferred embryos. 
Modification of the original Karyomapping protocol was performed to allow diagnosis within 24 hours. 
SNP genotyping proceeded using the Illumina Bead chip system (Illumina inc, Cambridge UK). 
Genomic DNA from father, mother, previously affected foetus and MDA product from the embryo 
samples were used to interrogate the arrays. Following scanning, image data were transferred to the 
GenomeStudio Software framework V2010.1 (Illumina inc, Cambridge UK) and converted from 
fluorescence data to genotypic data based on design algorithms consistent with bead chip content 
(BeadStudio Software Suite, v3.1, Illumina, Inc). The genotype data was exported as an Excel 
compatible file for Karyomapping analysis. 
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A VBA macro has been described previously (Handyside et al. 2010) to process and analyse the 
SNP genotype data and construct Karyomaps in Microsoft Excel. Karyomapping was performed for 
diagnostic and confirmatory purposes and results were compared with the original diagnosis of PCR 
analysis of markers linked to the DHCR7 gene and mini-sequencing of the mutation directly. 
Cytogenetic data was compared with the array CGH data derived from polar bodies. 
 
5.4. Results 
5.4.1. Case 1 
5.4.1.1. IVF and Embryo Biopsy 
10 cumulus oocyte complexes were collected and eight mature oocytes, arrested at metaphase II, 
inseminated by ICSI. The following morning the injected oocytes were checked and six had two 
pronuclei indicating normal fertilisation. All six embryos reached appropriate cleavage stages 
between the 6- and 10-cell stages on Day 3 post ICSI and one or two cells were biopsied for genetic 
analysis. 
 
5.4.1.2. Targeted Haplotyping and Direct Mutation Analysis 
Following WGA targeted haplotyping, with all three STR markers, and direct mutation analysis was 
successful in 7/8 (87.5%) of the single cells biopsied from six cleavage stage embryos (Table 5.2; 
Fig. 1). Two single cells were biopsied from two embryos but one of these from Embryo 5 failed to 
amplify. Analysis of the STR alleles present at the FBN 1 locus were consistent with the mutation 
status in five embryos and identified four as unaffected (Embryos 1, 3-5) and one as affected 
(Embryo 2). In the remaining single cell biopsied from Embryo 6 with a normal allele for the mutation, 
only one of the maternal alleles (200bp) and neither of the paternal specific alleles (176 and 180bp) 
were detected with D15S659.Furthermore, the other two STR markers had only a single allele 
shared by both parents (193bp and 275bp respectively).The interpretation was therefore that either 
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the paternal chromosome with the normal FBN1 allele was present but that ADO had occurred with 
D15S659, or the paternal chromosome 15 was absent from that cell and was reported as unaffected 




Table 5.2: Comparison of Targeted Haplotyping, Direct Mutation Analysis with Karyomapping for Linkage Based Diagnosis of Marfan 




















Gain Loss Gain Loss 
1 (1) 193 275 180/200 
Normal allele 
only 
Unaffected*** P2/M1 Yes    21 
Mosaic loss of 
chr21 
1 (2) 193 275 180/200 
Normal allele 
only 
Unaffected*** P2/M1 Yes     
2 185/193* 271/275* 176/200  * 
Normal & 
mutant allele 











Yes**  All chrs 10 (MeI) 19 
No paternal 
genome 
4 193 275 180/192 
Normal allele 
only 
Unaffected P2/M2 Yes  6qter****   
Embryo 
Transferred 
5 (1) 193 275 180/200 
Normal allele 
only 
Unaffected P2/M1 Yes     
Embryo 
Transferred 





NR N/A     No amp 





















* Linked marker alleles in bold are the ones associated with the mutant FBN1 allele. 
**Note an allele was originally determined to be present at 180bp but, after subsequent analysis, determined to be an artefact 
*** Although determined as not carrying the mutant Marfan allele, embryo not transferred for other (e.g. cytogenetic) reasons 
**** This apparent deletion was identified after retrospective closer analysis of Karyomapping traces. As call rates were low in this region, it is possible 
that the apparent deletion was a technical artefact.  
For chromosomal analysis:  
MeI/MeII=meiosis I/II; qter=terminal portion of long arm of the chromosome; dup=duplication; all chrs=all chromosomes 
For Karyomap analysis: P1=Paternal haplotype 1; P2=Paternal haplotype 2; M1=Maternal haplotype 1; M2=Maternal haplotype 
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5.4.1.3. Karyomapping Analysis 
SNP genotyping and Karyomapping analysis was successful with all seven single cells from 
which MDA products were available. Genomic DNA samples from the parents and affected child 
gave call rates of about 97% and heterozygous call rates of 28-29%. Overall SNP call rates were 
lower in single cells, ranging from 78-82% with a significant rate of ADO (approximately 15%) and 
heterozygous call rates ranging from 14-20% (excluding the cell from the parthenogenetic haploid 
embryo). Karyomapping identified the parental chromosomes present at the FBN1 locus on 
chromosome 15q21.1 in 11/12 (92%) of the chromosomes present in the seven cells analysed 
(Figure 5.2; Table 5.2). The only chromosome which could not be haplotyped confidently at the 
FBN1 locus was the maternal chromosome 15 in Embryo 3. In that case, there was a crossover 
immediately distal to FBN1 and without any intragenic informative SNP loci, the exact location of 
the recombination event could not be identified unequivocally. Otherwise, the paternal and 
maternal haplotypes identified (where present) were concordant with the targeted haplotyping 
and direct mutation analysis, including the proximal region of the maternal chromosome 15 in 








Consecutive informative SNP loci for the four parental chromosomes are represented by two pairs of columns in each case (paternal, left and maternal, 
right) in which each segment is an informative SNP. Single cell genotypes identifying the presence of one of the four parental chromosomes at 
informative SNP loci are coloured (paternal chromosomes P1 and P2 are indicated in blue and red respectively; maternal chromosomes M1 and M2 in 
yellow and green respectively). The Karyomaps of a 5-6Mb region of chromosome 15q21.1 of the affected child, known to be a carrier of both paternal 
mutations (P1-blue) and used as a reference for phase, and seven single blastomeres biopsied from six cleavage-stage embryos are presented (M1-
yellow chromosome also assigned). Otherwise, informative SNP genotypes, which indicate the absence of that chromosome or are not called, are 
coloured grey. The position of FBN1 relative to the SNP loci is indicated by the light blue bars. The positions of the three STR markers, D15S143, 
D15S196 and D15S659 used for conventional analysis are indicated on the left. Three embryos are identified as having the unaffected (red) paternal 
chromosome (Embryos 1, 4 and 5); one embryo has the affected paternal chromosome (blue) also present in the affected child (Embryo 2), and two 
embryos are missing the paternal chromosomes either because of the complete absence of the paternal genome in a parthenogenetically activated 
embryo (Embryo 3) or paternal monosomy 15 (Embryo 6). Crossover marked with X. * miscall. 
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In two embryos, Karyomapping revealed that the paternal chromosome 15 was absent with only 
a low proportion of random positive informative SNPs for both haplotypes (Embryos 3 and 6; Fig. 
7). For Embryo 3, examination of the Karyomaps for all the other chromosomes revealed that no 
paternal chromosomes were present, which may have resulted from fertilisation failure and 
parthenogenetic activation of development, whereas in Embryo 6, the missing chromosome was 
an isolated paternal monosomy (Table 2.2).  
Karyomapping analysis of the other chromosomes present in the single cells revealed several 
aneuploidies and structural abnormalities (Table 2.2). These included three maternal meiotic 
trisomies in three separate embryos: trisomy 1 in Embryo 2 in which both maternal chromosome 
haplotypes were detected on segments of both arms of the chromosome (meiosis II type), 
trisomy 10 in Embryo 3 with both maternal haplotypes additionally present across the centromere 
(meiosis I type) and trisomy 8 (meiosis II type) in Embryo 6. In addition, there was a mosaic loss 
of maternal chromosome 21 in Embryo 1, and possible deletions affecting paternal 6q and 20q in 
Embryos 4 and 6 respectively. The deletion for chromosome 6q in embryo 4 was discovered after 
a more detailed retrospective analysis and a low call rate in that region for this blastomere meant 
that this diagnosis was not 100% confident. Finally, both maternal chromosome haplotypes were 
present for a segment of the short arm only for chromosome 6 in Embryo 6 (partial trisomy 6p). 
As this abnormality was not confirmed in the whole embryo (see below), this may be an acentric 
fragment from the other maternal chromosome which arose by chromosome breakage during 
meiosis, and remained in the oocyte at fertilisation.  
 
5.4.1.4. Follow-up Analysis of Embryos 
Analysis of the three embryos that were not selected for transfer and were processed whole, 
confirmed the presence of the two meiotic trisomies and the maternal loss of chromosome 19 in 
Embryos 3 and 6 (Table 5.2). However, as expected the mosaic loss of maternal chromosome 21 
in Embryo 1 was not detected. Furthermore, the presence of both maternal chromosomes for 6p 
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in Embryo 6 was also not detected. This is consistent with the presence of an acentric fragment 
arising in meiosis and segregating to the biopsied blastomere since an extra whole chromosome 
would normally be present in most, if not all, cells as was observed for the other meiotic trisomies. 
A fourth embryo (Embryo 2) was disaggregated on Day 4 into eight single blastomeres and one 
two-cell sample (10 cells in total). All of these cells had identical Karyomaps and the presence of 
trisomy 1 was confirmed in each case (Table 5.2). There were no other mosaic chromosome 
abnormalities except for partial loss of maternal chromosome 13 (approximately 40.5Mb) in one 
cell. 
 
5.4.1.5. Clinical Outcome 
Based on the results of the targeted haplotype and direct mutation analysis (see above), two 
embryos diagnosed as unaffected were transferred resulting in a twin pregnancy. Delivery was 
premature at 28 weeks and subsequently one of the twins died following a perinatal infection. The 
remaining twin boy was healthy at 2 years. Another of the unaffected embryos (Embryo 1; Table 
5.2), cryopreserved by vitrification at the blastocyst stage on Day 6 post ICSI, was successfully 
thawed 16 months later and transferred in an unstimulated cycle; no pregnancy resulted. 
 
5.4.2. Case 2 
5.4.2.1. IVF and Biopsy 
Eight oocytes were retrieved, of which six were mature second meiotic division (MII) oocytes 
suitable for ICSI. The first polar body (PB1) was biopsied from each of the six oocytes. Following 







Array CGH analysis of PB1 and PB2 revealed a normal pattern in zygotes 1 and 4 with 
chromosome 22 gain (PB1) and loss (PB2) in embryo 2; in embryos 3 and 5 a normal pattern in 
PB1 contrasted with gain of chromosome 15 and 22 respectively in PB2 (Table 5.3). 
 









SLO status by 
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(see Figure 2.2 
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Each embryo had one blastomere biopsied and a combination of mini-sequencing plus analysis 
of linked markers made the initial diagnosis of Smith Lemli Opitz status. Maternal aneuploidy 
analysis was done by array CGH on both polar bodies. Karyomapping diagnosed both Smith 
Lemli Opitz status and chromosome copy number simultaneously. (NB family and clinic agreed 
that no Karyomapping information on transferred embryo would be communicated.) 
 
5.4.2.3. PGD 
Five of six 2PN zygotes formed embryos, which were biopsied. Mutation analysis revealed a 
normal pattern in embryos 1, 3 and 5 (Table 5.3). Embryo 1 was thus transferred. Concurrently, 
Karyomapping confirmed the DHCR7 status in all embryos examined (Figure 5.3, Table 5.4) (NB 
after discussions with the family, they made it clear they did not want us to disclose any 
Karyomapping result on the transferred embryo but were happy for results on all their other 
embryos to be disclosed) and the aneuploidy results were largely concordant with results 





Figure 5.3. Karyomapping analysis of embryos and blastomeres (Bm). 
The multiple blue, red, green and yellow bars each indicate informative SNPs. Together they denote which parental chromosome has been inherited 
(blue and red are paternal chromosomes, yellow and green are maternal chromosomes). The horizontal light blue lines denote the position of the SLO 
disease locus on each chromosome. In this case it is the blue (paternal) chromosome and green (maternal chromosome) that carry the SLO disease 
alleles (same pattern as affected foetus; 2). Red-yellow is thus the “unaffected-non-carrier” pattern, blue-yellow denotes a paternal carrier of SLO, red-
green is a maternal carrier of SLO. 
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Table 5.4: Interpretation of Results from Figure 5.3 
 Description  Pattern observed around 
SLO locus 
Diagnosis 
1 Child (reference) Blue - Yellow Paternal carrier 
2 Affected fetus Blue - Green Affected 
3 Embryo 2 blastomere 1 Blue - Yellow Paternal carrier 
4 Embryo 2 blastomere 2 Blue - Yellow Paternal carrier 
5 Embryo 3 blastomere 1 Red - Yellow Unaffected 
6 Embryo 4 blastomere 1 Blue - Green Affected 
7 Embryo 5 blastomere 1 Red - Yellow Unaffected 
8 Embryo 3 blastomere 2 Red - Yellow Unaffected 
9 Embryo 3 blastomere 3 Red – Yellow Unaffected 
10 Embryo 3 blastomere 4 Red – Yellow Unaffected 
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5.4.2.4. Clinical Outcome 
A pregnancy ensued leading to the live birth of a healthy male infant free of Smith-Lemli Opitz 
syndrome and with no apparent chromosome abnormality. 
 
5.5. Discussion 
Case 2 was the first published clinical use of Karyomapping leading to a live birth of a healthy 
PGD baby. Specifically the use of Karyomapping confirmed the primary diagnoses of SLO status 
(by mini-sequencing) and chromosome copy number (by aCGH on polar bodies). Karyomapping 
was nonetheless performed ‘in real time’ alongside the standard analyses providing proof of 
principle of its efficacy in a clinical setting. Concordance with established gold standards attest 
comprehensively that Karyomapping can detect monogenic disease. Analysis of polar bodies by 
aCGH and blastomeres by Karyomapping permitted the comparison of aneuploidy results from 
both polar bodies and the subsequent embryos. One advantage of Karyomapping over aCGH is 
that it distinguishes the parent and phase of origin of meiotic chromosome error. For example, as 
shown in Table 2.1, embryo 3, the gain of chromosome 15 in the PB2 suggested a meiosis II 
error, which was confirmed as a reciprocal loss of chromosome 15 in the embryo. This was also 
mirrored in embryo 5 for chromosome 22 and the normal diagnosis of embryo 4 matched in both 
polar bodies and blastomere. In embryos 3 and 5, Karyomapping confirmed that the further 
abnormalities were paternal in origin and thus would not have been detected in the polar bodies. 
In embryo 2 a reciprocal gain and loss of chromosome 22 in PB1 and PB2 respectively was not 
reflected as an abnormality in the embryo, thereby invoking the widely reported mechanism of 
precocious separation of sister chromatids in the first meiotic division, resulting in a euploid 
conceptus (Angell et al. 1991; Kuliev et al. 2011; Gabriel et al. 2011; Handyside et al. 2012). 
The results of these cases demonstrate the clinical utility of a novel, comprehensive approach for 
PGD (Karyomapping) that combines detection of any monogenic disorder (potentially) with 
comprehensive chromosome screening in a single test that requires no a priori development. 
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Comparison with a well-established strategy (minisequencing for direct mutation detection 
combined with linked STR marker analysis) suggests that Karyomapping could be applied 
clinically for the autosomal dominant condition, Marfan syndrome and the autosomal recessive 
condition, SLO syndrome. Specifically after whole genome amplification of single blastomeres 
biopsied from cleavage-stage embryos, both methods (performed in parallel) identified unaffected 
and affected embryos with high efficiency and accuracy. Karyomapping however had the added 
advantage of not requiring the clinical work-up of a specific test beforehand (only the SNP array 
information from the parents and a relative of known carrier status was needed). 
For Case 1 (published the following year – Thornhill et al. 2015) minisequencing in combination 
with the analysis of several STR markers, yielded results within 24 hours for all six embryos in 
which whole genome amplification of the single cells was successful. Furthermore, in all cases, 
each locus was successfully re-amplified from the MDA products with no detectable ADO. 
However, because STR analysis in this way is not quantitative, and two of the markers were only 
semi-informative, ADO cannot be completely excluded in the unaffected embryos (Figure 5.1). In 
the affected embryo, single paternal and maternal repeat alleles were detected for all three STR 
markers and both the normal and mutant alleles were detected by minisequencing. Although this 
would, in practice, lead to a low probability of misdiagnosis, the mere presence of ADO at one or 
two loci might nonetheless undermine confidence in the result. Indeed, one result (Embryo 6; 
Table 2.2) was reported to be of lower accuracy because no paternal specific repeat alleles were 
detected. Karyomapping following SNP genotyping on the other hand identified 122 informative 
SNP loci across each of the two paternal and two maternal chromosomes in an approximately 
5Mb and 6Mb region spanning the FBN1 locus on chromosome 15q21.1 (Figure 5.2). Even 
taking into account the significant incidence of ‘no calls’ at heterozygous loci, the density of 
positive informative SNPs for the chromosome present, together with the absence of positive 
informative markers for the other chromosome, delivered highly accurate haplotyping – 
significantly more accurate than haplotyping with individual loci. Conservatively, the accuracy of 
Karyomapping could be calculated as the probability of a double recombination between the 
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nearest flanking positive (or negative) informative SNP loci. For the single cells in this family, this 
ranged from about 0.5-1Mb across FBN1. Thus the probability of a double crossover in this 
region would be less than 0.25-0.5x10-4 assuming 1% recombination per megabase. 
Figure 5.4 illustrates also the flexibility and utility of Karyomapping in that it can in theory be used 
for multiple loci simultaneously. For instance there are 11 loci corresponding to disorders licensed 
for PGD by the Human Fertilisation and Embryology Authority (HFEA) in the region captured in 
this figure, including the HLA regions used for diagnoses involving so called ‘saviour siblings’. 
 
Figure 5.4. Karyomap of a single blastomere focussing on a region of chromosome 6 
(Thornhill et al. 2014). 
The image indicates that there are 11 loci in this region corresponding to disorders currently 




PGD aneuploidy screening (PGD-AS) for the purposes of improving IVF success rates has met 
with widespread controversy (Mastenbroek et al. 2007; Summers et al. 2009; Thornhill & 
Handyside 2009). One criticism, the fact that PGD-AS using fluorescent in-situ hybridisation 
(FISH) screened only a small proportion of the total chromosome complement (Summers et al. 
2009; Thornhill & Handyside 2009), can also be addressed through aCGH and clinical validation 
of this procedure is now established (reviewed in Fiorentino et al. 2010). Treff et al. (2010) 
reported the use of SNP arrays for the detection of chromosome imbalance both for PGD-AS and 
for the screening of translocation carriers. 
Karyomapping uses a similar approach (i.e. SNP arrays) to Treff et al. (2010) and, combined with 
a degree of quantitative analysis, has the ability to distinguish any numerical or structural 
chromosome abnormality as well as the parent and phase of origin of the abnormality. The latter 
has clinical implications when considering obstetric outcomes of mosaic pregnancies: mosaic 
trisomies of meiotic origin often lead to specific phenotypes such as pregnancy loss, intra-uterine 
growth retardation or excessive birth weight, whereas those of post-zygotic origin generally 
proceed to term without clinical consequence (Griffin 1996). Karyomapping can also detect 
uniparental disomy, which can lead to Prader-Willi or Angleman syndromes as well as abnormal 
patterns of genome duplication seen with, for example, molar pregnancies. 
The primary purpose of PGD cycles is to identify embryos with a high probability of transmitting a 
genetic disorder. The inclusion of comprehensive chromosome screening, in addition to diagnosis 
of a familial mutation, is a powerful combination, especially when applied in a single assay. Given 
that chromosomal errors are common in embryos, leading to high rates of embryo implantation 
failure, miscarriage and more birth defects, there is a sound basis for including comprehensive 
chromosome analysis alongside PGD. Furthermore, the additional information relating to parental 
origin of meiotic errors provided by Karyomapping (but not derivable from array comparative 
genomic hybridisation data) should be particularly helpful for couples in determining which 
therapeutic intervention to try next (e.g. donor oocytes or donor sperm). In theory, screening for 
spontaneously arising aneuploidies should increase the likelihood that the embryo chosen for 
124 
 
transfer will establish a viable pregnancy and ultimately a healthy child. Indeed, as a selection 
tool, aneuploidy screening can prioritise the embryo for transfer to achieve improved implantation 
rates and lower miscarriage rates in fresh transfer cycles (Scott et al. 2013) as well as support 
single embryo transfer policy as part of the drive towards reducing multiple birth rates (Yang et al. 
2012). 
In these two cases, the benefits of Karyomapping over, for instance, more established molecular 
cytogenetic approaches (e.g. array CGH) were immediately apparent. As an example, maternal 
meiotic trisomy of chromosome 1 was detected in a single cell of embryo 2 from Case 1, then 
subsequently detected in all other cells of that embryo. Meiotic errors are more likely to lead to 
clinical problems as they are more likely to affect all or most of the cells in the embryo, whereas 
post-zygotic errors might affect fewer cells depending on the cleavage division in which they 
occur. For instance the detection of monosomy 21 in embryo 1 for Case 1 was clearly a post-
zygotic one that affected one cell and not the rest of the embryo. The added advantage of 
knowing the meiotic origin of aneuploidy may thus further improve success rates of PGD following 
aneuploidy screening when compared to other techniques including array CGH and quantitative 
fluorescent PCR. The detection of structural chromosome imbalance is also currently an 
advantage of Karyomapping compared to state of the art use of comparative genomic 
hybridisation, which struggles to detect small abnormalities when using DNA amplified from single 
cells (e.g. Vanneste et al. 2009). Four structural abnormalities and their origins were clearly 
identified in this study, with a fifth possibly occurring in Case 1 in a single cell of an embryo that 
was transferred. In this case, the possibility of a deletion was only identified after a retrospective 
analysis of the Karyomapping data and thus, unlike the other four abnormalities discovered 
therefore, it cannot be certain whether the result was real or artefact. Nonetheless the absence of 
any congenital abnormality associated with a terminal 6q deletion in either the surviving twin or 
the one that perished suggests that it was not a chromosome abnormality present in the majority 
of the embryo. Finally, Karyomapping determined that embryo 3 of Case 1 had no paternal 
genome and presumably arose as a result of a parthenogenetically activated oocyte (maternal 
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diploid). Such conceptuses are not compatible with implantation; notably array comparative 
genomic hybridisation would have diagnosed such a conceptus as normal.  
There are a number of limitations to Karyomapping. For instance, a suitable informative family 
member, usually an affected child (as well as DNA from the parents) needs to be available. 
Obtaining parental DNA for analysis is not usually an issue as the parents are actively involved in 
the whole IVF process throughout the treatment cycle; theoretically however there may be issues 
with consent or technical problems with the SNP array on the parental genomic DNA. 
However, DNA from an informative family member can limit the use of Karyomapping; this is 
nonetheless the same as any PGD in which linkage analysis is involved. The higher density of 
markers when SNP arrays are used compared with the ‘standard’ PCR-based strategies means 
that there is a greater likelihood of the family member being informative, even if there is a 
crossover at or near the locus of interest. Nonetheless if a crossover in either reference individual 
or embryo is directly next to the locus of interest, this may (rarely) render individual diagnoses 
unreadable by this method. Like all PGD, Karyomapping does not a priori detect de-novo 
mutation (for demonstration of this see Rechitsky et al. 2011), nor the confounding effect of 
pseudogenes. Moreover Karyomapping does not detect post-zygotic chromosome duplication 
nor copy number variation. Karyomapping therefore has a number of limitations; in our view 
however use of Karyomapping, for the most part, represents an advancement on the current 
state of the art for PGD. 
Several authors have reported the simultaneous detection of monogenic and chromosomal 
disorders – to the best of my knowledge, the first of these was a case report by Brezina et al. 
(2011) but more recently Rechitsky et al. (2013), which described detection of cytogenetic 
disorders and cystic fibrosis simultaneously. These, however, ultimately used different 
approaches to detect the monogenic and chromosomal disorder and the issue of having to tailor 
the test to the disease in question thus remains. There has been abundant literature on the use of 
haplotyping for the detection of monogenic and chromosomal disorders (e.g. Rechitsky et al. 
2006; Renwick et al. 2006; 2010). Karyomapping is essentially an extension on this pioneering 
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work except that, rather than using tailored, linked markers, application of a whole genomic 
platform permits the use of a single test for each and every case. Karyomapping is moreover 
platform independent. Here I used Illumina SNP arrays, however the binary nature of the output 
means that any platform could potentially be used. This includes single cell whole genome 
sequencing where I propose that, even with the most robust whole genome amplification, 
sequence gaps would inevitably arise in the assembly. These could be overcome by adaptations 
of the Karyomapping algorithm. In a procedure where diagnostic speed is of the essence, it 
seems reasonable to suggest that a rudimentary whole genome sequence (which would take the 
shortest time) followed by Karyomapping would be the most accurate and expedient means of 
achieving a diagnosis. Karyomapping therefore has inherent ‘future-proofing’ in its design and 
adaptations of the algorithm could, I believe, form the basis of the majority of preimplantation 
genetic diagnoses worldwide. 
With each application of new technology there is an inevitable ethical debate, particularly in the 
area of assisted reproduction. Fortunately, the law regarding PGD in the UK is very clear. The 
indication for performing the procedure of embryo biopsy as a precursor to diagnostic testing 
must meet a series of legal tests. These include the seriousness of the disorder and the likelihood 
that any child born would suffer from it. In addition, the condition itself for which any 
preimplantation test is applied must be licensed (HFEA, 1990). However, there are several 
additional concerns raised by the ability to obtain large amounts of genetic information from the 
entire genome (Hens et al. 2013). One frequently raised ethical concern relating to the ability to 
screen an ever-increasing number of genes simultaneously is the notion of designing a baby. 
However, the probability of selecting an ‘ideal’ embryo from a typical cohort of approximately 10-
15 embryos is vanishingly small even when considering only five loci. Of more pragmatic concern 
is the very real possibility of incidental findings with unknown significance, as evidenced in this 
report for chromosomal disorders. The detection of hitherto unreported copy number variants as 
well as small or partial deletions and duplications of unknown pathological significance underlines 
the importance of and need for comprehensive genetic counselling throughout the PGD process. 
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6. Specific Aim 3: To apply Karyomapping to demonstrate its clinical utility as 
a genome-wide ‘chromosome fingerprint’ in a clinical setting 
As outlined in section 2.4.3 of the General Introduction, blastocyst biopsy is now widely used for 
both PGS and PGD. Although this approach yields good results, variable embryo quality and 
rates of development remain a challenge. Here, I report a case in which a blastocyst was 
biopsied for PGS by array CGH on Day 6 post insemination after having hatched completely. In 
addition to a small trophectoderm sample, excluded cell fragments from the subzonal space from 
this embryo were also sampled. Unexpectedly, the array CGH results from the fragments and 
trophectoderm sample were non-concordant: 47,XX,+19 and 46,XY respectively. DNA 
fingerprinting by short tandem repeat and amelogenin analysis confirmed the sex chromosome 
difference but appeared to show that the two samples were related but non-identical. Genome-
wide single nucleotide polymorphism genotyping and Karyomapping identified that the origin of 
the DNA amplified from the fragments was that of the second polar body corresponding to the 
oocyte from which the biopsied embryo developed. The fact that polar body DNA can persist to 
the blastocyst stage provides evidence that excluded cell fragments should not be used for 
diagnostic purposes and should be avoided when performing embryo biopsies since there is a 
risk of diagnostic errors. This work has been recently published as follows:  
Ottolini CS, Rogers S, Sage K, Summers MC, Capalbo A, Griffin DK, Sarasa J, Wells D and 
Handyside AH. Karyomapping identifies second polar body DNA persisting to the blastocyst 
stage: implications for embryo biopsy. Reprod Biomed Online. 2015 Dec;31(6):776-82. 
 
6.1. My Personal Contribution to the Work 
I was involved in the clinical management of the published case above, conceiving and designing 
the clinical follow-up. I performed Single Nucleotide Polymorphism (SNP) genotyping 
(Karyomapping), minisequencing (short tandem repeat, STR) and array comparative genomic 
hybridisation (CGH) and analysis. I was involved in the writing and editing of the published 
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Blastocyst biopsy (as discussed in section 3.6), by excision of small numbers of herniating 
trophectoderm cells, is now widely used and is increasingly replacing cleavage stage biopsy for 
both preimplantation genetic screening (PGS) for aneuploidy and preimplantation genetic 
diagnosis (PGD) of single gene defects and other abnormalities (Thornhill et al. 2012). The main 
reasons for this are the availability of improved culture media and the widespread adoption of 
blastocyst culture to select normally developing embryos for transfer with improved implantation 
and live birth rates. Also the original protocol, which used microneedles for partial zona dissection 
to promote herniation as the blastocyst expands, and mechanical excision of trophectoderm cells 
(Dokras et al. 1990; 1991), has now been superseded by the use of non-contact infrared lasers 
(Veiga et al. 1997; Boada et al. 1998; Kokkali et al. 2005). Zona drilling by laser allows precise 
control of the position of the herniating trophectoderm cells, away from the inner cell mass, and 
laser assisted excision causes minimal damage to the biopsied cells and the embryo (Scott et al. 
2013).  
Nevertheless, blastocyst biopsy remains challenging because of variability in embryo quality, 
particularly in the number of cells in the trophectoderm layer, and the rate of development to the 
expanded blastocyst stage. Whereas, most normally developing embryos reach the 6- to 10-cell 
stage on the morning of Day 3 post insemination, allowing cleavage stage biopsy, the timing of 
blastocyst expansion can vary by over 24 hours and occur on Day 5, 6 or even Day 7. 
Increasingly, therefore, vitrification is being used to cryopreserve biopsied blastocysts, allowing 
more flexibility in the timing of blastocyst biopsy (Liebermann 2015). One strategy is to biopsy any 
embryos reaching the expanded blastocyst stage on Day 5, perform the genetic analysis within 
24 hours and transfer unaffected fresh blastocysts on Day 6. Embryos reaching the expanded 
blastocyst stage on Day 6 or 7 are biopsied later, vitrified, tested and unaffected embryos are 
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transferred in a subsequent cycle. Alternatively, all biopsied blastocysts can be vitrified and 
replaced in subsequent cycles. Indeed, recent evidence indicates that a strategy involving 
trophectoderm biopsy, vitrification and PGS is highly effective clinically, since euploid blastocysts 
all have similarly high implantation and clinical pregnancy rates despite differences in morphology 
and developmental rate (Capalbo et al. 2014).  
Here, I report a case in which a slow developing embryo only reached the blastocyst stage on 
Day 6 post insemination and had hatched completely before being biopsied for PGS by array 
CGH. Biopsy of hatched blastocysts is more difficult and because the trophectoderm sample 
obtained was relatively small, excluded cell fragments present in the subzonal space were also 
sampled. Excluded fragments and cells, some of which are nucleated, are commonly observed at 
the morula stage onwards and are a potential source of DNA for genetic analysis. Unexpectedly, 
however, the array CGH results from the fragments and trophectoderm samples were non-
concordant in this case. To investigate the cause of this non-concordance, DNA fingerprinting 
using a panel of informative STR markers including amelogenin to determine the sex, and SNP 
genotyping and Karyomapping analysis was performed on all samples. The results of both tests 
were completely concordant and Karyomap analysis identified beyond doubt that the origin of the 
DNA amplified from the fragments was exclusively that of the second polar body corresponding to 
the fertilised oocyte that gave rise to the embryo from which the trophectoderm had been 
biopsied. The implications for blastocyst biopsy and the risk of diagnostic errors are discussed.  
 
6.3. Materials and Methods 
6.3.1. Patient History and IVF Treatment Cycle 
Following genetic counselling, a couple (maternal age 40yr; paternal age 34yr) requested in vitro 
fertilisation (IVF) with PGS by array CGH for advanced maternal age after failing to conceive 
naturally for more than a year. The woman had never previously been pregnant but otherwise 
had no known cause for infertility. The man had never fathered a child and had a history of 
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surgery to correct undescended testicles. However, semen analysis showed that he was 
normozoospermic. 
Ovarian stimulation was achieved by a standard antagonist regimen with hCG trigger after 12 
days of stimulation. Oocyte collection followed 35h post hCG and six mature second meiotic 
division (MII) oocytes were retrieved. All oocytes underwent IVF with the male partner’s sperm 
and all six fertilised normally with two pronuclei visible the following day (Day 1 post 
insemination). The embryos were cultured in a time-lapse incubator (Embryoscope; Fertilitech, 
Denmark) to enable continuous observation. On Day 6, three embryos had reached the 
expanded blastocyst stage, with one of the three embryos having hatched completely from the 
zona pellucida. The remaining three embryos arrested at the cleavage stage and were discarded. 
 
6.3.2. Blastocyst Biopsy and Vitrification 
The two expanded, non-hatched blastocysts were biopsied by first making a small hole in the 
zona pellucida using a laser (Saturn; Research Instruments, Penryn, UK) opposite to the position 
of the inner cell mass. Three to 10 cells were then drawn through the breach in the zona into a 
sampling pipette and excised using a series of laser pulses across the join between adjacent 
trophectoderm cells. With the hatched blastocyst, the embryo was immobilised directly by suction 
onto the holding pipette and biopsied by drawing a small number of trophectoderm cells into a 
sampling pipette as above. In addition, excluded fragments left behind in the subzonal space 
(Figure 6.1) were also sampled separately. Finally, all three biopsied blastocysts were vitrified 





Figure 6.1. Hatched blastocyst (embryo 5) on Day 6 post insemination prior to biopsy 
(Ottolini et al. 2015a). 








6.3.3. Array Comparative Genomic Analysis (Array CGH) 
The biopsied cells and fragments were each placed in 2µl of phosphate buffered saline (PBS) in 
0.2ml PCR tubes and whole genome amplification (WGA) performed using a PCR-library based 
method (Sureplex, Illumina, Cambridge). The WGA products were then used for 24 chromosome 
copy number analysis by array CGH (24Sure; Illumina, Cambridge) with dedicated software 
(Bluefuse Multi v3; Illumina, Cambridge) according to the manufacturer’s instructions. For detailed 
methodology see Fragouli et al. 2011. 
 
6.3.4. DNA Fingerprinting 
All of the WGA products and parental genomic DNAs were DNA fingerprinted by analysis of five 
Informative STR markers on different autosomes (D2S389, D3S1581, D4S2964, D7S2847, 
D15S659) and on the sex chromosomes (AMELX/Y). The STR markers were amplified in 
separate single-plex fluorescent PCRs (Hot Master Taq DNA polymerase; 5PRIME, Hilden, 
Germany), and the amplified fragments sized by capillary electrophoresis (3130 Genetic Analyzer 
(Applied Biosystems, USA) with dedicated software (GeneMapper v4.0; Applied Biosystems, 
USA). 
 
6.3.5. Single Nucleotide Polymorphism (SNP) Genotyping and Karyomapping 
All of the WGA products and parental genomic DNAs were also genotyped at approximately 
300K SNP loci genome wide for karyomap analysis using a dedicated beadarray (Human 
Karyomap; Illumina, USA) as described previously (Natesan et al. 2014) using a 24-hour protocol 
(Konstandinidis et al. 2015). Genotype data was then exported into Microsoft Excel and 
karyomap analysis preformed using a dedicated Visual Basic for Applications (VBA) macro. To 
phase heterozygous SNPs, one of the embryo samples was used as a reference and this was 
then repeated using another embryo to check the analysis. Finally, the positions of meiotic 
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crossovers between parental chromosomes for each chromosome were located and marked 
(excluding reference crossovers) and other custom VBA macros used for processing. 
 
6.4. Results 
6.4.1. Array CGH 
Whole genome amplification and array CGH was successful with all four samples biopsied from 
the three biopsied blastocysts (Table 6.1). One embryo (embryo 3) was missing a copy of 
chromosome 22 (monosomy 22), one embryo was euploid and the two samples from the third 
embryo were non-concordant. The trophectoderm biopsy (sample 5a) was euploid and male 
(46,XY) whereas the excluded fragment sample (sample 5b) had an extra chromosome 19 
(trisomy 19) and was female (47,XX,+19) (Figure 6.2). 
 
Table 6.1: 24 Chromosome Copy Number Analysis of Biopsied Blastocysts by Array 
Comparative Genomic Hybridisation (array CGH) and Single Nucleotide Polymorphism 
(SNP) Genotyping and Karyomapping (Ottolini et al. 2015a) 
Sample ID Sample type Array CGH Karyomapping 
3 Trophectoderm 45 XX, -22 45 XX, -22 (maternal) 




47 XX, +19 
23 X haploid 
(maternal) 










Note that both samples have normal copy number for all chromosomes except that the ratio of probes on chromosome 19 are consistently raised in 
(b). Also the gender of the trophectoderm sample (a) is identified as male since there is only a single copy of the X chromosome when compared to the 
sex-mismatched female DNA and a single Y chromosome (pink line). Whereas the fragment sample (b) is identified as female with the same copy 
number for autosomes and the X chromosome and missing the Y chromosome when compared with sex-mismatched male DNA (blue line). (c) 
Magnified portion of (b) showing the elevated ratio for chromosome 19 (circled) not reaching the level of the internal X chromosome control (bold red 
line) on the array. 
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6.4.2. DNA Fingerprinting 
STR analysis at five loci on different chromosomes demonstrated that all four samples had 
unique combinations of parental alleles indicating they were related but distinct individuals (Table 
6.2). Furthermore, amelogenin analysis confirmed the sex of each sample as originally 
ascertained by array CGH. There was a high allele dropout (ADO) rate across the samples, as 
typically observed for STR analysis applied to WGA products. In addition, however, the excluded 
fragment sample was anomalous because only a single maternal allele was detected at each of 
the three STRs which amplified and no paternal alleles were observed for any of the STRs. 






































































































Maternal alleles, blue and red; maternal alleles, green and yellow; semi informative alleles, orange; uninformative alleles, no shading. *Presumed allele 
dropout of AMELY (110). Samples 3, 5a and 6 are trophectoderm samples. Sample 5b is the excluded cell fragment sample related to sample 5a. Bold 
type highlights the opposite maternal alleles present in samples 5a and 5b. 
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6.4.3. Single Nucleotide Polymorphism (SNP) Genotyping and Karyomapping 
SNP genotyping and Karyomapping was successful with all four WGA products. Conventional 
analysis of the SNPs on the X and Y chromosomes confirmed the sex indicated by array CGH in 
all cases. In addition, Karyomapping confirmed the absence of the maternal copy of chromosome 
22 in embryo 3 (Table 6.1) and in agreement with the euploid array CGH result, failed to detect 
any meiotic trisomies or missing chromosomes in the trophectoderm sample from embryo 5 
(sample 5a) and embryo 6. However, for the excluded fragment sample from embryo 5 (sample 
5b), only maternal SNP markers for a single maternal chromosome were detected across all 
chromosomes (including chromosome 19) indicating that it was haploid. 
Comparing the karyomaps and the positions of the crossovers in the excluded fragment sample 
(sample 5b) and the results for maternal chromosomes in the trophectoderm sample (sample 5a), 
it was clear that all 22 autosomes and the X chromosome were derived from the same maternal 
homologue in both samples, i.e. the maternal haplotype (yellow or green) detected around the 
centromere was identical (Figure 6.3). This proves that the maternal chromosome sets from the 
two samples are derived from the same oocyte. Moreover, the presence of only a maternal set of 
chromosomes and the pattern of crossovers identifies the origin of the DNA in the excluded 
fragment sample as being derived exclusively from the second polar body, i.e. the majority of 
crossovers were in different positions, except for 12 distal crossovers in closely similar positions, 
as would be expected for reciprocal crossovers between sister chromatids (Ottolini et al. 2015). 
This genetic data rules out the possibility of the two samples originating from sibling embryos. 
Similar comparisons with the maternal chromosomes in the other two embryos demonstrated that 
they had distinct maternal chromosome sets and crossover patterns (data not shown). Finally, the 
maternal haplotypes identified with Karyomapping in the two samples from embryo 5 on the 
relevant chromosomes were concordant with the results of the STR analysis, which showed 




Figure 6.3. Comparison of the karyomaps for the maternal chromosome sets for the 
excluded cell fragments (on the left in each case) and the trophectoderm biopsy (right) 
(Ottolini et al. 2015a). 
Maternal haplotypes, yellow and green; centromeres, black; satellite regions, grey. Note the 
crossovers from one maternal haplotype to the other are mostly different except for 12 common 
crossovers between sister chromatids (red ellipses). The positions of the three STR markers 
which amplified in both samples are indicated on the relevant chromosomes. Note that the 




A major advantage of blastocyst biopsy is that multiple trophectoderm cells, in the range of 3-10 
cells, can be biopsied from each embryo. Compared with genetic analysis of single cells, whole 
genome amplification bias and chromosome copy number artefacts are reduced in multiple cell 
samples and also ADO at, for example, mutation sites decreases dramatically (Handyside et al. 
2004). On the other hand, a disadvantage is that chromosomal mosaicism arising through 
abnormal processes of nuclear and cell division, mainly during cleavage, can persist at the 
blastocyst stage. In the context of PGS of aneuploidy by any quantitative method, this can result 
in intermediate chromosome copy number changes, which may be difficult to interpret. Although 
most multiple trophectoderm biopsies are concordant, a few give results consistent with 
mosaicism (Capalbo et al. 2013b). 
In the case reported here, one of the embryos only reached the blastocyst stage on Day 6 but 
had hatched completely from the zona prior to biopsy. Biopsy of fully hatched blastocysts is 
technically challenging and in this situation, the blastocyst has to be held directly by gentle suction 
to the holding pipette while the trophectoderm cells to be biopsied are drawn up into a sampling 
pipette and a laser used to excise them. The blastocyst then collapses initially preventing any 
second attempt to obtain more cells if deemed necessary. As only a small number of cells were 
biopsied from this particular embryo, a cluster of excluded cell fragments that had remained within 
the zona pellucida were also biopsied separately for analysis. Although there is no published 
evidence, these cells were sampled on the assumption that they were the remnants of arrested 
cells not incorporated into the developing blastocyst. The array CGH results for the fragments 
(47,XX,+19) and the trophectoderm sample (46,XY), however, were non-concordant. Although it 
was assumed that the more reliable result for this embryo was the latter, despite rigorous 
witnessing protocols, I could not rule out that the samples had been mixed up as the embryo 
biopsied following this one was also a euploid male (46,XY). To exclude this possibility, therefore, 
all samples were DNA fingerprinted using a panel of informative STR markers and amelogenin to 
determine the sex and subsequently SNP genotyped for Karyomapping. 
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The results of the DNA fingerprinting and amelogenin analysis confirmed the sex of three of the 
samples determined by array CGH and ruled out any sample mix up since the sampled 
fragments had a distinct set of STR alleles. In the fourth sample, only AMELX amplified from 
embryo 6 presumably as a result of ADO (Table 6.2). Furthermore, the absence of any paternal 
alleles and the presence of only a single maternal allele at each locus suggested that the DNA 
may have originated in a polar body with a haploid set of maternal chromosomes. Finally, 
genome-wide SNP genotyping and Karyomapping identified beyond doubt that the DNA from the 
fragments was exclusively that of the second polar body corresponding to the embryo from which 
the trophectoderm cells had been sampled. The evidence for this is threefold: (1) no paternal 
SNP markers were detected for any of the chromosomes; (2) the grandparental origin of each of 
the 23 maternal chromosomes in both samples was identical (theoretically the chance of an 
identical set is 223:1); and (3) although most crossovers were in different positions, there were 12 
crossovers in identical positions in both sets of maternal chromosomes consistent with distal 
crossovers between sister chromatids (Ottolini et al. 2015) (Figure 6.3). Furthermore, the 
maternal haplotypes identified by Karyomapping at the STR loci are all concordant with the alleles 
detected by direct analysis (Table 6.2). 
Interestingly, contrary to the array CGH result, only a single maternal chromosome 19 was 
detected by karyomap analysis in both samples from embryo 5. However, the trisomy 19 in the 
fragment sample was reported on the assumption that it was a multiple cell sample, which could 
include mosaic copy number abnormalities. Close inspection of the array CGH plot for sample 5b 
(Figure 6.2) reveals that this is most likely the explanation for this discrepancy. The ratio of all of 
the probes on chromosome 19 is raised consistently as indicated by the software (green line). 
However, the ratio shift is much less than the X chromosome internal control compared with the 
male sex mismatched control DNA that would qualify as a trisomy in a single cell sample. In this 
case, therefore, this may be an example of whole genome amplification bias which is known to 
occur with polar body samples (Christopikou et al. 2013; Capalbo et al. 2013a). Knowing that this 
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can occur, experienced array CGH laboratories typically employ more stringent criteria for calling 
aneuploidies in polar bodies, especially those affecting chromosome 19. 
The persistence of polar body DNA for almost a week after extrusion following fertilisation is 
unexpected since both polar bodies appear to fragment and are generally not visible at the 
blastocyst stage. In this case, a relatively large group of excluded fragments has been shown to 
have DNA originating exclusively from the second polar body. The origin of most of the fragments 
therefore was presumably anucleate fragments, which commonly appear during cleavage 
divisions. Larger studies of such fragments will be needed to assess how frequently this occurs 
and whether there is evidence of the persistence of DNA from the first polar body also or 
excluded nucleated cells, which have subsequently fragmented. 
The implications of the persistence of polar body DNA in excluded fragments in the sub-zonal 
space up to the blastocyst stage, are important for both cleavage and blastocyst stage embryo 
biopsy. Clearly the assumption that these fragments are representative of the embryo is not 
always the case. Therefore, there is a risk of misdiagnosis for several reasons. PGD for single 
gene defects by conventional targeted haplotype and mutation analysis, for example, may give 
the opposite result for maternal loci in distal regions of the affected chromosome as was 
demonstrated here for the three STR loci. Polar body DNA may be more prone to whole genome 
amplification bias artefacts for chromosome copy number analysis (Christopikou et al. 2013; 
Capalbo et al. 2013a). Biopsy samples which inadvertently include these fragments could be 
contaminated with DNA which is not representative of the embryo, potentially giving false results 
or appearing to be mosaic. Until further studies have been done, therefore, harvesting samples of 
excluded fragments for diagnostic purposes should be avoided and efforts made to prevent them 
contaminating any embryo biopsy samples. 
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7. Specific Aim 4. To investigate the use of a calcium ionophore protocol to 
activate human oocytes, ultimately to investigate the incidence of 
chromosomal aneuploidy in the activated oocytes using array CGH and 
Karyomapping  
The results from this chapter have been accepted for publication and are in press. Capalbo A*,  
Ottolini CS*, Griffin DK,  Ubaldi FM, Handyside AH and Rienzi L. Artificial oocyte activation with 
calcium ionophore does not cause a widespread increase in chromosome segregation errors in 
the second meiotic division of the oocyte. Fertility and Stirility (in press) *Joint first author 
 
7.1. My Personal Contribution to the Work 
I was integral to conceiving and designing the experiments for this chapter with the help of Dr 
Antonio Capalbo. I performed the majority of the embryology including oocyte warming, biopsy, 
tubing and whole genome amplification of the samples. I performed some of the SNP genotyping 
and array CGH and analysed all of the CGH and SNP data. I was involved in the writing of the 
submitted manuscript and designed and created the figures. What follows is an adaptation of the 
manuscript submitted to MHR (2015). 
 
7.2. Introduction  
Failure of fertilisation resulting in few or no embryos for transfer continues to be a significant 
clinical challenge for a minority of patients undergoing in vitro fertilisation (IVF). The introduction of 
intra-cytoplasmic sperm injection (ICSI) in the early 1990s, significantly improved the clinical 
outcome for patients with male factor infertility, particularly those with low sperm counts who could 
not achieve normal levels of fertilisation with conventional IVF (Palermo et al. 1992). Typical 
fertilisation rates with ICSI average 70% for most patients, including those with poor semen 
parameters or surgically retrieved sperm. However, a significant proportion of ICSI cycles still 
result in fertilisation rates below 50% (Montag et al. 2012) with between 1% and 4% resulting in 
144 
 
total failed fertilisation (Esfandiari et al. 2005; Liu et al. 1995; Shinar et al. 2014). Although the 
invasive nature of the ICSI procedure itself may contribute to a proportion of oocytes not fertilising 
normally, most commonly the failure of an oocyte to fertilise after sperm injection is failure of 
oocyte activation (Flaherty et al. 1995; Rawe et al. 2000; Sousa & Tesarik 1994).  
In most mammals, the mature ovulated oocyte is arrested in metaphase of the second meiotic 
division (meiosis II) until fertilisation by a sperm. Sperm binding with the oolemma activates the 
oocyte triggering a series of pulsatile increases in intracellular calcium concentration, which in turn 
results in the resumption and completion of the second meiotic division with the extrusion of the 
second polar body, and the initiation of preimplantation development (Kline & Kline 1992). PLCζ, 
a sperm-specific phospholipase, is considered the trigger for the molecular pathway within the 
oocyte resulting in the release of calcium stores from the endoplasmic reticulum (Saunders et al. 
2002). Recent studies have shown that fertilisation failure following ICSI can be linked to sperm 
devoid of PLCζ or sperm with abnormal PLCζ function (Heytens et al. 2009; Lee et al. 2014; Yoon 
et al. 2008). It has also been demonstrated that oocyte factors as well as sperm factors are 
involved in failed fertilisation following ICSI (Tesarik et al. 2002). 
Artificially increasing intracellular calcium with a variety of stimuli, from a brief exposure to low 
concentrations of ethanol to calcium ionophore exposure to allow the influx of calcium ions from 
the medium, triggers oocyte activation in several mammalian species (Kaufman 1982; 
Whittingham 1980). In assisted conception, artificial activation of human oocytes (AOA) with 
calcium ionophore has been used clinically in cases of failed fertilisation following ICSI, resulting 
in completion of normal fertilisation in a significant proportion of oocytes and live births following 
embryo transfer (Nasr-Esfahani, Deemeh & Tavalaee 2010). Indeed, there is evidence to show 
that AOA can overcome both oocyte and sperm related failed fertilisation (Heindryckx et al. 2005). 
However, information on the effect of AOA and its biosafety is limited to clinical follow-up of 21 
children conceived using the technique, which demonstrated that their early development is within 
the expected normal range (Vanden Meerschaut et al. 2014). Also, because of the abnormal, 
sustained increase in intracellular calcium concentration, which may have effects on downstream 
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molecular events, it has been argued that AOA should only be used in failed fertilisation cases 
and not as a routine adjuvant to ICSI (Van Blerkom et al. 2015). 
Since very little preclinical evidence about the safety of AOA has been reported in the literature, 
here, I have investigated the effect of AOA with calcium ionophore on the incidence of female 
meiotic errors resulting in abnormal chromosome copy number, or aneuploidy, in the activated 
oocytes. Chromosome copy number was analysed by array comparative genomic hybridisation 
(array CGH) and combined with genome-wide single nucleotide polymorphism (SNP) genotyping 
of the oocyte donors and oocytes to identify the meiotic origin of any chromosome gains. As all of 
the oocytes were arrested in metaphase of meiosis II prior to activation, any effect of exposure to 
calcium ionophore should only affect the segregation of chromosomes at anaphase of meiosis II 
following resumption of meiosis. 
 
7.3. Materials and Methods 
All oocytes for the study were obtained from 12 patients that had undergone IVF treatment at the 
Centre for Reproductive Medicine GENERA in Rome between June 2008 and May 2009 (Table 
7.1). According to Italian law at the time of the patient’s IVF cycles, a maximum of three oocytes 
could be inseminated per patient and any surplus mature oocytes were vitrified. Surplus vitrified 
oocytes were later recruited for the study after informed consent was obtained from the patients. 
Consent was also obtained from all donors to obtain buccal cell swabs for genotyping. The study 
was approved by the Institutional Review Board of the Clinica Valle Giulia, where the oocytes 
were stored, and did not influence treatment in any way. 
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1 male factor Agonist 33.2 12 2 2 yes 
2 endometriosis Agonist 37.9 10 7 5 yes 
3 idiopathic Agonist 37.4 10 10 4 no 
4 male factor Antagonist 40.6 12 6 5 yes 
5 male factor Antagonist 37.6 15 10 10 yes 
6 male factor & tubal Agonist 37.3 11 6 3 yes 
7 male factor Agonist 35.7 11 5 5 no 
8 Tubal Agonist 38.4 16 9 6 yes 
9 male factor Agonist 29.0 12 6 6 yes 
10 male factor Agonist 31.7 14 5 4 yes 
11 male factor Agonist 39.0 18 18 3 no 
12 male factor Agonist 36.2 6 3 3 yes 
  Mean 36.2 12.3 7.3 4.6  
  ±SD 3.3 3.2 4.2 2.1  
  Range 29.0-40.6 6-18 2-18 2-10  
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7.3.1. Oocyte Collection, Vitrification and Warming 
Ovarian hyperstimulation was achieved using long down regulation agonist or standard 
antagonist protocols and transvaginal oocyte collection was performed 35 hours post-human 
Chorionic Gonadotrophin (hCG) administration. The vitrification and warming procedures were 
performed according to a published protocol (Kuwayama et al. 2005; Kuwayama 2007) using 
commercially available vitrification and warming kits (Kitazato BioPharma Co., Japan). Vitrification 
was performed a maximum of 40h post-hCG administration and the oocytes were stored on 
Cryotop vitrification tools (Kitazato BioPharma Co., Japan) in liquid nitrogen. 
 
7.3.2. Oocyte Culture and Activation 
All oocyte culture was performed at 37°C in 6% CO2 and 5% O2. Individual oocytes were cultured 
separately and culture drops and wells were numbered to allow traceability throughout the 
experiment. Immediately after warming, the surviving oocytes were moved to 35µl microdrops of 
cleavage medium +10% human serum albumin (HSA) under mineral oil (Sage; Cooper Surgical, 
USA) and cultured for 2h prior to activation. Oocytes were activated by exposure to 100µM 
calcium ionophore (A23187; Sigma-Aldrich, USA) in cleavage +10% HSA from a stock solution in 
DMSO (Sigma-Aldrich, USA) diluted 1:40. Oocytes were transferred to 35µl drops of the 
activation medium under oil, for 40 min. The oocytes were then moved, after thorough washing, 
to separate wells of multiwell slides (Unisence Fertilitech, Denmark) in cleavage medium under oil 
(medium as used directly following oocyte warming). The slides were placed in the time lapse 
incubator (Embryoscope; Unisence Fertilitech, Denmark) for assessment of second polar body 
(PB2) extrusion and appearance of pronuclei.  
 
7.3.3. Oocyte Isolation and Tubing 
The zona pellucida was removed from activated oocytes and the polar bodies were isolated by 
micromanipulation (Narishige, Japan) on an inverted microscope (Nikon Ltd, Japan) equipped 
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with Hoffman Modulation contrast and a 37°C heated stage (Linkam Scientific Instruments, UK) 
as previously described (Capalbo et al. 2013). Oocytes were secured by suction with the holding 
pipette (TPC, Australia) and a large aperture was made in the zona pellucida with a series of 
laser (Saturn laser; Research Instruments, UK) pulses. The aspiration pipette (Zona drilling 
pipette; TPC, Australia) was then inserted through the opening and the polar bodies removed with 
gentle suction. The oocyte was then removed from the zona by both displacement and zona 
manipulation techniques using the aspiration pipette. Once free from the zona, the oocytes were 
washed and transferred to polymerase chain reaction (PCR) tubes ensuring the polar bodies did 
not contaminate the samples. Transfer of the oocytes to PCR tubes was performed using a 
plastic denuding pipette (COOK Medical, Ireland) with a 130μm lumen. Individually labelled PCR 
tubes (Cell Projects Ltd, UK) were primed with 2μl Dulbecco's phosphate buffered saline (DPBS) 
(Gibco; Life technologies, USA) with 0.1% poly vinyl alcohol (Sigma-Aldrich, USA). Individual 
oocytes were expelled into the DPBS in around 1μl of the medium containing the samples. The 
PCR tubes were then briefly centrifuged, snap frozen in liquid nitrogen and stored at -20°C prior 
to whole genome amplification. 
 
7.3.4. Whole Genome Amplification (WGA) and Genomic DNA Extraction 
DNA from all oocytes in the study were amplified by either multiple displacement amplification 
(MDA) (REPLI-g Single Cell Kit; Qiagen, UK ) or PCR library based whole genome amplification 
(WGA) (SurePlex; Illumina, USA) according to the manufacturer’s instructions to obtain sufficient 
DNA for downstream analysis. MDA was performed with a short, 2h incubation. genomic DNA 
(gDNA) from all oocyte donors was obtained using buccal cell swabs (Isohelix, Cell Projects Ltd, 
UK). Extraction of the gDNA from the buccal cells was performed using a proteinase K extraction 





7.3.5. Array CGH and SNP Genotyping  
When feasible, both array CGH and SNP genotyping were performed on each sample. For array 
CGH analysis, 4µl aliquots of WGA products from the oocytes were processed on 24Sure 
microarray slides (Illumina, USA) according to the manufacturer’s instructions. The data was 
imported and analysed using dedicated software (BlueFuse Multi v 4.0; Illumina, USA). 400ng of 
genomic DNA or 8µl of WGA products from the oocyte samples were processed on an SNP 
genotyping BeadChips for ~300K SNPs genome-wide (HumanCytoSNP-12 or HumanKaryomap-
12; Illumina, USA), according to the manufacturer’s instructions. The genotype data was exported 
as a Microsoft Excel file, using genotyping software (GenomeStudio; Illumina, USA) for analysis.  
 
7.3.6. SNP Analysis 
To detect aneuploidies of meiotic origin, each of the patients donating oocytes were genotyped 
and informative maternal heterozygous SNP loci were phased by reference to either a presumed 
haploid sibling oocyte (or PB2 if no sibling oocyte was available). In cases where the reference 
was itself aneuploid for a particular chromosome, a second reference was also used to confirm 
the status of the chromosome(s) involved. Mendelian analysis of the genotype of each of the 
activated oocytes at these informative SNP loci then allowed the identification of meiotic errors 
resulting in two chromatids instead of the normal single chromatid segregating to the oocyte 
(chromatid gain) by the presence of heterozygous regions. Furthermore, the distribution of these 
heterozygous regions allows the classification of these errors into: 1) those that occur in the first 
meiotic division (meiosis I) and have chromatids from both homologous chromosomes, which 
result in heterozygosity in the pericentromeric and more distal regions of the chromosome arms; 
and 2) errors in the second division (meiosis II) and have chromatids from the same homolog, 
which result in homozygosity in the pericentromeric region of the chromosome but are 
heterozygous in more distal regions. Finally the absence of any informative maternal SNPs 
(chromatid loss) indicates the absence of a chromosome and thus the meiotic origin of losses 
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cannot be determined with this methodology. Therefore, chromatid loss in the oocyte could not be 
used for the study. 
 
7.4. Results 
7.4.1. Artificial Oocyte Activation (AOA) 
56 oocytes arrested at metaphase of the second meiotic division (meiosis II), which had been 
cryopreserved by vitrification, from 12 patients with a mean age of 36.2 years ± SD 3.3, most of 
whom had pregnancies and live births following successful IVF treatment, mainly for male factor 
infertility, were donated for the study (Table 7.1). 49 (88%) survived thawing and 39 (80%) 
activated following exposure to calcium ionophore as demonstrated by the formation of one or 
more pronuclei and/or the extrusion of the PB2 (Table 7.2). Most of the activated oocytes 
extruded the PB2 and formed a single pronucleus (2PB, 1PN: 30/39; 77%) as expected. 
However, five (13%) activated oocytes with a PB2 failed to form a pronucleus (2PB, 0PN) and 
three (8%) formed two pronuclei (2PB, 2PN). Finally, one activated oocyte failed to extrude the 














1PN, 2PB  0PN, 2PB 
Abnormal activated 
>2PN, 1PB     2PN, 2PB 
1 2 2 2 2 0 0 0 
2 5 5 5 3 1 0 1 
3 4 4 2 1 1 0 0 
4 5 4 4 4 0 0 0 
5 10 5 3 3 0 0 0 
6 3 3 3 2 0 1 0 
7 5 5 5 2 2 0 1 
8 6 6 5 5 0 0 0 
9 6 6 1 1 0 0 0 
10 4 4 4 4 0 0 0 
11 3 2 2 0 1 0 1 
12 3 3 3 3 0 0 0 




7.4.2. Chromosome Copy Number Analysis 
Chromosome copy number was analysed in 31 activated oocytes (2PB, 1 or 0PN n=27; 2PB, 
2PN n=3; 1PB, >2PN n=1) by array CGH (n=26) and/or SNP genotyping (n=25) (Table 4.3). In 
total 20/31 activated oocytes were analysed by both array CGH and SNP genotyping, 6/31 were 
analysed by array CGH only and 5/31 were analysed by SNP genotyping only (Table 7.3). 
Overall, 13 (42%) activated oocytes had one or more chromosome copy number abnormalities 
(mean 2.0 per aneuploid oocyte; range 1-7) including two partial chromosome gains (+15qter and 
+8pter). In the 10 aneuploid activated oocytes analysed by both array CGH and SNP genotyping, 
all 17 whole chromosome aneuploidies were detected by the two methods (Table 7.3) (100% 
concordance). Of the two partial gains, identified as isolated heterozygous regions by SNP 
analysis and therefore likely to be of meiotic origin (not gonadal mosaicism), only the +15qter was 
confirmed by array CGH (50% concordance). However, Sample 7.4 (with the +8pter) was 
amplified by MDA, which is not optimised for the CGH array used, and can thus explain the non-
concordance (Table 7.3). 
 








No of polar bodies 




1 1.1 -5, -10, +20 -5, -10, +20 2PB, 1PN SurePlex 
 
1.2 +11, +15qter, -21 +11, +15qter, -21 2PB, 1PN SurePlex 
2 2.1 +22 +22 2PB, 1PN SurePlex 
 
2.2 +15 +15 2PB, 1PN SurePlex 
 
2.3 +1 +1 2PB, 0PN SurePlex 
 2.4 -13 -13 2PB, 2PN SurePlex 
 
2.5 Euploid Euploid 2PB, 1PN SurePlex 
3 3.1 Euploid Euploid 2PB, 0PN SurePlex 










No of polar bodies 





4.2 Euploid Euploid 2PB, 1PN SurePlex 
 
4.3 Euploid Euploid 2PB, 1PN SurePlex 
 
4.4 Euploid Euploid 2PB, 1PN SurePlex 
5 5.1 Euploid N/A 2PB, 1PN SurePlex 
 
5.2 -13 N/A 2PB, 1PN SurePlex 
 
5.3 Euploid N/A 2PB, 1PN SurePlex 
6 6.1 Euploid N/A 1PB, >2PN MDA 
 
6.2 Euploid Euploid 2PB, 1PN MDA 
 
6.3 Euploid Euploid 2PB, 1PN MDA 
7 7.1 Euploid N/A 2PB, 2PN MDA 
 
7.2 -13, +20, -22 -13, +20, -22 2PB, 0PN MDA 
 
7.3 Euploid Euploid 2PB, 1PN MDA 
 
7.4 -4 -4, +8pter 2PB, 1PN MDA 
8 8.1 -6, -18, +20 -6, -18, +20 2PB, 1PN MDA 
 8.2 Euploid Euploid 2PB, 1PN MDA 
 8.3 Euploid Euploid 2PB, 1PN MDA 
9 9.1 N/A Euploid 2PB, 1PN MDA 
10 10.1 N/A -17 2PB, 1PN MDA 
 
10.2 N/A Euploid 2PB, 1PN MDA 
 
10.3 N/A Euploid 2PB, 1PN MDA 
 
10.4 N/A Euploid 2PB, 1PN MDA 
11 11.1 
+1, +4, +15, +16, 
+17, -18, -22 




7.4.3. SNP Analysis of Meiotic Errors 
SNP analysis of 24 activated oocytes, which extruded the PB2 and formed a single pronucleus as 
expected (2PB, 1PN) or which failed to form a visible pronucleus (2PB, 0PN), were all shown by 
SNP genotype analysis to have a haploid set of maternal chromosomes with the exception of the 
aneuploid chromosomes. Of the seven chromosome gains identified by SNP genotype analysis, 
five had patterns of heterozygosity of meiosis I type errors including the pericentromere and only 
two had patterns consistent with meiosis II type errors (Table 7.3; Figure 7.1). The remaining one 
activated oocyte analysed by SNP genotyping, which had extruded the PB2 and formed two 
pronuclei (2PB, 2PN), was shown to be diploid (digynic) with patterns of heterozygosity consistent 
with the presence of both sets of meiosis II chromosomes. The only exception was chromosome 
13, which had only a single copy consistent with the loss observed with array CGH (Figure 7.2a). 
Similar interrogation of the array CGH plot of another oocyte that formed two pronuclei (2PB, 
2PN) (oocyte 11.1) also showed that the separation of the two chromosome losses 
(chromosomes 18 and 21) was consistent with a single copy indicating a diploid (digynic) 





Figure 7.1. Diagrammatic representation of all chromosome gains from oocytes 
demonstrating single or no pronucleus formation with the extrusion of the second polar 
body after activation. 
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Homozygous regions of the chromosomes are coloured yellow or green (depending on the 
maternal haplotype present) and heterozygous regions in blue (both maternal haplotypes 
present). The centromeres are shown in black and satellite DNA is coloured grey. The scale bar 
to the left denotes the Megabase pair (Mbp) position along the chromosomes. The gains present 
with either pericentromeric heterozygosity (yellow or green around the centromere) as MI errors 
or pericentromeric homozygosity (blue around the centromere) as MII errors. 
 
 
Figure 7.2. Array CHG plots of two activated diploid oocytes displaying two pronuclei 
consistent with diploid state. 
This can be determined by the single chromatid loss (a) and multiple chromatid gains and losses 
(b). The Log2 separation ratio of X chromosome and Y chromosome when the diploid oocytes 
are compared to sex mismatched male DNA are indicated by the orange and blue lines 
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respectively. a) Separation for all probes on chromosome 13 do not reach the blue line, 
consistent with a single copy of the chromosome or chromatid loss from diploid state. b) 
Separation of all gains and losses do not reach the orange and blue lines respectively. The gains 
are consistent with three copies of the chromosome or chromatid gain from the diploid state. As in 




Artificial activation of oocytes (AOA) by exposure to calcium ionophore is being used increasingly 
to overcome low or failed fertilisation following ICSI and there are now several reports of 
pregnancies and healthy live births (Kashir et al. 2010; Vanden Meerschaut et al. 2014). 
Following exposure of oocytes arrested in metaphase of the second meiotic division (meiosis II) 
to calcium ionophore, chromosome copy number analysis of activated oocytes demonstrated a 
high incidence of aneuploidy of meiotic origin (13/31; 42%). However, the incidence is 
comparable to the incidence in normally fertilised embryos in women of a similar age range 
(Franasiak et al. 2014). Also, analysis of informative heterozygous maternal SNP loci showed that 
five chromosome gains in the activated oocytes had patterns of heterozygosity including the 
pericentromeric region of the chromosomes, indicating their origin in the first meiotic division 
(meiosis I) and only two with meiosis II type patterns (Table 7.3; Table 7.1). This level of second 
meiotic division (MII) errors is in line with studies on meiotic errors following IVF only (Capalbo et 
al. 2013). Therefore, there is no evidence in this preliminary dataset to suggest that AOA with 
calcium ionophore causes a global increase in meiotic chromosome segregation errors. 
In contrast, SNP analysis of an activated oocyte, which had extruded PB2 but then formed two 
pronuclei (2PB, 2PN), clearly demonstrated that all chromosomes had a pattern of heterozygosity 
consistent with the presence of both sets of meiosis II chromosomes and was therefore diploid 
(digynic). The exception was chromosome 13 which had no regions of heterozygosity indicating 
the presence of a single chromosome and consistent with the log2 ratio observed by array CGH 
158 
 
(Figure 7.2a). Notably, array CGH does not detect the overall ploidy of a cell since it normalises 
copy number across the genome for comparison with individual chromosomes. As this array 
CGH pattern of putative single loss (and single gain) from diploid copy number was observed in a 
second oocyte (Figure 7.2b). It is likely therefore that all activated oocytes in our data set with two 
or more pronuclei were similarly digynic. This would suggest that the main risk following AOA with 
calcium ionophore is failure to coordinate telophase of meiosis II with extrusion of the PB2 
resulting in retention of both chromosome sets in the oocyte (4/39; 10%). Thus, in clinical 
practice, these data suggest that a careful examination for PB2 extrusion and pronucleus 
formation by time-lapse imaging is essential to avoid the transfer of digynic triploid embryos 
following AOA. Similarly, following failed fertilisation by ICSI and AOA, measures should be taken 
to avoid transfer of digynic parthenotes that appear morphologically identical to normally fertilised 
zygotes (2PB, 2PN) and that can equally progress to the blastocyst stage and implant. To a more 
general extent, these data reiterate the importance of performing further evaluation of fertilised 
eggs following regular IVF and showing abnormal zygote pronuclear patterns (such as, but not 
limited to, 1PN, 3PN  and micro PNs) with the use of new powerful technologies able to give a 
clear and unbiased picture about chromosomal segregation during female meiosis. 
Although preliminary evidence has been provided that AOA is likely not to affect oocyte 
aneuploidy, I do not recommend it to be applied as routine practice in IVF to generally increase 
fertilisation rates. I agree with the recent cautionary note that suggests that further validation is 
necessary for the clinical use of AOA and that it should be selectively applied to patients with 
known aetiology (van Blerkom, Cohen, & Johnson 2015). Further to this point, there is direct 
evidence from our data suggesting that the clinical application of AOA may not benefit all infertility 
patients. Although using my activation protocol I was able to achieve a consistently high rate of 
normal oocyte activation in the majority of our donors, one outlier (Patient 9) had a low activation 
rate of 1/6 (17% activation) (Table 7.2). This is further evidence in support of previous reports 
demonstrating that AOA is not beneficial for all patients to maximise fertilisation rates (Vanden 
Meerschaut et al. 2012; Montag et al. 2012). Furthermore, oocytes used in this study belong 
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mostly to patients who had a successful pregnancy outcome using sibling oocytes from the same 
stimulation (Table 7.1). 
Finally, the protocol used for activation here involved prolonged exposure (40 min) to higher 
concentrations of calcium ionophore (100µM) than are currently used clinically, to ensure a high 
level of activation (39/49; 80%). Therefore, it will be important to extend this study to normal 
clinical AOA protocols in failed fertilised oocytes and to analyse the incidence and meiotic origin 
of aneuploidies in activated oocytes/embryos by SNP genotyping of both parents using karyomap 
analysis (Handyside et al. 2010; Natesan et al. 2014). 
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8. Specific Aim 5: To develop an algorithm based on Karyomapping (termed 
MeioMapping) to investigate the mechanisms of human female meiosis by 
recovering of all three products of human female meiosis from individual 
oocytes (termed Trio) to allow exploration of the full extent of meiotic 
chromosome recombination and segregation that occurs in the female 
germline 
For this specific aim of the thesis I have worked in collaboration with several groups to develop a 
highly successful oocyte activation, biopsy and genotyping protocol for creating recombination 
and chromosome segregation maps for the three products of human female meiosis. Following 
ovarian stimulation and oocyte retrieval, I am able to successfully induce arrested MII human 
oocytes to complete the second meiotic division and extrude the second polar body. This, in 
conjunction with sequential biopsy of the polar bodies, allows separate genotyping of all meiotic 
products without the creation of embryos from fertilised eggs for research purposes. Our unique 
algorithms allow simultaneous analysis of meiotic recombination and chromosome segregation 
across the three products of meiosis, which provides new mechanistic insight into maternally-
derived aneuploidies. MeioMapping could be clinically applied to improve outcomes for infertility 
patients undergoing IVF. Our protocol works with a greater than 80% oocyte activation rate and 
segregation errors at meiosis II are not increased relative to fertilised oocytes. Oocyte activation 
and sequential biopsy of meiotic products has uncovered new insights into the basis of meiotic 
errors that may aid future reproductive therapies. The protocol from this part of my thesis was 
commissioned by the Editors of the Nature Protocols journal and has been submitted and 
accepted for publication; Ottolini CS, Capalbo A, Newnham L, Cimadomo C, Natesan SA, 
Hoffmann ER, Ubaldi FM, Rienzi L and Handyside AH. Generating maps of genome-wide 
recombination and chromosome segregation in human oocytes and embryos. Nature Protocols 





8.1. My Personal Contribution to the Work 
I was integral to conceiving and designing the embryological component of the submitted protocol 
with the help of Dr Antonio Capalbo and assisted Professor Alan Handyside in developing the 
Microsoft Excel tools based on Karyomapping (Handyside et al. 2010) to perform what has been 
termed MeioMapping. I was involved in the writing of the submitted manuscript and the design 
and creation of the figures. What follows is an adaptation of the manuscript commissioned by 
Nature Protocols (2015). 
 
8.2. Introduction 
8.2.1. Development of the Protocol 
As discussed in section 2.1 of the general discussion, meiosis in the human female is 
exceptionally error prone with 30-70% of human adult oocytes displaying chromosome copy 
number abnormalities, and >90% of human aneuploidies being of maternal meiotic origin 
(Hassold & Hunt 2001). Chromosome segregation errors in human female meiosis are the 
principal cause of embryo aneuploidy leading to failed implantation, miscarriage, and live births 
affected with chromosomal disorders (Down syndrome). The main contributing factors to these 
errors are maternal age and altered genetic recombination in maternal meiosis (Nagaoka et al. 
2012). Our knowledge of chromosome segregation in human female meiosis is largely based on 
linkage analysis on trisomic conceptions and quantitative chromosome analysis of the polar 
bodies and embryo biopsies following in vitro fertilisation (IVF) treatment.  
Until recently, nondisjunction of chromosomes (homologs) in the first meiotic division was thought 
to be the predominant mechanism by which chromosome imbalances arose in embryos. 
Population studies as well as cytological observations on foetal oocytes are historically the only 
sources of information on recombination and position of crossovers. Generating complete 
genome-wide maps of recombination requires all three products of meiosis, which up until 
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recently has been unattainable owing to difficulty sourcing adult material and the need for 
fertilisation to complete the second meiotic division. Here I describe my approach that overcomes 
the need to fertilise oocytes in order to obtain complete ‘MeioMaps’ of recombination and 
chromosome segregation (Ottolini et al. 2015). Obtaining MeioMaps is important for fully 
understanding the differences in recombination as well as their effects on chromosome 
segregation, for genome evolution as well as the genesis of human aneuploidies. Moreover, 
MeioMaps also reveal the meiotic origin of monosomies, which until now have been limited to 
copy number analyses of polar bodies. 
The MeioMap protocol was developed as a tool to study patterns of meiotic segregation and 
recombination in human oocytes. To fully study genome-wide crossover patterns and 
chromosome segregation in adult oocytes from human females, one must recover all three 
products of a single meiosis (Figure 8.1). I set out to develop a protocol which would enable us to 





Figure 8.1. Schematic showing an adult oocyte completing the first and second meiotic divisions. 
In the adult ovary, primary oocytes contain 23 pairs of homologous chromosomes held together by crossovers in the ‘bivalent’ configuration. Oocytes 
complete meiosis I in vivo and extrude one set of homologs into the first polar body (PB1), the mature oocyte then arrests at metaphase II. Completion 
of meiosis II normally only occurs upon fertilisation, but I utilise a calcium ionophore to trigger meiosis II without fertilisation by sperm. At meiosis II one 
set of sister chromatids are extruded to the second polar body (PB2) resulting in a haploid oocyte. The first and second polar bodies are biopsied 
sequentially, followed by tubing of the activated oocyte. 
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To this end, I obtained donated human oocytes that had extruded polar body 1 (PB1) in vivo and 
were arrested at metaphase II (MII). I biopsied the PB1, followed by exposure of the oocyte to a 
calcium ionophore (A23187), which mimics fertilisation thereby activating the oocyte to complete 
meiosis II and extrude the polar body 2 (PB2). I then separated the PB2 and oocyte and 
performed whole genome amplification (WGA) on the three individually recovered meiotic 
products (Figure 8.2). The WGA products as well as extracted genomic DNA from the oocyte 
donor were Single Nucleotide Polymorphism (SNP) genotyped and the heterozygous SNPs were 
used to perform genome-wide inheritance analysis of maternal haplotypes. With these data, I was 
able create genome-wide genetic recombination and chromosome segregation MeioMaps of the 




Figure 8.2. Images showing set up for the first polar body (PB1; arrow in image 1) biopsy and oocyte activation culture (Sections 8.3.1. to 
8.3.3 and 8.3.5). 
The mature oocyte with biopsied PB1 is activated using a calcium ionophore and PB2 is then biopsied (not shown). Note the appearance of the PB2 
and a single pronucleus in the activated oocyte (arrows in images 3 and 4 respectively). 
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The first aim was to obtain high quality genotype data. With this in mind I explored avenues to 
parthenogenically activate oocytes to eliminate the need for fertilisation by sperm, which 
contaminates the egg with the sperm DNA. It was first discovered in the 1970s that increasing the 
intracellular free Ca2+ in mammalian oocytes could induce the sequence of events normally 
following fertilisation, including the completion of meiosis II and subsequent cell division (Fulton & 
Whittingham 1978). Since then, many groups have published their findings using a calcium 
ionophore for either parthenogenic activation of human oocytes or assisted activation of human 
oocytes following poor fertilisation outcomes in IVF (Nasr-Esfahani et al. 2010). Instead of direct 
injection of Ca2+ the ionophore binds with the cell membrane allowing passage of ions across the 
membrane therefore creating the influx of Ca2+ (Saunders et al. 2002). Using my protocol I was 
able to induce the extrusion of PB2 in >80% oocytes without perturbing the second meiotic 
division.  
The second aim was to ensure proper identification of the polar bodies and oocytes for 
downstream applications. I did this by integrating an adapted clinical strategy, which uses the 
sequential biopsy of the two polar bodies). Using this technique, I was able to ensure that there 
was no sample mix up or cross contamination between samples (Capalbo et al. 2013).  
The final aim was to genotype the separated products of meiosis and apply algorithms for 
detecting heterozygosity and haplotype changes to analyse recombination and 
chromosome/chromatid segregation across the PB1, PB2 and the oocyte. I term this 
MeioMapping (Ottolini et al. 2015). To map the positions of crossovers in the two polar bodies 
(PB1, PB2) and the corresponding activated oocyte (oocyte-PB trio), a simple Mendelian 
algorithm is used to phase heterozygous (AB) maternal SNPs distributed across each 
chromosome (including the non-PAR region of the X chromosome and excluding the Y 
chromosome) using a haploid PB2 or activated oocyte as a reference. This results in two notional 
maternal haplotypes at consecutive loci across each chromosome: Maternal haplotype 1 
(reference) and 2 (non-reference) colour coded in yellow and green respectively (Table 5.1). The 
genotypes at all of these informative loci are then examined in each of the other trio samples and 
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compared to the reference. If the sample genotype is homozygous and identical to the reference 
it is Maternal haplotype 1 (yellow). If homozygous for the other SNP allele then it is Maternal 
haplotype 2 (green). Finally, if heterozygous it is colour coded in red or if there is no call for that 
SNP in grey (Table 8.1). 
Table 8.1: Table Showing Representation of Phasing of Maternal SNPs in Oocyte-PB Trios 
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Only heterozygous maternal SNPs are informative for phasing. Where the sample SNP matches 
the reference it is assigned maternal haplotype 1 and is coloured yellow in the MeioMap. Where 
the sample SNP differs from the reference, it is assigned maternal haplotype 2 and coloured 
green. Where both SNPs are present (AB) the region is heterozygous and is coloured red. When 
no SNP calls, the SNP is coloured grey. Crossovers between homozygous regions of PB2 and 
oocyte occur at SNP 6 and 14. A crossover between heterozygous and homozygous regions in 
PB1 and oocyte occurs at SNP 10. A ‘common crossover’ (see text for full explanation) occurs at 
SNP 14. Examples of allele drop out (ADO) and allele drop in (ADI) are as follows: ADO in 
homozygous region (grey cell, SNP 4 PB2) leads to loss of resolution; ADO in heterozygous 
region (SNP 4 or 9 in PB1) leads to loss of heterozygosity and creates ‘noise’ in the data; Double 
ADO (SNP 7 in PB1) results in no call and a reduced resolution; ADI without ADO (SNP 13 in 
PB2) results in erroneous heterozygous calls and ‘noise’ in the data; ADI with ADO (SNP 17 in 
oocyte) leads to erroneous call of opposing haplotype and ‘noise’ in the data.  
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Theoretically, all maternal heterozygous SNPs should be informative. In practice, however, 
selecting heterozygous maternal SNPs, which are, as an additional requirement, genotyped as 
homozygous in the chosen reference, significantly improves the consistency of haplotype calling. 
Note that because of the principle of independent segregation, each chromosome in the 
reference has a random grandparental origin. 
When the colour coded SNPs are displayed in columns as a consecutive series for each 
chromosome, the transitions which occur as a result of recombination are evident. For PB1, each 
recombination is marked by a transition from a heterozygous (red) region to a homozygous 
region for one of the two maternal haplotypes (yellow or green) or vice versa. For PB2 and the 
activated oocyte, the transitions occur between the two homozygous maternal haplotypes (yellow 
to green or green to yellow; Figure 8.3). At this stage, the reference sample, which for phasing 
purposes is assumed to have no recombination, displays only one maternal haplotype i.e. all 
SNPs coded yellow. However, in most cases the reference chromosome will in fact be 
recombinant. This assumption has the effect of creating an apparent recombination in all of the 
other samples at that position (common recombination), though it will not be observed in the 
heterozygous regions of PB1. Each sample, therefore, has a combination of true recombinations 
and common recombinations. Secondary analysis is then required to identify the common 






Figure 8.3. Screenshot of SNP patterns in an oocyte-polar body trio. 
Opposing grandparental SNPs are shown as yellow or green cells. When both grandparental 
SNPs are present (i.e. in heterozygous regions) the cells are coloured red. Grey cells denote 
SNPs that have failed to call (ADO). Transitions between haplotypes mark points of crossovers. 
Crossovers are ‘tagged’ (step X) by copying the two SNPs flanking a crossover into the right-
hand adjacent column. The dashed box illustrates where a crossover has occurred in the 
reference resulting in a ‘common crossover’ at the same position across all homozygous 




Figure 8.4. Informative SNPs are phased using a reference chromatid to reveal positions of haplotype switches (crossovers). 
A haploid cell containing a single chromatid (either PB2 or oocyte) with a good call rate is chosen as the reference chromatid. Oocyte-PB trios from the 
same individual are compared to the reference chromatid and crossovers are mapped at positions where the haplotypes switch from the ‘assumed 
ancestral phasing’ in the reference. When a crossover occurs on the reference chromatid, this manifests as a ‘common crossover’ that appears across 
all homozygous samples at the same position (dotted red boxes). These common crossovers are identified, removed and replaced to the reference 
chromatid using a macro. This process is repeated with a second reference to confirm crossover positions. 
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8.2.2. Applications of the Method 
This protocol is an important advance to human oocyte research within an ethical framework that 
facilitates a new era of investigation into various aspects of female meiosis. It does not require the 
creation or destruction of fertilised human embryos and the protocol was paramount to 
uncovering several novel findings (Ottolini et al. 2015). These include a previously undescribed 
meiotic segregation pattern termed ‘reverse segregation’ which has shed new light on the meiotic 
origin of both monosomies and trisomies. It has led to direct evidence showing that lower, 
genome-wide recombination rates are associated with increased mis-segregation of 
chromosomes in human female meiosis, suggesting that higher recombination rates are selected 
for in the female germline. The studies also revealed the first direct evidence of meiotic drive, in 
which non-recombinant chromatids are preferentially excluded from the oocyte. Moving forward 
this protocol is central for further oocyte-PB trio analysis and is the protocol devised by the 
Human MeioMap Project (www.sussex.ac.uk/lifesci/hoffmannlab/research/meiomap) to explore 
human female meiosis on a broader population scale. 
The protocol outlined below is theoretically platform-independent, relying only on the detection of 
genetic variation. Therefore, with minor adaptation, the protocol will move forward with advances 
in single cell technology, including next generation sequencing, which will increase the resolution 
and may enable the detection of de novo gene conversions. 
Currently the protocol is optimised for oocytes arrested at metaphase II. However, with further 
development it could be employed to utilise surplus immature (MI or GV) oocytes from human 
IVF cycles that are otherwise unused. This is a potentially large resource that could enable easy 
and ethical access to material for the study of human female meiosis. Application of this method 
will also allow assessment of the efficacy of the first meiotic division following the in vitro 
maturation process. 
MeioMapping of female meioses can also be done by analysing the SNP genotype of PB1, PB2 
and the fertilised embryo (embryo-PB trio). For embryo-PB trios, the presence of the paternal 
genome in the embryo samples has to be taken into account. One option is to use the 
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Karyomapping algorithm, which is designed to identify four sets of informative SNPs for the four 
parental chromosomes, using an embryo sample, for example, as a reference (Handyside et al. 
2010). This has the advantage that recombinations between the paternal chromosomes can be 
identified in the same embryos. However, the resolution is lower because distinct sets of 
informative SNPs are used to define each haplotype and the number of these SNP loci is 
significantly reduced. Alternatively, exactly the same algorithm as used for oocyte-PB trios can be 
used with either a PB2 or embryo as reference, with the requirement that the reference SNP 
genotype is homozygous. In comparison with oocyte-PB trios, the number of informative SNP loci 
will be reduced because the paternal contribution will result in heterozygosity at some loci. 
However, the resolution is significantly higher than with Karyomapping as all of these informative 
loci identify both maternal haplotypes. For purposes of simplicity I have concentrated on oocyte-
trios only for this protocol. Modifications to the protocol required for MeioMapping embryo-trios 
are available on request. 
 
8.2.3. Comparison to Other Methods 
Until the introduction of MeioMapping, the relationship between recombination and meiotic 
chromosome segregation in humans were confined to population-based studies (Zaragoza et al. 
1994; Hassold et al. 1995; Oliver et al. 2008; Middlebrooks et al. 2013; Kong et al. 2004). This 
type of analysis is limited to trisomies that are compatible with in utero development. By its nature, 
this could not be performed on aneuploidies that are incompatible with in utero development and 
so excludes embryos that fail to give rise to clinically recognised pregnancies. Furthermore, by 
only examining one product of meiosis, chromosome mis-segregation patterns and total 
recombination rates can only be inferred.  
One major advantage of MeioMapping is its power to detect global recombination rates in human 
oocytes. Previously, the only method of detecting recombination across all 23 homologs was 
through cytological analysis of Mlh1 (that marks crossovers) in foetal oocytes (Gruhn et al. 2013; 
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Tease et al. 2002). However, this method cannot determine crossovers that may have arisen 
through Mlh1-independent pathways (e.g. Mus81-dependent crossovers). 
The second major advantage of MeioMapping is its capacity to reveal the chromosome 
segregation patterns that result in aneuploidy. Previously this could only be inferred from the 
SNPs surrounding the pericentromere in trisomic conceptions (Zaragoza et al. 1994; Hassold et 
al. 1995), which are potentially subject to interpretation errors. More recently however, 
chromosome copy number analysis of polar bodies such as array comparative genomic 
hybridisation (CGH) has enabled new insight into the prevalence of segregation errors in 
preimplantation embryos following IVF (Handyside et al. 2012; Capalbo et al. 2013; Christopikou 
et al. 2013). However, this quantitative analysis is also subject to interpretation errors regarding 
the meiotic origins of aneuploidy. 
To obtain similar results to our protocol, Hou et al. used intracytoplasmic sperm injection (ICSI) to 
induce resumption of the second meiotic division in mature (MII arrested) human oocytes (Hou et 
al. 2013). The female pro-nucleus was then removed from the resulting normally fertilised zygotes 
(human embryos) thus destroying them. Our oocyte activation protocol is less technically involved 
and does not result in the creation or destruction of human embryos for research purposes. 
Furthermore, my protocol results in an activation rate equal to or higher than performing ICSI in 
an clinical IVF setting (Palermo et al. 1995). 
An advantage of the simple Mendelian approach compared to other advanced bioinformatic 
algorithms, which identify haplotypes by analysing multiple reference samples (Hou et al. 2013) is 
that a single reference is sufficient to detect recombination and chromosome segregation 
patterns. However, running the analysis with a second reference, ideally from another trio, can be 
helpful to resolve rare ambiguous recombinations (for example at the extreme ends of 
chromosomes). It becomes necessary to use a second reference if there are one or more 
aneuploidies in the original reference. This also provides an opportunity to check that the 
common recombinations restored to the reference sample are correct (see step 46).  
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Finally, different platforms exist for detecting SNPs across the genome that can be applied to this 
type of analysis. In contrast to Hou et al. who used a sequencing-based approach (Hou et al. 
2013) I validated the protocol using genome-wide SNP arrays. Although my method could be 
adapted to a sequencing-based approach, the efficacy and resolution depends on the read depth 
and level of SNP overlap across all samples (including maternal and reference genotypes). At 
present, the depth of sequencing required for my approach is not cost-effective and thus has not 
been explored. 
 
8.2.4. Level of Expertise Needed 
Clinical: 
 Registered medical practitioner licensed for oocyte collection from the donors 
Molecular biology: 
 Basic molecular biology skills are required to amplify single cell DNA and extract gDNA 
from tissue samples. Knowledge of array scanners and their software is also required. 
Embryology: 
 Advanced micromanipulation and basic cell culture skill. Mammalian embryologists with 
embryo biopsy expertise recommended as operators. 
Data analysis: 




As a minimum, this strategy requires that the reference is from a second trio and therefore 
requires more than one oocyte-PB trio per donor. Otherwise, reciprocal recombinations between 
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the sister chromatids in PB2 and the activated oocyte will not be detectable (see Figure 8.4). If 
this requirement is fulfilled, the complete pattern of recombinations for each trio can be identified 
(or inferred in any trio with the genotypes of only two out of the three products of meiosis). At 
present the protocol does not allow for the separation of the two sister chromatids in the PB1. 
Reciprocal crossovers in the PB1 are unidentifiable as they exist in heterozygous regions of PB1 
that cannot be phased (Ottolini et al. 2015). 
Perhaps the largest limitation of the protocol is obtaining the oocytes themselves. This relies upon 
patients undergoing an invasive medical procedure to retrieve oocytes directly from the ovarian 
follicles prior to ovulation. Obtaining material relies on patients either donating oocytes as part of a 
clinical IVF cycle (Ottolini et al. 2015), or a specific donation for research purposes (Hou et al. 
2013). 
This protocol also relies upon single cell WGA, which results in a certain level of amplification 
error (Findlay et al. 1995). Random failure to amplify one of the parental SNPs (known as ‘allele 
dropout’; ADO) will reduce resolution in haploid homozygous regions and result in erroneous 
homozygous calls in heterozygous regions (Table 8.1). WGA can also introduce random 
erroneous amplification of the incorrect allele at certain loci. This is known as allele drop in and 
will introduce low-level ‘noise’ to the data (Table 8.1).  
 
8.3. Materials 
8.3.1. Essential Equipment 
 A dedicated tissue culture facility suitable for the culture of human gametes and embryos 
 Class 2 flow cabinet work station with a stereo microscope and 37°C heated work surface 
 Incubators for embryo media equilibration and embryo activation culture 




 Micromanipulators (e.g. Narishige, Japan) fitted with a single hand operated aspirator and 
a mouth pipette to control micro-pipette 
 Inverted microscope (e.g. Eclipse TS100; Nikon Ltd, Japan) equipped with Hoffman 
Modulation contrast, 37°C heating stage and a laser objective (e.g. Saturn laser; 
Research Instruments, UK) 
 Holding micro-pipette (Holding pipette; TPC, Australia) and aspiration micro-pipette for 
biopsy (zona drilling pipette; TPC, Australia) 
 Stripper hand piece and plastic denuding pipette tips with 130μm lumen (COOK Medical, 
Ireland) 
 Culture Dishes appropriate for applications 
 PC running Microsoft Excel 
 
8.3.2. Essential Reagents 
 Oocyte culture medium (e.g. Quinn’s Advantage Cleavage medium; Cooper surgical, 
USA) 
 Oocyte handling medium (e.g. Quinn's Advantage Medium w/HEPES; Cooper surgical, 
USA)  
 Human serum albumen (e.g. HSA, Cooper surgical, USA) 
 Mineral oil (e.g. Oil; Cooper surgical, USA)  
 Calcium ionophore (Sigma-Aldrich, USA)  





8.3.3. Reagent Set-up 
 Prepare Calcium ionophore stock solution 
o Dilute 20.94mg of calcium ionophore in 10ml of DMSO to make 4mM stock 
solution 
o Store at -20°C for up to three months 
 Supplement all media with 10% HSA 
o Store at 3-5°C for up to a week 
 Prepare working activation culture medium 
o Add 100μl of stock solution to 3.9ml of Sage cleavage +10% HSA for a final 
100uM working solution 
o Use within 12 hours 
 Dish preparation and equilibration 
o Prepare culture medium drops within dishes and cover with mineral oil 
o Allow to equilibrate in gassed incubator for a minimum of three hours prior to use 
 Prepare handling medium drops (for biopsy) within dishes and cover with mineral oil 




Obtaining mature (MII) human oocytes: 
Oocytes can be obtained from a natural menstrual cycle or after a period of any standard clinical 
ovarian hyperstimulation protocol. Oocytes should be collected by surgical means ~35 hours post 
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LH surge or administration of HCG trigger. All collected oocytes must undergo enzymatic and 
mechanical removal of all cumulus cells and the cells of the corona radiata.  
Critical step – incomplete removal of all maternal somatic cell surrounding the oocyte 
could result in contamination of downstream applications. At this point oocytes may be 
vitrified for batching purposes prior to starting the protocol. For best results the protocol should 
begin 38-40 hours post LH surge (natural cycle) or administration of HCG trigger (stimulated 
cycle). In the case of vitrified oocytes, the protocol should begin 1-2 hours post oocyte warming. 
All oocyte culture is performed in a humidified incubator set at 37°C in 6% CO2 and 5% O2. 
To enable tracking of the oocytes and their corresponding PBs throughout the protocol, individual 
samples must remain separated. Thus, all culture drops, wells and tubes should be uniquely 
numbered and recorded to allow traceability throughout the experiment. 
The protocol requires genomic DNA from all egg donors. In our experience, the genomic DNA 
can be easily obtained in three ways for the protocol. Depending on when and how the oocytes 
are obtained: 1) Washed cumulus cell can be used from the donated oocytes collected at the 
time of oocyte denuding; 2) Blood samples can be taken from the donor at any time; 3) Buccal 
cell swabs can be taken from the donor at any time. N.B: This is especially useful if the 
oocytes are donated retrospectively as buccal cell swab kits can be sent in the post. DNA 
extraction can be performed at any time as per the instructions accompanying commercially 
available kits.  
 
8.4. Step-by-Step Protocol 
8.4.1. First Polar Body (PB1) Biopsy  
N.B: The activation and biopsy steps below could feasibly be performed by a single 
operator. However, it is recommended that two operators work in tandem at time points 
where certain activities can be performed in parallel (e.g. biopsy and tubing) to avoid 
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delays in processing to preserving the sample’s integrity especially when performing the 
protocol on more than six oocytes at a time. 
1. At a stereo microscope work station, move the oocytes to a biopsy dish with individually 
numbered 10µl microdrops of HEPES medium +10% HSA under Sage oil. Use a wash 
drop per oocyte to ensure that each oocyte is free from any cellular debris before 
allocating them to their biopsy drop. The number of oocytes per dish is dependent on the 
skill of the operator. I recommend that no more than 15 minutes should pass between the 
oocytes entering the dish and them being removed after biopsy (from 1-6 oocytes per 
dish). 
2. Place the dish containing the oocytes on the inverted microscope (with micromanipulators 
and laser attached) to give a clear view of the PB and secure the oocyte by suction with 
the holding pipette ensuring that the oocyte is just above the bottom of the dish.  
3. Rotate the oocyte using the aspiration pipette until the PB is clearly in focus at around 12 
or six o’clock orientation. If done correctly, the zona pellucida should also be clearly in 
focus (Figure 8.2). It is essential to maintain a gentle yet constantly full seal between the 
holding pipette and the oocyte as even a small break in the seal could result in a poor 
outcome. 
4. Once the oocyte is correctly positioned for biopsy make a small aperture with a series of 
laser pulses in the zona pellucida, no larger than the diameter of the aspiration pipette, 
adjacent to the PB on the side of the aspiration pipette. Work inwards from the outer 
surface of the zona. Attention must be given so as not to fire a laser pulse at the 
cytoplasm of the oocyte or PB. 
5. Insert the aspiration pipette through the opening in the zona and position the lumen of the 
pipette adjacent to the PB. 
6. Use the aspirator to create a small amount of suction and slowly withdraw to remove the 
PB. If avoidable, the PB should not entirely enter the pipette as this could result in lysis. 
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Laser assistance may be required if the PB is still attached to the oocyte to break the 
intercellular bond. A single laser pulse, on the lowest intensity setting, can be used at the 
cell junction to release the bond. If PB1 is fragmented, or fragments during biopsy, ensure 
all fragments are removed for tubing. 
7. Once successfully removed, separate the PB and oocytes to separate areas of the drop 
to ensure safe transfer of the oocyte to further culture without disturbing the PB. Make a 
note of the position of the PB in each drop for future reference. 
 
8.4.2. Activation Culture 
8. Move the dish containing the biopsied oocytes to a stereo microscope work station. 
9. Identify both the PB and the oocyte down the microscope. Use a stripper pipette to 
transfer the oocytes to activation culture drops making sure not to disturb the PB. Care 
must be taken from this point onwards not to excerpt too much pressure on the biopsied 
oocytes when pipetting. Slow pipetting with gentle aspiration and expulsion is 
recommended. 
10. Move the oocytes to individually numbered activation culture drops, leaving the biopsied 
PB1 behind in the biopsy dish for immediate tubing. Use a wash drop to gently wash each 
oocyte before allocating them to their activation culture drop. Begin a 40 minute timer 
from the time the last oocyte is transferred to activation culture and put the dish in the 
incubator until the timer ends. 
At this point, further PB1 biopsy can be performed following the steps above (steps 1-10). If so a 






8.4.3. PB1 Tubing 
11. Prime the appropriate number of 0.2ml, RNase and DNase free thin walled, flat cap 
polymerase chain reaction (PCR) tubes with 1ul of phosphate buffered saline (PBS) for 
the number of polar bodies to be tubed and label each tube appropriately. 
12. To avoid evaporation and contamination, close the cap on the tubes gently (loose cap). 
Caps should be closed but easily releasable for depositing the samples. The 1μL of PBS 
should remain at the bottom of the tubes. If not, or small drops form on the side of the 
tube, give the tubes a quick spin on the micro centrifuge prior to depositing the samples. 
13. Focus on the polar body with the stereo microscope using the mirror to create contrast for 
best visibility. 
14. Set the stripper pipette to 1μL and using a 120μm pipette tip prime as much as possible 
with PBS. Depress the plunger all the way, aspirating PBS into the pipette until the 
plunger is entirely released. For best results change to a new stripper tip for each sample. 
15. Enter the drop with the pipette tip whilst gently expelling a small amount of PBS to ensure 
no oil blocks the tip. If any oil droplets are visible in the pipette tip, try to clear it by 
vigorous aspiration in clean PBS or replace it and restart from step 14. 
16. Place the pipette tip over and adjacent to the PB and release the plunger entirely (PB 
should enter the pipette and remain there). Ensure that the plunger and the pipette are 
not knocked at this stage as the sample could be lost. 
17. Open a pre-primed and labelled PCR tube and hold the tube between thumb and index 
finger so as to have a clear view through the tube from top to bottom.  
18. Insert the pipette containing the sample into the tube so that the tip enters the PBS. Avoid 
touching the sides of the tube or the bottom if possible. 
19. Expel the contents of the pipette into the tube stopping when 1μL mark is reached. This 
should be when a point of more resistance is felt when depressing the plunger. 
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20. Keep the plunger depressed to this point and re-enter the sample drop, expelling the 
remaining PBS whilst observing any objects exiting the pipette. Pipette up and down once 
or twice with the media in the drop to ensure the PB is not stuck to the pipette wall. If no 
PB is observed, tightly cap the tube. 
Move on to the remaining samples following the same instructions. 
21. Once all samples have been tubed, briefly centrifuge them to ensure the samples and all 
the media are in the bottom of the tubes. 
22. Submerge the bottom of every tube (not the entire tube) in a shallow LN2 bath to snap 
freeze and store tubes in racks at -20°C. 
 
8.4.4. Post Activation Culture 
Ideally, post activation culture should be performed within a time lapse incubator for easy 
assessment of PB2 extrusion and pronuclear formation. For my protocol I specifically use the 
EmbryoScope system that has its own proprietary dishes called EmbryoScope Slides. 
23. After 40 minutes of activation culture, remove the dish containing the oocytes from the 
incubator and move it to the stereo microscope work station. 
24. Move each oocyte to a separate well of an EmbryoScope slide with a 170μm pipette tip. 
Wash using gentle pipetting in the provided wash well prior to depositing in the final 
culture well. Ensure each oocyte is positioned in the centre of the micro-well for best 
visibility on the time lapse system. 
25. Move the EmbryoScope slide to the EmbryoScope incubator unit and insert following the 
prompts. It is important that the slide is seated in its position securely using substantial 
downward force. 
If time lapse is not available, move the oocytes to a dish containing individually labelled 30μl 
drops of post activation culture medium. Wash thoroughly (yet gently) through a series of wash 
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drops (2) in the dish prior to depositing in the final culture drop. Place the dish in the standard 
incubator. 
 
8.4.5. Assessing activation 
Assessment of PB2 extrusion should be performed around 16 hours after the oocytes are moved 
to post activation culture.  
26. Use the EmbryoScope time lapse viewer to scroll through the images of each oocyte 
whilst the EmryoScope slide containing the oocytes remains in the incubator unit. 
Scrolling at different focal depths may be necessary to properly identify PB2 extrusion. 
Pronuclei may also become visible by this time however normal activation is not 
dependent on it (Figure 8.2). 
If time lapse is not available, move the dish containing the oocytes to the inverted microscope 
work station. Gradually focus through the oocytes to identify the presence of PB2. Again, 
pronuclei may also be visible by this time; however normal activation is not dependent on it. 
 
8.4.6. PB2 Biopsy 
27. Repeat steps 1-7 ensuring extra care is taken when pipetting (step 1) and that suction 
with the holding pipette (steps 2-3) avoids the existing aperture in the zona pellucida. 
If PB2 biopsy is to be performed on more than one dish of activated oocytes (maximum six 
oocytes) a second operator should perform the tubing procedure below in parallel. 
 
8.4.7. PB2 Tubing 
28. Repeat steps 11-20 whist the oocyte remains in the drop with the PB2. It is important that 
the oocyte and PB2 are well separated in the drop and that the oocyte is avoided when 
pipettes enter the drop (steps 15-16 & 20). 
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29. Leave the biopsy dish, now containing only the oocytes (devoid of their PB1 and PB2), on 
the heated stage of the stereo microscope if working alone. If working in tandem with 
another operator, move biopsy dish to inverted microscope for zona removal procedure 
(step 31). 
30. Repeat steps 21-22 with tubed PB2 samples. 
 
8.4.8. Zona removal  
31. Place the dish containing the oocytes on the inverted microscope (with micromanipulators 
and laser attached) to give a clear view of the zona pellucida and secure the oocyte by 
suction with the holding pipette ensuring that the oocyte is just above the bottom of the 
dish. Be careful to avoid the two existing apertures in the zona. 
32. Once in position, make a large aperture in the zona pellucida using a series of laser 
pulses. The aperture should be between a quarter and half of the zona around. Ablate the 
zona using laser pulses approximately the same diameter of the zona thickness, working 
in a circular fashion.  
33. Insert the aspiration pipette under the zona and gently expel medium to displace the 
oocyte so that it is free from the zona. Ensure that the pipette is well primed and be 
careful not to blow any bubbles. Gentle manual manipulation with the aspiration pipette to 
move the oocyte may also be necessary to help the displacement process. 
34. Whilst still attached to the zona move the holding pipette to the edge of the drop and 
deposit the zona there leaving the oocyte in the centre of the drop. 
 
8.4.9. Oocyte tubing 
35. Repeat steps 11-22 to complete the tubing of the oocyte. Try to avoid the Zona pellucida 
when aspirating the oocyte (steps 15-16). 
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8.4.10. Whole Genome Amplification (WGA) and Genotyping  
N.B. The following two points are performed following the clinical Karyomapping protocol 
for single cells provided by Illumina within the Karyomapping product. For further details 
refer to Natesan et al. (Karyomapping validation paper). Briefly; 
36. The PCR tubes containing the trios samples were brought to an end volume of 4μl with 
PBS and multiple displacement amplification (MDA) protocol performed according to the 
instructions provided (SureMDA, Illumina). 
37. 400ng  of the donor’s genomic DNA or 8µl of the WGA products from the trio’s samples 
(PB1, PB2 or oocyte) were processed on SNP genotyping beadchips (Human CytoSNP-
12 or Human Karyomapping beadarray; Illumina, San Diego, CA, USA) for ~300K SNPs, 
following the instructions provided. 
N.B. This part of the protocol can be performed by a third party if necessary. If so, the 
samples can be shipped in racks on ice to the commissioned laboratory. 
Key point. Do not ship on dry ice. Insure care is taken with the parcel and shipping time 
does not exceed three hours. 
 
8.4.11. MeioMapping 
38. The SNP genotypes for maternal genomic DNA, and the WGA products for PB1, PB2 
and activated oocyte for each trio are exported from Genomestudio (Illumina, USA) as a 
text file along with the chromosome location and base pair position. 
39. This data is then imported into Microsoft Excel and sorted according to (1) chromosome 
and (2) base pair (bp) position. This file is then saved and archived following step 38. 
Steps 38 onwards are carried out using a series of Visual Basic for Applications (VBA) 
macros in Microsoft Excel. 
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40. The SNP genotype data for each of the 23 chromosomes is imported separately into a 
second Excel spreadsheet for MeioMapping and arranged in blocks side-by-side. Note 
that the original data and processed data are stored in separate Excel workbooks to keep 
the size of the files to a manageable size. 
41. The call rates and heterozygous call rates are calculated for all samples. 
42. A reference sample (either a PB2 or activated oocyte) is selected. Note that to maximise 
the number of informative SNP loci a reference sample with a high call rate and low 
heterozygous call rate should be selected. 
43. Informative maternal heterozygous SNP loci for each chromosome, which genotype as 
homozygous in the reference sample (AA or BB), are identified and defined as Maternal 
haplotype 1 (yellow) (Table 8.1). 
44. Sample genotypes at informative maternal SNP loci for each chromosome are compared 
to the reference genotype and identified as: (1) homozygous for the same allele – 
Maternal haplotype 1 (yellow); (2) homozygous for the other allele – Maternal haplotype 2 
(green); (3) heterozygous – combination of Maternal haplotypes 1 and 2 (red); or (4) no 
call (grey). See Figure 8.3 and Table 8.1. 
45. The results of (6) are displayed as a consecutive series of informative SNPs in vertical 
columns, colour coded with their bp position, for each chromosome, again in separate 
blocks arranged side-by-side in a separate worksheet (Figure 8.3). 
46. The positions of any recombinations indicated by the transitions described above are 
tagged either manually or using a macro. For manual tagging, the informative SNPs 
flanking the recombination are copied and pasted into the adjacent right-hand column, 






(1) Each recombination should always be present in two out of three of the products of 
meiosis at the same position. 
(2) Regions of heterozygosity which indicate the presence of two non-sister chromatids, 
typically in PB1 may, depending on amplification efficiency, have variable levels of ADO 
and ‘no calls’ (Table 8.1). The transition from these regions to homozygous regions of 
sister chromatids is generally clearly evident but less well defined for this reason. 
Whereas transitions between homozygous maternal haplotypes are sharply defined since 
they are not affected by ADO and have lower no call rates than heterozygous loci. The 
nearest flanking heterozygous (red) SNP and homozygous SNP (yellow or green) should 
therefore be tagged and the corresponding transition in PB2 or the activated oocyte used 
to define the position of the recombination event. 
47. The flanking tags for each recombination in each sample are imported into a separate 
worksheet. 
48. ‘Common crossovers’ are identified by their presence in all homozygous samples at the 
same position (Figure 8.4), defined by an overlapping range for the two flanking tags in 
each sample. Note that common crossovers cannot be identified in heterozygous regions, 
typically in PB1. Reciprocal recombination between segregated sister chromatids in PB2 
and the activated oocyte, one of which is the reference, will not be identified in the non-
reference component and needs to be added back to this component also (Figure 8.4). 
49. Common crossovers are removed from each non-reference sample and added to the 
reference sample (Figure 8.4). 
50. The position of all crossovers is calculated as an average of the base pair position of the 
flanking tags. 
51. The haplotype colours across each true recombination are corrected following the 
removal of the common crossovers. 
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52. The pattern of recombinations in each component of each trio is displayed according to its 
position to generate the MeioMap (Figure 8.4). 
 
Notes: 
(1) Secondary analysis of the numbers and positions of the recombinations can be done 
either with the use of further macros within Excel or by exporting the relevant data. 
(2) Segregation errors in female meiosis can be inferred by atypical patterns of 
homozygous and heterozygous regions in the three components in the MeioMap (Ottolini 
et al. 2015). 
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9. Specific Aim 6: To combine the techniques developed above and use both 
Karyomapping and MeioMapping to explore the full extent of meiotic 
chromosome recombination and segregation that occurs in the human oocyte 
As outlined in sections 2.2.2 and 2.8 of the General Introduction, crossover recombination 
reshuffles genes and prevents errors in segregation that lead to extra or missing chromosomes 
(aneuploidy) in human eggs, a major cause of pregnancy failure and congenital disorders. To 
explore this further, I generated genome-wide maps of crossovers and chromosome segregation 
patterns by recovering all three products of single female meiosis (as described in Specific Aim 
5). Genotyping>4 million informative SNPs from 23 complete meioses allowed us to map 2,032 
maternal and 1,342 paternal crossovers and to infer the segregation patterns of 529 chromosome 
pairs. I uncover: a) a novel reverse chromosome segregation pattern in which both homologs 
separate their sister chromatids at meiosis I; b) detect selection for higher recombination rates in 
the female germline by the elimination of aneuploid embryos; and c) report chromosomal drive 
against non-recombinant chromatids at meiosis II. Collectively, the findings of this specific aim 
reveal that recombination not only affects homolog segregation at meiosis I but also the fate of 
sister chromatids at meiosis II. This work has been recently published as follows: 
Ottolini CS, Newnham LJ, Capalbo A, Natesan SA, Joshi HA, Cimadomo D, Griffin DK, Sage K, 
Summers MC, Thornhill AR, Housworth E, Herbert AD, Rienzi L, Ubaldi FM, Handyside AH, and 
Hoffmann ER, Genome-wide maps of recombination and chromosome segregation in human 









9.1. My Personal Contribution to the Work 
I was integral to conceiving and designing the experiments for this chapter. I performed the 
majority of the embryology including oocyte warming and oocyte and embryo biopsy as well as 
tubing and whole genome amplification of the samples. I performed some of the SNP genotyping 
and array CGH and analysed all of the CGH and SNP data. I was involved in the writing and 
editing of the published manuscript and the design and creation of the figures. What follows is an 
adaptation of the published manuscript. 
 
9.2. Introduction 
Errors in chromosome segregation during the meiotic divisions in human female meiosis are a 
major cause of aneuploid conceptions, leading to implantation failure, pregnancy loss and 
congenital disorders (Nagaoka et al. 2012). The incidence of human trisomies increases 
exponentially in women from ~35 years of age, but despite conservative estimates that 10-30% of 
natural conceptions are aneuploid (Hassold & Hunt 2001), the underlying causes and their 
relative contributions are still unclear. In addition to maternal age, one important factor that 
predisposes to mis-segregation in both sexes is altered recombination. Recombinant 
chromosomes in the offspring are the result of crossovers, the reciprocal exchange of DNA 
between homologous chromosomes (homologs). Together with sister chromatid cohesion, 
crossovers physically link the homolog pair together during the prophase stage of meiosis (Figure 
9.1a), which takes place during foetal development in females. The linkages have to be 
maintained for decades, because the two rounds of chromosome segregation only occur in the 
adult woman. By following the pattern of genetic markers such as single nucleotide 
polymorphisms (SNPs) on the two chromosomes inherited from the mother in trisomic 
conceptions, it has been inferred that some crossovers occur too close to centromeres (Hassold 
et al. 1980; Hassold & Jacobs 1984; Zaragoza et al. 1994; Freeman et al. 2007; Nagaoka et al. 
2012), where they may disrupt the cohesion between the two sister chromatids (Koehler et al. 
1996; Rockmill et al. 2006). Other crossovers have been suggested to be too far from the 
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centromeres to mediate correct attachment, or to be lacking altogether (non-exchange, E0) 
(Hassold et al. 1980; Hassold & Jacobs 1984; Zaragoza et al. 1994; Freeman et al. 2007; 
Nagaoka et al. 2012). If these inferences are correct, it follows that events that shape the 
recombination landscape in oocytes during foetal development affect the risk of women having an 
aneuploid conception decades later in adult life.  
A limitation of these extensive population-based studies, however, is that only one of the products 
of meiosis is analysed (the oocyte). This prevents direct identification of the origin of chromosome 
segregation errors and provides only partial information on the crossovers during prophase of 
meiosis I. The ‘missing data’ problem is so significant that even the meiotic origin of age-related 
trisomies has been challenged recently (Hulten et al. 2010). Another confounding factor is that 
spontaneous miscarriages, still and live births on which our current knowledge is based represent 
only a minor fraction of the aneuploid embryos at conception. The majority of affected embryos 
are lost throughout pregnancy resulting in major preclinical and clinical losses (Hassold & Hunt 
2001). Thus, to understand the origin of human aneuploidies, I need to assess all three meiotic 





Figure 9.1. Human MeioMaps from embryos and oocytes together with their 
corresponding polar bodies (Ottolini et al. 2015).  
(a,b) The genotypes of the two maternal chromosomes are shown as green and yellow. 
Crossovers, shown in the dashed box, occur during foetal development. The two polar bodies 
were sequentially biopsied (grey arrows) to avoid misidentification. Maternal MeioMaps were 
deduced from the embryo following intracytoplasmic sperm injection (ICSI) or directly assessed in 
the haploid oocyte, after artificial activation (b).  
(c) An activated oocyte with a single pronucleus (arrow) and PB2. Scale bar: 110µm. 
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(d) An example of a MeioMap after genome-wide SNP detection and phasing (see Methods). 
Each chromosome is represented by three vertical columns representing the three cells of the trio 
(PB1, PB2, and embryo or oocyte). The two phased maternal haplotypes are represented by 
green and yellow. Blue represents the detection of both haplotypes. Regions where SNPs are not 
available on the array are shown in white (repetitive sequences on chr. 1 and 9) or gray (rDNA). 
Black bars illustrate the position of the centromere. Red bars show the last informative SNPs to 
call. Crossovers are manifested as reciprocal breakpoints in haplotypes (green to yellow, blue to 
green, etc.) in two of the three cells. Note that the colours of the haplotype blocks between 
different chromosomes are not necessarily derived from the same grandparent. Histograms of the 
resolution of the crossovers are shown in (e). The resolution was 352kb and 311kb for maternal 
(m) and paternal (p) crossovers in the embryos respectively. 
 
9.3. Methods 
The processing of oocytes for this section was performed following the protocol developed in 




All material for the study was ethically sourced with fully informed patient consent. All oocytes for 
the study were obtained from donors after completion of their in vitro fertilisation (IVF) treatment 
and were destroyed for analysis. The oocytes used were vitrified in accordance with Italian law in 
place at the time of oocyte retrieval for IVF treatment. Use of the oocytes for the study was 
approved by the Institutional Review Board of the Valle Giulia Clinic where the oocytes were 
stored and did not influence patient treatment. All embryo samples for the study were either 
obtained by tubing embryos in their entirety (destroyed) for analysis following a previous 
abnormal outcome in clinical tests or reanalysis of  clinical biopsy samples after embryos were 
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transferred, stored or discarded depending on the clinical result. SNP genotyping was performed 
as clinical follow up/validation of clinical genetic analysis and covered by the Human Fertilisation 
and Embryology Authority (HFEA) code of practice. All primary data were encoded such that 
informative SNPs were represented as A and B. Only secondary data with informative SNPs 
encoded A and B were used for data analysis. 
 
9.3.2. Oocyte-PB Trios 
9.3.2.1. Patient Participation and Consent 
All second meiotic division (MII) oocytes for the study were obtained from patients undergoing 
intra-cytoplasmic sperm injection (ICSI) treatment in the Centre for Reproductive Medicine 
GENERA in Rome between 2 September 2008 and 15 May 2009 following controlled ovarian 
hyperstimulation performed using two different protocols: GnRH-agonist long protocol and GnRH-
antagonist protocol. According to the Italian law in force when these oocytes were collected, a 
maximum of three oocytes could be inseminated per patient. The remaining MII oocytes were 
vitrified and later recruited for the study after informed consent was obtained from the patients. 
The study and the informed consent were approved by the Institutional Review Board of the Valle 
Giulia Clinic and did not influence patient treatment. 
 
9.3.2.2. Oocyte Collection 
Oocyte collection was performed at 35h post-human Chorionic Gonadotrophin (hCG) 
administration. Removal of the cumulus mass was performed by brief exposure to 40IU/ml 
hyaluronidase solution in Sage fertilisation medium +10% human serum albumin (HSA) (Cooper 
Surgical, USA), followed by mechanical removal of the corona radiata with the use of plastic 
‘denuding’ pipettes of defined diameters (COOK Medical, Ireland) in a controlled 6% CO2 and 
37°C environment. This procedure was performed between 37h and 40h post-hCG 
administration. MII oocytes were then identified for vitrification. 
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9.3.2.3. Oocyte Vitrification and Warming 
The vitrification and warming procedures were performed according to Kuwayama et al. 
(Kuwayama et al. 2005; Kuwayama 2007). Commercially available vitrification and warming kits 
were used (Kitazato BioPharma Co., Japan). The vitrification procedure was performed a 
maximum of 40 hours post-hCG administration. The oocytes were stored on a cryotop vitrification 
tool (Kitazato BioPharma Co., Japan) with a plastic cap for protection during storage in liquid 
nitrogen. All oocytes were stored submerged in liquid nitrogen until warming was performed. 
Following oocyte warming degenerated oocytes were discarded and the surviving oocytes were 
cultured before biopsy of the first polar body (PB1) and activation. 
 
9.3.2.4. Oocyte Culture and Activation 
All oocyte culture was performed at 37°C in 6% CO2 and 5% O2. To enable tracking of the 
oocytes and PBs, individual culture was performed and culture drops and wells were numbered 
to allow traceability throughout the experiment. 
Immediately after warming, the surviving oocytes were allocated to individually numbered 35µl 
microdrops of Sage cleavage medium +10% HSA under mineral oil (Cooper Surgical, USA) and 
cultured for two hours prior to PB1 biopsy and activation.  
Oocytes were activated by exposure to activation medium: 100µM calcium ionophore (A23187, 
C7522 Sigma-Aldrich) in Sage cleavage +10% HSA (Cooper Surgical, USA) from a stock 
solution in DMSO (Sigma-Aldrich) diluted 1:40. Oocytes were transferred to 35µl drops of the 
activation medium under Sage oil, numbered appropriately. Activation culture was performed for 
40-120 mins. The oocytes were then moved to post activation culture. 
Post activation culture was performed in separate wells of EmbryoScope slides (Unisence 
Fertilitech, Denmark) in cleavage medium – medium as used in post warm culture under Sage oil. 
The slides were placed in the EmbryoScope time lapse incubator (Unisence Fertilitech, Denmark) 
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for assessment of second polar body (PB2) extrusion and appearance of pronuclei prior to PB2 
biopsy.  
 
9.3.2.5. Polar Body Biopsy 
Polar bodies were biopsied sequentially in order to discriminate between the three products of 
meiosis using micromanipulators (Narishige, Japan) on an inverted microscope (Nikon Ltd, 
Japan) equipped with Hoffman Modulation contrast and a 37°C heating stage (Linkam Scientific 
Instruments, UK). The PB1 was biopsied prior to oocyte activation and the PB2 was biopsied 
following its extrusion, post activation as previously described by Capalbo et al. (Capalbo et al. 
2013). All biopsies were performed in individually numbered 10µl microdrops of HEPES medium 
+10% HSA under Sage oil (Cooper Surgical, USA) for tractability. For both PB1 and PB2 
biopsies, oocytes were positioned on the microscope to give a clear view of the PB and secured 
by suction with the holding pipette (TPC, Australia). An aperture was made in the zona pellucida 
with a series of laser pulses (Saturn laser; Research Instruments, UK) working inwards from the 
outer surface of the zona. The aspiration pipette (zona drilling pipette; TPC, Australia) was then 
inserted through the opening and the PB removed with gentle suction. PB1 biopsy: Once 
biopsied the oocytes were moved to activation culture leaving the biopsied PB1 in the microdrop 
for immediate transfer to a 0.2ml, RNase and DNase free thin walled, flat cap polymerase chain 
reaction (PCR) tube (Corning, Sigma-Aldrich) for DNA amplification. PB2 biopsy: once biopsied 
the PB2 was immediately transferred to a PCR tube for DNA amplification with the oocyte still in 
the microdrop. The oocyte was then returned to the micromanipulator for full zona removal. The 
zonae were removed from the oocytes using the same setup for the biopsy procedure. The 
oocyte was anchored to the holding pipette and a larger aperture was made in the zona using 
laser pulses. The oocyte was removed from the zona using both displacement and zona 
manipulation techniques with the aspiration pipette. Once free from the zonae, the oocytes were 
transferred to PCR tubes for DNA amplification. 
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Transfer of the samples to PCR tubes was performed using a plastic denuding pipette (COOK 
Medical, Ireland) with a 130μm lumen. Individually labelled PCR tubes were primed with 2μl 
Dulbecco's phosphate buffered saline (DPBS) (Gibco, Life technologies) with 0.1% polyvinyl 
alcohol (Sigma-Aldrich). Individual samples were expelled into the DPBS in around 1μl of the 
medium containing the samples, leaving a final volume of no more than 4μl of medium with the 
sample in the PCR tubes. The PCR tubes were then briefly centrifuged, snap frozen in liquid 
nitrogen and stored at -20C prior to whole genome amplification (WGA). 
 
9.3.3. DNA Extraction and Whole Genome Amplification (WGA) 
Genomic DNA (gDNA) from all oocyte donors was obtained using buccal cell swabs (Isohelix, 
Cell Projects Ltd). Extraction of the gDNA from the swabs was performed using a proteinase K 
extraction kit to a final volume of 30µl, following the manufacturer’s instructions. DNA from all 
three products of meiosis was obtained by lysis of the cells and WGA. The PCR tubes containing 
the samples were brought to an end volume of 4μl with phosphate buffered saline (PBS) and 
REPLI-g Single Cell Kit multiple displacement amplification (SureMDA, Illumina) or PCR library 
based SurePlex amplification (Illumina) was performed according to the manufacturer’s 
instructions. Multiple displacement amplification (MDA) was performed with a short 2h incubation.  
 
9.3.4. Embryos and Embryo-PB Trios 
9.3.4.1. Embryo Samples 
35 embryos diagnosed as affected and/or aneuploid were analysed from four clinical cases for 
either preimplantation genetic diagnosis (PGD) of single gene defects or preimplantation genetic 
screening (PGS) for aneuploidy following standard IVF protocols at The Bridge Centre, London 
with patients’ informed consent. SNP genotyping was performed for quality control purposes 
following clinical biopsy and genetic testing of the embryos under the HFEA clinic licence L0070-
14-a using similar methods to those described for the processing of the oocyte-PB trios.  
199 
 
In one of the PGD cases, two surplus denuded first meiotic division (MI) oocytes were allowed to 
mature in vitro by overnight culture in Sage fertilisation medium +10% HSA under mineral oil 
(Cooper Surgical). Biopsy of PB1, tubing and WGA of the oocyte and PB1 were then performed 
as described for the oocyte-PB trios. 
 
9.3.4.2. Embryo-PB Trios 
In another PGS case, in which array comparative genomic hybridisation (CGH) had been used to 
detect aneuploidy by copy number analysis of both polar bodies, the WGA products (Sureplex; 
Illumina, San Diego, CA, USA) from both polar bodies were SNP genotyped along with parental 
genomic DNAs and, with patients’ informed consent, WGA products (SureMDA; Illumina, San 
Diego, CA, USA) of nine corresponding fertilised embryos which had all been diagnosed as 
aneuploid.  
 
9.3.5. Array CGH, SNP Bead Array and Data Analysis 
For array CGH analysis, 4µl aliquots of Sureplex single cell amplified DNA Products (PB1, PB2, 
oocyte or blastomere) were processed on microarray slides (24Sure; Illumina, USA). The data 
was imported and analysed using dedicated software (BlueFuse Multi v 4.0; Illumina, USA). 
For SNP genotyping, 400ng of genomic DNA or 8µl of WGA products from the single cell and 
embryo samples (PB1, PB2, oocyte, single blastomere or whole embryo) were processed on a 
SNP genotyping beadarray (Human CytoSNP-12 or Human Karyomapping beadarray; Illumina, 
San Diego, CA, USA) for ~300K SNPs, using a shortened protocol and the genotype data 
analysed using a dedicated software programme for Karyomapping (Bluefuse Multi v4.0; Illumina, 
San Diego, CA, USA) or exported as a text file for analysis in Microsoft Excel (Natesan, Bladon et 




9.3.6. MeioMap Analysis 
Following SNP genotyping, MeioMaps were constructed and displayed by importing the data into 
Microsoft Excel and processing using custom macros written in Visual Basic for Applications. For 
the oocyte-PB trios, a simple algorithm was used to phase all heterozygous maternal SNP loci 
using a haploid PB2 or oocyte sample as a reference. This defined a reference set of 
homozygous SNP loci (haplotype) genome-wide (AA or BB), across each chromosome. The 
genotype of each of the samples including the reference were then interrogated at each of these 
informative SNP loci and displayed as either the same as the reference (yellow) or opposite to the 
reference (green) or heterozygous (blue) indicating the presence of both maternal haplotypes. 
Phase transitions at crossovers were then manually tagged in Excel by copying the closest SNP 
calls bracketing the crossover and the type and position of these SNPs imported into a second 
spreadsheet for further processing. Because phasing is achieved using a reference sample, any 
phase transitions caused by crossovers in that particular sample appear in identical positions in 
all other samples analysed (with the exception of any crossover between the reference and the 
PB2 or oocyte in that trio). Macros in the second spreadsheet therefore identified these common 
crossovers, restored them to the reference sample and removed them from all of the other 
samples. The MeioMaps were then displayed, checked and further edited manually as 
necessary. All oocyte-PB trios were run with at least two references to MeioMap any aneuploid 
chromosomes in the reference trio and to double-check all crossovers. 
For embryo-PB trios, two methods were used. Where the SNP genotype of a close relative or, in 
some cases, a sibling embryo was available, the samples were Karyomapped using the standard 
algorithm which identifies informative SNP loci for all four parental haplotypes in either Excel or 
using dedicated software (Bluefuse Multi v4.0; Illumina, San Diego, CA) (Handyside et al. 2010; 
Natesan et al. 2014). Alternatively to improve resolution, a modified Karyomapping algorithm with 
a PB2 or oocyte as reference was used. This algorithm identified all combinations of parental 
genotypes that were informative for the maternal haplotype only. In either case, the phase 
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transitions were manually tagged and imported into the second spreadsheet for further 
processing, display and final editing as above. 
The workflow was validated on single cells by comparing recombination maps in 15 individual 
cells from a donor to the genomic DNA of the child, and by assessing 10 individual blastomeres 
from the same embryo for direct comparison. In all cases, concordance of recombination rates 
and positions was >99% (data not shown).  
 
9.3.7. Simulation: Crossover Distribution Amongst Chromosomes and Distances 
Between Crossovers Along Chromosomes 
Simulations were performed to allocate a specified number of crossover events to set of 
chromosomes. Chromosomes were allocated a specified length using the minimum and 
maximum crossover locations mapped within the experimental dataset. Crossovers were 
allocated randomly to chromosomes with weighted probability using the chromosome length, thus 
longer chromosomes receive more crossovers. The allocation was either totally random (non-
obligate) or random following allocation of one crossover per chromosome (obligate). For each 
chromosome the positions of the allocated crossovers was determined iteratively by randomly 
selecting an available location. The available locations were all possible positions not within a 
minimum distance (107kb) from the existing crossover positions. The simulation reported the total 
number of crossovers per chromosome and the inter-crossover distances. The distance from the 
outermost crossover to the chromosome termini was not included. 10,000 simulations were 
performed to create the distributions.  
To estimate the fraction of missed crossovers, 125 crossovers were randomly distributed 
amongst chromosomes with a minimum distance of 0kb between them. A cumulative distribution 
of inter-crossover distances was constructed, ignoring crossover distances that were adjacent to 
telomeres. The cumulative frequencies were 0.04% at 10kb, 0.15% at 30kb, 0.52% at 107kb, 
0.75% at 150kb, and 1% at 200kb. 
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9.3.8. Chromatid Interference 
To detect chromatid interference, I identified 134 chromosome pairs with two crossovers and I 
asked whether the same two chromatids were less or more likely to be involved in both crossover 
events compared to random participation. I was unable to reject the null hypothesis of no 
chromatid interference (p>0.5; t-test for proportions), consistent with reports that negative 
chromatid interference is weak (Hou et al. 2013).  
 
9.3.9. Statistics, Modelling, and Graphics 
All statictical analysis, modelling and graphics in this specific aim were performed on the advice of 
Dr Eva Hoffmann and Professor Alan Handyside and were either performed by them or following 
their direct instructions.  Specifically, Statistical tests and modelling were carried out in Perl or R. 
All tests were permutation and non-parametric tests, or logistic regression analysis as indicated 
throughout the manuscript. For logistic regression,  the AIC was used to choose the appropriate 
link function. Binomial distribution of error variances were assessed using the plot (model) 
function of R. Residual variance and degrees of freedom was tested using chi-square and 
rejected if below 5%. Two-sided tests were employed, unless otherwise indicated. The lme4, 
lmPerm, psperman libraries were used in R. Graphics were rendered using the basic functions in 
R or the ggplot2 library (Wickham 2009).  
 
9.4. Results 
9.4.1. MeioMaps of Single Meioses in Oocytes and Embryos 
To follow genome-wide recombination and chromosome segregation simultaneously, I recovered 
all three products of female meiosis, which include the first and second polar bodies (PB1 and 
PB2) and the corresponding activated oocytes (as described in Specific Aim 5) or fertilised 
embryos. These are referred to as oocyte-PB or embryo-PB trios (Figure 9.1a-c). 10 embryo-PB 
trios were obtained after fertilisation of the oocyte following ICSI. The embryos reached various 
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stages of preimplantation development and originated from a single donor having preimplantation 
genetic screening for recurrent miscarriage and who consented to follow up genetic analysis of 
her embryos (Figure 9.1a, Table 9.1). 
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Table 9.1: Donor Information for Embryosa (Ottolini et al. 2015) 
 
a From The Bridge Centre, UK. Diagnostic follow-up in compliance with the code of practice (HFEA) 
b Donor of the two MII-arrested oocyte-PB1 duos (see Methods) 
c Corresponding embryo with both polar bodies analysed for MeioMapping 
d embryo giving rise to live births not mapped 
e Paternal translocation chromosomes were excluded from the analysis 
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A further 13 trios were generated following the protocol developed in Specific Aim 5 of this thesis, 
without fertilisation by activating mature MII-arrested oocytes with a calcium ionophore, which 
induced completion of MII and extrusion of the PB2 (Figure 9.1b,c). This protocol was highly 
successful (85%, n=40, Table 9.2) and did not alter the rate of meiosis II errors in the activated 
oocytes compared to embryos generated by ICSI (six of 299 versus four of 230; Table 9.3) (see 
also Specific Aim 4). The oocyte-PB trios were obtained from five healthy female donors, who 
had cryopreserved unfertilised eggs in the course of fertility treatment. Four of the five donors had 
achieved a pregnancy and live birth following IVF and all five consented to their remaining eggs 
being activated and undergoing genome analyses. The principle of isolating all three meiotic 
products is similar to the approach of using the polar bodies and recovering the female 
pronucleus from zygotes (Hou et al. 2013). 
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Table 9.2: Donor Information for Oocyte-PB Trios (Ottolini et al. 2015) 
 
* Trios used to generate MeioMaps. Average age: 37.2 years 
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Table 9.3: Origin and Incidence of Maternal Aneuploidies (Ottolini et al. 2015) 



























MI MII MI MII 
Oocyte-
PB trios 
37.3          
(33-41) 
13 62% 26 12 2 4 4 2 299 
Embryo-
PB trios 
38.3 10 70% 19 8 4 1 0 3 230 
Embryo 
only  
37.1      
(34-42)       
29
c
 54% n.d. 19 5 4 n.d n.d. 667 
 
a Mean age and range 
b Number of trios or embryos analysed 
c 28 embryos and 1 chorionic villus sample 
d Statistical test for significance of MII nondisjunction rates in oocyte-PB and embryo-PB trios: 6 
out of 299 compared to 4 out of 230, respectively, G-test with Williams’ correction, p=0.82 
n.d. not determined since no information from polar bodies. 
 
The trio datasets were complemented with data on recombination and aneuploidy rates from 29 
embryos (without polar bodies) in which SNP genotyping and Karyomapping (Handyside et al. 
2010) had previously been used for preimplantation genetic diagnosis. Because informative 
SNPs were available from both the mother and father, I was able to compare recombination in 




Table 9.4: Recombination Frequencies in Embryos (Ottolini et al. 2015) 

























































                          
1 LB02 *1.1 Embryo Recombination Mother 4 2 3 1 3 2 2 2 2 3 2 2 2 1 3 2 1 2 3 2 
 
2 1 NA 47 
1 LB02 *1.1 Embryo Recombination Father 2 0 2 1 2 2 0 1 0 2 2 1 2 1 0 0 1 0 2 0 1 0 NA 0 22 
2 LB02 *1.2 Embryo Recombination Mother 4 2 3 1 3 2 2 2 2 3 2 2 2 1 3 2 1 2 3 2 0 2 1 NA 47 
2 LB02 *1.2 Embryo Recombination Father 2 0 2 1 2 2 0 1 0 2 2 1 2 1 0 0 1 0 2 0 1 0 NA 0 22 
3 LB02 2 Embryo Recombination Mother 7 2 1 2 1 3 4 5 3 1 0 3 2 1 2 2 1 1 1 2 0 0 2 NA 46 
3 LB02 2 Embryo Recombination Father 2 2 0 1 2 1 2 1 0 2 1 1 1 1 1 2 2 0 1 2 1 1 NA 0 27 
4 LB02 3 Embryo Recombination Mother 2 1 2 1 2 2 3 2 2 2 1 1 1 4 3 1 1 0 
 
0 0 0 1 NA 32 
4 LB02 3 Embryo Recombination Father NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 0 
5 LB02 4 Embryo Recombination Mother 4 1 3 3 1 5 2 2 2 2 3 1 3 1 2 2 2 2 2 2 1 2 4 NA 52 
5 LB02 4 Embryo Recombination Father 1 2 2 0 2 2 2 2 1 0 2 1 2 1 1 2 2 0 2 0 0 0 0 
 
27 
6 LB02 *5.1 Embryo Recombination Mother 0 5 4 2 1 3 1 0 3 3 3 3 2 1 1 1 1 1 0 2 1 0 4 NA 42 
6 LB02 *5.1 Embryo Recombination Father 3 2 2 3 3 
 
2 1 2 1 2 1 1 2 1 2 1 1 1 3 1 1 0 0 36 
7 LB02 6 Embryo Recombination Mother 4 1 4 4 2 2 0 4 0 1 2 2 0 2 2 0 1 2 1 2 0 1 1 NA 38 
7 LB02 6 Embryo Recombination Father 3 2 1 1 4 0 1 0 1 3 1 3 1 1 
 
1 2 0 1 2 1 2 0 0 31 
8 LB02 7 Embryo Recombination Mother 1 3 5 2 2 2 1 0 3 1 2 3 0 1 0 0 2 2 1 2 0 0 1 NA 34 
8 LB02 7 Embryo Recombination Father 3 3 0 0 0 3 2 3 1 1 2 2 1 1 1 2 1 0 1 1 1 1 0 0 30 
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Daughter Recombination Mother 6 4 4 2 4 4 1 1 1 4 5 3 2 1 2 0 3 0 1 0 0 0 3 NA 51 
9 LB01 
 
Daughter Recombination Father 2 3 1 2 0 2 2 1 0 2 3 2 1 1 2 1 2 2 0 0 1 1 0 0 31 
10 LB01 CVS CVS Recombination Mother 7 1 4 0 1 2 3 1 0 3 4 0 1 1 1 2 3 1 2 2 0 1 4 NA 44 
10 LB01 CVS CVS Recombination Father 2 3 1 2 0 2 2 1 0 2 3 2 1 1 2 1 2 2 0 0 1 1 0 0 31 
11 LB01 *2.1 Embryo Recombination Mother 4 4 2 6 4 5 4 2 2 0 1 3 1 2 1 2 1 1 1 1 0 1 3 NA 51 
11 LB01 *2.1 Embryo Recombination Father 2 2 0 1 0 1 1 1 1 1 0 1 0 1 0 2 1 0 1 1 0 0 0 0 17 
12 LB01 *2.2 Embryo Recombination Mother 4 4 2 6 4 5 4 2 2 0 1 3 1 2 1 2 1 1 1 1 
 
1 3 NA 51 
12 LB01 *2.2 Embryo Recombination Father 2 2 0 1 0 1 1 1 1 1 0 1 0 1 0 2 1 0 1 1 0 0 0 0 17 
13 LB01 *3.1 Embryo Recombination Mother 8 3 4 2 2 4 1 4 1 5 2 5 3 2 
 
2 3 2 1 2 2 0 2 NA 60 
13 LB01 *3.1 Embryo Recombination Father 4 3 3 1 2 2 
 
2 1 2 2 2 2 2 1 1 1 2 0 1 1 0 0 0 35 
16 LB01 *3.2 Embryo Recombination Mother 8 3 4 2 2 4 1 4 1 5 2 5 3 2 
 
2 3 2 1 2 2 0 2 NA 60 
16 LB01 *3.2 Embryo Recombination Father 4 3 3 1 2 2 
 
2 1 2 2 2 2 2 1 1 1 2 0 1 1 0 0 0 35 
14 LB01 4 Embryo Recombination Mother 5 4 3 2 2 0 2 3 2 3 2 1 1 1 1 0 1 1 1 1 1 1 0 NA 38 
14 LB01 4 Embryo Recombination Father 2 2 1 3 2 1 2 1 3 2 2 1 0 2 1 1 1 1 2 1 0 1 0 0 32 
15 LB01 5 Embryo Recombination Mother 6 5 2 5 5 1 2 2 3 4 2 3 0 2 3 1 1 3 0 0 1 
 
3 NA 54 
15 LB01 5 Embryo Recombination Father 1 1 2 1 3 0 1 2 0 2 2 1 1 0 1 1 1 1 1 1 1 1 0 0 25 
17 LB03 2 Embryo Recombination Mother 2 3 2 4 3 2 3 1 0 3 3 1 2 1 0 1 0 3 2 1 1 1 3 NA 42 
17 LB03 2 Embryo Recombination Father 2 2 1 1 1 1 0 1 0 2 2 0 2 0 1 1 0 0 1 1 0 0 0 0 19 
18 LB03 5 Embryo Recombination Mother 7 2 3 5 0 3 1 3 3 1 0 3 1 2 1 2 3 3 2 0 
 
1 1 NA 47 
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18 LB03 5 Embryo Recombination Father 2 0 2 1 1 2 3 1 1 2 1 1 0 0 2 2 0 0 0 2 0 0 0 0 23 
19 LB03 6 Embryo Recombination Mother 3 3 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 6 
19 LB03 6 Embryo Recombination Father 2 1 
 




2 1 2 2 2 2 2 2 2 1 1 
 
0 30 
20 LB03 7 Embryo Recombination Mother 2 2 3 3 3 3 
 
1 2 2 
 
2 1 1 2 2 2 0 0 1 1 
 
2 NA 35 
20 LB03 7 Embryo Recombination Father 0 0 2 2 2 1 2 1 0 0 2 2 2 1 1 1 1 1 0 0 1 1 0 0 23 
21 LB03 8 Embryo Recombination Mother 3 4 2 3 3 3 2 4 3 3 0 1 2 2 0 2 3 1 1 3 1 1 3 NA 50 
21 LB03 8 Embryo Recombination Father 3 0 3 0 2 1 2 1 0 2 1 2 0 0 0 1 1 0 0 2 1 0 0 0 22 
22 LB03 10 Embryo Recombination Mother 2 0 5 3 2 0 3 1 2 1 2 1 1 1 2 1 2 2 0 2 1 0 3 NA 37 
22 LB03 10 Embryo Recombination Father 3 0 2 1 1 1 1 0 1 1 1 1 2 0 0 2 2 2 1 1 1 0 
 
0 24 
23 LB03 11 Embryo Recombination Mother 1 2 4 4 2 0 2 0 1 1 1 3 0 2 1 2 0 0 0 1 2 1 1 NA 31 
23 LB03 11 Embryo Recombination Father 3 2 1 1 1 2 0 1 1 2 0 0 1 1 0 1 1 1 0 0 0 0 0 0 19 
24 LB03 12 Embryo Recombination Mother 5 4 4 6 5 3 7 4 6 3 2 4 0 1 3 3 1 4 1 0 2 1 2 NA 71 
24 LB03 12 Embryo Recombination Father 1 3 3 2 1 1 1 3 1 1 1 1 2 1 1 1 0 2 2 0 0 0 0 0 28 
25 LB03 14 Embryo Recombination Mother 4 5 2 4 3 1 3 1 1 2 3 3 3 3 1 3 1 2 
 
0 1 0 1 NA 47 
25 LB03 14 Embryo Recombination Father 1 3 3 2 3 1 1 0 3 1 1 2 1 1 1 1 1 1 0 1 0 0 0 0 28 
26 LB03 16 Embryo Recombination Mother 3 3 3 1 2 2 4 1 1 1 1 1 1 2 3 1 2 2 0 2 
 
0 0 NA 36 
26 LB03 16 Embryo Recombination Father 2 2 1 0 2 1 2 1 1 3 0 1 1 0 1 1 1 1 3 2 0 1 0 0 27 
27 LB04 1 Embryo Recombination Mother 3 2 2 4 2 0 3 0 1 2 1 2 2 1 2 1 2 1 0 0 0 0 0 NA 31 
27 LB04 1 Embryo Recombination Father 2 3 1 1 0 0 2 2 1 0 1 2 1 0 2 1 0 1 0 2 1 1 0 0 24 
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28 LB04 2 Embryo Recombination Mother 5 3 3 3 3 2 3 1 1 2 3 2 0 2 2 
 
1 2 0 1 
  
1 NA 40 
28 LB04 2 Embryo Recombination Father 3 4 3 2 2 1 1 1 1 2 1 1 1 1 2 0 0 1 1 1 1 2 0 0 32 
29 LB04 3 Embryo Recombination Mother 5 2 6 1 2 1 4 2 3 4 0 3 1 4 3 2 2 1 0 1 2 1 1 NA 51 
29 LB04 3 Embryo Recombination Father 1 3 2 0 2 1 1 1 0 1 1 2 0 2 1 2 0 0 2 0 0 2 0 0 24 
34 LB04 4 Embryo Recombination Mother 2 4 3 1 0 3 2 3 4 3 1 0 1 1 0 1 2 1 0 2 1 0 1 NA 36 
34 LB04 4 Embryo Recombination Father 1 1 1 1 1 0 1 2 0 0 2 2 1 0 0 1 1 1 0 0 0 2 0 0 18 
30 LB04 5 Embryo Recombination Mother 2 2 4 4 3 4 4 0 2 1 3 2 2 2 3 
 
1 1 1 1 1 0 1 NA 44 
30 LB04 5 Embryo Recombination Father 1 1 2 1 2 2 0 2 2 0 2 0 0 2 1 2 0 1 1 0 0 1 0 0 23 
31 LB04 6 Embryo Recombination Mother 3 1 3 2 0 1 4 2 3 1 2 1 2 0 1 3 1 1 1 1 2 1 4 NA 40 
31 LB04 6 Embryo Recombination Father 2 3 3 1 0 0 2 0 1 1 1 1 0 1 0 2 2 0 0 1 0 2 0 0 23 
32 LB04 7 Embryo Recombination Mother 2 3 3 1 2 0 1 2 3 0 1 2 1 1 1 3 3 1 1 0 2 0 3 NA 36 
32 LB04 7 Embryo Recombination Father 2 0 1 1 1 1 1 0 0 0 2 1 0 0 1 0 0 1 2 1 0 3 0 0 18 
33 LB04 8 Embryo Recombination Mother 1 4 1 2 2 2 1 2 2 2 3 2 1 2 2 0 2 1 2 2 1 1 0 NA 38 
33 LB04 8 Embryo Recombination Father 1 2 1 2 3 1 1 0 1 2 2 0 1 2 1 2 1 1 2 1 0 0 0 0 27 
35 LB05 1 Embryo Recombination Mother 4 0 2 2 3 1 0 2 
 
1 1 2 0 1 1 1 0 0 1 1 
 
0 1 NA 24 
35 LB05 1 Embryo Recombination Father 2 1 0 2 1 2 2 2 1 1 1 3 2 2 1 1 0 0 1 2 0 0 0 0 27 
36 LB05 2 Embryo Recombination Mother 5 2 2 3 1 3 3 2 3 2 3 3 1 3 1 0 0 3 0 2 1 1 2 NA 46 
36 LB05 2 Embryo Recombination Father 2 2 1 1 3 1 2 3 3 1 1 0 1 1 2 1 1 1 1 2 1 0 0 0 31 
37 LB05 3 Embryo Recombination Mother 2 3 1 2 1 3 0 3 1 0 2 2 1 
 
1 2 3 1 1 1 1 1 1 NA 33 
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37 LB05 3 Embryo Recombination Father 1 3 1 2 1 1 0 2 1 1 1 1 2 1 2 2 1 0 2 1 1 0 0 0 27 
38 LB05 4 Embryo Recombination Mother 0 
 
0 0 0 
 
0 






   
NA 0 
38 LB05 4 Embryo Recombination Father 4 1 1 1 0 2 1 0 0 1 2 0 0 1 1 1 0 2 0 1 0 1 0 0 20 
39 LB05 5 Embryo Recombination Mother NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 
39 LB05 5 Embryo Recombination Father 1 0 3 0 2 1 1 2 1 2 1 1 1 1 1 1 1 1 1 0 1 1 0 0 24 
40 LB05 6 Embryo Recombination Mother 4 3 2 4 3 3 5 1 1 1 2 0 3 1 1 3 0 1 2 2 0 1 0 NA 43 
40 LB05 6 Embryo Recombination Father 1 1 2 0 2 0 2 2 1 1 1 2 1 1 0 1 1 1 2 0 0 0 0 0 22 
41 LB05 7 Embryo Recombination Mother 3 3 3 2 2 4 3 3 3 2 3 1 1 1 3 3 1 1 0 2 0 1 2 NA 47 
41 LB05 7 Embryo Recombination Father 2 1 0 1 0 0 2 0 0 2 0 2 1 0 0 2 0 0 1 0 1 1 0 0 16 
42 LB05 8 Embryo Recombination Mother 3 4 2 5 4 4 3 3 3 1 2 4 2 1 1 2 2 1 1 0 1 2 1 NA 52 
42 LB05 8 Embryo Recombination Father 1 0 1 0 0 1 1 1 0 0 1 1 0 1 0 2 1 0 2 1 0 0 0 0 14 
43 LB05 9 Embryo Recombination Mother 4 4 1 3 2 2 1 4 0 4 1 1 2 0 1 3 0 1 2 1 0 2 4 NA 43 
43 LB05 9 Embryo Recombination Father 1 3 1 1 2 2 1 0 2 1 0 1 0 1 
 
2 0 0 0 1 0 1 0 0 20 
44 LB05 10 Embryo Recombination Mother 3 5 3 1 4 3 2 2 1 1 2 3 2 2 
 
2 0 2 2 1 1 1 1 NA 44 
44 LB05 10 Embryo Recombination Father 3 1 2 2 1 0 2 1 2 1 0 0 1 1 2 1 1 0 0 1 0 1 0 0 23 
Combined Recombination 242 154 157 133 130 116 120 103 94 120 108 118 78 86 82 91 87 76 63 73 43 44 63 0 2,339 
N sex combined 
 
86 86 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 85 82 44 
 
Population-average CO/chr sex combined 
 
2.81 1.79 1.85 1.56 1.53 1.36 1.41 1.21 1.11 1.41 1.27 1.39 0.92 1.01 0.96 1.07 1.02 0.89 0.74 0.86 0.51 0.52 0.77 0.00 36.08 
N Maternal 
 

























































43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 40 44 
 
Population-average CO/chr Maternal 
 
3.65 2.74 2.83 2.71 2.29 2.36 2.31 2.00 1.88 2.00 1.81 2.12 1.36 1.48 1.45 1.52 1.43 1.40 0.93 1.21 0.71 0.67 1.76 NA 85.57 
Population-average CO/chr Paternal 
 
1.98 1.70 1.49 1.14 1.47 1.14 1.26 1.16 0.88 1.35 1.28 1.26 0.98 0.98 0.88 1.30 0.91 0.74 0.98 0.93 0.49 0.70 0.00 0.00 51.14 
Hou et al. (2013) Maternal 
 
5.72 5.44 4.76 4.44 4.21 4.03 3.65 3.56 3.32 3.68 3.26 3.46 2.50 2.37 2.37 2.79 2.65 2.60 2.26 2.21 1.32 1.31 3.04 - 74.96 
Gruhn et al. 
Oocyte Mlh1 foci 
5.9 ± 
0.18 


























Sperm Mlh1 foci 
3.7 ± 
0.06 



























* More than one sample per embryo analysed. Key below. 
NA Not applicable or not available 
  Non-recombinant (R0) 
  Monosomy 
  Trisomy- maternal 
  Trisomy- paternal 
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All samples were amplified by whole genome amplification and genotyped at ~300,000 SNP loci genome-wide (Handyside et al. 2010). Across the 23 
complete trios (meioses), >4 million informative SNPs were detected at high stringency with an average resolution of 30kb. The SNPs spanned >92% 
of the genome. For the oocyte-PB trios, genomic DNA from each donor was also genotyped to identify informative heterozygous SNP loci (hetSNPs). 
For the oocyte-PB trios, all hetSNPs in the mother’s genomic DNA are informative, whereas in embryos, maternal and paternal hetSNPs may be 
shared. Hence, the pattern of recombination in the paternal chromosomes was analysed by Karyomapping (Handyside et al. 2010; Natesan et al. 
2014) and only the two subsets of SNP loci which were heterozygous in the father and homozygous in the mother (or vice versa) were identified and 
used to phase the two haplotypes from the given parent in the embryo (Handyside et al. 2010; Natesan et al. 2014). The informative SNPs were 
phased using ‘siblings’ (Hou et al. 2013) that contain only a single chromatid from their mother (PB2, oocytes or maternal chromatid in embryo) or 
father (embryos). The informative SNPs were phased by selecting a PB2 or oocyte/embryo as a reference (also known as ‘assumed ancestor’) (Hou et 
al. 2013) and inferring the crossover positions in the assumed offspring (i.e. trios from the same parent; Figure 9.2). Crossovers in the same position in 
the assumed offspring are highly unlikely to occur and these common crossovers can therefore be used to re-form the reference genome from which 
the two haplotypes can be deduced as described in Specific Aim 5 (Figure 9.2). Since many of the samples were single cells, the workflow was 
validated by comparing recombination maps in 15 individual cells from a donor to the genomic DNA of the child, and by assessing 10 individual 




Figure 9.2. Phasing of maternal haplotypes (Ottolini et al. 2015). 
Informative SNPs are phased using the assumed ancestor method (Hou et al. 2013). A haploid cell containing a single chromatid (1C; either PB2 or 
Egg) is chosen as the ‘assumed ancestor’, also known as the reference. Trios from the same mother (or embryos from the same father) are ‘assumed 
offspring’. Using the reference, crossovers in all other assumed offspring are mapped where haplotypes change in comparison to the assumed 
ancestral phasing. Crossovers shared by sibling trios (or assumed offspring; red boxes) can be used to infer crossovers in the assumed ancestor. 
Iterative phasing using all available oocytes and PB2 allows deduction of the maternal haplotypes.  
216 
 
A typical MeioMap from a normal embryo-PB trio is shown in Figure 9.1d. MeioMaps reveal 
Mendelian segregation of sequence polymorphisms (green and yellow segregate 2:2 across 
haplotype regions) and independent assortment of different chromosomes in meiosis I 
(pericentromeric SNPs are used as a chromosome’s fingerprint). Crossovers, which result in 
recombinant chromosomes, are evident by transitions between the two maternal haplotypes 
(green or yellow) in the PB2 and oocyte, or between a single maternal haplotype and 
heterozygous regions (PB1). 39 cases of aneuploidy were detected by the absence or presence 
of SNPs from an entire chromosome (Table 9.3). The inferred chromosomal aneuploidies can be 
observed by array CGH (Figure 9.3). I also detected three gross structural rearrangements to 
chromosomes. Since two of the three meiotic products were affected (reciprocal gain and loss), it 
rules out that these rearrangements occurred during germline development and demonstrates 
that such rearrangements can occur during meiosis (Table 9.5). Aneuploidy rates and the 
contribution of MI and MII errors were similar to those expected for this age range (33-41 years; 
Table 9.3) (Alfarawati et al. 2011; Gutierrez-Mateo et al. 2011; Kuliev et al. 2011; Capalbo et al. 




Figure 9.3. Validation of whole-chromosome aneuploidy by aCGH (Ottolini et al. 2015). 
An example of chromosome segregation abnormalities inferred from the SNP array patterns in 
oocyte-PB trios and confirmed by aCGH of the same amplified DNA from all three samples. In the 
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aCGH output, the green and pink lines are the internal female samples and the blue trace 
indicates the male reference. The log2 ratios of the X chromosomes of the reference genomes 
are used for internal calibration of whole-chromosome loss or gain. The MeioMaps for three 
chromosomes in the same oocyte-PB trio are shown below the aCGH traces (G04_1). For 
chromosome 13, three chromatids segregated to the first polar body, and a single chromatid was 
present in the second polar body and missing in the oocyte. This is consistent with precocious 
separation of sister chromatids (PSSC) at meiosis I. Chromosome 20 segregated normally at 
meiosis I (normal PB1), but there was a gain in the oocyte and a corresponding loss in the PB2, 
consistent with meiosis II nondisjunction. Chromosome 22 underwent a partial gain in PB1 and a 
corresponding loss in the oocyte. This is consistent with a gross structural rearrangement 
whereby the majority of chromosome 22 segregated to the PB1 along with the intact homolog 
(Table 9.5). In the SNP representations, yellow and green blocks represent the two different 
grandparental haplotypes and blue blocks denote regions where both haplotypes are present. All 
aneuploidies in the oocyte-PB trio data set were verified using aCGH. Validation for embryos has 
been published previously (Natesan et al. 2014). 
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Table 9.5: Gross Structural Rearrangements in Meiosis Detected by MeioMapping (Ottolini 
et al. 2015) 
.  
 
All gains and losses were reciprocal and involved two meiotic products, such that a gain in the 
oocyte was matched by the loss of the chromosome in the PB1 or PB2. Of the 529 chromosome 
pairs assessed in the trios, I did not detect any deviation from the four chromatids expected to 
participate in meiosis. These observations firmly establish meiotic errors as the main contributor 
of aneuploid conceptions and do not support germline mosaicism in chromosome number prior to 
meiosis (Hulten et al. 2010) as a significant factor in the maternal age-related increase in human 
trisomies. 
 
9.4.2. A Novel, Reverse Segregation Pattern in Human Meiosis 
To understand the nature of mis-segregation, I inferred chromosome segregation from the trios 
by following the informative SNPs at the pericentromere. Trisomies that occur at a high rate in the 
natural population of women of advanced maternal age (Hassold & Jacobs 1984) were originally 
hypothesised to arise by MI nondisjunction (MI NDJ) where both homologs segregate to the 
oocyte at meiosis I, followed by a normal second division (Reiger, Michaelis et al. 1968) (Figure 
9.4a; Figure 9.5a). However, cytological examination of human oocytes that failed to fertilise in 
IVF clinics suggested that PSSC was the major cause of human age-related trisomies (Angell 
1991), at least in a clinical setting (Figure 9.4a; Figure 9.5b). Having the genetic identity of the 
chromatids not only from the embryos or oocytes but also their matched polar bodies allows the 
two segregation patterns to be distinguished, because the chromosome signatures in the two 
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PBs will differ (Figure 9.4a). Confirming previous studies using array CGH for copy number 
analysis in trios (Handyside et al. 2012), classical meiosis I nondisjunction was relatively rare and 
precocious separation of sister chromatids was more frequent, at least in stimulated IVF-treated 
patients (Figure 9.4a-c). The preponderance of PSSC compared to meiosis I nondisjunction is 
consistent with findings in oocytes from younger Chinese donors, although aneuploidy rates are 




Figure 9.4. MeioMaps reveal origin of aneuploidies and a novel chromosome segregation 
pattern (Ottolini et al. 2015).  
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(a) Segregation patterns revealed from following the pericentromeric haplotypes (yellow and 
green around centromere) in all three products of female meiosis. Only examples leading to 
trisomic conceptions are shown. For all possible segregation patterns detected by MeioMapping 
see Figure 9.5. MI NDJ: meiosis I nondisjunction; Rev Seg reverse segregation; PSSC: 
precocious separation of sister chromatids; MII NDJ: meiosis II nondisjunction. 
(b) Incidence and type of segregation errors in oocyte-PB and embryo-PB trios. Errors detected 
in MeioMaps generated from the female pronucleus (FPN-PB) from a younger donor population 
(Hou, Fan et al. 2013) are shown for comparison. The number of donors and average (av.) age 
are shown. Age ranges were 25-35 for FPN-PB (Hou et al. 2013) and 33-41 for oocyte-PB trios. 
The embryo donor was 38 years (Table 9.1 and 9.2). Bars: standard error of a proportion. 
(c) Chromosome abnormalities resulting in aneuploid oocytes or embryos (upper panel) and all 
non-canonical segregation patterns (lower panel). 
(d) Inferred mode of reverse segregation (Rev Seg). Frequencies are shown in Table 9.6. 
Alternative segregation outcomes at meiosis II (euploid and aneuploid, n=26; p<0.025; binomial 
exact test with correction for continuity). 
(e) Detection of the inferred intermediate of reverse segregation, a mature oocyte and PB1 
containing two non-sister chromatids each. Two mature oocytes that contained a PB1 but were 
unactivated were biopsied and the SNPs detected genome-wide. The expected chromosome 
fingerprints that contained heterozygous SNPs around the centromeres are shown in blue. Two 
examples were found in this egg (chromosomes 4 and 16; Table 9.6). 
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Figure 9.5. Non-canonical segregation patterns (Ottolini et al. 2015). 
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(a) Meiosis I nondisjunction yields a PB1 containing all four chromatids and an empty oocyte and 
PB2 (top) or an empty first polar body and two non-sister chromatids in the oocyte and PB2 
(bottom).  
(b) PSSC has four possible segregation outcomes (i–iv). The green homolog has separated 
precociously at meiosis I, and the yellow homolog segregates normally either to the oocyte (top) 
or the PB1 (bottom). At meiosis II, the green chromatid segregates randomly to the oocyte (i) and 
(iii), or to the PB2 (ii) and (iv). Note that one of the nine PSSC events involved a structural change 
in combination with the precocious separation of the sister chromatids in meiosis I.  
(c) Meiosis II nondisjunction results in two sister chromatids in either the oocyte or PB2 (shown 
for green only). This pattern could also arise from an earlier PSSC event, where the two sister 
chromatids have come apart and both stay in the oocyte at meiosis I.  
(d) Reverse segregation. Both homologs segregate their sister chromatids at meiosis I, giving rise 
to an intermediate where both the oocyte and PB1 contain the correct content but two non-sister 
chromatids (Figure 9.4e). At meiosis II, the two non-sister chromatids either segregate into the 
PB2 and oocyte, remain in the oocyte or both segregate to the PB2 (Figure 9.4d). Dotted boxes 
highlight three different segregation errors that would give rise to the same pattern of maternal 
pericentromeric SNPs in a trisomic conception (i.e. two non-sister chromatids). Without the 
information from the polar bodies, these three patterns are indistinguishable. 
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Unexpectedly, the most frequent non-canonical segregation pattern gave rise to a PB1 that 
contained two non-sister chromatids (green and yellow fingerprints around the centromere, 
n=26). In 20 of the 26 instances, both the oocyte and the PB2 contained a normal chromosome 
content, but with non-sisters instead of sister chromatids (Figure 9.4a, Rev Seg). This pattern 
cannot be detected by copy number analysis used previously (Handyside et al. 2012), since the 
complement of chromosomes in the three cells is normal. I refer to this novel pattern as reverse 
segregation, since I infer that sister chromatids of both homologs separated first in meiosis I, 
followed by non-sister chromatids in meiosis II (Figure 9.4d). The equational division at MI is 
unlikely to be the result of two independent PSSC events, because the observed frequency of 
both homologs separating their sister chromatids is more than 100× greater than the predicted 
frequency based on two independent PSSC events (p<0.001). Consistent with equational 
divisions of both homologs at meiosis I, I observed the predicted intermediate of reverse 
segregation, a mature oocyte and PB1 that contain two non-sister chromatids (Figure 9.4e; Table 
9.6). Both acrocentric and larger metacentric chromosomes displayed this reverse segregation 
pattern (Figure 9.4c; Table 9.6), which was observed in all donors, ruling out that it was specific to 
certain women (Table 9.7). In the remaining six cases, the two non-sister chromatids mis-
segregated into the egg or the PB2, resulting in an aneuploid oocyte (Figure 9.4a, Rev Seg w. 
MII; Figure 9.5d). In summary, I have observed a novel segregation pattern where both homologs 
undergo an equational division at meiosis I, followed by a weak preference for accurate 
disjunction of the two non-sister chromatids at meiosis II. This is reminiscent of ‘inverted meiosis’ 




Table 9.6: Incidence of Reverse Segregation (Ottolini et al. 2015) 
Sample type Incidence Chromosomes involved 
Oocyte-PB1 duos 
(unactivated)a 
8.7 ± 4.2% (n=46)   4, 13, 14, 16 
Oocyte-PB1-PB2 trios 3.7 ± 1.1% (n=299)   4, 11, 14, 15, 16, 19, 22 
Embryo-PB1-PB2 trios 7.2 ± 1.8% (n=207)   4, 9, 16, 17, 19, 21, 22 
 











1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X 
Oocyte-PB Trios: 
                           
G04 3 
PB1 6 4 4 3 3 2 3 3 3 3 2 2 0 1 1 3 1 1 2 2 1 1 3 54 
PB2 3 1 3 1 1 1 2 1 2 1 1 3 0 0 0 2 0 0 0 n/a 0 0 3 25 
Egg 3 3 1 2 2 1 1 2 1 2 1 1 n/a 1 1 1 1 1 2 2 1 0 0 30 
Total 6 4 4 3 3 2 3 3 3 3 2 3 0 1 1 3 1 1 2 2 1 1 3 55 
G04 4 
PB1 6 5 4 3 4 4 3 5 4 2 2 3 2 2 0 2 3 3 3 2 1 1 3 67 
PB2 3 2 1 5 4 2 2 2 4 3 3 2 4 1 0 2 3 4 1 0 0 0 2 50 
Egg 5 7 3 4 2 2 1 5 0 1 3 1 2 1 1 0 0 1 2 2 1 1 3 48 
Total 7 7 4 6 5 4 3 6 4 3 4 3 4 2 1 2 3 4 3 2 1 1 4 83 
G04 5 
PB1 5 6 5 4 4 5 5 3 4 4 3 4 2 2 3 5 3 2 3 2 1 1 4 80 
PB2 3 5 2 4 2 2 0 1 4 3 3 3 4 0 2 2 2 2 0 0 0 0 3 47 
Egg 2 3 3 n/a 2 5 5 4 0 1 0 1 2 2 3 3 1 2 3 2 1 1 3 49 








1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X 
G06 1 
PB1 4 5 4 0 5 7 2 2 5 2 2 4 3 3 2 2 4 2 3 2 2 1 0 66 
PB2 4 5 3 0 3 3 1 3 4 2 0 2 2 0 0 1 3 2 0 1 1 1 n/a 41 
Egg 0 0 1 n/a 2 4 1 1 1 4 2 2 1 3 2 1 1 0 3 1 1 0 0 31 
Total 4 5 4 0 5 7 2 3 5 4 2 4 3 3 2 2 4 2 3 2 2 1 0 69 
G06 2 
PB1 6 6 5 5 4 5 3 4 4 5 3 3 4 0 3 3 3 2 2 2 1 2 6 81 
PB2 5 6 4 7 6 2 4 4 3 3 1 1 1 1 2 2 2 3 0 3 1 2 5 68 
Egg 3 4 5 2 6 3 5 2 1 2 2 2 3 1 1 1 1 3 2 1 0 0 1 51 
Total 7 8 7 7 8 5 6 5 4 5 3 3 4 1 3 3 3 4 2 3 1 2 6 100 
G06 3 
PB1 6 8 6 4 5 4 5 2 3 5 3 4 4 3 2 2 5 2 2 2 1 1 5 79 
PB2 5 4 6 4 2 2 4 1 0 5 0 4 1 3 2 0 3 3 1 0 0 0 1 50 
Egg 3 6 4 4 3 4 1 1 3 2 3 4 3 0 2 2 2 1 1 2 1 1 4 53 
Total 7 9 8 6 5 5 5 2 3 6 3 6 4 3 3 2 5 3 2 2 1 1 5 96 
G06 4 
PB1 5 6 3 2 4 4 3 3 2 2 3 3 3 1 3 3 2 2 0 2 1 2 2 59 
PB2 2 8 1 3 1 2 0 1 1 3 2 1 2 1 1 1 2 1 1 1 0 1 2 36 
Egg 3 4 2 3 3 2 3 2 3 3 1 2 3 2 2 2 0 1 1 3 1 1 0 47 








1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X 
G07 2 
PB1 3 5 7 4 3 5 2 3 4 5 4 2 1 2 0 3 3 2 2 3 2 1 2 68 
PB2 1 3 3 2 2 2 2 2 2 1 3 1 1 0 n/a 0 2 2 0 2 1 1 2 33 
Egg 2 2 4 2 1 3 0 1 2 4 1 1 0 2 0 3 1 0 2 1 1 0 0 35 
Total 3 5 7 4 3 5 2 3 4 5 4 2 1 2 0 3 3 2 2 3 2 1 2 68 
G08 1 
PB1 3 3 4 0 2 2 2 2 2 3 2 3 1 2 1 3 1 2 2 2 1 1 2 46 
PB2 2 3 1 4 0 1 1 1 1 1 3 2 1 1 3 1 0 1 1 1 1 0 1 31 
Egg 1 2 3 4 2 1 3 1 1 4 1 1 0 1 2 2 1 3 1 1 0 1 1 37 
Total 3 4 4 4 2 2 3 2 2 4 3 3 1 2 3 3 1 3 2 2 1 1 2 57 
G08 2 
PB1 4 6 5 4 4 2 2 2 3 3 5 2 2 1 0 3 2 2 2 2 1 1 3 61 
PB2 1 3 2 1 3 3 3 1 2 2 2 1 0 1 n/a 0 3 0 0 1 0 1 4 34 
Egg 3 3 3 3 1 5 1 1 3 1 3 3 2 2 0 3 1 2 2 1 1 2 1 47 
Total 4 6 5 4 4 5 3 2 4 3 5 3 2 2 0 3 3 2 2 2 1 2 4 71 
G08 3 
PB1 5 2 7 4 6 4 2 2 5 3 3 4 4 2 3 3 3 2 2 2 2 1 2 73 
PB2 n/a 2 3 1 3 1 1 0 3 2 0 2 3 0 1 1 2 1 0 1 1 1 0 29 
Egg 5 2 4 3 3 3 1 2 2 1 3 2 1 2 2 2 1 1 2 1 1 0 2 46 








1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X 
G09 1 
PB1 3 2 3 2 3 2 2 2 2 0 2 1 3 3 1 0 1 1 1 0 1 1 1 37 
PB2 2 2 3 2 3 1 0 1 1 1 2 0 2 1 2 n/a 1 0 1 1 1 1 0 28 
Egg 3 2 2 2 n/a 1 2 1 1 n/a 0 1 2 3 3 0 0 1 0 1 0 0 1 26 
Total 4 3 4 3 3 2 2 2 2 1 2 1 4 4 3 0 1 1 1 1 1 1 1 47 
G09 2 
PB1 3 4 2 2 5 3 3 2 4 2 3 3 1 1 1 1 2 2 1 3 0 1 2 51 
PB2 1 2 0 1 1 1 2 0 2 0 n/a 1 1 0 0 0 1 1 0 3 0 1 1 19 
Egg 2 2 2 1 4 2 1 2 2 2 3 2 0 1 1 1 1 1 1 0 n/a 0 1 32 
Total 3 4 2 2 5 3 3 2 4 2 3 3 1 1 1 1 2 2 1 3 0 1 2 51 
Embryo-PB Trios: 
                           
LB03 2 
PB1 4 6 3 3 2 3 2 3 3 3 3 3 3 2 2 2 1 2 3 2 2 1 3 61 
PB2 2 5 1 3 3 1 3 2 3 2 2 2 1 1 2 1 1 1 1 1 1 0 2 41 
Embryo 2 3 2 4 3 2 3 1 0 3 3 1 2 1 0 1 0 3 2 1 1 1 3 42 
Total 4 7 3 5 4 3 4 3 3 4 4 3 3 2 2 2 1 3 3 2 2 1 4 72 
LB03 7 
PB1 5 2 3 3 3 3 2 2 2 2 3 2 2 1 1 2 3 2 2 3 1 1 2 52 
PB2 2 2 2 1 2 0 1 3 0 2 2 2 1 2 1 0 1 1 1 2 0 1 0 29 
Embryo 3 2 3 2 3 3 1 1 2 2 1 2 1 1 2 2 2 1 1 1 1 0 2 39 








1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X 
LB03 8 
PB1 7 7 4 4 6 5 4 5 3 2 2 4 3 2 n/a 3 5 3 2 2 1 2 2 78 
PB2 4 3 2 4 3 2 2 1 0 3 1 4 1 0 n/a 1 2 2 1 0 0 1 3 40 
Embryo 3 4 2 2 3 3 2 4 3 3 1 2 2 2 3 2 3 1 1 2 1 1 3 53 
Total 7 7 4 5 6 5 4 5 3 4 2 5 3 2 3 3 5 3 2 2 1 2 4 87 
LB03 10 
PB1 4 4 4 5 2 5 2 4 5 2 3 3 2 2 1 0 4 2 0 2 2 1 6 65 
PB2 4 3 2 3 3 4 4 5 1 1 1 4 1 2 3 1 2 2 0 0 3 1 3 53 
Embryo 2 1 4 2 3 1 4 1 4 1 2 1 1 2 2 1 2 2 0 2 1 0 3 42 
Total 5 4 5 5 4 5 5 5 5 2 3 4 2 3 3 1 4 3 0 2 3 1 6 80 
LB03 11 
PB1 2 5 3 4 3 3 2 4 2 3 3 2 2 1 2 2 3 2 2 2 1 n/a 2 55 
PB2 2 3 1 1 4 2 2 4 1 3 1 2 2 2 1 0 2 2 1 1 1 1 1 40 
Embryo 2 2 4 3 1 1 2 0 1 2 2 2 0 3 1 2 1 0 1 1 2 1 1 35 
Total 3 5 4 4 4 3 3 4 2 4 3 3 2 3 2 2 3 2 2 2 2 1 2 65 
LB03 12 
PB1 9 10 6 6 9 5 5 7 5 5 5 6 1 2 3 4 3 3 2 3 2 1 3 105 
PB2 5 6 5 3 4 2 2 3 4 4 3 6 1 4 2 1 2 1 3 3 0 0 3 67 
Embryo 4 4 5 5 5 3 7 4 7 3 2 4 0 2 3 3 1 4 1 0 2 1 2 72 








1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X 
LB03 13 
PB1 3 3 2 2 2 3 3 2 2 2 2 2 3 1 1 2 2 2 2 2 0 0 2 45 
PB2 3 2 2 1 1 1 2 1 1 0 0 2 2 3 2 1 1 2 0 0 0 0 3 30 
Embryo 2 3 0 1 3 2 1 1 3 2 2 0 1 2 1 1 1 2 2 2 0 0 1 33 
Total 4 4 2 2 3 3 3 2 3 2 2 2 3 3 2 2 2 3 2 2 0 0 3 54 
LB03 14 
PB1 5 3 3 4 5 5 5 2 2 3 2 3 3 3 1 4 1 3 0 2 1 0 3 63 
PB2 1 4 3 1 2 4 4 1 3 1 3 2 0 0 0 3 2 1 0 2 0 0 4 41 
Embryo 4 5 2 3 3 1 3 1 1 2 3 3 3 3 1 3 1 2 0 0 1 0 1 46 
Total 5 6 4 4 5 5 6 2 3 3 4 4 3 3 1 5 2 3 0 2 1 0 4 75 
LB03 16 
PB1 7 2 5 2 4 3 5 4 3 2 3 2 2 3 3 3 2 2 2 2 0 1 2 64 
PB2 6 2 2 2 2 3 2 3 2 1 1 2 1 1 0 2 2 0 2 0 0 1 2 39 
Embryo 3 2 3 0 2 2 3 1 1 1 2 2 1 2 3 1 2 2 0 2 0 0 0 35 









Premature separation of sister chromatids (PSSC) - 
aneuploid 
 
Nondisjunction in first meiotic division (MI) 
 
Nondisjunction in second meiotic division (MII) 
 
Reverse segregation (RS) - aneuploid 
 
Reverse segregation (RS) - euploid 
 




9.4.3. Variation in Global Recombination Rates in Adult Oocytes 
Variation in recombination in foetal oocytes has been hypothesised to give rise to vulnerable 
crossover configurations that predispose chromosome pairs to mis-segregation decades later in 
the adult woman. To assess recombination in adult oocytes and embryos, I mapped 883 
maternal crossovers in the oocyte-PB trios and 1,149 and 1,342 maternal and paternal 
crossovers, respectively, in the embryos (Figure 9.6a; Tables 9.7-9.11). 12% of the reciprocal 
crossover events mapped to non-sister chromatids in the PB2 and oocyte, whilst the PB1 was 
heterozygous for the SNPs. A similar proportion would be expected to be present in the PB1 and 
are undetectable, since the two DNA strands cannot currently be separated and phased 
individually (Hou et al. 2013). Using the 300K SNP arrays gave median resolutions of 107kb and 
331kb for crossovers in the oocyte-PB and embryos, respectively (Figure 9.1e). This is similar to 
high-resolution population-based studies employing SNP arrays (Kong et al. 2002; Coop et al. 





Figure 9.6. Variation in genome-wide recombination rates between/within individuals 
(Ottolini et al. 2015). 
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(a) Boxplot of global recombination rates showing the interquartile range (box), median (horizontal 
bar), and whiskers (1.5× IQR). Numbers analysed are in parentheses. Rates from foetal oocytes 
(‘Gruhn’)(Gruhn, Rubio et al. 2013) and female pronucleus-PB trios (‘Hou’) (Hou, Fan et al. 2013).  
(b) Recombination rates for the 10 donors. Black: rates using information from oocyte or embryo 
only. Magenta: rates using the information from the complete oocyte-PB trios.  
(c) Inter-crossover distances, excluding centromeric distances. The fitted curve is based on 
maximum likelihood estimation of the gamma distribution, shape: 2.6141 ± 0.14 (S.E.), rate 0.066 
± 0.0039 (S.E.). Estimated fitted mean: 39.3Mb, log-likehood of fitting: -2802.738; AIC: 5609.476.  
(d) Average and standard deviation of chromosome-specific recombination (Table 9.4). GLM 
analysis revealed that chromosome size had a significant effect on sex-specific recombination 
frequencies. Spearman correlation test is shown for the p-value for individual, pair-wise 
comparisons between maternal and paternal recombination frequencies per chromosome. As 
chromosome size decreases, the contribution of sex to crossover frequencies decreases (see 
Source Data for Figure 9.6d).  
(e) Crossover position relative to centromeres (CEN), normalised to chromosome length. 
Statistics: Two-sided Kolmogorov-Smirnov test of normalised and absolute lengths; p<0.0005; X 
chr. excluded; Figure 9.8). 
(f) Length of haplotype blocks (not inter-crossover distances), according to position relative to 
telomeres (blue), centromeres (yellow), or interstitial (green). Statistics: non-parametric ANOVA 
(p<0.0001). Centromeric blocks excluded the ~3×106 base pairs of alpha-satellite DNA. 




Table 9.8: Map Distances in Embryos (Ottolini et al. 2015) 




















































Type Event Sex 
                          
1.1 Embryo Recombination Mother 1.60 0.80 1.20 0.40 1.20 0.80 0.80 0.80 0.80 1.20 0.80 0.80 0.80 0.40 1.20 0.80 0.40 0.80 1.20 0.80 NA 0.80 0.40 NA 18.81 0.82 
1.1 Embryo Recombination Father 0.80 0.00 0.80 0.40 0.80 0.80 0.00 0.40 0.00 0.80 0.80 0.40 0.80 0.40 0.00 0.00 0.40 0.00 0.80 0.00 0.40 0.00 NA 0.00 8.80 0.38 
1.2 Embryo Recombination Mother 1.60 0.80 1.20 0.40 1.20 0.80 0.80 0.80 0.80 1.20 0.80 0.80 0.80 0.40 1.20 0.80 0.40 0.80 1.20 0.80 0.00 0.80 0.40 NA 18.81 0.82 
1.2 Embryo Recombination Father 0.80 0.00 0.80 0.40 0.80 0.80 0.00 0.40 0.00 0.80 0.80 0.40 0.80 0.40 0.00 0.00 0.40 0.00 0.80 0.00 0.40 0.00 NA 0.00 8.80 0.38 
2 Embryo Recombination Mother 2.80 0.80 0.40 0.80 0.40 1.20 1.60 2.00 1.20 0.40 0.00 1.20 0.80 0.40 0.80 0.80 0.40 0.40 0.40 0.80 0.00 0.00 0.80 NA 18.41 0.80 
2 Embryo Recombination Father 0.80 0.80 0.00 0.40 0.80 0.40 0.80 0.40 0.00 0.80 0.40 0.40 0.40 0.40 0.40 0.80 0.80 0.00 0.40 0.80 0.40 0.40 NA 0.00 10.80 0.47 
3 Embryo Recombination Mother 0.80 0.40 0.80 0.40 0.80 0.80 1.20 0.80 0.80 0.80 0.40 0.40 0.40 1.60 1.20 0.40 0.40 0.00 0.00 0.00 0.00 0.00 0.40 NA 12.80 0.56 
3 Embryo Recombination Father NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0.00 0.00 0.00 
4 Embryo Recombination Mother 1.60 0.40 1.20 1.20 0.40 2.00 0.80 0.80 0.80 0.80 1.20 0.40 1.20 0.40 0.80 0.80 0.80 0.80 0.80 0.80 0.40 0.80 1.60 NA 20.81 0.90 
4 Embryo Recombination Father 0.40 0.80 0.80 0.00 0.80 0.80 0.80 0.80 0.40 0.00 0.80 0.40 0.80 0.40 0.40 0.80 0.80 0.00 0.80 0.00 0.00 0.00 0.00 0.00 10.80 0.47 
5.1 Embryo Recombination Mother 0.00 2.00 1.60 0.80 0.40 1.20 0.40 0.00 1.20 1.20 1.20 1.20 0.80 0.40 0.40 0.40 0.40 0.40 0.00 0.80 0.40 0.00 1.60 NA 16.81 0.73 
5.1 Embryo Recombination Father 1.20 0.80 0.80 1.20 1.20 0.00 0.80 0.40 0.80 0.40 0.80 0.40 0.40 0.80 0.40 0.80 0.40 0.40 0.40 1.20 0.40 0.40 0.00 0.00 14.41 0.63 
6 Embryo Recombination Mother 1.60 0.40 1.60 1.60 0.80 0.80 0.00 1.60 0.00 0.40 0.80 0.80 0.00 0.80 0.80 0.00 0.40 0.80 0.40 0.80 0.00 0.40 0.40 NA 15.21 0.66 
6 Embryo Recombination Father 1.20 0.80 0.40 0.40 1.60 0.00 0.40 0.00 0.40 1.20 0.40 1.20 0.40 0.40 0.00 0.40 0.80 0.00 0.40 0.80 0.40 0.80 0.00 0.00 12.40 0.54 
REF Embryo Recombination Mother 0.40 1.20 2.00 0.80 0.80 0.80 0.40 0.00 1.20 0.40 0.80 1.20 0.00 0.40 0.00 0.00 0.80 0.80 0.40 0.80 0.00 0.00 0.40 NA 13.61 0.59 
REF Embryo Recombination Father 1.20 1.20 0.00 0.00 0.00 1.20 0.80 1.20 0.40 0.40 0.80 0.80 0.40 0.40 0.40 0.80 0.40 0.00 0.40 0.40 0.40 0.40 0.00 0.00 12.00 0.52 
REF Daughter Recombination Mother 2.40 1.60 1.60 0.80 1.60 1.60 0.40 0.40 0.40 1.60 2.00 1.20 0.80 0.40 0.80 0.00 1.20 0.00 0.40 0.00 0.00 0.00 1.20 NA 20.41 0.89 
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REF Daughter Recombination Father 0.80 1.20 0.40 0.80 0.00 0.80 0.80 0.40 0.00 0.80 1.20 0.80 0.40 0.40 0.80 0.40 0.80 0.80 0.00 0.00 0.40 0.40 0.00 0.00 12.40 0.54 
CVS 
 
Recombination Mother 2.80 0.40 1.60 0.00 0.40 0.80 1.20 0.40 0.00 1.20 1.60 0.00 0.40 0.40 0.40 0.80 1.20 0.40 0.80 0.80 0.00 0.40 1.60 NA 17.61 0.77 
CVS 
 
Recombination Father 0.80 1.20 0.40 0.80 0.00 0.80 0.80 0.40 0.00 0.80 1.20 0.80 0.40 0.40 0.80 0.40 0.80 0.80 0.00 0.00 0.40 0.40 0.00 0.00 12.40 0.54 
2.1 Embryo Recombination Mother 1.60 1.60 0.80 2.40 1.60 2.00 1.60 0.80 0.80 0.00 0.40 1.20 0.40 0.80 0.40 0.80 0.40 0.40 0.40 0.40 0.00 0.40 1.20 NA 20.41 0.89 
2.1 Embryo Recombination Father 0.80 0.80 0.00 0.40 0.00 0.40 0.40 0.40 0.40 0.40 0.00 0.40 0.00 0.40 0.00 0.80 0.40 0.00 0.40 0.40 0.00 0.00 0.00 0.00 6.80 0.30 
2.2 Embryo Recombination Mother 1.60 1.60 0.80 2.40 1.60 2.00 1.60 0.80 0.80 0.00 0.40 1.20 0.40 0.80 0.40 0.80 0.40 0.40 0.40 0.40 0.00 0.40 1.20 NA 20.41 0.89 
2.2 Embryo Recombination Father 0.80 0.80 0.00 0.40 0.00 0.40 0.40 0.40 0.40 0.40 0.00 0.40 0.00 0.40 0.00 0.80 0.40 0.00 0.40 0.40 0.00 0.00 0.00 0.00 6.80 0.30 
3.1 Embryo Recombination Mother 3.20 1.20 1.60 0.80 0.80 1.60 0.40 1.60 0.40 2.00 0.80 2.00 1.20 0.80 0.00 0.80 1.20 0.80 0.40 0.80 0.80 0.00 0.80 NA 24.01 1.04 
3.1 Embryo Recombination Father 1.60 1.20 1.20 0.40 0.80 0.80 0.00 0.80 0.40 0.80 0.80 0.80 0.80 0.80 0.40 0.40 0.40 0.80 0.00 0.40 0.40 0.00 0.00 0.00 14.01 0.61 
3.2 Embryo Recombination Mother 3.20 1.20 1.60 0.80 0.80 1.60 0.40 1.60 0.40 2.00 0.80 2.00 1.20 0.80 0.00 0.80 1.20 0.80 0.40 0.80 0.80 0.00 0.80 NA 24.01 1.04 
3.2 Embryo Recombination Father 1.60 1.20 1.20 0.40 0.80 0.80 0.00 0.80 0.40 0.80 0.80 0.80 0.80 0.80 0.40 0.40 0.40 0.80 0.00 0.40 0.40 0.00 0.00 0.00 14.01 0.61 
4 Embryo Recombination Mother 2.00 1.60 1.20 0.80 0.80 0.00 0.80 1.20 0.80 1.20 0.80 0.40 0.40 0.40 0.40 0.00 0.40 0.40 0.40 0.40 0.40 0.40 0.00 NA 15.21 0.66 
4 Embryo Recombination Father 0.80 0.80 0.40 1.20 0.80 0.40 0.80 0.40 1.20 0.80 0.80 0.40 0.00 0.80 0.40 0.40 0.40 0.40 0.80 0.40 0.00 0.40 0.00 0.00 12.80 0.56 
5 Embryo Recombination Mother 2.40 2.00 0.80 2.00 2.00 0.40 0.80 0.80 1.20 1.60 0.80 1.20 0.00 0.80 1.20 0.40 0.40 1.20 0.00 0.00 0.40 0.00 1.20 NA 21.61 0.94 
5 Embryo Recombination Father 0.40 0.40 0.80 0.40 1.20 0.00 0.40 0.80 0.00 0.80 0.80 0.40 0.40 0.00 0.40 0.40 0.40 0.40 0.40 0.40 0.40 0.40 0.00 0.00 10.00 0.43 
2 Embryo Recombination Mother 0.80 1.20 0.80 1.20 1.20 0.80 1.20 0.00 0.00 1.20 1.20 0.40 0.80 0.40 0.00 0.40 0.00 1.20 0.80 0.40 0.40 0.40 1.20 NA 16.01 0.70 
2 Embryo Recombination Father 0.80 0.80 0.40 0.40 0.40 0.40 0.00 0.40 0.00 0.80 0.80 0.00 0.80 0.00 0.40 0.40 0.00 0.00 0.40 0.40 0.00 0.00 0.00 0.00 7.60 0.33 
5 Embryo Recombination Mother 2.80 0.80 1.20 2.00 0.00 1.20 0.40 1.20 1.20 0.40 0.00 1.20 0.40 0.80 0.40 0.80 1.20 1.20 0.80 0.00 0.00 0.40 0.40 NA 18.81 0.82 
5 Embryo Recombination Father 0.80 0.00 0.80 0.40 0.40 0.80 1.20 0.40 0.40 0.80 0.40 0.40 0.00 0.00 0.80 0.80 0.00 0.00 0.00 0.80 0.00 0.00 0.00 0.00 9.20 0.40 
6 Embryo Recombination Mother 1.20 1.20 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 2.40 0.10 
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6 Embryo Recombination Father 0.80 0.40 0.00 0.40 0.80 0.40 0.40 0.00 0.40 0.80 0.00 0.80 0.40 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.40 0.40 0.00 0.00 12.00 0.52 
7 Embryo Recombination Mother 0.80 0.80 1.20 1.20 1.20 1.20 0.00 0.40 0.80 0.80 0.00 0.80 0.40 0.40 0.80 0.80 0.80 0.00 0.00 0.40 0.40 0.00 0.80 NA 14.01 0.61 
7 Embryo Recombination Father 0.00 0.00 0.80 0.80 0.80 0.40 0.80 0.40 0.00 0.00 0.80 0.80 0.80 0.40 0.40 0.40 0.40 0.40 0.00 0.00 0.40 0.40 0.00 0.00 9.20 0.40 
8 Embryo Recombination Mother 1.20 1.60 0.80 1.20 1.20 1.20 0.80 1.60 1.20 1.20 0.00 0.40 0.80 0.80 0.00 0.80 1.20 0.40 0.40 1.20 0.40 0.40 1.20 NA 20.01 0.87 
8 Embryo Recombination Father 1.20 0.00 1.20 0.00 0.80 0.40 0.80 0.40 0.00 0.80 0.40 0.80 0.00 0.00 0.00 0.40 0.40 0.00 0.00 0.80 0.40 0.00 0.00 0.00 8.80 0.38 
10 Embryo Recombination Mother 0.80 0.00 2.00 1.20 0.80 0.00 1.20 0.40 0.80 0.40 0.80 0.40 0.40 0.40 0.80 0.40 0.80 0.80 0.00 0.80 0.40 0.00 1.20 NA 14.81 0.64 
10 Embryo Recombination Father 1.20 0.00 0.80 0.40 0.40 0.40 0.40 0.00 0.40 0.40 0.40 0.40 0.80 0.00 0.00 0.80 0.80 0.80 0.40 0.40 0.40 0.00 0.00 0.00 9.60 0.42 
11 Embryo Recombination Mother 1.14 0.57 0.23 0.51 0.57 0.74 1.26 0.97 0.57 0.57 0.17 0.51 0.40 1.09 0.74 0.57 0.57 -0.11 -0.06 0.34 NA -0.06 0.40 NA 13.10 0.57 
11 Embryo Recombination Father 1.10 0.59 0.10 0.53 0.50 0.73 1.39 1.01 0.59 0.50 0.07 0.49 0.33 1.21 0.76 0.59 0.60 -0.21 -0.24 0.31 0.08 -0.14 NA 0.00 13.07 0.57 
12 Embryo Recombination Mother 1.06 0.60 -0.03 0.54 0.43 0.71 1.51 1.06 0.60 0.43 -0.03 0.46 0.26 1.34 0.77 0.60 0.63 -0.31 -0.43 0.29 0.05 -0.23 0.40 NA 13.04 0.57 
12 Embryo Recombination Father 1.01 0.61 -0.16 0.56 0.36 0.70 1.64 1.10 0.61 0.36 -0.13 0.43 0.19 1.47 0.79 0.61 0.66 -0.41 -0.61 0.26 0.01 -0.31 NA 0.00 13.00 0.57 
14 Embryo Recombination Mother 0.97 0.63 -0.29 0.57 0.29 0.69 1.77 1.14 0.63 0.29 -0.23 0.40 0.11 1.60 0.80 0.63 0.69 -0.51 -0.80 0.23 -0.02 -0.40 0.80 NA 12.97 0.56 
14 Embryo Recombination Father 0.93 0.64 -0.41 0.59 0.21 0.67 1.90 1.19 0.64 0.21 -0.33 0.37 0.04 1.73 0.81 0.64 0.71 -0.61 -0.99 0.20 -0.06 -0.49 NA 0.00 12.94 0.56 
16 Embryo Recombination Mother 0.89 0.66 -0.54 0.60 0.14 0.66 2.03 1.23 0.66 0.14 -0.43 0.34 -0.03 1.86 0.83 0.66 0.74 -0.71 -1.17 0.17 -0.09 -0.57 0.40 NA 12.91 0.56 
16 Embryo Recombination Father NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0.00 12.87 0.56 
1 Embryo Recombination Mother 1.22 0.58 0.78 1.02 0.78 0.65 0.64 0.78 0.48 1.04 0.56 0.74 0.41 0.48 0.39 0.54 0.38 0.65 0.35 0.31 0.24 0.13 0.27 NA 12.84 0.56 
1 Embryo Recombination Father 1.21 0.56 0.77 1.03 0.79 0.64 0.64 0.79 0.48 1.06 0.54 0.73 0.40 0.48 0.39 0.54 0.37 0.66 0.35 0.30 0.24 0.12 0.26 0.00 12.81 0.56 
2 Embryo Recombination Mother 1.21 0.54 0.76 1.04 0.79 0.62 0.64 0.80 0.47 1.07 0.53 0.73 0.40 0.47 0.39 0.54 0.36 0.68 0.34 0.29 0.24 0.11 0.24 NA 12.78 0.56 
2 Embryo Recombination Father 1.20 0.53 0.75 1.05 0.79 0.61 0.64 0.80 0.47 1.09 0.51 0.72 0.39 0.47 0.39 0.54 0.34 0.69 0.34 0.28 0.24 0.11 0.23 0.00 12.74 0.55 
3 Embryo Recombination Mother 1.20 0.51 0.74 1.06 0.79 0.59 0.64 0.81 0.47 1.10 0.49 0.72 0.38 0.47 0.38 0.54 0.33 0.70 0.34 0.27 0.24 0.10 0.21 NA 12.71 0.55 
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3 Embryo Recombination Father 1.19 0.49 0.73 1.07 0.79 0.58 0.64 0.82 0.47 1.12 0.48 0.71 0.38 0.47 0.38 0.54 0.31 0.71 0.34 0.26 0.25 0.09 0.20 0.00 12.68 0.55 
4 Embryo Recombination Mother 1.19 0.47 0.72 1.08 0.80 0.56 0.64 0.83 0.47 1.13 0.46 0.71 0.37 0.47 0.38 0.54 0.30 0.72 0.33 0.24 0.25 0.08 0.19 NA 12.65 0.55 
4 Embryo Recombination Father 1.18 0.45 0.71 1.09 0.80 0.55 0.64 0.83 0.46 1.15 0.44 0.71 0.37 0.46 0.38 0.54 0.29 0.73 0.33 0.23 0.25 0.08 0.17 0.00 12.61 0.55 
5 Embryo Recombination Mother 1.18 0.43 0.70 1.10 0.80 0.53 0.64 0.84 0.46 1.16 0.43 0.70 0.36 0.46 0.38 0.54 0.27 0.74 0.33 0.22 0.25 0.07 0.16 NA 12.58 0.55 
5 Embryo Recombination Father 1.17 0.41 0.69 1.11 0.80 0.52 0.64 0.85 0.46 1.18 0.41 0.70 0.36 0.46 0.38 0.54 0.26 0.75 0.33 0.21 0.25 0.06 0.14 0.00 12.55 0.55 
6 Embryo Recombination Mother 1.17 0.40 0.68 1.12 0.80 0.50 0.64 0.86 0.46 1.19 0.39 0.69 0.35 0.46 0.37 0.54 0.25 0.76 0.32 0.20 0.25 0.05 0.13 NA 12.52 0.54 
6 Embryo Recombination Father 1.17 0.38 0.67 1.13 0.80 0.49 0.64 0.86 0.45 1.21 0.38 0.69 0.35 0.45 0.37 0.54 0.23 0.77 0.32 0.19 0.25 0.04 0.11 0.00 12.48 0.54 
7 Embryo Recombination Mother 1.16 0.36 0.66 1.14 0.81 0.47 0.64 0.87 0.45 1.22 0.36 0.68 0.34 0.45 0.37 0.54 0.22 0.78 0.32 0.18 0.25 0.04 0.10 NA 12.45 0.54 
7 Embryo Recombination Father 1.16 0.34 0.65 1.15 0.81 0.46 0.64 0.88 0.45 1.24 0.34 0.68 0.34 0.45 0.37 0.54 0.20 0.79 0.32 0.17 0.25 0.03 0.08 0.00 12.42 0.54 
8 Embryo Recombination Mother 1.15 0.32 0.64 1.15 0.81 0.44 0.64 0.89 0.45 1.25 0.33 0.68 0.33 0.45 0.37 0.54 0.19 0.80 0.31 0.16 0.25 0.02 0.07 NA 12.39 0.54 
8 Embryo Recombination Father 1.15 0.30 0.63 1.16 0.81 0.43 0.64 0.89 0.44 1.27 0.31 0.67 0.32 0.44 0.37 0.54 0.18 0.81 0.31 0.15 0.25 0.01 0.05 0.00 12.35 0.54 
1 Embryo Recombination Mother 1.14 0.28 0.62 1.17 0.81 0.41 0.64 0.90 0.44 1.28 0.29 0.67 0.32 0.44 0.36 0.55 0.16 0.82 0.31 0.13 0.25 0.01 0.04 NA 12.32 0.54 
1 Embryo Recombination Father 1.14 0.27 0.61 1.18 0.82 0.40 0.64 0.91 0.44 1.30 0.28 0.66 0.31 0.44 0.36 0.55 0.15 0.83 0.31 0.12 0.25 0.00 0.02 0.00 12.29 0.53 
2 Embryo Recombination Mother 1.13 0.25 0.60 1.19 0.82 0.38 0.64 0.92 0.44 1.31 0.26 0.66 0.31 0.44 0.36 0.55 0.13 0.85 0.30 0.11 0.25 -0.01 0.01 NA 12.26 0.53 
2 Embryo Recombination Father 1.13 0.23 0.59 1.20 0.82 0.37 0.64 0.92 0.43 1.33 0.24 0.65 0.30 0.43 0.36 0.55 0.12 0.86 0.30 0.10 0.25 -0.02 -0.01 0.00 12.22 0.53 
3 Embryo Recombination Mother 1.12 0.21 0.58 1.21 0.82 0.35 0.64 0.93 0.43 1.34 0.23 0.65 0.30 0.43 0.36 0.55 0.11 0.87 0.30 0.09 0.25 -0.03 -0.02 NA 12.19 0.53 
3 Embryo Recombination Father 1.12 0.19 0.57 1.22 0.82 0.34 0.64 0.94 0.43 1.36 0.21 0.64 0.29 0.43 0.36 0.55 0.09 0.88 0.30 0.08 0.25 -0.03 -0.04 0.00 12.16 0.53 
4 Embryo Recombination Mother 1.11 0.17 0.56 1.23 0.83 0.32 0.64 0.95 0.43 1.37 0.19 0.64 0.29 0.43 0.35 0.55 0.08 0.89 0.29 0.07 0.25 -0.04 -0.05 NA 12.13 0.53 
4 Embryo Recombination Father 1.11 0.16 0.55 1.24 0.83 0.31 0.64 0.96 0.42 1.39 0.18 0.64 0.28 0.42 0.35 0.55 0.06 0.90 0.29 0.06 0.25 -0.05 -0.06 0.00 12.09 0.53 
5 Embryo Recombination Mother 1.11 0.14 0.54 1.25 0.83 0.29 0.64 0.96 0.42 1.40 0.16 0.63 0.28 0.42 0.35 0.55 0.05 0.91 0.29 0.05 0.25 -0.06 -0.08 NA 12.06 0.52 
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5 Embryo Recombination Father 1.10 0.12 0.53 1.26 0.83 0.28 0.64 0.97 0.42 1.42 0.14 0.63 0.27 0.42 0.35 0.55 0.04 0.92 0.29 0.03 0.25 -0.06 -0.09 0.00 12.03 0.52 
6 Embryo Recombination Mother 1.10 0.10 0.52 1.27 0.83 0.26 0.64 0.98 0.42 1.43 0.13 0.62 0.26 0.42 0.35 0.55 0.02 0.93 0.28 0.02 0.25 -0.07 -0.11 NA 12.00 0.52 
6 Embryo Recombination Father 1.09 0.08 0.51 1.28 0.83 0.25 0.64 0.99 0.41 1.45 0.11 0.62 0.26 0.41 0.35 0.55 0.01 0.94 0.28 0.01 0.25 -0.08 -0.12 0.00 11.96 0.52 
7 Embryo Recombination Mother 1.09 0.06 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 11.93 0.52 
7 Embryo Recombination Father 1.08 0.04 1.60 0.63 0.57 0.23 0.97 0.46 0.51 0.46 0.69 0.34 0.57 0.00 0.00 0.51 0.74 0.63 0.06 0.69 0.40 -0.06 0.57 0.00 11.90 0.52 
8 Embryo Recombination Mother 1.08 0.03 1.76 0.60 0.50 0.14 1.06 0.46 0.51 0.41 0.77 0.27 0.59 -0.10 -0.10 0.49 0.74 0.67 0.01 0.70 0.40 -0.11 0.60 NA 11.87 0.52 
8 Embryo Recombination Father 1.07 0.01 1.92 0.57 0.43 0.06 1.14 0.46 0.51 0.37 0.86 0.20 0.60 -0.20 -0.20 0.46 0.74 0.71 -0.03 0.71 0.40 -0.17 0.63 0.00 11.83 0.51 
9 Embryo Recombination Mother 1.07 -0.01 2.07 0.54 0.36 -0.03 1.23 0.46 0.51 0.33 0.94 0.13 0.61 -0.30 -0.30 0.43 0.74 0.76 -0.07 0.73 0.40 -0.23 0.66 NA 11.80 0.51 
9 Embryo Recombination Father 1.06 -0.03 2.23 0.51 0.29 -0.11 1.31 0.46 0.51 0.29 1.03 0.06 0.63 -0.40 -0.40 0.40 0.74 0.80 -0.11 0.74 0.40 -0.29 0.69 0.00 11.77 0.51 
10 Embryo Recombination Mother 1.06 -0.05 2.39 0.49 0.21 -0.20 1.40 0.46 0.51 0.24 1.11 -0.01 0.64 -0.50 -0.50 0.37 0.74 0.84 -0.16 0.76 0.40 -0.34 0.71 NA 11.74 0.51 
10 Embryo Recombination Father 1.06 -0.07 2.54 0.46 0.14 -0.29 1.49 0.46 0.51 0.20 1.20 -0.09 0.66 -0.60 -0.60 0.34 0.74 0.89 -0.20 0.77 0.40 -0.40 0.74 0.00 11.70 0.51 
Chromosome size (Mb) hGRCb37 (full length) 250 243 198 192 181 171 159 146 141 136 135 134 115 107 103 90.4 81.5 78.1 59.4 63.0 48.2 51.3 155 59.4 3038.7 132.12 
Population-average sex combined Embryo 1.13 0.74 0.93 0.81 0.85 0.80 0.89 0.82 0.78 1.04 0.94 1.04 0.80 0.94 0.94 1.18 1.26 1.15 1.25 1.36 1.06 1.01 0.49 NA 22.20 0.97 
Population-average Maternal Embryo 1.46 1.13 1.43 1.40 1.26 1.38 1.45 1.35 1.33 1.48 1.34 1.58 1.18 1.38 1.42 1.69 1.75 1.80 1.56 1.93 1.52 1.30 1.13 NA 33.24 1.45 
Population-average Paternal Embryo 0.79 0.70 0.75 0.59 0.81 0.67 0.79 0.79 0.62 1.00 0.95 0.94 0.85 0.91 0.86 1.44 1.11 0.95 1.64 1.48 1.01 1.36 NA NA 21.02 0.96 
Population-average Rec rate Oocyte 1.03 1.36 1.34 1.31 1.32 1.33 1.13 1.13 1.33 1.53 1.22 1.32 1.37 1.07 1.24 1.40 1.65 1.82 1.75 1.95 1.28 1.20 0.97 NA 31.06 1.30 
deCODE Maternal Population 1.34 1.28 1.35 1.35 1.37 1.36 1.38 1.39 1.32 1.52 1.39 1.47 1.27 1.15 1.36 1.65 1.87 1.75 1.94 1.75 1.39 1.29 1.11 NA 33.05 1.40 
HapMap Paternal Population 1.15 1.10 1.13 1.12 1.13 1.12 1.18 1.15 1.18 1.34 1.17 1.30 1.09 1.12 1.38 1.48 1.58 1.50 1.81 1.71 1.29 1.44 1.16 NA 29.63 1.23 




Table 9.9: Crossovers in Oocytes (Ottolini et al. 2015) 









Trio 3 4 5 1 2 3 4 1 1 2 3 1 2 
   
Table 
S5 
Type Oocyte Oocyte Oocyte Oocyte Oocyte Oocyte Oocyte Oocyte Oocyte Oocyte Oocyte Oocyte Oocyte Oocyte 
  
Oocyte 




Chr1 6 7 5 4 7 7 5 3 3 4 5 4 3 63 4.85 5.72 
5.9 ± 
0.18 
Chr2 4 7 7 5 8 9 9 5 4 6 3 3 4 74 5.69 5.44 NA 
Chr3 4 4 5 4 7 8 3 7 4 5 7 4 2 64 4.92 4.76 NA 
Chr4 3 6 4 NA 7 6 4 4 4 4 4 3 2 51 4.25 4.44 NA 
Chr5 3 5 4 5 8 5 4 3 2 4 6 3 5 57 4.38 4.21 NA 
Chr6 2 4 6 7 5 5 4 5 2 5 4 2 3 54 4.15 4.03 
3.7 ± 
0.19 
Chr7 3 3 5 2 6 5 3 2 3 3 2 2 3 42 3.23 3.65 NA 
Chr8 3 6 4 3 5 2 3 3 2 2 2 2 2 39 3.00 3.56 NA 
Chr9 3 4 4 5 4 3 3 4 2 4 5 2 4 47 3.62 3.32 
2.8 ± 
0.05 
Chr10 3 3 4 4 5 6 4 5 4 3 3 1 2 47 3.62 3.68 NA 
Chr11 2 4 3 2 3 3 3 4 3 5 3 2 3 40 3.08 3.26 NA 
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Chr12 3 3 4 4 3 6 3 2 3 3 4 1 3 42 3.23 3.46 NA 
Chr13 NA 4 4 3 4 4 4 1 1 2 4 4 1 36 3.00 2.50 
2.6 ± 
0.07 
Chr14 1 2 2 3 1 3 2 2 2 2 2 4 1 27 2.08 2.37 
2.2 ± 
0.1 
Chr15 1 1 4 2 3 3 3 NA 3 NA 3 3 1 27 2.45 2.37 
2.3 ± 
0.15 
Chr16 3 2 5 2 3 2 3 3 3 3 3 NA 1 33 2.75 2.79 
2.5 ± 
0.07 
Chr17 1 3 3 4 3 5 2 3 1 3 3 1 2 34 2.62 2.65 NA 
Chr18 1 4 3 2 4 3 2 2 3 2 2 1 2 31 2.38 2.60 
2.3 ± 
0.07 
Chr19 2 3 3 3 2 2 1 2 2 2 2 1 1 26 2.00 2.26 NA 
Chr20 2 2 2 2 3 2 3 3 2 2 2 1 3 29 2.23 2.21 NA 
Chr21 1 1 1 2 1 1 1 2 1 1 2 1 NA 15 1.25 1.32 
1.2 ± 
0.03 
Chr22 1 1 1 1 2 1 2 1 1 2 1 1 1 16 1.23 1.31 
1.4 ± 
0.04 
ChrX 3 4 5 NA 6 5 2 2 2 4 2 1 2 38 3.45 3.04 NA 
ChrY NA NA NA NA NA NA NA NA NA NA NA NA NA NA - - NA 







Table 9.10: Recombination Frequencies in Oocytes (Ottolini et al. 2015) 
















































Donor Trio Cell Type 
                        
G04 3 PB2 
Recombination 
rate 
3 1 3 1 1 1 2 1 2 1 1 3 0 0 0 2 0 0 0 0 0 0 3 25 
G04 3 Egg 
Recombination 
rate 
3 3 1 2 2 1 1 2 1 2 1 1 0 1 1 1 1 1 2 2 1 0 0 30 
G04 4 PB2 
Recombination 
rate 
3 2 1 5 4 2 2 2 4 3 3 2 4 1 0 2 3 4 1 0 0 0 2 50 
G04 4 Egg 
Recombination 
rate 
5 7 3 4 2 2 1 5 0 1 3 1 2 1 1 0 0 1 2 2 1 1 3 48 
G04 5 PB2 
Recombination 
rate 
3 5 2 4 2 2 0 1 4 3 3 3 4 0 2 2 2 2 0 0 0 0 3 47 
G04 5 Egg 
Recombination 
rate 
2 3 3 0 2 5 5 4 0 1 0 1 2 2 3 3 1 2 3 2 1 1 3 49 
G06 1 PB2 
Recombination 
rate 
4 5 3 0 3 3 1 3 4 2 0 2 2 0 0 1 3 2 0 1 1 1 0 41 
G06 1 Egg 
Recombination 
rate 
0 0 1 0 2 4 1 1 1 4 2 2 1 3 2 1 1 0 3 1 1 0 0 31 
G06 2 PB2 
Recombination 
rate 
5 6 4 7 6 2 4 4 3 3 1 1 1 1 2 2 2 3 0 3 1 2 5 68 
G06 2 Egg 
Recombination 
rate 
3 4 5 2 6 3 5 2 1 2 2 2 3 1 1 1 1 3 2 1 0 0 1 51 
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G06 3 PB2 
Recombination 
rate 
5 4 6 4 2 2 4 1 0 5 0 4 1 3 2 0 3 3 1 0 0 0 3 53 
G06 3 Egg 
Recombination 
rate 
3 6 4 4 3 4 1 1 3 2 3 4 3 0 2 2 2 1 1 2 1 1 2 55 
G06 4 PB2 
Recombination 
rate 
2 8 1 3 1 2 0 1 1 3 2 1 2 1 1 1 2 1 1 1 0 1 0 36 
G06 4 Egg 
Recombination 
rate 
3 4 2 3 3 2 3 2 3 3 1 2 3 2 2 2 0 1 1 3 1 1 0 47 
G07 1 PB2 
Recombination 
rate 
1 3 3 2 2 2 2 2 2 1 3 1 1 0 0 0 2 2 0 2 1 1 0 33 
G07 1 Egg 
Recombination 
rate 
2 2 4 2 1 3 0 1 2 4 1 1 0 2 0 3 1 0 2 1 1 0 2 35 
G08 1 PB2 
Recombination 
rate 
2 3 1 4 0 1 1 1 1 1 3 2 1 1 3 1 0 1 1 1 1 0 1 31 
G08 1 Egg 
Recombination 
rate 
1 2 3 4 2 1 3 1 1 4 1 1 0 1 2 2 1 3 1 1 0 1 1 37 
G08 2 PB2 
Recombination 
rate 
1 3 2 1 3 3 3 1 2 2 2 1 0 1 0 0 3 0 0 1 0 1 4 34 
G08 2 Egg 
Recombination 
rate 
3 3 3 3 1 5 1 1 3 1 3 3 2 2 0 3 1 2 2 1 1 2 1 47 
G08 3 PB2 
Recombination 
rate 
0 2 3 1 3 1 1 0 3 2 0 2 3 0 1 1 2 1 0 1 1 1 0 29 
G08 3 Egg 
Recombination 
rate 
5 2 4 3 3 3 1 2 2 1 3 2 1 2 2 2 1 1 2 1 1 0 2 46 
G09 1 PB2 
Recombination 
rate 
2 2 3 2 3 1 0 1 1 1 2 0 2 1 2 0 1 0 1 1 1 1 0 28 
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G09 1 Egg 
Recombination 
rate 
3 2 2 2 0 1 2 1 1 0 0 1 2 3 3 0 0 1 0 1 1 0 1 27 
G09 2 PB2 
Recombination 
rate 
1 2 0 1 1 1 2 0 2 0 0 1 1 0 0 0 1 1 0 3 0 1 1 19 
G09 2 Egg 
Recombination 
rate 




67 86 69 65 62 59 47 43 49 54 43 46 41 30 33 33 35 37 27 32 16 16 39 1029 
 
GRC_h37 (Total Lengths) 
 
249.9 243.2 198.02 191.54 180.92 171.12 159.32 146.44 141.7 135.53 135.05 133.85 115.17 107.35 102.53 90.355 81.53 78.082 59.381 63.026 48.158 51.305 155.27 3038.7 
 
Rec. rate (cM/Mb)-build 37 
 








Table 9.11: Map Distances in Oocytes (Ottolini et al. 2015) 
















































Donor Trio Cell Type 
                         
G04 3 PB2 
Recombination 
rate 
1.20 0.41 1.51 0.52 0.55 0.58 1.26 0.68 1.41 0.74 0.74 2.24 0.00 0.00 0.00 2.21 0.00 0.00 0.00 0.00 0.00 0.00 1.93 0.82 0.70 
G04 3 Egg 
Recombination 
rate 
1.20 1.23 0.50 1.04 1.11 0.58 0.63 1.37 0.71 1.48 0.74 0.75 0.00 0.93 0.98 1.11 1.23 1.28 3.37 3.17 2.08 0.00 0.00 0.99 1.11 
G04 4 PB2 
Recombination 
rate 
1.20 0.82 0.50 2.61 2.21 1.17 1.26 1.37 2.82 2.21 2.22 1.49 3.47 0.93 0.00 2.21 3.68 5.12 1.68 0.00 0.00 0.00 1.29 1.65 1.66 
G04 4 Egg 
Recombination 
rate 
2.00 2.88 1.51 2.09 1.11 1.17 0.63 3.41 0.00 0.74 2.22 0.75 1.74 0.93 0.98 0.00 0.00 1.28 3.37 3.17 2.08 1.95 1.93 1.58 1.56 
G04 5 PB2 
Recombination 
rate 
1.20 2.06 1.01 2.09 1.11 1.17 0.00 0.68 2.82 2.21 2.22 2.24 3.47 0.00 1.95 2.21 2.45 2.56 0.00 0.00 0.00 0.00 1.93 1.55 1.45 
G04 5 Egg 
Recombination 
rate 
0.80 1.23 1.51 0.00 1.11 2.92 3.14 2.73 0.00 0.74 0.00 0.75 1.74 1.86 2.93 3.32 1.23 2.56 5.05 3.17 2.08 1.95 1.93 1.61 1.86 
G06 1 PB2 
Recombination 
rate 
1.60 2.06 1.51 0.00 1.66 1.75 0.63 2.05 2.82 1.48 0.00 1.49 1.74 0.00 0.00 1.11 3.68 2.56 0.00 1.59 2.08 1.95 0.00 1.35 1.38 
G06 1 Egg 
Recombination 
rate 
0.00 0.00 0.50 0.00 1.11 2.34 0.63 0.68 0.71 2.95 1.48 1.49 0.87 2.79 1.95 1.11 1.23 0.00 5.05 1.59 2.08 0.00 0.00 1.02 1.24 
G06 2 PB2 
Recombination 
rate 
2.00 2.47 2.02 3.65 3.32 1.17 2.51 2.73 2.12 2.21 0.74 0.75 0.87 0.93 1.95 2.21 2.45 3.84 0.00 4.76 2.08 3.90 3.22 2.24 2.26 
G06 2 Egg 
Recombination 
rate 
1.20 1.64 2.52 1.04 3.32 1.75 3.14 1.37 0.71 1.48 1.48 1.49 2.60 0.93 0.98 1.11 1.23 3.84 3.37 1.59 0.00 0.00 0.64 1.68 1.63 
G06 3 PB2 
Recombination 
rate 
2.00 1.64 3.03 2.09 1.11 1.17 2.51 0.68 0.00 3.69 0.00 2.99 0.87 2.79 1.95 0.00 3.68 3.84 1.68 0.00 0.00 0.00 1.93 1.74 1.64 
G06 3 Egg 
Recombination 
rate 
1.20 2.47 2.02 2.09 1.66 2.34 0.63 0.68 2.12 1.48 2.22 2.99 2.60 0.00 1.95 2.21 2.45 1.28 1.68 3.17 2.08 1.95 1.29 1.81 1.85 
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G06 4 PB2 
Recombination 
rate 
0.80 3.29 0.50 1.57 0.55 1.17 0.00 0.68 0.71 2.21 1.48 0.75 1.74 0.93 0.98 1.11 2.45 1.28 1.68 1.59 0.00 1.95 0.00 1.18 1.19 
G06 4 Egg 
Recombination 
rate 
1.20 1.64 1.01 1.57 1.66 1.17 1.88 1.37 2.12 2.21 0.74 1.49 2.60 1.86 1.95 2.21 0.00 1.28 1.68 4.76 2.08 1.95 0.00 1.55 1.67 
G07 1 PB2 
Recombination 
rate 
0.40 1.23 1.51 1.04 1.11 1.17 1.26 1.37 1.41 0.74 2.22 0.75 0.87 0.00 0.00 0.00 2.45 2.56 0.00 3.17 2.08 1.95 0.00 1.09 1.19 
G07 1 Egg 
Recombination 
rate 
0.80 0.82 2.02 1.04 0.55 1.75 0.00 0.68 1.41 2.95 0.74 0.75 0.00 1.86 0.00 3.32 1.23 0.00 3.37 1.59 2.08 0.00 1.29 1.15 1.23 
G08 1 PB2 
Recombination 
rate 
0.80 1.23 0.50 2.09 0.00 0.58 0.63 0.68 0.71 0.74 2.22 1.49 0.87 0.93 2.93 1.11 0.00 1.28 1.68 1.59 2.08 0.00 0.64 1.02 1.08 
G08 1 Egg 
Recombination 
rate 
0.40 0.82 1.51 2.09 1.11 0.58 1.88 0.68 0.71 2.95 0.74 0.75 0.00 0.93 1.95 2.21 1.23 3.84 1.68 1.59 0.00 1.95 0.64 1.22 1.32 
G08 2 PB2 
Recombination 
rate 
0.40 1.23 1.01 0.52 1.66 1.75 1.88 0.68 1.41 1.48 1.48 0.75 0.00 0.93 0.00 0.00 3.68 0.00 0.00 1.59 0.00 1.95 2.58 1.12 1.09 
G08 2 Egg 
Recombination 
rate 
1.20 1.23 1.51 1.57 0.55 2.92 0.63 0.68 2.12 0.74 2.22 2.24 1.74 1.86 0.00 3.32 1.23 2.56 3.37 1.59 2.08 3.90 0.64 1.55 1.73 
G08 3 PB2 
Recombination 
rate 
0.00 0.82 1.51 0.52 1.66 0.58 0.63 0.00 2.12 1.48 0.00 1.49 2.60 0.00 0.98 1.11 2.45 1.28 0.00 1.59 2.08 1.95 0.00 0.95 1.08 
G08 3 Egg 
Recombination 
rate 
2.00 0.82 2.02 1.57 1.66 1.75 0.63 1.37 1.41 0.74 2.22 1.49 0.87 1.86 1.95 2.21 1.23 1.28 3.37 1.59 2.08 0.00 1.29 1.51 1.54 
G09 1 PB2 
Recombination 
rate 
0.80 0.82 1.51 1.04 1.66 0.58 0.00 0.68 0.71 0.74 1.48 0.00 1.74 0.93 1.95 0.00 1.23 0.00 1.68 1.59 2.08 1.95 0.00 0.92 1.01 
G09 1 Egg 
Recombination 
rate 
1.20 0.82 1.01 1.04 0.00 0.58 1.26 0.68 0.71 0.00 0.00 0.75 1.74 2.79 2.93 0.00 0.00 1.28 0.00 1.59 2.08 0.00 0.64 0.89 0.92 
G09 2 PB2 
Recombination 
rate 
0.40 0.82 0.00 0.52 0.55 0.58 1.26 0.00 1.41 0.00 0.00 0.75 0.87 0.00 0.00 0.00 1.23 1.28 0.00 4.76 0.00 1.95 0.64 0.63 0.74 
G09 2 Egg 
Recombination 
rate 
0.80 0.82 1.01 0.52 2.21 1.17 0.63 1.37 1.41 1.48 2.22 1.49 0.00 0.93 0.98 1.11 1.23 1.28 1.68 0.00 0.00 0.00 0.64 1.05 1.00 
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1.15 1.10 1.13 1.12 1.13 1.12 1.18 1.15 1.18 1.34 1.17 1.30 1.09 1.12 1.38 1.48 1.58 1.50 1.81 1.71 1.29 1.44 1.16 29.63 1.29 
Hou et al. 2013 
 




Several observations support the conclusion that recombination rates in the adult oocytes and 
embryos are highly variable, like those seen in unselected, foetal oocytes (Lenzi et al. 2005; 
Cheng et al. 2009; Gruhn et al. 2013). At the same time, the average recombination frequencies 
are reminiscent of those reported for human populations. The average number of maternal 
crossovers in the oocyte or embryos was 41.6 ± 11.3 S.D. (n=51; Tables 9.7-9.11). This rate is 
consistent with estimates from foetal oocytes and population-based assessments (Broman et al. 
1998; Kong et al. 2002; Tease et al. 2002; Kong et al. 2004; Myers et al. 2005; Coop et al. 2008; 
Kong et al. 2008; Hou et al. 2013; Kong et al. 2014) and those detected in the female pronucleus 
(42.5 ± 9.0 S.D., n=52) (Kong et al. 2010). The frequencies of crossovers detected in the egg 
correlated well with those in the PB1 or PB2 (Figure 9.7). The maternal recombination rates and 
the lengths of haplotype blocks were highly variable between donors as well as within donors 
(Lenzi et al. 2005; Cheng et al. 2009; Chowdhury et al. 2009; Kong et al. 2010), varying by as 
much as two-fold (Figure 9.6b, f and g; Figure 9.7). Using the oocyte-PB trios, maternal 
crossovers displayed a median distance of 32.4Mb, which was in excess of the 18.3Mb predicted 
by random distribution of crossovers along chromosomes described in the Methods section 9.3.8. 





Figure 9.7. Correlation of recombination detected in the oocytes and polar bodies (Ottolini et al. 2015). 
(a–c) Spearman correlation (ρ) between crossover frequencies per meiosis estimated from the oocyte-PB trio and correlated with counts in PB1 only (a), 
oocyte only (b) and PB2 (c).  
(d) Correlation of crossover events detected in the oocyte as compared to the PB2. (n=13; 5 donors).  
(e) Heterogeneity in haplotype lengths in the five different oocyte-PB donors. 
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Embryos contain informative markers of both maternal and paternal origin. This allows us to 
assess recombination of both sexes in unselected embryos for the first time. Maternal 
recombination rates were 1.63-fold higher than paternal rates in the embryos, consistent with 
population-based studies and molecular approaches on single sperm and foetal oocytes (Kong et 
al. 2002; Lenzi et al. 2005; Cheng et al. 2009; Gruhn et al. 2013; Broman et al. 1998; Tease, 
Hartshorn & Hulten 2002; Kong et al. 2004). The additional maternal recombination events are in 
part from female-only recombination along the X chromosome and in part from higher crossover 
frequencies on larger autosomes (Figure 9.6d). Maternal recombination was more centromeric 
compared to paternal events (Figure 9.6e; Figure 9.8), although centromeres tended to suppress 
nearby recombination (Hou et al. 2013; Kong et al. 2002; Lenzi et al. 2005; Cheng et al. 2009; 
Gruhn et al. 2013; Broman et al. 1998; Tease, Hartshorn & Hulten 2002; Kong et al. 2004) 
(Figure 9.6f). However, the suppression of centromeric crossovers varied amongst oocyte-PB 
trios, even within the same woman (Figure 9.6g). This variation may predispose some oocytes to 
crossovers positioned too close to centromeres that may interfere with segregation. Collectively, 
these observations reveal that the variation in total crossover numbers detected in adult oocytes 
is analogous to the variation in Mlh1 counts observed in foetal oocytes (Lenzi et al. 2005; Cheng 
et al. 2009; Gruhn et al. 2013), suggesting that Mlh1 foci serve as a good proxy for crossover 




Figure 9.8. Chromosome-specific responses to recombination rates and positions in male and female meiosis (Ottolini et al. 2015). 
(a) Density curves of the normalised distance of crossovers to centromeres (CEN). Statistics: Kolmogorov-Smirnov test, two-sided. (b,c) Histograms 
and density curves of absolute distances of crossovers to centromeres. Statistics: Kolmogorov-Smirnov test, two-sided. (d) Chromosome-specific 
responses in crossover position along chromosomes in the two sexes. 
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Simultaneously, the average recombination rates are reminiscent of those in the human 
population. This validates our approach and lends support to the hypothesis that the variability in 
the rates and distribution of recombination events between and within individuals give rise to 
vulnerable crossover configurations in foetal oocytes that are propagated to adult oocytes and, 
ultimately, embryos.  
 
9.4.4. Global Recombination Rates as a Risk Factor for Aneuploidy 
To understand how the variability of maternal recombination rates affects human aneuploidy, I 
addressed whether the global, genome-wide recombination rates were correlated with the 
incidence of aneuploidy in individual oocytes and embryos. Indeed, the global recombination rate 
was a strong predictor of aneuploidy (Figure 9.9a), even when I excluded an outlier embryo, 
which contained 12 aneuploidies and no detectable crossovers amongst any of the chromosome 
pairs. The recombination rate is an important factor, accounting for 18% of the variation in the 




Figure 9.9. Higher global recombination rates protect against aneuploidy and are selected 
for in the human female germline (Ottolini et al. 2015).  
(a) Logistic regression of the frequency of aneuploid chromosomes as a function of global 
recombination rate in the embryo or oocyte. Black lines shows logistic regression model and 95% 
confidence interval (dashed line; binomial family). When the outlier with 0 recombination events 
was omitted, the regression coefficient β was -0.06 and still highly significant (p<0.003). The 
outlier was omitted from all subsequent statistical analyses.  
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(b) Recombination rates in normal versus aneuploid oocytes and embryos. The arithmetic mean 
is shown above of the median (magenta, vertical bar). Statistics: Mann-Whitney-Wilcoxon test; 
one-sided.  
(c) Incidence of bivalents containing at least one non-recombinant chromatid (R0) as a function of 
global recombination rates in oocyte-PB and embryo-PB trios. Statistics as in (a).  
(d) Segregation errors amongst chromosomes that contained one or more R0 or where all four 
chromatids had recombined (‘rec’). p-values from G-test of heterogeneity (two-sided) are shown. 




If lower global recombination rates predispose oocytes to meiotic chromosome segregation 
errors, then normal euploid embryos should contain chromosomes that underwent higher 
maternal genome-wide recombination frequencies than those of aneuploid embryos. To examine 
whether this was the case, I divided the embryos and oocytes into two groups (euploid or 
aneuploid) and determined their respective recombination rates (Figure 9.9b). Normal, euploid 
oocytes and embryos had on average 5.8 recombination events more than aneuploid ones. This 
difference was significant even when I accounted for crossovers that may not be detected due to 
the presence of two chromosomes in the aneuploid oocyte (Hou et al. 2013). Notably, the overlap 
in the distribution of recombination rates between the euploid and aneuploid groups is consistent 
with the presence of other factors that influence the fidelity of chromosome segregation (Nagaoka 
et al. 2012). The findings suggest that higher global recombination frequencies, which are 
determined during foetal development, protect against errors in chromosome segregation 
decades later in the adult woman. When errors do occur, they give rise to aneuploidy, many of 
which are selected against prior to the implantation of the embryo (Capalbo et al. 2014). One 
implication of this is that recombination rates may be under selection in women as they enter their 
30s, increasing rates by as much as 14% in women of advanced maternal age (5.8/41.5, the 
overall average).  
 
9.4.5. Non-Recombinant Chromatids Are at Risk of PSSC 
How do global recombination rates affect the segregation outcomes of individual homolog pairs? I 
hypothesised that lower global recombination rates might increase the risk of generating 
vulnerable crossover configurations. I first considered non-exchange E0 homolog pairs, which 
would give rise to trios, where the PB1 contains one homolog (green or yellow) and the oocyte 
and PB2 one sister each from the other homolog (Figure 9.10a). Of 529 chromosome pairs, no 
such example was observed in our data, although one case was observed by Hou et al. (personal 
communication, Hou et al. 2013). E0 may be extremely rare, or another possibility is that they mis-
segregate. Indeed, I observed 13 putative E0 from the 529 chromosome pairs across the 23 trios 
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(Figure 9.10d-g). The overall incidence (2.6%, n=506) and the overrepresentation of the two 
smallest chromosomes (21 and 22) are reminiscent of observations of cytological markers for 
crossovers on foetal chromosomes in meiotic prophase (Lenzi et al. 2005; Cheng et al. 2009; 
Gruhn et al. 2013). The observed incidence of presumed E0 was much lower than expected if 
crossovers were randomly distributed amongst chromosomes (Figure 6.10h), suggestive of 
crossover assurance mechanism(s) in human oocytes. None of the presumed E0 chromosomes 
followed a classical meiotic segregation pattern. Instead they all underwent PSSC or reverse 
segregation (with or without MII mis-segregation; Figure 9.10). This is consistent with the bi-
orientation of sister chromatids of univalent chromosomes at meiosis I in model organisms 




Figure 9.10. Crossover assurance in human female meiosis (Ottolini et al. 2015). 
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(a) A non-exchange or exchange-less chromosome pair (E0) (left). In normal meiosis, non-
exchange chromosome pairs can be detected by a single haplotype in the PB1 and the other 
haplotype in the oocyte and PB2.  
(b) E0 chromosomes that undergo reverse segregation cannot be detected directly. This is 
because the informative SNPs on the two chromatids in the PB1 cannot be phased; hence, 
potential crossovers (far right) cannot be detected.  
(c) PSSC events can result in three chromatids in the PB1. Both maternal SNPs will be present 
and detected (blue). Since reciprocal crossovers cannot be mapped, the lack of crossovers can 
only be presumed.  
(d-g) Trios with chromosomal content consistent with presumed or putative exchange-less (E0) 
homologs due to reverse segregation (RS) resulting in two aneuploid cells (d), reverse 
segregation resulting in normal chromosomal content in all three cells (e), or precocious 
separation of sister chromatids (PSSC) with an aneuploid (f) or euploid (g) oocyte.  
(h) Modelled risk of a chromosome pair failing to receive a crossover (E0) as a function of global 
recombination rates, using the range of rates observed in our data sets. Crossovers were 
allocated randomly to chromosomes with weighted probability using chromosome length; thus, 




Informative SNPs on mis-segregated chromosomes cannot be phased, making crossovers 
undetectable (Figure 9.11). However, most of the presumed E0 contained non-recombinant 
chromatids (R0). Figure 9.9c shows that global recombination rates are important for determining 
the generation of R0, which in turn are at increased risk of mis-segregation compared to fully 
recombinant bivalents (all four chromatids engaged in recombination; ‘rec’, Figure 9.9d). Bivalents 
that contained a R0 were preferentially involved in PSSC, suggesting that non-recombinant 
chromatids are at risk of precociously separating from their sister at meiosis I. It is possible that 
non-recombinant chromatids are at elevated risk of becoming dissociated from the rest of the 
bivalent during the decades-long dictyate arrest (Wolstenholme & Angell, 2000; Garcia-Cruz et al. 
2010). I conclude that recombination affects not only the generation and segregation of putative 
non-exchange homolog pairs, but also influences the dynamics of sister chromatid segregation.  
 
9.4.6. Meiotic Drive for Recombinant Chromatids at Meiosis II 
Nonrecombinant chromatids are not only at risk of PSSC, but their segregation at meiosis II is 
also affected by the lack of recombination. The MeioMaps revealed 135 chromatids in the oocyte 
or PB2 that were non-recombinant and had segregated normally (Figure 9.11a). These R0 are 
expected to be randomly distributed amongst the oocyte and the PB2. Contrary to this 
expectation, R0 were nearly twice as likely to be found in the PB2 than the oocyte. The selection 
appears to be against non-recombinant chromatids, because when both sisters recombined, their 
segregation was random and the recombination rates were similar in the oocyte and PB2 (Table 
9.7). I infer that when the two sister chromatids segregated at meiosis II, non-recombinant 
chromatids were preferentially driven into the PB2 and thus eliminated from the human germline 
(Figure 9.11b,c). The use of the asymmetric cell divisions during oogenesis for the preferential 
inclusion of an allele (Sandler & Novitski 1957) or even whole chromosomes (Dawe & Cande 
1996; Pardo-Manuel de Villena & Sapienza 2001; Bongiorni et al. 2004) is referred to as meiotic 
or chromosomal drive. The meiotic drive against non-recombinant chromatids resulted in a 6.6% 
elevation in the recombination rates in oocytes compared to the PB2s (Table 9.7). These findings 
262 
 
imply that recombination is not only important for the accurate segregation of homologs at 
meiosis I, but also acts as a driving force during sister chromatid segregation at meiosis II. 
Selection against non-recombinant chromatids may prevent entire chromosomes from being 
inherited as a single haplotype block, thereby reducing the probability of inbreeding or 
propagation of segregation distorters (Haig & Grafen 1991; Brandvain & Coop 2012; Chmatal et 
al. 2014). This may be significant in terms of population structure and the genomic health of 
children. The difference in genome structure between the PB2 and oocyte is particularly relevant, 





Figure 9.11. Meiotic drive for recombinant chromatids at meiosis II increases 
recombination rates in the human female germline (Ottolini et al. 2015).  
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(a) Sister chromatids are expected to segregate randomly at meiosis II. However, when 
chromosomes that contained one non-recombinant chromatid and one recombinant one 
segregated, the recombinant chromatid was twice as likely to segregate to the oocyte. G-test for 
proportions (two-sided). 
(b) Chromosome-specific frequencies of R0 chromatids segregating to the PB2 or oocyte. 
(c) Diagrammatic representation of meiotic drive against non-recombinant chromatids at meiosis 




Until recently, recombination and chromosome segregation were studied in populations, where 
missing polar body information was not available; or in foetal oocytes, which arise decades prior 
to the segregation events being studied. MeioMaps from unselected adult oocytes, the female 
pronucleus in zygotes (Hou et al. 2013), and embryos, now provide a ‘missing link’ between 
events that occur during foetal development and their influence on chromosome segregation 
outcomes decades later in the adult oocyte.  
Recombination rates in the unselected oocytes were 1.6-fold higher than in males and showed a 
broad distribution, similar to the high degree of variation in foetal oocytes (Lenzi et al. 2005; 
Cheng et al. 2009; Gruhn et al. 2013). Sex-specific differences in chromosome structure during 
meiotic prophase have been suggested to explain this difference, with female chromosomes 
having a longer axis and shorter chromatin loops (Lynn et al. 2002). The increased loop number 
correlates with the increased recombination rate in female meiosis (Lynn et al. 2002; Gruhn et al. 
2013). Although the mean female recombination rates were similar to those seen in populations, 
the range was substantially broader. I found that lower genome-wide recombination rates were 
selected against because they were less likely give rise to a euploid oocyte. This is consistent 
with findings that Down Syndrome individuals have lower genome-wide recombination rates 
compared to their euploid siblings (Middlebrooks et al. 2013). The degree of selection is not 
observed in younger women (Hou et al. 2013) and could contribute to the higher recombination 
rates in children as mothers age (Kong et al. 2004; Coop et al. 2008; Campbell et al. 2015). This 
model predicts that children born to younger mothers should display a broader range in 
recombination frequencies compared to those born to women of advanced maternal age. 
Lower genome-wide recombination rates increase the risk of at least two types of vulnerable 
crossover configurations: non-recombinant chromatids (R0) and putative non-exchange homologs 
(E0). R0 are a risk factor for PSSC and their preferential segregation to the second polar body at 
meiosis II (meiotic drive). The putative E0 either underwent PSSC or a novel reverse segregation 
pattern, where sister chromatids of both homologs separated at meiosis I, followed by a weak 
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preference of accurate division of the two non-sister chromatids at meiosis II. The reverse 
segregation pattern is not limited to E0 and could be the result of centromeric crossovers that fall 
at or within 1-2Mb of the centromeres, the positions of the last informative SNPs (Table 9.12). 
Centromeric crossovers interfere with segregation of sister chromatids in Drosophila and budding 
yeast (Rockmill et al. 2006), and are associated with an increased risk of aneuploidy in humans 
(Nagaoka et al. 2012). The relatively high incidence of MII nondisjunction (23%, n=26) associated 





Table 9.12: Heterozygous SNP (or Informative SNP) Resolution Near Centromeres of Chromosomes Undergoing Reverse Segregation 
(Ottolini et al. 2015) 
























































G04 - Trio 
1 
16 GRCh37 35.336 35.070 33.910 1.160 1.426 24.926 10.143 38.336 47.018 47.379 0.361 9.043 78.929 31.911 3 
G04 - Trio 
3 
15 GRCh37 n/a n/a n/a n/a n/a n/a n/a 20.000 20.192 22.870 2.678 2.870 29.194 9.002 4 
G06 - Trio 
2 
14 GRCh37 n/a n/a n/a n/a n/a n/a n/a 19.000 20.296 20.503 0.207 1.503 97.164 76.868 1 
G06 - Trio 
3 
14 GRCh37 n/a n/a n/a n/a n/a n/a n/a 19.000 20.296 20.373 0.077 1.373 51.414 31.119 3 
G06 - Trio 
3 
15 GRCh37 n/a n/a n/a n/a n/a n/a n/a 20.000 22.779 22.837 0.058 2.837 38.007 15.228 3 
G08 - Trio 
1 
4 GRCh37 49.660 48.749 48.749 0.000 0.911 25.598 22.846 52.660 52.991 54.194 1.202 1.534 170.819 118.133 3 
G08 - Trio 
1 
19 GRCh37 24.682 24.468 24.468 0.000 0.214 n/a n/a 27.682 28.002 28.175 0.174 0.493 37.489 4.904 2 
G08 - Trio 
2 
15 GRCh37 n/a n/a n/a n/a n/a n/a n/a 20.000 20.176 20.176 0.000 0.176 n/a n/a n/a 
G09 - Trio 
2 
11 GRCh36 51.451 51.369 48.966 2.403 2.484 24.795 n/a 54.451 55.039 55.708 0.669 1.257 95.106 40.067 3 
G09 - Trio 
2 
15 GRCh36 n/a n/a n/a n/a n/a n/a n/a 18.260 19.970 20.556 0.586 2.296 44.246 24.276 3 
G09 - Trio 
2 
22 GRCh36 n/a n/a n/a n/a n/a n/a n/a 14.330 15.468 15.468 0.000 1.138 26.000 10.532 1 
LB03 - 
Trio 7 
16 GRCh37 35.336 34.928 33.910 1.018 1.426 10.422 n/a 38.336 47.379 48.978 1.599 10.643 78.622 31.243 2 
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21 GRCh37 n/a n/a n/a n/a n/a n/a n/a 14.288 14.880 15.617 0.737 1.329 41.202 25.708 1 
LB03 - 
Trio 8 
9 GRCh37 47.368 38.757 38.721 0.036 8.647 6.309 32.412 50.368 71.036 71.310 0.274 20.942 113.346 42.302 3 
LB03 - 
Trio 10 
16 GRCh37 35.336 34.928 33.837 1.092 1.499 n/a n/a 38.336 47.379 47.379 0.000 9.043 83.935 36.556 1 
LB03 - 
Trio 10 
19 GRCh37 24.682 24.060 23.763 0.297 0.919 none n/a 27.682 28.485 28.485 0.000 0.803 none n/a 0 
LB03 - 
Trio 10 
21 GRCh37 n/a n/a n/a n/a n/a n/a n/a 14.288 14.880 14.880 0.000 0.592 16.417 1.537 3 
LB03 - 
Trio 10 
22 GRCh37 n/a n/a n/a n/a n/a n/a n/a 16.000 17.133 17.203 0.069 1.203 37.081 19.948 1 
LB03 - 
Trio 11 
4 GRCh37 49.660 49.054 48.995 0.058 0.665 38.306 10.689 52.660 52.732 52.732 0.000 0.072 97.943 45.211 4 
LB03 - 
Trio 13 
16 GRCh37 35.336 34.928 34.428 0.501 0.908 16.987 17.441 38.336 47.379 47.755 0.376 9.419 69.587 21.832 2 
LB03 - 
Trio 13 
21 GRCh37 n/a n/a n/a n/a n/a none n/a 14.288 14.880 15.495 0.615 1.207 none n/a 0 
LB03 - 
Trio 13 
22 GRCh37 n/a n/a n/a n/a n/a none n/a 16.000 17.133 17.203 0.069 1.203 none n/a 0 
LB03 - 
Trio 14 
17 GRCh37 22.263 22.099 22.013 0.085 0.250 18.279 3.735 25.263 25.376 25.376 0.000 0.113 55.403 30.027 2 
LB03 - 
Trio 14 
19 GRCh37 24.682 24.060 24.060 0.000 0.622 none n/a 27.682 28.485 28.485 0.000 0.803 none n/a 0 
LB03 - 
Trio 14 
22 GRCh37 n/a n/a n/a n/a n/a none n/a 16.000 17.133 17.203 0.069 1.203 none n/a 0 
LB03 - 
Trio 16 
21 GRCh37 n/a n/a n/a n/a n/a none n/a 14.288 14.880 15.538 0.658 1.250 none n/a 0 
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Another possible mechanism that seems particularly plausible for the larger metacentric 
chromosomes where two crossovers would have to occur within 1Mb on both sides of the 
centromere, is that homologs segregated their sister chromatids in an equational fashion in MI, 
followed by a weak preference for accurate non-sister chromatid segregation at MII (77% 
compared to 50% expected from random; n=26; p<0.05). It is possible that failure to establish 
crossovers (E0) or maintain the bivalent structure during the extended dictyate arrest may 
predispose to the equational division at meiosis I. This could occur by deterioration of cohesion 
between sister chromatids, sister kinetochores, or bivalents falling apart into univalents. There is 
evidence for the latter in human MI oocytes (Angell 1997; Garcia-Cruz et al. 2010), but it is 
unknown whether their frequencies and chromosome-specific effects match the maternally-
derived, age-related component underlying human aneuploidies. In mouse oocytes, univalents 
preferentially segregate sister chromatids at meiosis I (LeMaire-Adkins & Hunt 2000; 
Kouznetsova et al. 2007) and this may also be case in humans. At meiosis II, non-sister 
chromatids could be physically attached by unresolved recombination intermediates (joint 
molecules) (Copsey et al. 2013), other threads (Hughes et al. 2009; Cabral et al. 2014; 
Heckmann et al. 2014), or the oocyte may use segregation mechanisms that do not rely on 
physical attachment between chromosomes (Hughes-Schrader 1969). The relative contributions 
of reverse segregation mechanisms and centromeric crossovers remain to be determined, but in 
either case demonstrate that events attributed to mistakes in chromosome segregation in meiosis 
II can have their origin at meiosis I in human female meiosis. 
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10. General Discussion 
Since the introduction of molecular cytogenetics into the field of human preimplantation embryos, 
much information has been gathered on the incidence, origin and aetiology of aneuploidy. 
However, research into the origin of human aneuploidy is still clearly much needed and will 
continue to provide new and exciting insights in the field. This thesis has helped to provide some 
such insight as well as developing tools that could prove useful in both clinical and research areas 
of preimplantation genetics. In this thesis:  
1. State of the art standard protocol set have been produced as frames of reference for 
embryo biopsy and array CGH. 
2. Karyomapping has been confirmed as a tool to detect monogenic disorders (phase and 
parent of origin), chromosome copy number (including parent of origin of aneuploidies) 
and meiotic origin of trisomies simultaneously, and be used to pinpoint points of meiotic 
recombination in preimplantation embryos. 
3. The utility of Karyomapping as a genome-wide fingerprint was demonstrated by 
presenting the first data that polar body DNA can persist to the blastocyst stage of embryo 
development. 
4. By investigating calcium ionophore for oocyte activation, sequential biopsy protocols and 
adapting the principals of Karyomapping a novel tool was developed to investigate the 
mechanisms of human female meiosis. This tool was termed MeioMapping. 
5. Finally, and most importantly, MeioMapping was used to demonstrate; 
a. Reverse segregation in human oocytes, a pattern of meiotic segregation 
previously undescribed. 
b. Selection for higher recombination rates in the female germline. 




d. Meiotic drive for recombinant chromatids at meiosis II in human female meiosis. 
The improvement of current technology, including SNP genotyping and MeioMapping-related 
techniques, will further improve our knowledge of preimplantation aneuploidy. Hopefully the 
information provided (and published) in this thesis brings these techniques to further application. 
What has not been discussed in this thesis is that it has been hypothesised that the high rates of 
aneuploidy and mosaicism following in vitro fertilisation (IVF) procedures may in fact be an 
iatrogenic artefact of the procedure itself. Ovarian hyperstimulation (Baart et al. 2007), fertilisation 
in vitro (Bean et al. 2002) and in vitro culture environments (IVC) (Carrell et al. 2005; Sabhnani et 
al. 2011; Xu et al. 2011) appear to affect embryo aneuploidy. A recent randomised controlled trial 
(RCT) of ovarian stimulation protocols revealed that minimal stimulation, although associated with 
a reduced number of oocytes, results in higher proportion of chromosomally ‘normal’ embryos. It 
was hypothesised that conventional stimulation protocols result mainly in an increase of post 
zygotic chromosome segregation errors. Altered ovarian function (recruitment of follicles), 
gonadotrophin dose and GnRH analogue have been offered as potential correlates for further 
investigation. Furthermore, mouse studies have shown increased meiotic and post zygotic error 
rates following IVF and IVC respectively (Bean et al. 2002; Sabhnani et al. 2011). The sensitivity 
of mouse oocytes to different culture regimens resulting in differing aneuploidy rates corroborates 
the hypothesis that IVF affects aneuploidy (Carrell et al. 2005). In humans, follicle stimulating 
hormone (FSH) levels associated with in vitro maturation correlate with chromosome mal-
segregation in the first meiotic division (Xu et al. 2011). Animal models could be further employed 
for manipulation of IVF parameters in an effort to induce or suppress aneuploidy, although clinical 
IVF itself may provide the best ‘experiment’ to gain a better understanding of the mechanisms 
involved in human aneuploidy. 
Full genetic sequencing seems the logical next technological advance for preimplantation genetic 
screening (PGS) and appears technically possible following successful genomic sequencing of 
microbial single cells (Zhang et al. 2006; Lasken 2007). Additional data at the highest possible 
resolution should inevitably prove more reliable for chromosome copy number analysis and, as 
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with SNP genotyping, points of recombination as well as points of partial aneuploidy along 
chromosomes could be analysed with more precision. Currently, increased resolution of PGS is 
limited by the whole genome amplification (WGA) step (Ling et al. 2009). Achieving the highest 
possible resolution is directly restricted by the phenomenon of allele dropout (ADO) when 
amplifying single or very few cells. Thus it necessary to invest effort in improving WGA technology 
before the full benefits of genomic sequencing could be realised. It should be noted at this point 
that the Karyomapping and MeioMapping work performed in this thesis would adapt easily to 
sequencing technologies providing a platform with which to move forward for future investigations 
into the genome of human gametes and preimplantation embryos. 
With the increasing amount of data obtained from PGS technologies comes the issue of an 
increasing amount of ‘incidental’ findings of unknown pathological significance. Careful 
considerations of the social, ethical and legal aspects of these findings are required to combat 
potential problems prior to implementing higher resolution technologies.  
The ultimate goal of PGS is to provide maximum benefit (in terms of information to the 
parent/healthcare provider) with minimal cost to the embryo. The possibility of gaining 
chromosome copy number information with no cost to the embryo would enable PGS to be used 
routinely as an embryo selection tool for IVF. An indirect aneuploidy screening test was first 
explored by associations with conventional embryo morphology scoring. However, morphological 
embryo grading is apparently at its limits to improve IVF success rates and has only shown very 
limited correlation with aneuploidy (Munné 2006; Gianaroli et al. 2007; Alfarawati et al. 2011a). 
The implementation of time-lapse imaging to embryo culture has facilitated high-resolution 
morphokinetic analysis of embryo development in an attempt to improve IVF success rates and 
eliminate potentially abnormally developing embryos. Morphokinetic analysis involves continual 
analysis of the morphological state and rates of change during oocyte and embryo development 
and provides evidence of developmental milestones that can predict embryo implantation 
(Meseguer et al. 2011). Since, cells of different genotypes are known to have slightly different cell 
cycle times (Varrela et al. 1989), it follows that algorithms involving multiple developmental time 
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points could be used to predict embryo aneuploidy at no cost to the embryo. Embryos with an 
abnormal karyotype (particularly those with multiple abnormalities) may have aberrant cell cycles, 
detectable by morphokinetic analysis, compared with normal embryos. New studies into the 
morphological rates of change, including such developmental markers as PB extrusion, syngamy 
and early mitotic divisions, could find more significant correlations with chromosome mal-
segregation than embryo morphology alone. However investigators must be sure to perform the 
correct analysis of results as premature implementation of new screening tests may end up 
creating a similar situation to Fluorescent In-situ Hybridisation (FISH) in the mid-2000s. It is 
potentially easy to fall into the trap of publishing unsound data in the rush to uncover a non-
invasive chromosome screening test that would revolutionise the field of IVF. 
Take for example two recently published papers demonstrating the utility of algorythms using 
time-lapse imaging for aneuploidy detection. These two articles by Campbell et al. (2013a, b) 
prematurely describe an algorithm using time-lapse imaging for aneuploidy risk classification of 
human preimplantation embryos. What follows is adapted from a published commentary (Ottolini, 
Capalbo & Rienzi 2013). On the basis of their results, the authors of these two papers postulated 
that by using specific morphokinetic markers they could reliably select euploid embryos for 
transfer. Thus, increasing pregnancy rates and reducing miscarriage rates due to aneuploidy. 
Although I believe that the authors have identified developmental time points – time from 
insemination to blastulation (tSB) and time of insemination to full blastocyst (tB) – that can be 
used to establish an embryo’s implantation potential in their culture system, I believe that the 
study is underpowered and that maternal age rather than specifically embryo aneuploidy is likely 
to be the causative factor. First, it is my opinion that there may be no need to analyse both tSB 
and tB since these time points appear to be highly linked, as shown by the authors (Campbell et 
al. 2013a). The apparent linear relationship between the two variables, from the point of 
insemination, suggests that using only one of the variables would likely result in similar statistically 
significant findings. I conclude that the two articles by Campbell et al. are based on the premise 
that faster developing blastocysts are more likely to be euploid and hence implant and result in a 
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pregnancy. Kroener et al. (2012) clearly show that delayed blastulation is not associated with 
increased aneuploidy rates. Based on these data, and some observations from the work in this 
thesis, I believe that there is no evidence to suggest that Day 6 blastocysts have a higher rate of 
aneuploidy and lower rate of implantation when compared with Day 5 blastocysts (at least when 
comparing embryos within the same IVF cycle or from an age-matched population), rendering 
any screening test for early blastocyst formation impractical as a risk assessment for embryo 
aneuploidy. I therefore postulate that the observed difference in implantation in the author’s data 
set could be attributed to factors other than chromosome copy number. A recent meta-analysis of 
data from the Society for Assisted Reproductive Technologies in the USA highlighted the 
significant difference in success rates of IVF when treating patients of differing age groups 
(Cohen et al. 2012). It is well established in human IVF that implantation potential of embryos 
from patients of advanced maternal age are reduced when compared with younger patient 
groups (Scott et al. 2012) and that blastocyst formation and hatching are negatively correlated 
with maternal age (Porter et al. 2002). It is also well established that embryo aneuploidy levels 
increase with advancing maternal age (Munné et al. 2007). Thus, in a non-age-controlled study 
population, there should always be higher aneuploidy rates in slower developing blastocysts. In 
the paper by Campbell et al. in which they modelled the risk classification (Campbell et al. 2013a), 
the reader was informed that 25 couples were enrolled in the study group, with an age range of 
31-47 years. No data was provided about maternal age of the 97 analysed embryos that fell 
within the three aneuploidy risk classifications (low, medium and high). As no maternal age data 
of the embryos within each risk classification was provided, it is logical to assume (from the 
evidence presented above) that the differential of embryo development and rates of aneuploidy 
between younger and older patients have created a bias in the findings. This is a confounding 
factor in the study and a serious statistical flaw resulting in potential bias in the results. It is 
therefore possible that the algorithm is predictive of maternal age alone. In order for this 
retrospective study to rule out an age-related affect, the authors needed to perform a logistic 
regression analysis adjusted for maternal age to see if the algorithm was predictive of aneuploidy 
alone. I conclude that using their algorithm, the authors are in fact able to predict the 
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chromosome copy number of any one particular embryo from their study group as a whole. 
However, the authors have failed to demonstrate whether the algorithm has the same predictive 
value of aneuploidy and implantation potential when applied within a cohort of embryos from a 
single IVF cycle or a controlled patient population. Likewise in the retrospective implantation 
analysis paper (Campbell et al. 2013b), no age data were presented for the embryos that were 
within the three risk classification groups. I propose that, although the implantation rates between 
the three classification groups were found to be significantly different, the large maternal age 
range of patients enrolled in the study (from 25 to 47 years) creates a bias. Maternal age must be 
considered as a potential confounder of these observed differences. Again, as we know that 
embryos from younger patients have a greater change of implantation, the authors should 
provide age data for the classification groups. This is the only way to rule out the possibility that 
they are not merely separating their study group into three age classifications (low, medium and 
high). It should be also noted that both studies – the one in which the algorithm was developed 
(Campbell et al. 2013a) and the one in which it was applied retrospectively (Campbell et al. 
2013b) – are based on a relatively small sample size (97 and 88 blastocysts respectively) with 
significant overlap within the low and medium classification groups. In the retrospective analysis, 
the only group without overlapping was the high-risk group where only four embryos were 
included, making this classification totally underpowered to be of statistical and clinical relevance. 
I fundamentally disagree with the author’s statements that their algorithm has the ability to screen 
out embryos with the highest risk for aneuploidy, and could be offered to patients as an 
alternative to PGS with potentially as much as a 3-fold increase in implantation rate. Making such 
conclusions are misleading without data from a larger, age-matched study group or a prospective, 
randomised controlled trial to confirm their findings. In fact, in more recently published data on a 
larger patient population, using logistic regression analysis adjusted for the maternal age effect, 
no evidence of association between blastocyst aneuploidy and morphokinetic assessment was 
observed (Rienzi et al. 2015).  
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There are however potentially more promising approaches to non-invasive assessment of 
embryo viability include the measurement of what is used by or what is secreted by the oocyte or 
embryo. All culture media contain substances that are required for embryo development. Culture 
media will also contain all products secreted by the oocyte or embryo. Levels of these can be 
measured in a variety of ways to establish embryo viability (for review see Aydiner et al. 2010).  
Analysis of spent culture media is an area already being explored as potential for a new indirect 
PGS platform. A recent study analysing uptake patterns of amino acids has shown that regulation 
of amino acid metabolism correlates with embryo aneuploidy. The study using FISH analysis of 
five chromosomes (13, 18, 21, X and Y) demonstrated altered amino acid turnover in embryos 
with grossly abnormal karyotypes when compared to genetically normal embryos (Picton et al. 
2010). Although promising, this early data lacks specificity and further work is needed to more 
accurately establish how embryo metabolism may be indicative of its chromosomal complement. 
Precise metabolic profiling of embryos with known copy number aberrations is proposed as a 
specific experiment to establish more meaningful correlations. 
A further approach is based on the hypothesis of altered gene expression and protein synthesis 
of chromosomally abnormal embryos. One study, using a proteomic approach, has identified the 
first protein secreted by human blastocysts – Lipocalin-1 that is associated with generic 
chromosome aneuploidy (McReynolds et al. 2011) – promising the biggest step to date towards a 
non-invasive PGS test.  
Although the idea of a non-invasive aneuploidy screening test for embryos is very appealing, the 
reality is that embryo biopsy is likely to remain the only viable option for many years to come and 
PGS is likely to continue to be one of the most controversial areas of reproductive medicine. 
However, the entire community is united in its collective will to improve IVF success, reduce 
miscarriage rates and ensure that couples avoid children with developmental abnormalities. Thus, 
advancing our knowledge of aneuploidy in the preimplantation embryo remains key. The means 
by which this is achieved remains the subject of intense debate. What can be clear however is 
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that the controversy will serve to increase the interest in PGS, hopefully leading to new and 
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